

Giuseppe Remuzzi, M.D.

List of publications/Lista delle pubblicazioni

Publications/Pubblicazioni

1. G. Miragliotta, G. Remuzzi, B. Minetti, G. de Gaetano. ADP, Ristocetin, bovine Factor VIII and thromboasthenic platelets. *Thromb Haemost* 1976;36:286-288.
2. G. Remuzzi, G. Mingardi, G. Mecca, M.B. Donati, G. de Gaetano. Does aspirin precipitate major gastrointestinal bleeding in patients on haemodialysis? *Lancet* 1977;2:359-360.
3. G. Remuzzi, E. Marchesi, G. de Gaetano, M.B. Donati. Abnormal tissue repair in Glanzmann's thromboasthenia. *Lancet* 1977;1:374-375.
4. M.B. Donati, G. Balconi, G. Remuzzi, R. Borgia, L. Morasca, G. de Gaetano. Skin fibroblasts from a patient with Glanzmann's thromboasthenia do not induce fibrin clot retraction. *Thromb Res* 1977;10:173-174.
5. G. Remuzzi, R. Misiani, M. Livio, A. dall'Olio, M.B. Donati, G. de Gaetano. Possible role of HLA-B8 antigen as a genetic marker of autoimmune thrombocytopenia in a patient with myasthenia gravis. *Thromb Haemost* 1977;38:593-594.
6. G. Remuzzi, M. Livio, M.C. Roncaglioni, G. Mecca, M.B. Donati, G. de Gaetano. Bleeding in renal failure: is von Willebrand factor implicated? *Br Med J* 1977;2:359-361.
7. G. Remuzzi, A.E. Cavenaghi, G. Mecca, M.B. Donati, G. de Gaetano. Prostacyclin-like activity and bleeding in renal failure. *Lancet* 1977;2:1195-1197.
8. G. Remuzzi, A.E. Cavenaghi, G. Mecca, M.B. Donati, G. de Gaetano. Prostacyclin (PGI₂) and bleeding time in uremic patients. *Thromb Res* 1977;11:919-920.
9. G. Remuzzi, M. Livio, M.B. Donati, G. de Gaetano. Myasthenia gravis, thrombocytopenia and HLA antigens. *Ann Intern Med* 1977;87:250-251.
10. G. Remuzzi, D. Marchesi, M. Livio, A.E. Cavenaghi, G. Mecca, M.B. Donati, G. de Gaetano. Altered platelet and vascular prostaglandin-generation in patients with renal failure and prolonged bleeding times. *Thromb Res* 1978;13:1007-1015.
11. G. Remuzzi, A.E. Cavenaghi, G. Mecca, M.B. Donati, G. de Gaetano. Human renal cortex generates prostacyclin-like activity. *Thromb Res* 1978;12:363-366.
12. G. Remuzzi, M. Livio, G. Marchiari, G. Mecca, G. de Gaetano. Bleeding in renal failure: altered platelet function in chronic uraemia only partially corrected by haemodialysis. *Nephron* 1978;22:347-353.
13. G. Remuzzi, T. Bertani, G. Mecca, M.B. Donati, G. de Gaetano. Factor VIII-related protein on vascular intima of patients with chronic renal failure and prolonged bleeding times. *Br Med J* 1978;1:70-72.

14. G. Remuzzi, R. Misiani, G. Mecca, G. de Gaetano, M.B. Donati. Thrombotic thrombocytopenic purpura. A deficiency of plasma factors regulating platelet-vessel-wall interaction? *N Engl J Med* 1978;299:311.
15. G. Remuzzi, M. Livio, A.E. Cavenaghi, D. Marchesi, G. Mecca, M.B. Donati, G. de Gaetano. Unbalanced prostaglandin synthesis and plasma factors in uraemic bleeding. A hypothesis. *Thromb Res* 1978;13:531-536.
16. G. Remuzzi, R. Misiani, D. Marchesi, M. Livio, G. Mecca, G. de Gaetano, M.B. Donati. Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity? *Lancet* 1978;2:871-872.
17. R. Misiani, T. Bertani, R. Licini, G. Remuzzi, G. Mecca. Asphyxia in Goodpasture's syndrome: early treatment by immunosuppression and plasma exchange. *Lancet* 1978;1:552.
18. G. Remuzzi, T. Bertani, M. Livio, A.E. Cavenaghi, M. Mysliwiec, D. Marchesi, M.B. Donati, G. de Gaetano, G. Mecca. Vascular factors in the pathogenesis of uraemic bleeding. In: *Dialysis, Transplantation, Nephrology. Proceedings of the European Dialysis and Transplant Association*. Edited by B.H.B. Robinson, J.B. Hawkins, Pitman Medical, Tunbridge Wells 1978, pp. 449-455.
19. G. Remuzzi, M. Livio, R. Misiani, G. Mecca, G. de Gaetano, M.B. Donati. Plasma factors modulating prostaglandin synthesis: a possible role in uraemic bleeding and in thrombotic thrombocytopenic purpura. *Atherogenesis* 1979;4:9-13.
20. G. Remuzzi, D. Marchesi, A.E. Cavenaghi, M. Livio, M.B. Donati, G. de Gaetano, G. Mecca. Bleeding in renal failure: a possible role of vascular prostacyclin (PGI₂). *Clin Nephrol* 1979;12:127-131.
21. G. Remuzzi, D. Marchesi, R. Misiani, G. Mecca, G. de Gaetano, M.B. Donati. Familial deficiency of a plasma factor stimulating vascular prostacyclin activity. *Thromb Res* 1979;16:517-525.
22. G. Remuzzi, G. Mingardi, T. Bertani. Pathogenesis of glomerulonephritis. *Spectrum Int* 1979;22:6-7.
23. G. Remuzzi, R. Misiani, D. Marchesi, M. Livio, G. Mecca, G. de Gaetano, M.B. Donati. Treatment of the haemolytic uraemic syndrome with plasma. *Clin Nephrol* 1979;12:279-284.
24. R. Misiani, G. Remuzzi, T. Bertani, R. Licini, P. Levoni, A. Crippa, G. Mecca. Plasmapheresis in the treatment of acute renal failure in multiple myeloma. *Am J Med* 1979;66:684-688.
25. G. de Gaetano, G. Remuzzi, M. Mysliwiec, M.B. Donati. Vascular prostacyclin and plasminogen activator activity in experimental and clinical conditions of disturbed haemostasis or thrombosis. *Haemostasis* 1979;8:300-311.

26. G. Remuzzi, R. Misiani, D. Muratore, D. Marchesi, M. Livio, A. Schieppati, G. Mecca, G. de Gaetano, M.B. Donati. Prostacyclin and human fetal circulation. *Prostaglandins* 1979;18:341-348
27. G. Remuzzi, G. Mecca, D. Marchesi, M. Livio, G. de Gaetano, M.B. Donati, M.J. Silver. Platelet hyperaggregability and the nephrotic syndrome. *Thromb Res* 1979;16:345-354.
28. G. Remuzzi, T. Bertani, G. Mecca, M.B. Donati, G. de Gaetano: Factor VIII-related protein on vascular intima of patients with chronic renal failure and prolonged bleeding time. *Urology Digest* 1979;32-33.
29. G. Remuzzi, A. Schieppati, G. Mecca. Abnormal platelet function in haemodialysis patient: current concepts. *Int J Artif Organs* 1979;2:109-112.
30. G. Remuzzi, D. Marchesi, G. Mecca, G. de Gaetano, M. Silver. Platelet hypersensitivity in the nephrotic syndrome. In: *Proceedings of the European Dialysis and Transplant Association*. Edited by B.H.B. Robinson, J.B. Hawkins and R.B. Naik, Pitman Medical, Tunbridge Wells 1979, pp.487-494.
31. F. Pusineri, E. Gotti, G. Remuzzi, G. Mecca, M.B. Donati, G. de Gaetano. Platelets from uraemic patients react normally to prostacyclin. *Int J Artif Organs* 1980;3:125.
32. G. Remuzzi, G. Mecca, M. Livio, G. de Gaetano, M.B. Donati, J.D. Pearson, J.L. Gordon. Prostacyclin generation by cultured endothelial cells in haemolytic uraemic syndrome. *Lancet* 1980;1:656-657.
33. G. Remuzzi, D. Marchesi, C. Zoja, D. Muratore, G. Mecca, R. Misiani, E. Rossi, M. Barbato, P. Capetta, M.B. Donati, G. de Gaetano. Reduced umbilical and placental vascular prostacyclin in severe pre-eclampsia. *Prostaglandins* 1980;20:105-110.
34. G. Remuzzi, E.C. Rossi, R. Misiani, D. Marchesi, G. Mecca, G. de Gaetano, M.B. Donati. Prostacyclin and thrombotic microangiopathy. *Semin Thromb Haemost* 1980;6:391-394.
35. G. Remuzzi, D. Marchesi, G. Mecca, R. Misiani, E. Rossi, M.B. Donati, G. de Gaetano. Reduction of fetal vascular prostacyclin activity in pre-eclampsia. *Lancet* 1980; 2:310.
36. G. Remuzzi, D. Marchesi, A. Schieppati, E. Poletti, G. Mecca, E.C. Rossi, M.B. Donati, G. de Gaetano. Aspirin and thrombosis in patients undergoing hemodialysis. *N Engl J Med* 1980;302:1420-1421.
37. F. Pusineri, A. Bini, L. Mussoni, G. Remuzzi, M.B. Donati. Intermittent heparin treatment does not induce hypercoagulability in haemodialysed patients. *J Clin Pathol* 1980;33:631-634.
38. R. Misiani, F. Trevisan, D. Marchesi, T. Bertani, G. Remuzzi, G. Mecca. Plasmapheresis and plasma infusion in the treatment of Hemolytic-Uremic Syndrome.

- In: Hemostasis, Prostaglandins and Renal Disease. Edited by G. Remuzzi, G. Mecca and G. de Gaetano, Raven Press, New York 1980, pp. 423-431.
39. M.B. Donati, R. Misiani, D. Marchesi, M. Livio, G. Mecca, G. Remuzzi, G. de Gaetano. Hemolytic-uremic syndrome, prostaglandins and plasma factors. In: Hemostasis, Prostaglandins and Renal Disease. Edited by G. Remuzzi, G. Mecca and G. de Gaetano, Raven Press, New York 1980, pp.283-290.
 40. G. Remuzzi, D. Marchesi, M. Livio, A. Schieppati, G. Mecca, M.B. Donati, G. de Gaetano. Prostaglandins, plasma factors and hemostasis in uremia. In: Hemostasis, Prostaglandins and Renal Disease. Edited by G. Remuzzi, G. Mecca, and G. de Gaetano, Raven Press, New York 1980, pp. 273-281.
 41. G. Remuzzi, R. Misiani, D. Marchesi, M. Livio, G. de Gaetano, M.B. Donati, G. Mecca. Haemolytic uraemic syndrome: report of a case and new pathogenetic concepts. In: Proceedings of the European Dialysis and Transplant Association. Edited by B.H.B. Robinson and J.B. Hawkins, Pitman Medical, London 1980, pp. 598-602.
 42. G. Remuzzi, C. Zoja, D. Marchesi, A. Schieppati, G. Mecca, R. Misiani, M.B. Donati, G. de Gaetano. Plasmatic regulation of vascular prostacyclin in pregnancy. *Br Med J* 1981;282:512-514.
 43. D. Marchesi, A. Parbtani, G. Frampton, M. Livio, G. Remuzzi, J.S. Cameron. Thrombotic tendency in systemic lupus erythematosus. *Lancet* 1981;1:719.
 44. G. de Gaetano, M. Livio, M.B. Donati, G. Remuzzi. Platelet and vascular prostaglandins in uraemia, thrombotic microangiopathy and pre-eclampsia, *Philos Trans R Soc Lond (Biol)* 1981;294:339-342.
 45. G. Remuzzi, M. Livio, G. Mecca, G. de Gaetano, M.B. Donati. Prostacyclin and kidney disease: focus on uremia and thrombotic microangiopathy. In: *Clinical Pharmacology of Prostacyclin*. Edited by P.J. Lewis and J. O' Grady, Raven Press, New York 1981, pp. 63-71.
 46. R. Misiani, G. Remuzzi, G. Mecca. Prostacyclin generation by human umbilical and placental vessels in normal and hypertensive pregnancy. In: *Clinical Pharmacology of Prostacyclin*. Edited by P.J. Lewis and J. O' Grady, Raven Press, New York 1981, pp. 137-140.
 47. G. Remuzzi, A. Benigni, P. Dodesini, A. Schieppati, M. Livio, E. Poletti, G. Mecca, G. de Gaetano. Parathyroid hormone inhibits human platelet function. *Lancet* 1981;2:1321-1323.
 48. G. Remuzzi, M. Livio, A. Benigni, P. Dodesini, D. Marchesi, A. Schieppati, E. Gotti, F. Pusineri, G. Mecca, M.B. Donati, G. de Gaetano. Bleeding in renal failure. In: *Uremia*. Edited by C. Giordano and E.A. Friedman, Wichtig Editore, Milano 1981, pp. 287-296.
 49. G. Remuzzi, M. Livio, G. de Gaetano. Platelet and vascular prostaglandins in uremia.

Mineral Electrolyte Metab 1981;6:68-75.

50. G. Remuzzi, L. Imberti, G. de Gaetano. Prostacyclin deficiency in thrombotic microangiopathy. *Lancet* 1981;2:1422-1423.
51. T. Bertani, A. Poggi, R. Pozzoni, F. Delaini, G. Sacchi, Y. Thoua, G. Mecca, G. Remuzzi, M.B. Donati. Adriamycin-induced nephrotic syndrome in rats. Sequence of pathologic events. *Lab Invest* 1982;46:16-23.
52. G. Remuzzi, A. Benigni, P. Dodesini, A. Schieppati, E. Gotti, M. Livio, G. Mecca, M.B. Donati, G. de Gaetano. Platelet function in patients on maintenance hemodialysis: depressed or enhanced? *Clin Nephrol* 1982;17:60-63.
53. G. Remuzzi, N. Perico. Prostacyclin in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. In: *Prostaglandins in Clinical Medicine*. Edited by K.K. Wu and E.C. Rossi, Year Book Medical Publishers Inc., Chicago 1982, pp. 319-324.
54. G. Remuzzi. Pregnancy and the arachidonic-acid cascade. (Editorial) *Lancet* 1982;1:997-998.
55. N. Perico, A. Schieppati, G. Mecca, E.C. Rossi, G. Remuzzi. Prostacyclin and renal diseases. *Clin Nephrol* 1982;18:111-119.
56. M. Livio, D. Marchesi, G. Remuzzi, E. Gotti, G. Mecca, G. de Gaetano. Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions. *Lancet* 1982;2:1013-1015.
57. R. Misiani, A.C. Appiani, A. Edefonti, E. Gotti, A. Bettinelli, M. Giani, E. Rossi, G. Remuzzi, G. Mecca. Haemolytic uraemic syndrome: therapeutic effect of plasma infusion. *Br Med J* 1982;285:1304-1306.
58. G. Remuzzi. AN69 membrane for hemodialysis: long term effects on the uremic hemostatic abnormalities. In: *Proceedings of the First American AN69 membrane scientific exchange*. Atlantic City, October 1982, pp. 83-89.
59. P. M. Mannucci, G. Remuzzi, F. Pusineri, R. Lombardi, C. Valsecchi, G. Mecca, T.S. Zimmerman. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. *N Engl J Med* 1983;308:8-12.
60. D. Marchesi, G. Remuzzi. Platelet and vascular prostaglandins in uremia and thrombotic microangiopathy. In: *Prostaglandins and the Kidney*. Edited by M.J. Dunn, C. Patrono and G.A. Cinotti, Plenum Publishing Corporation, New York and London 1983, pp. 319-325.
61. A. Schieppati, G. Remuzzi. Platelet prostaglandin production in the nephrotic syndrome. In: *Prostaglandins and the Kidney*. Edited by M.J. Dunn, C. Patrono and G.A. Cinotti, Plenum Publishing Corporation, New York and London 1983, pp. 327-331.

62. T. Bertani, G. Remuzzi, A. Poggi, F. Delaini, G. Sacchi, L. Morassi, P. Verroust, G. Mecca, M.B. Donati. Severe glomerular epithelial cell damage does not prevent passive Heymann nephritis in rats. *Clin Exp Immunol* 1983;51:38-44.
63. G. Remuzzi, A. Benigni, P. Dodesini, A. Schieppati, M. Livio, G. de Gaetano, J.S. Day, W.L. Smith, E. Pinca, P. Patrignani, C. Patrono. Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect. *J Clin Invest* 1983;71:762-768.
64. G. Frampton, A. Parbtani, D. Marchesi, P. Duffus, M. Livio, G. Remuzzi, J.S. Cameron. In vivo platelet activation with in vitro hyperaggregability to arachidonic acid in renal allograft recipients. *Kidney Int* 1983;23:506-513.
65. T. Bertani, G. Remuzzi. Stagnations and regressions in the treatment of primary glomerulonephritis. *Lancet* 1983;2:90-92.
66. G. Gregorini, M. Ongari, L. Imberti, G. Mecca, G. Remuzzi. Plasmatic regulation of prostacyclin production in pregnancy. In: *Prostacyclin in Pregnancy*. Edited by P.J. Lewis, S. Moncada and J. O'Grady, Raven Press, New York 1983, pp. 153-158.
67. T. Bertani, G. Remuzzi. Epithelial cell damage. In: *Glomerular Injury: 300 years after Morgagni*, edited by T. Bertani and G. Remuzzi, Wichtig Editore, Milan 1983, pp. 163-178.
68. G.H. Neild, G. Rocchi, L. Imberti, F. Fumagalli, Z. Brown, G. Remuzzi, D.G. Williams. Effect of Cyclosporin A on prostacyclin synthesis by vascular tissue. *Thromb Res* 1983;32:373-379.
69. G.H. Neild, G. Rocchi, L. Imberti, F. Fumagalli, Z. Brown, G. Remuzzi, D.G. Williams. Effect of cyclosporine on prostacyclin synthesis by vascular tissue in rabbits. *Transplant Proc* 1983;15:2398-2400.
70. A. Schieppati, P. Dodesini, A. Benigni, M. Massazza, G. Mecca, G. Remuzzi, M. Livio, G. de Gaetano, E.C. Rossi. The metabolism of arachidonic acid by platelets in nephrotic syndrome. *Kidney Int* 1984;25:671-676.
71. G. Mingardi, N. Perico, F. Pusineri, M. Massazza, E. Marchesi, G. Mecca, G. Remuzzi, M.B. Donati. Heparin for hemodialysis: practical guidelines for administration and monitoring. *Int J Artif Organs* 1984;7:269-274.
72. N. Perico, F. Pusineri, G. Remuzzi. The lupus anticoagulant. *Proc Soc Exp Biol & Med* 1984;176:337-341.
73. E. Gotti, G. Rocchi, G. Remuzzi. Prostacyclin deficiency in haemolytic uraemic syndrome. In: *Paediatric Nephrology*. Edited by J. Brodehl and J.H.H. Ehrich, Springer-Verlag, Berlin 1984, pp. 289-292.
74. E. Gotti, G. Mecca, C. Valentino, E. Cortinovis, T. Bertani, G. Remuzzi. Renal biopsy in patients with acute renal failure and prolonged bleeding time. *Lancet* 1984;2:978-

979.

75. A. Benigni, G. Remuzzi. Hamorrhagische diathese bei chronischer urämie. *Hamostaseologie* 1984;4:134-137.
76. E. Dejana, F. Breviario, G. Balconi, V. Rossi, G. Remuzzi, G. de Gaetano, A. Mantovani. Stimulation of prostacyclin synthesis in vascular cells by mononuclear cell products. *Blood* 1984;64:1280-1283.
77. G. Remuzzi. Coagulation Disturbances in Uremia. In: *Current therapy in Nephrology and Hypertension 1984-1985*. Edited by R.J. Glassock, B.C. Decker Inc. Publisher, Philadelphia 1984, pp. 290-293.
78. T. Bertani, G. Remuzzi, G. Rocchi, F. Delaini, G. Sacchi, M. Falchetti, M.B. Donati. Steroids and Adriamycin nephrosis. *Appl Pathol* 1984;2:32-38.
79. A. Benigni, M. Livio, G. Remuzzi. Prostanoid-related platelet abnormalities in renal disease. *Nephrology. Proceedings of the IXth International Congress of Nephrology 1984*. Edited by R.R. Robinson, Springer-Verlag, New York 1984, pp. 1406-1411.
80. G. Remuzzi, L. Imberti, M. Rossini, C. Morelli, C. Carminati, G.M. Cattaneo, T. Bertani. Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis. *J Clin Invest* 1985;75:94-101.
81. D. Macconi, G. Morzenti, M. Livio, C. Morelli, M. Cassina, G. Remuzzi. Acetyl glycerylphosphorylcholine aggregates human platelet through two distinct pathways, both dependent on arachidonic acid metabolism. *Lab Invest* 1985;52:159-168.
82. M. Livio, A. Benigni, G. Remuzzi. Coagulation abnormalities in uremia. *Semin Nephrol* 1985;5:82-90.
83. G. Remuzzi, C. Zoja, A. Remuzzi, M. Rossini, C. Battaglia, M. Broggin, T. Bertani. Low-protein diet prevents glomerular damage in adriamycin-treated rats. *Kidney Int* 1985;28:21-27.
84. A. Benigni, M. Livio, P. Dodesini, A. Schieppati, M. Panigada, G. Mecca, G. de Gaetano, G. Remuzzi. Inhibition of human platelet aggregation by parathyroid hormone: is cyclic AMP implicated? *Am J Nephrol* 1985;5:243-247.
85. C. Patrono, G. Ciabattoni, G. Remuzzi, E. Gotti, S. Bombardieri, O. Di Munno, G. Tartarelli, G.A. Cinotti, B.M. Simonetti, A. Pierucci. Functional significance of renal prostacyclin and thromboxane A₂ production in patients with systemic lupus erythematosus. *J Clin Invest* 1985;76:1011-1018.
86. G. Remuzzi, E.C. Rossi. The hemolytic uremic syndrome. *Int J Artif Organs* 1985;8:171-174.
87. E. Gotti, G. Mecca, C. Valentino, E. Cortinovis, T. Bertani, G. Remuzzi. Renal biopsy in patients with acute renal failure and prolonged bleeding time: A report. *Am J*

Kidney Dis 1985;6:397-399.

88. G. Gregorini, N. Perico, G. Remuzzi. Pathogenesis of preeclampsia. In: The kidney in pregnancy. Edited by V.E. Andreucci, Martinus Nijhoff Publishing, Boston 1986, pp. 13-33.
89. T. Bertani, G. Rocchi, G. Sacchi, G. Mecca, G. Remuzzi. Adriamycin-induced glomerulosclerosis in the rat. *Am J Kidney Dis* 1986;7:12-19.
90. M. Livio, A. Benigni, G. Viganò, G. Mecca, G. Remuzzi. Moderate doses of aspirin and risk of bleeding in renal failure. *Lancet* 1986;1:414-416.
91. G. Gregorini, G. Setti, G. Remuzzi. Recurrent abortion with lupus anticoagulant, and pre-eclampsia: a common final pathway for two different diseases? (Case Report) *Br J Obstet Gynaecol* 1986;93:194-196.
92. T. Bertani, A. Benigni, F. Cutillo, G. Rocchi, C. Morelli, C. Carminati, P. Verroust, G. Remuzzi. Effect of aspirin and sulindac in rabbit nephrotoxic nephritis. *J Lab Clin Med* 1986;107:261-268.
93. T. Bertani, G. Mecca, G. Sacchi, G. Remuzzi. Superimposed nephritis: a separate entity among glomerular diseases? *Am J Kidney Dis* 1986;7:205-212.
94. N. Perico, A. Benigni, E. Bosco, M. Rossini, S. Orisio, F. Ghilardi, A. Piccinelli, G. Remuzzi. Acute cyclosporine A nephrotoxicity in rats: which role for renin-angiotensin system and glomerular prostaglandins? *Clin Nephrol* 1986;25(Suppl. 1):S83-S88.
95. G. Mingardi, G. Viganò, M. Massazza, G. Remuzzi, G. Mecca. Polyacrylonitrile membrane for hemodialysis: long-term effect on primary hemostasis. In: Immune and Metabolic Aspects of Therapeutic Blood Purification Systems. Edited by L.C. Smeby, S. Jorstad and T.E. Wideroe, Karger, Basel 1986, pp. 310-314.
96. T. Bertani, M. Abbate, G. Mecca, G. Sacchi, G. Remuzzi. Adriamycin-induced epithelial cell disease in the rat. In: Drugs and Kidney. Edited by T. Bertani, G. Remuzzi and S. Garattini, Raven Press, New York 1986, pp. 1-14.
97. G. Remuzzi, C. Zoja, A. Remuzzi, M. Rossini, C. Battaglia, M. Broggin, T. Bertani. Low-protein diet prevents glomerular damage in adriamycin-treated rats. In: Drugs and Kidney. Edited by T. Bertani, G. Remuzzi and S. Garattini, Raven Press, New York 1986, pp. 251-256.
98. G. Remuzzi. Prevention and therapeutic management of bleeding in dialysis patients. In: Dialysis Therapy. Edited by A.R. Nissenson and R.N. Fine, Hanley and Belfus Inc., Philadelphia 1986, pp. 94-96.
99. M. Livio, P.M. Mannucci, G. Viganò, G. Mingardi, R. Lombardi, G. Mecca, G. Remuzzi. Conjugated estrogens for the management of bleeding associated with renal failure. *N Engl J Med* 1986;315:731-735.

100. T. Bertani, F. Cutillo, C. Zoja, M. Broggin, G. Remuzzi. Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. *Kidney Int* 1986;30:488-496.
101. A. Benigni, C. Zoja, A. Remuzzi, S. Orisio, A. Piccinelli, G. Remuzzi. Role of renal prostaglandins in normal and nephrotic rats with diet-induced hyperfiltration. *J Lab Clin Med* 1986;108:230-240.
102. C. Zoja, L. Furci, F. Ghilardi, P. Zilio, A. Benigni, G. Remuzzi. Cyclosporin-induced endothelial cell injury. *Lab Invest* 1986;55:455-462.
103. N. Perico, A. Benigni, C. Zoja, F. Delaini, G. Remuzzi. Functional significance of the exaggerated renal thromboxane A2 synthesis induced by cyclosporin A. *Am J Physiol* 1986;251:F581-F587.
104. N. Perico, C. Zoja, A. Benigni, F. Ghilardi, L. Gualandris, G. Remuzzi. Effect of short-term cyclosporine administration in rats on renin-angiotensin and thromboxane A2: possible relevance to the reduction in glomerular filtration rate. *J Pharmacol Exp Ther* 1986;239:229-235.
105. N. Perico, C. Zoja, A. Benigni, E. Bosco, M. Rossini, C. Morelli, G.M. Cattaneo, G. Remuzzi. Renin-angiotensin system and glomerular prostaglandins in early nephrotoxicity of ciclosporin. *Contr Nephrol* 1986;51:120-125.
106. S. Garattini, T. Bertani, G. Remuzzi. What is the basis for the use of steroids in the treatment of idiopathic membranous nephropathy? *Nephron* 1987;45:1-6.
107. G. Remuzzi, A. Benigni, N. Perico. Renal prostaglandins and hyperfiltration. In: *Advances in Prostaglandin, Thromboxane, and Leukotriene Research*. Edited by B. Samuelsson and R. Paoletti, Raven Press, New York 1987, vol.17, pp. 719-724.
108. M. Livio, D. Macconi, M. Morigi, S. Orisio, A. Benigni, C. Patrono, G. Remuzzi. A platelet activating factor receptor antagonist protects against renal function deterioration in nephrotoxic nephritis. In: *Advances in Prostaglandin, Thromboxane, and Leukotriene Research*. Edited by B. Samuelsson and R. Paoletti, Raven Press, New York 1987, vol.17, pp. 824-828.
109. N. Perico, C. Zoja, T. Bertani, G. Remuzzi. Models of experimental glomerulopathies in search of new drugs. In: *New Tests for New Drugs*. Edited by S. Garattini, Wichtig Editore, Milano 1987, pp. 125-138.
110. A. Remuzzi, G. Remuzzi. Proteinuria and glomerulosclerosis. New clues from experimental models. *Contr Nephrol* 1987;55:50-59.
111. N. Perico, F. Delaini, C. Lupini, G. Remuzzi. Renal response to atrial peptides is reduced in experimental nephrosis. *Am J Physiol* 1987;252:F654-F660.
112. G. Remuzzi, C. Zoja, E.C. Rossi. Prostacyclin in thrombotic microangiopathy. *Semin Hematol* 1987;4:110-118.

113. T. Bertani, M. Livio, D. Macconi, M. Morigi, G. Bisogno, C. Patrono, G. Remuzzi. Platelet-activating factor (PAF) as a mediator of injury in nephrotoxic nephritis. *Kidney Int* 1987;31:1248-1256.
114. C. Zoja, A. Benigni, P. Verroust, P. Ronco, T. Bertani, G. Remuzzi. Indomethacin reduces proteinuria in Passive Heymann Nephritis in rats. *Kidney Int* 1987;31:1335-1343.
115. G. M. Ghiggeri, G. Candiano, C. Queirolo, R. Gusmano, F. Ginevri, T. Bertani, G. Remuzzi. Studies by conventional and "low denaturing" isoelectric focusing on albumin microheterogeneity under normal conditions and in experimental nephrosis. *Electrophoresis* 1987;8:215-220.
116. F. Gaspari, G. Viganò, S. Orisio, M. Bonati, M. Livio, G. Remuzzi. Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition. *J Clin Invest* 1987;79:1788-1797.
117. C. Chiabrando, A. Benigni, A. Piccinelli, C. Carminati, E. Cozzi, G. Remuzzi, R. Fanelli. Antibody-mediated extraction/negative ion chemical ionization mass spectrometric measurement of thromboxane B2 and 2,3-dinor-thromboxane B2 in human and rat urine. *Anal Biochem* 1987;163:255-262.
118. G. Remuzzi. Thrombotic thrombocytopenic purpura and allied disorders. In: *Thrombosis and Haemostasis*. Edited by M. Verstraete, J. Vermynen, R. Lijnen and J. Arnout, Leuven University Press, Louvain 1987, pp. 673-708.
119. T. Bertani, N. Perico, M. Abbate, C. Battaglia, G. Remuzzi. Renal injury induced by long-term administration of cyclosporin A to rats. *Am J Pathol* 1987;127:569-579.
120. G. Remuzzi. Thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome. In: *Current Therapy in Nephrology and Hypertension (2nd Edition)*. Edited by R.J. Glassock, B.C. Decker Inc. Publisher, Philadelphia 1987, pp. 156-160.
121. G. Remuzzi, E. Gotti. Coagulation abnormalities in uremia. In: *Current Therapy in Nephrology and Hypertension (2nd Edition)*. Edited by R.J. Glassock, B.C. Decker Inc. Publisher, Philadelphia 1987, pp. 273-276.
122. A. Remuzzi, C. Battaglia, L. Rossi, C. Zoja, G. Remuzzi. Glomerular size-selectivity in nephrotic rats exposed to diets with different protein content. *Am J Physiol* 1987;253:F318-F327.
123. G. Remuzzi. HUS and TTP: Variable expression of a single entity. *Kidney Int* 1987;32:292-308.
124. P. Ruggenenti, G. Mecca, G. Remuzzi, D. Coen. Are "routine" clinical and laboratory examinations of any help in the treatment of chronic hemodialysis patients? *Am J Kidney Dis* 1987;10:23-27.

125. G. Remuzzi, C. Zoja, G. de Gaetano, E.C. Rossi. Prostacyclin and hemolytic uremic syndrome: from laboratory data to the institution of an international registry. *Int J Artif Organs* 1987;10:337-340.
126. C. Zoja, A. Remuzzi, G. Remuzzi. Low-protein diet prevents glomerular damage in experimental nephrosis. *Contr Nephrol* 1988;60:94-100.
127. G. Remuzzi, T. Bertani. Thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, and acute cortical necrosis. In: *Diseases of the Kidney*. Edited by R.W. Schrier and C.W. Gottschalk, Little, Brown and Co., Boston 1988, vol. 2, pp. 2301-2333.
128. G. Remuzzi, F. Pusineri. Coagulation defects in uremia. *Kidney Int* 1988;33(S24):S13.
129. N. Perico, F. Delaini, M. Tagliaferri, M. Abbate, M. Cucchi, T. Bertani, G. Remuzzi. The effect of platelet-activating factor and its specific receptor antagonist on glomerular permeability to proteins in isolated perfused rat kidney. *Lab Invest* 1988;58:163-171.
130. F. Gaspari, G. Vigano', M. Locatelli, G. Remuzzi. Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis. *Am J Kidney Dis* 1988;11:338-342.
131. G. Rizzoni, A. Claris-Appiani, A. Edefonti, P. Facchin, F. Franchini, R. Gusmano, E. Imbasciati, L. Pavanello, F. Perfumo, G. Remuzzi. Plasma infusion for hemolytic uremic syndrome in children: results of a multicenter controlled trial. *J Pediatr* 1988;112:284-290.
132. G. Remuzzi. Bleeding in renal failure. *Lancet* 1988;1:1205-1208
133. M. Galbusera, S. Garattini, G. Remuzzi, T. Mennini. Cathecolamine receptor binding in rat kidney: effect of aging. *Kidney Int* 1988;33:1073-1077.
134. F. Delaini, N. Perico, M. Tagliaferri, C. Lupini, O. Patino, G. Remuzzi, S. Garattini. Tertatolol ameliorates renal function in rats with chronic renal failure. *J Pharmacol Exp Ther* 1988;246:287-293.
135. M. Livio, C. Chiabrando, D. Macconi, A. Benigni, M. Zimei, M.T. De Pietro, G. Remuzzi. Metabolism of arachidonic acid in isolated glomeruli from pig kidney. *Biochim Biophys Acta* 1988;961:110-121.
136. A. Benigni, C. Chiabrando, A. Piccinelli, N. Perico, M. Gavinelli, L. Furci, O. Patino, M. Abbate, T. Bertani, G. Remuzzi. Increased urinary excretion of thromboxane B2 and 2,3-dinor-TxB2 in cyclosporin A nephrotoxicity. *Kidney Int* 1988;34:164-174.
137. M. Livio, G. Vigano', M. Morigi, A. Ubiali, M. Galbusera, G. Remuzzi. Role of platelet-activating factor on primary hemostasis. *Am J Physiol* 1988;254:H1218-H1223.

138. S. Garattini, T. Bertani, G. Remuzzi. Steroids and cytotoxic drugs in the treatment of membranous glomerulopathy. *Nephron* 1988;50:263-264.
139. A. Remuzzi, S. Puntorieri, A. Mazzoleni, G. Remuzzi. Sex related differences in glomerular ultrafiltration and proteinuria in newly selected Munich-Wistar rats. *Kidney Int* 1988;34:481-486.
140. C. Zoja, G. Viganò, A. Bergamelli, A. Benigni, G. de Gaetano, G. Remuzzi. Prolonged bleeding time and increased vascular prostacyclin in rats with chronic renal failure: effects of conjugated estrogens. *J Lab Clin Med* 1988;112:372-376.
141. G. Viganò, F. Gaspari, M. Locatelli, F. Pusineri, M. Bonati, G. Remuzzi. Dose-effect and pharmacokinetics of estrogens given to correct abnormal bleeding time in uremia. *Kidney Int* 1988;34:853-858.
142. F. del Greco, G. Remuzzi, D.M. Ruxe, E.C. Rossi. Systemic lupus erythematosus and haemostasis. In: *Haemostasis and the Kidney*. Edited by G. Remuzzi and E.C. Rossi, Butterworths, London 1989, pp. 80-91.
143. C. Zoja, M. Livio, A. Benigni, G. Remuzzi. Eicosanoids and platelet-activating factor as mediators of injury in renal disease. In: *Haemostasis and the Kidney*, edited by Remuzzi G. and Rossi E.C., Butterworths, London 1989, pp. 92-104.
144. G. Remuzzi, F. Pusineri. The uremic platelet. In: *Haemostasis and the Kidney*. Edited by G. Remuzzi and E.C. Rossi, Butterworths, London 1989, pp. 107-118.
145. E. Gotti, G. Remuzzi. Uremic bleeding: clinical presentation and management. In: *Haemostasis and the Kidney*. Edited by G. Remuzzi and E.C. Rossi, Butterworths, London 1989, pp. 131-141.
146. B.S. Kaplan, G. Remuzzi. The hemolytic uremic syndrome. In: *Haemostasis and the Kidney*. Edited by G. Remuzzi and E.C. Rossi, Butterworths, London 1989, pp. 201-235.
147. N. Perico, G. Remuzzi. Thromboembolic complications during cyclosporin A therapy: possible causes and incidence. In: *Haemostasis and the Kidney*, edited by Remuzzi G. and Rossi E.C., Butterworths, London 1989, pp. 321-330.
148. G. Remuzzi. Bleeding and coagulation abnormalities. In: *Textbook of Nephrology (Second Edition)*. Edited by S.G. Massry and R.J. Glassock, Williams & Wilkins Co., Baltimore 1989, vol. 2, pp. 1205-1209.
149. A. Benigni, N. Perico, G. Remuzzi. Abnormalities of arachidonate metabolism in experimental cyclosporin nephrotoxicity. *Am J Nephrol* 1989;9(Suppl. 1):72-77.
150. T. Bertani, C. Zoja, M. Abbate, M. Rossini, G. Remuzzi. Age-related nephropathy in rats with intact kidneys exposed to diets with different protein content. *Lab Invest* 1989;60:197-204.

151. M. Livio, A. Benigni, C. Zoja, R. Begnis, C. Morelli, M. Rossini, S. Garattini, G. Remuzzi. Differential inhibition by aspirin of platelet thromboxane and renal prostaglandins in the rat. *J Pharmacol Exp Ther* 1989;248:334-341.
152. T. Bertani, M. Abbate, C. Zoja, D. Corna, N. Perico, P. Ghezzi, G. Remuzzi. Tumor necrosis factor (TNF) induces glomerular damage in the rabbit. *Am J Pathol* 1989;134:419-430.
153. G. Remuzzi, T. Bertani. Renal vascular and thrombotic effects of cyclosporin. *Am J Kidney Dis* 1989;13:261-272.
154. G.C. Viberti, A. Benigni, E. Bognetti, G. Remuzzi, M.J. Wiseman. Glomerular hyperfiltration and urinary prostaglandins in insulin-dependent diabetes mellitus. *Diabetic Med* 1989;6:219-223.
155. D. Macconi, A. Benigni, M. Morigi, A. Ubiali, S. Orisio, M. Livio, N. Perico, T. Bertani, G. Remuzzi, C. Patrono. Enhanced glomerular thromboxane A₂ mediates some pathophysiologic effect of platelet-activating factor in rabbit nephrotoxic nephritis: Evidence from biochemical measurements and inhibitor trials. *J Lab Clin Med* 1989;113:549-560.
156. C. Zoja, N. Perico, G. Remuzzi. Abnormalities in arachidonic acid metabolites in nephrotoxic glomerular injuries. *Toxicol Lett* 1989;46:65-75.
157. G. Viganò, P.M. Mannucci, A. Lattuada, A. Harris, G. Remuzzi. Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia. *Am J Hematol* 1989;31:32-35.
158. C. Zoja, A. Benigni, M. Livio, A. Bergamelli, S. Orisio, M. Abbate, T. Bertani, G. Remuzzi. Selective inhibition of platelet thromboxane generation with low-dose aspirin does not protect rats with reduced renal mass from the development of progressive disease. *Am J Pathol* 1989;134:1027-1038.
159. C. Zoja, A. Benigni, G. Remuzzi. Role of eicosanoids as mediators of glomerular injury in immune-mediated nephropathies. *Contr Nephrol* 1989;69:18-26.
160. N. Perico, F. Delaini, C. Lupini, A. Benigni, M. Galbusera, P. Boccardo, G. Remuzzi. Blunted excretory response to atrial natriuretic peptide in experimental nephrosis. *Kidney Int* 1989;36:57-64.
161. G. Remuzzi. Modèles de néphropathies humaines. In: *Nécessité de l'expérimentation animale pour la sécurité et le progrès de la recherche biomédicale*. Edited by J. Bridges, J.R. Claude, L. Cittanova, S. Garattini, K.J. Netter and D.W. van Bekkum, ACTAM, Neuilly sur Seine 1989, pp. 194-225.
162. P.M. Mannucci, R. Lombardi, A. Lattuada, E. Perticucci, R. Valsecchi, G. Remuzzi. Supranormal von Willebrand factor multimers in scleroderma. *Blood* 1989;73:1586-1591.

163. G. Remuzzi. Bleeding disorders in uremia: pathophysiology and treatment. *Adv Nephrol* 1989;18:171-186.
164. A. Benigni, G. Gregorini, T. Frusca, C. Chiabrando, S. Ballerini, A. Valcamonico, S. Orisio, A. Piccinelli, V. Pinciroli, R. Fanelli, A. Gastaldi, G. Remuzzi. Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. *N Engl J Med* 1989;321:357-362.
165. A. Benigni, C. Chiabrando, N. Perico, R. Fanelli, C. Patrono, G.A. FitzGerald, G. Remuzzi. Renal metabolism and urinary excretion of thromboxane B₂ in the rat. *Am J Physiol* 1989;257:F77-F85.
166. A. Remuzzi, A. Schieppati, C. Battaglia, G. Remuzzi. Angiotensin-converting enzyme inhibition ameliorates the defect in glomerular size selectivity in hyponatremic hypertensive syndrome. *Am J Kidney Dis* 1989;14:170-177.
167. P.M. Mannucci, R. Lombardi, A. Lattuada, P. Ruggerenti, G.L. Viganò, T. Barbui, G. Remuzzi. Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. *Blood* 1989;74:978-983.
168. G. Remuzzi, G. Tognoni. Thrombotic Thrombocytopenic Purpura (TTP) and Haemolytic Uraemic Syndrome (HUS): A clinical puzzle or a methodological challenge? *J Nephrol* 1989;2:77-81
169. N. Perico, G. Remuzzi. Effects of tertatolol on the renal function in the isolated perfused rat kidney. *Am J Hypertens* 1989;2:S223-S227.
170. T. Bertani, M. Abbate, C. Zoja, D. Corna, G. Remuzzi. Sequence of glomerular changes in experimental endotoxemia: a possible model of hemolytic uremic syndrome. *Nephron* 1989;53:330-337.
171. C. Chiabrando, V. Pinciroli, N. Perico, A. Campoleoni, A. Benigni, G. Remuzzi, R. Fanelli. Metabolism of thromboxane B₂ in the isolated perfused rat Kidney: mass spectrometric identification of urinary products. *Biochim Biophys Acta* 1989;1006:167-172.
172. G. Viganò, E. Gotti, E. Comberti, A. Giangrande, R. Trevisan, G. Remuzzi. Hyperparathyroidism does not influence the abnormal primary hemostasis in patients with chronic renal failure. *Nephrol Dial Transpl* 1989;4:971-974.
173. G. Remuzzi. Eicosanoids and platelet activating factor as possible mediators of injury in experimental nephropathies. In: *Renal Eicosanoids*. Edited by M.J. Dunn, C. Patrono and G. Cinotti, Plenum Publishing Corporation, New York 1989; 259: pp. 221-247.
174. E. Benfenati, D. Macconi, M. Noris, G. Icardi, L. Bettazzoli, G. De Bellis, M. Gavinelli, S. Rotondo, G. Remuzzi. Development of mass spectrometric method to

- quantitate platelet activating factor in mouse urine. *J Lipid Res* 1989;30:1977-1981.
175. F. Gaspari, N. Perico, M. Locatelli, D. Corna, G. Remuzzi, S. Garattini. Renal handling of aspirin in the rat. *J Pharmacol Exp Ther* 1989;251:295-304.
 176. G. Opocher, F. Mantero, S. Rocco, R. Trevisan, P. Fioretto, A. Semplicini, A. Morocutti, G. Zanette, V. Donadon, N. Perico, C. Giorato, A. Carraro, G. Remuzzi, R. Nosadini. Atrial natriuretic factor in hypertensive and normotensive insulin-dependent diabetics. *J Hypertens* 1989;7:S236-S237.
 177. M. Rossini, A. Belloni, G. Remuzzi, N. Perico. Thromboxane receptor blockade attenuates the toxic effect of cyclosporine in experimental renal transplantation. *Circulation* 1990;81(Suppl 1):61-67.
 178. A. Remuzzi, S. Puntorieri, C. Battaglia, T. Bertani, G. Remuzzi. Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. *J Clin Invest* 1990;85:541-549.
 179. C. Zoja, D. Corna, D. Macconi, P. Zilio, T. Bertani, G. Remuzzi. Tissue plasminogen activator therapy of rabbit nephrotoxic nephritis. *Lab Invest* 1990;62:34-40.
 180. P. Ruggenenti, G. Viganò, G. Mecca, G. Cassina, G. Remuzzi. Failure of prostacyclin to improve peripheral arterial disease in dialysis patients. *Nephron* 1990;54:93-94.
 181. P. Ruggenenti, G. Remuzzi. Thrombotic Thrombocytopenic Purpura and Related Disorders. *Hematology/Oncology Clinics of North America* 1990;4:219-241.
 182. C. Zoja, A. Benigni, D. Renzi, A. Piccinelli, N. Perico, G. Remuzzi. Endothelin and eicosanoids synthesis in cultured mesangial cells. *Kidney Int* 1990;37:927-933.
 183. C. Zoja, N. Perico, A. Bergamelli, M. Pasini, M. Morigi, J. Dadan, A. Belloni, T. Bertani, G. Remuzzi. Ticlopidine prevents renal disease progression in rats with reduced renal mass. *Kidney Int* 1990;37:934-942.
 184. G. Viganò, C. Zoja, D. Corna, M. Rossini, F. Pusineri, S. Garattini, G. Remuzzi. 17 β -Estradiol is the most active component of the conjugated estrogen mixture active on uremic bleeding by a receptor mechanism. *J Pharmacol Exp Ther* 1990;252:344-348.
 185. N. Perico, J. Dadan, M. Gabanelli, G. Remuzzi. Cyclooxygenase products and natriuretic peptide modulate the renal response to endothelin. *J Pharmacol Exp Ther* 1990;252:1213-20.
 186. A. Schieppati, G. Remuzzi. Eicosanoids and acute renal failure. In: *Current Concepts in Critical Care*. Edited by D. Bihari and G. Neild, Springer-Verlag, London 1990; 11: pp. 115-129.
 187. R. Trevisan, P. Fioretto, A. Semplicini, G. Opocher, F. Mantero, S. Rocco, G. Remuzzi, A. Morocutti, G. Zanette, V. Donadon, N. Perico, C. Giorato, R. Nosadini. Role of insulin and atrial natriuretic peptide in sodium retention in insulin-treated

- IDDM patients during isotonic volume expansion. *Diabetes* 1990;39:289-298.
188. T. Bertani, G. Remuzzi. Pathogenesis of glomerulosclerosis and therapeutic complications. In: *Néphrologie*. Edited by G. Richet, J.D. Sraer and P. Verroust, Ellipses, Paris 1990; pp. 213-231.
 189. A. Benigni, N. Perico, J. Dadan, M. Gabanelli, M. Galbusera, P. Boccardo, T. Mennini, G. Remuzzi. Functional implications of decreased renal cortical ANP binding in experimental diabetes. *Circ Res* 1990;66:1453-1460.
 190. C. Zoja, G. Viganò, D. Corna, M. Salmona, G. Remuzzi, S. Garattini. Oral zeranol shortens the prolonged bleeding time of uremic rats. *Kidney Int* 1990;38:96-100.
 191. C. Zoja, N. Perico, G. Remuzzi. Models of human renal disease. In: *The importance of animal experimentation for safety and biomedical research*. Edited by S. Garattini and D.W. van Bekkum, Kluwer Academic Publishers, Dordrecht 1990, pp. 111-123.
 192. G. Remuzzi, T. Bertani. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? *Kidney Int* 1990;38:384-394.
 193. P. Salvati, C. Ferti, R.G. Ferrario, E. Lamberti, L. Duzzi, G. Bianchi, G. Remuzzi, N. Perico, A. Benigni, P. Braidotti, G. Coggi, F. Pugliese, C. Patrono. Role of enhanced glomerular synthesis of thromboxane A2 in progressive kidney disease. *Kidney Int* 1990;38:447-458.
 194. C. Farina, G. Gavazzeni, A. Caprioli, G. Remuzzi. Haemolytic uremic syndrome associated with verocytotoxin-producing *escherichia coli* infection in acquired immunodeficiency syndrome. *Blood* 1990;75:2465-2468.
 195. N. Perico, J. Dadan, G. Remuzzi. Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. *J Am Soc Nephrol* 1990;1:76-83.
 196. A. Benigni, G. Rizzoni, A. Antolini, A. Piccinelli, G. Remuzzi. Preliminary report: renal thromboxane A2 synthesis in children with frequent relapsing nephrotic syndrome. *Lancet* 1990;336:533-534.
 197. N. Perico, G. Remuzzi. Changes in arachidonate biosynthesis and metabolism in normal pregnancy and pre-eclampsia. In: *Hematologic Disorders in Maternal-Fetal Medicine*. Edited by M.M. Bern and F.D. Frigoletto, Wiley-Liss, Inc., New York 1990, pp. 329-348.
 198. N. Perico, G. Remuzzi. Role of platelet-activating factor in renal immune injury and proteinuria. *Am J Nephrol* 1990;10(suppl 1):98-104.
 199. G. Remuzzi, N. Perico, C. Zoja, D. Corna, D. Macconi, G. Viganò. Role of endothelium-derived nitric oxide in the bleeding tendency of uremia. *J Clin Invest* 1990;86:1768-1771.
 200. M. Noris, N. Perico, D. Macconi, V. Nanni, J. Dadan, F. Peterlongo, G. Remuzzi.

- Renal metabolism and urinary excretion of platelet-activating factor in the rat. *J Biol Chem* 1990;265:19414-19419.
201. A. Remuzzi, G. Viberti, P. Ruggenenti, C. Battaglia, R. Pagni, G. Remuzzi. Glomerular response to hyperglycemia in human diabetic nephropathy. *Am J Physiol* 1990;259:F545-F552.
 202. C. Zoja, N. Perico, D. Corna, A. Benigni, M. Gabanelli, M. Morigi, T. Bertani, G. Remuzzi. Thromboxane synthesis inhibition increases renal prostacyclin and prevents renal disease progression in rats with remnant kidney. *J Am Soc Nephrol* 1990;1:799-807.
 203. C. Zoja, N. Perico, T. Bertani, G. Remuzzi. Effect of ticlopidine on the evolution of renal disease in rats with reduced renal mass. *Contrib Nephrol* 1990;81:279-288.
 204. C. Zoja, S. Orisio, N. Perico, A. Benigni, M. Morigi, L. Benatti, A. Rambaldi, G. Remuzzi. Constitutive expression of endothelin gene in cultured human mesangial cells and its modulation by transforming growth factor- β , thrombin and a thromboxane A2 analogue. *Lab Invest* 1991;64:16-20.
 205. P. Ruggenenti, G. Remuzzi, E.C. Rossi. Epidemiology of the hemolytic uremic syndrome. *N Engl J Med* 1991;324:1065-1066.
 206. D. Macconi, M. Noris, E. Benfenati, R. Quaglia, G. Pagliarino, G. Remuzzi. Increased urinary excretion of platelet activating factor in mice with lupus nephritis. *Life Sci* 1991;48:1429-1437.
 207. N. Perico, G. Remuzzi. Cyclosporine-induced renal dysfunction in experimental animals and humans. *Transplant Rev* 1991;5:63-80
 208. A. Remuzzi, S. Puntorieri, B. Brugnetti, T. Bertani, G. Remuzzi. Renoprotective effect of low iron diet and its consequence on glomerular hemodynamics. *Kidney Int* 1991;39:647-652.
 209. G. Remuzzi, M. Rossini, O. Imberti, N. Perico. Kidney graft survival in rats without immunosuppressive drugs after intrathymic glomerular transplantation. *Lancet* 1991;337:750-752.
 210. A. Benigni, F. Gaspari, S. Orisio, L. Bellizzi, G. Amuso, T. Frusca, G. Remuzzi. Human placenta expresses the endothelin gene and the corresponding protein is excreted in the urine in increasing amounts during the course of normal pregnancy. *Am J Obstet Gynecol* 1991;164:844-848.
 211. A. Benigni, N. Perico, F. Gaspari, C. Zoja, L. Bellizzi, M. Gabanelli, G. Remuzzi. Increased renal endothelin production in rats with reduced renal mass. *Am J Physiol* 1991;260:F331-F339.
 212. C. Zoja, J.M. Wang, S. Bettoni, M. Sironi, D. Renzi, F. Chiaffarino, H.E. Abboud, A. Mantovani, G. Remuzzi, A. Rambaldi. Interleukin-1 β and tumor necrosis factor- α

- induce gene expression and production of leukocyte chemotactic factors, colony stimulating factors and interleukin-6 in human mesangial cells. *Am J Pathol* 1991;138:991-1003.
213. A. Remuzzi, E. Peticucci, P. Ruggenenti, L. Mosconi, M. Limonta, G. Remuzzi. Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. *Kidney Int* 1991;39:1267-1273.
 214. A. Remuzzi, E. Peticucci, C. Battaglia, G. D'Amico, M.G. Gentile, G. Remuzzi. Low-protein diet and glomerular size-selective function in membranous glomerulopathy. *Am J Kidney Dis* 1991;17:317-322.
 215. G. D'Amico, G. Remuzzi, G. Maschio, M.G. Gentile, E. Gotti, L. Oldrizzi, G. Manna, G. Mecca, C. Rugiu, G. Fellin. Effect of dietary proteins and lipids in patients with membranous nephropathy and nephrotic syndrome. *Clin Nephrol* 1991;35:237-242.
 216. C. Zoja, N. Perico, G. Remuzzi. Antiplatelet agents: effects on the progressive renal disease. *Am J Kidney Dis* 1991;17(Suppl 1):98-102.
 217. T. Bertani, P. Ferrazzi, A. Schieppati, P. Ruggenenti, A. Gamba, L. Parenzan, G. Mecca, N. Perico, O. Imberti, A. Remuzzi, G. Remuzzi. Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. *Kidney Int* 1991;40:243-250.
 218. N. Perico, A. Remuzzi, J. Dadan, C. Battaglia, G. Remuzzi. Platelet-activating factor alters glomerular barrier size selectivity for macromolecules in the rat. *Am J Physiol* 1991;1:F85-F90.
 219. G. Viganò, A. Benigni, D. Mendogni, G. Mingardi, G. Mecca, G. Remuzzi. Recombinant human erythropoietin to correct uremic bleeding. *Am J Kidney Dis* 1991;18:44-49.
 220. A. Benigni, N. Perico, J.R. Ladny, O. Imberti, L. Bellizzi, G. Remuzzi. Increased urinary excretion of endothelin-1 and its precursor, big-endothelin-1 in rats chronically treated with cyclosporine. *Transplantation* 1991;52:175-177.
 221. G. Remuzzi, P. Ruggenenti. Prevention and treatment of pregnancy-hypertension: what have we learned in the last 10 years? *Am J Kidney Dis* 1991;18:285-305.
 222. G. Remuzzi, N. Perico. Induction of unresponsiveness via intrathymic inoculation. *Lancet* 1991;338:450.
 223. M. Morigi, D. Macconi, E. Riccardi, P. Boccardo, P. Zilio, T. Bertani, G. Remuzzi. Platelet activating factor receptor blocking reduces proteinuria and improves survival in lupus autoimmune mice. *J Pharmacol Exp Ther* 1991;258:601-606.
 224. D. Boraschi, A. Rambaldi, A. Sica, P. Ghiara, F. Colotta, J.M. Wang, M. de Rossi, C. Zoja, G. Remuzzi, F. Bussolino, G. Scapigliati, A. Stoppacciaro, L. Ruco, A. Tagliabue, A. Mantovani. Endothelial cells express the IL-1 receptor type I. *Blood*

1991;78:1262-1267.

225. Gruppo Italiano per lo Studio della Nefrite Lupica (G.I.S.N.E.L.). Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. *Am J Kidney Dis* 1991;18:240-248.
226. N. Perico, C. Zoja, G. Remuzzi. Altered renovascular endothelial functions during nephrotoxicity. In: *Vascular endothelium: physiological basis of clinical problems*. Edited by J.D. Catravas, A.D. Callow, C.N. Gillis, U.S. Ryan, Plenum Publishing Corporation, New York, 1991, pp. 157-166.
227. N. Perico, R. Plata Cornejo, A. Benigni, B. Malanchini, J.R. Ladny, G. Remuzzi. Endothelin induces diuresis and natriuresis in the rat by acting on proximal tubular cells through a mechanism mediated by lipoxygenase products. *J Am Soc Nephrol* 1991;2:57-69.
228. E.M. Faioni, F. Franchi, A. Krachmalnicoff, C. Valsecchi, G.L. Viganò, G. Remuzzi, M. Mannucci. Low levels of the anticoagulant activity of protein C in patients with chronic renal insufficiency: an inhibitor of protein C is present in uremic plasma. *Thromb Hemost* 1991;66:420-425.
229. N. Perico, A. Remuzzi, O. Imberti, D. Cavallotti, T. Bertani, G. Remuzzi. Morphometrical analysis of glomerular changes induced by Cyclosporine in the rat. *Am J Kidney Dis* 1991;17:537-543.
230. F. Gaspari, L. Mainardi, P. Ruggenenti, G. Remuzzi. High performance liquid chromatographic analysis of iothalamic acid in human plasma and urine. *J Chromatogr* 1991;570:435-440.
231. Italian Collaborative Study. Multicenter randomized Italian study of low-dose aspirin for the prevention of pre-eclampsia and intrauterine growth retardation. *J Nephrol* 1991;2:127-129.
232. C. Zoja, M. Noris, D. Corna, G. Viganò, N. Perico, G. de Gaetano, G. Remuzzi. L-arginine, the precursor of nitric oxide, abolishes the effect of estrogens on bleeding time in experimental uremia. *Lab Invest* 1991;65:479-483.
233. N. Perico, M. Pasini, F. Gaspari, M. Abbate, G. Remuzzi. Co-participation of thromboxane A₂ and leukotriene C₄ and D₄ in mediating cyclosporine-induced acute renal failure. *Transplantation* 1991;52:873-878.
234. N. Perico, C.S. Amuchastegui, C. Zoja, A. Benigni, M. Morigi, G. Remuzzi. FK 506 does not affect the glomerular filtration rate and renal plasma flow in the rat. *Transplant Proc* 1991;23:3123-3125.
235. P. Ruggenenti, G. Remuzzi. Thrombotic Microangiopathies. In: *Critical Reviews in Oncology/Hematology* 1991;11:243-265.
236. Gruppo Italiano Studi Epidemiologici in Nefrologia (G.I.S.E.N.). Effect of

- recombinant human erythropoietin on renal function deterioration in patients with anemia and progressive renal failure. *J Nephrol* 1991;4:269-273.
237. Gruppo Italiano Studi Epidemiologici in Nefrologia (G.I.S.E.N.). A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. *J Nephrol* 1991;3:193-202.
 238. N. Perico, M. Rossini, O. Imberti, G. Remuzzi. Thymus-mediated immune tolerance to renal allografts donor but not tissue-specific. *J Am Soc Nephrol* 1991;2:1063-1071.
 239. G. Remuzzi, G. Viganò. Coagulation abnormalities in uremia. In: *Current therapy in nephrology and hypertension (3rd Edition)*. Edited by R.J. Glassock, B.C., Decker Inc, Philadelphia 1992, pp. 346-350.
 240. G. Viganò, G. Remuzzi. Coagulation abnormalities of patients with chronic renal failure. In: *Oxford Textbook of Clinical Nephrology*. Edited by J.S. Cameron, A.M. Davison, J.-P. Grunfeld, D.N. Kerr and E. Ritz, Oxford University Press, Oxford 1992, pp. 1361-1364.
 241. A. Benigni, P. Boccardo, M. Noris, G. Remuzzi, R.L. Siegler. Urinary excretion of platelet-activating factor in hemolytic uremic syndrome. *Lancet* 1992;339:835-836.
 242. N. Perico, M. Rossini, O. Imberti, B. Malanchini, R. Plata Cornejo, F. Gaspari, T. Bertani, G. Remuzzi. Thromboxane receptor blockade attenuates chronic cyclosporine nephrotoxicity and improves survival in rats with renal isograft. *J Am Soc Nephrol* 1992;2:1398-1404.
 243. F. Gaspari, L. Mosconi, G. Viganò, N. Perico, L. Torre, G. Virotta, C. Bertocchi, G. Remuzzi, P. Ruggenenti. Measurement of GFR with a single intravenous injection of nonradioactive iothalamate. *Kidney Int* 1992;41:1081-1084.
 244. C. Zoja, A. Remuzzi, D. Corna, N. Perico, T. Bertani, G. Remuzzi. Renal protective effect of angiotensin converting enzyme inhibition in aging rats. *Am J Med* 1992;92(Suppl 4B):60S-63S.
 245. N. Perico, A. Benigni, M. Gabanelli, A. Piccinelli, M. Rog, C. De Riva, G. Remuzzi. Atrial natriuretic peptide and prostacyclin act synergistically in mediating hyperfiltration and hyperperfusion of diabetic rats. *Diabetes* 1992;41:533-538.
 246. T. Barbui, A. Rambaldi, L. Parenzan, M. Zucchelli, N. Perico, G. Remuzzi. Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy. *Lancet* 1992;339:1421.
 247. C. Zoja, G. Remuzzi. Current indications and usefulness of antiplatelet agents in renal diseases. *Séminaires d'Uro-Néphrologie, Pitié-Salpêtrière*. Edited by C. Chatelain, Jacobs C.L. Masson, Paris 1992, pp. 76-79.
 248. G. Remuzzi, G.A. FitzGerald, C. Patrono. Thromboxane synthesis and action within the kidney. *Kidney Int* 1992;41:1483-1493.

249. M. Noris, A. Benigni, R. Siegler, F. Gaspari, F. Casiraghi, M.L. Mancini, G. Remuzzi. Renal prostacyclin biosynthesis is reduced in children with hemolytic uremic syndrome in the context of systemic platelet activation. *Am J Kidney Dis* 1992;20:144-149.
250. A. Schieppati, P. Ruggenenti, R. Plata Cornejo, F. Ferrario, G. Gregorini, P. Zucchelli, E. Rossi, G. Remuzzi. Renal function at hospital admission as a prognostic factor in adult haemolytic uraemic syndrome. *J Am Soc Nephrol* 1992;2:1640-1644.
251. C. Zoja, D. Corna, C. Farina, G. Sacchi, C. Lingwood, M.P. Doyle, V.V. Padhye, M. Abbate. Verotoxin glycolipid receptors determines the localization of microangiopathic process in rabbits challenged with Verotoxin-1. *J Lab Clin Med* 1992;120:229-238.
252. Gruppo Italiano per lo Studio della Nefrite Lupica (G.I.S.NE.L.). Lupus nephritis: Prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. *Am J Kidney Dis* 1992;19(5):473-479.
253. N. Perico, G. Remuzzi. Vascular Endothelin and Renal Disease Progression. *Contrib Nephrol* 1992;100:236-253.
254. S. Rota, A. Rambaldi, F. Gaspari, M. Noris, E. Daina, A. Benigni, A. Perna, R. Donadelli, G. Remuzzi, S. Garattini. Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis. *Kidney Int* 1992;42:981-990.
255. N. Perico, P. Ruggenenti, F. Gaspari, L. Mosconi, A. Benigni, C.S. Amuchastegui, F. Gasparini, G. Remuzzi. Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. *Transplantation* 1992;54:56-60.
256. D. Macconi, G. Viganò, G. Bisogno, M. Galbusera, S. Orisio, G. Remuzzi, M. Livio. Defective platelet aggregation in response to platelet activating factor in uremia associated with low platelet thromboxane A₂ generation. *Am J Kidney Dis* 1992;19:318-325.
257. C. Zoja, S. Bettoni, M. Morigi, G. Remuzzi, A. Rambaldi. Interleukin-1 regulates cytokine gene expression in human mesangial cells through the Interleukin-1 receptor type1. *J Am Soc Nephrol* 1992;2:1709-1715.
258. C. Zoja, A. Benigni, G. Remuzzi. The eicosanoids. In: *The Progressive Nature of Renal Disease*. Edited by J.H. Stein, W.M. Mitch (2nd edition), Churchill Livingstone, New York 1992, pp. 77-97.
259. Benfenati E, Perico N, Peterlongo F, Imberti O, Schieppati A, Remuzzi G. Analysis by fast atom bombardment mass spectrometry of phospholipids from tubuli, glomeruli, and urine of normal rats and rats with acute renal failure. *Biochem Med Metab Biol* 1992;48:219-226.
260. C. Zoja, G. Remuzzi. The pivotal role of the endothelial cell in the pathogenesis of

- HUS. In: *The Hemolytic Uremic Syndromes and Thrombotic Thrombocytopenic Purpura*. Edited by B.S. Kaplan, R.S. Trompeter, J.L. Moake, Marcel Dekker, New York 1992, pp. 389-404.
261. A. Remuzzi, B.M. Brenner, V. Pata, G. Tebaldi, R. Mariano, A. Belloro, G. Remuzzi. Three-dimensional reconstructed glomerular capillary network: blood flow distribution and local filtration. *Am J Physiol* 1992;263:F562-F572.
 262. A. Benigni, G. Remuzzi. Aspirin in hypertension of pregnancy. In: *International Yearbook of Nephrology 1993*. Edited by V.E. Andrecci and L.G. Fine, Springer-Verlag, New York 1992, pp. 93-105.
 263. A. Benigni, S. Orisio, F. Gaspari, T. Frusca, G. Amuso, G. Remuzzi. Evidence against a pathogenetic role for endothelin in preeclampsia. *Br J Obstet Gynecol* 1992;99:798-802.
 264. A. Remuzzi, S. Puntorieri, M. Alfano, D. Macconi, M. Abbate, T. Bertani, G. Remuzzi. Pathophysiologic implications of proteinuria in a rat model of progressive glomerular injury. *Lab Invest* 1992;67:572-579.
 265. G. Taraboletti, M. Morigi, M. Figliuzzi, R. Giavazzi, C. Zoja, G. Remuzzi. Thrombospondin induces glomerular mesangial cell adhesion and migration. *Lab Invest* 1992;67:566-571.
 266. A. Benigni, M. Morigi, N. Perico, C. Zoja, C.S. Amuchastegui, A. Piccinelli, R. Donadelli, G. Remuzzi. The acute effect of FK506 and Cyclosporine on endothelial cell function and renal vascular resistance. *Transplantation* 1992;54:775-780.
 267. N. Perico, M. Rossini, O. Imberti, G. Remuzzi. Evidence of the central role of the thymus in the induction of donor specific unresponsiveness to renal allograft. *Transplantation* 1992;54:943-945.
 268. S. Orisio, M. Morigi, C. Zoja, N. Perico, G. Remuzzi. Tumor necrosis factor stimulates endothelin-1 gene expression in cultured bovine endothelial cells. *Mediators Inflamm* 1992;1:263-266.
 269. G. Remuzzi, P. Ruggenenti. Plasma manipulation in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. *Ann Med Int* 1992;143(Suppl.1):19-26.
 270. N. Perico, C. Barbui, G. Remuzzi. Studies of privileged sites and organ transplantation. *Exp Nephrol* 1993;1:120-127.
 271. G. Remuzzi. Renal pathophysiology. (Editorial overview) *Curr Opin Nephrol Hypertens* 1993;2:597-601.
 272. G. Remuzzi. Introduction. *Exp Nephrol* 1993;1:69-71.
 273. N. Perico, G. Remuzzi. The possible role of endothelin in the process of progressive renal deterioration in experimental and human glomerulopathies. *Semin Nephrol*

1993;13:137-143.

274. G. Viganò, G. Remuzzi. Prevention and therapeutic management of bleeding in dialysis patients. In: *Dialysis Therapy*. Edited by A.R. Nissenson, R.N. Fine (2nd Ed), Vol. 9. Hanley & Belfus, Inc., Philadelphia 1993, pp. 124-128
275. G. Remuzzi, A. Schieppati, P. Ruggenenti, T. Bertani. Thrombotic Thrombocytopenic Purpura, Hemolytic-Uremic Syndrome, and Acute Cortical Necrosis. In: *Diseases of the Kidney*. Edited by R.W. Schrier, C.W. Gottschalk (Fifth Ed), Vol. 2. Little, Brown and Company, Boston 1993, pp. 2063-2094.
276. M. Abbate, D. Macconi, G. Remuzzi. Mechanisms of Glomerular Injury. In: *Toxicology of the Kidney*. Edited by J.B. Hook, R.S. Goldstein (2nd Ed), Raven Press, New York 1993, pp. 153-200.
277. M. Noris, A. Benigni, P. Boccardo, E. Gotti, E. Benfenati, S. Aiello, M. Todeschini, G. Remuzzi. Urinary excretion of platelet activating factor in patients with immune-mediated glomerulonephritis. *Kidney Int* 1993;43:426-429.
278. S. Orisio, A. Benigni, I. Bruzzi, D. Corna, N. Perico, C. Zoja, L. Benatti, G. Remuzzi. Renal endothelin gene expression is increased in remnant kidney and correlates with the disease progression. *Kidney Int* 1993;43:354-358.
279. G. Viganò, G. Remuzzi. Low dose aspirin and bleeding in uremia (Letter). *Am J Hematol* 1993;42:235-236
280. Italian Study of Aspirin in Pregnancy. Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. *Lancet* 1993;341:396-400.
281. P. Ruggenenti, N. Perico, L. Mosconi, F. Gaspari, A. Benigni, C.S. Amuchastegui, I. Bruzzi, G. Remuzzi. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. *Kidney Int* 1993;43:706-711.
282. N. Perico, M. Rossini, O. Imberti, M. Bontempelli, G. Remuzzi. Intrathymic transplantation of donor cells allows a stabilized incompatible renal transplant to survive indefinitely after cyclosporine withdrawal. *Exp Nephrol* 1993;1:185-189.
283. V. Gambarà, G. Mecca, G. Remuzzi, T. Bertani. Heterogeneous nature of renal lesions in type II diabetes. *J Am Soc Nephrol* 1993;3:1458-1466.
284. A. Benigni, G. Remuzzi. Mechanisms of Progression of Renal Disease and Possible Sites of Action of n-3 Fatty Acids. In: *n-3 Fatty Acids and Vascular Disease*. Edited by R. De Caterina, S. Endres, S.D. Kristensen, E.B. Schmidt, Springer-Verlag, London 1993, pp. 85-91.
285. C. Zoja, A. Rambaldi, G. Remuzzi. Interleukin-1 and glomerular mesangial cells. *Renal Physiol Biochem* 1993;16:89-92.

286. A. Remuzzi, P. Ruggenenti, L. Mosconi, V. Pata, G. Viberti, G. Remuzzi. Effect of low-dose enalapril on glomerular size-selectivity in human diabetic nephropathy. *J Nephrol* 1993;6:36-43.
287. G. Remuzzi, C. Zoja, T. Bertani. Glomerulonephritis. *Curr Opin Nephrol Hypertens* 1993;2:465-474.
288. M. Morigi, C. Zoja, M. Figliuzzi, G. Remuzzi, A. Remuzzi. Supernatant of endothelial cells exposed to laminar flow inhibits mesangial cell proliferation. *Am J Physiol* 1993;264:C1080-C1083.
289. S. Orisio, N. Perico, L. Benatti, L. Longaretti, C.S. Amuchastegui, G. Remuzzi. Renal cyclophilin-like protein gene expression parallels changes in sodium excretion in experimental nephrosis and is positively modulated by atrial natriuretic peptide. *J Am Soc Nephrol* 1993;3:1710-1716.
290. A. Schieppati, L. Mosconi, A. Perna, G. Mecca, T. Bertani, S. Garattini, G. Remuzzi. Prognosis of untreated patients with idiopathic membranous nephropathy. *N Engl J Med* 1993;329:85-89.
291. N. Perico, G. Remuzzi. Role of endothelin in glomerular injury. *Kidney Int* 1993;43:S76-S80.
292. P. Ruggenenti, M. Galbusera, R. Plata Cornejo, P. Bellavita, G. Remuzzi. Thrombotic thrombocytopenic purpura: Evidence that infusion rather than removal of plasma induces remission of the disease. *Am J Kidney Dis* 1993;21:314-318.
293. A. Schieppati, G. Remuzzi. Hypertension in renal disease: pathophysiological, functional, and clinical implications. Prevalence and significance of hypertension in systemic lupus erythematosus. *Am J Kidney Dis* 1993;21(Suppl.2)58-60.
294. D. Macconi, A.F. Zanolì, S. Orisio, L. Longaretti, L. Magrini, S. Rota, A. Radice, C. Pozzi, G. Remuzzi. Methylprednisolone normalizes superoxide anion production by polymorphs from patients with ANCA-positive vasculitides. *Kidney Int* 1993;44:215-220.
295. F. Gaspari, P. Ruggenenti, L. Torre, C. Bertocchi, G. Remuzzi, N. Perico. Failure to predict cyclosporine area under the curve using a limited sampling strategy. *Kidney Int* 1993;44:436-439.
296. M. Noris, A. Benigni, P. Boccardo, S. Aiello, F. Gaspari, M. Todeschini, M. Figliuzzi, G. Remuzzi. Enhanced nitric oxide synthesis in uremia: Implications for platelet dysfunction and dialysis hypotension. *Kidney Int* 1993;44:445-450.
297. A. Benigni, C. Zoja, D. Corna, S. Orisio, L. Longaretti, T. Bertani, G. Remuzzi. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. *Kidney Int* 1993;44:440-444.
298. A. Remuzzi, N. Perico, C.S. Amuchastegui, B. Malanchini, M. Mazerska, C.

- Battaglia, T. Bertani, G. Remuzzi. Short and long-term effect of Angiotensin II receptor blockade in rats with experimental diabetes. *J Am Soc Nephrol* 1993;4:40-49.
299. A. Gianviti, A. Perna, A. Caringella, A. Edefonti, R. Penza, G. Remuzzi, G. Rizzoni. Plasma exchange in children with hemolytic uremic syndrome at risk of poor outcome. *Am J Kidney Dis* 1993;22:264-266.
 300. M.H. Sayegh, N. Perico, O. Imberti, W.W. Hancock, C.B. Carpenter, G. Remuzzi. Thymic recognition of class II major histocompatibility complex allopeptides induces donor-specific unresponsiveness to renal allografts. *Transplantation* 1993;56:461-465.
 301. G. Remuzzi, A. Benigni. Endothelins in the control of cardiovascular and renal function. *Lancet* 1993;342:589-594.
 302. A. Benigni, P. Boccardo, M. Galbusera, J. Monteagudo, L. De Marco, G. Remuzzi, Z.M. Ruggeri. Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia. *Am J Kidney Dis* 1993;22:668-676.
 303. G. Remuzzi, P. Ruggenenti. Slowing the progression of diabetic nephropathy (Editorial). *N Engl J Med* 1993;329:1496-1497.
 304. G. Viganò, G. Remuzzi. Hemostatic effectiveness of desmopressin in the bleeding disorders of uremia. In: *Desmopressin in bleeding disorders*. Edited by G. Mariani, P.M. Mannucci, M. Cattaneo. Plenum Press, New York 1993, pp. 127-133.
 305. H.E. Abboud, F. P. Schena, J.J. Cohen, G. Striker, L. Gesualdo, L.G. Fine, L. Striker, E. Peten, N. Thomson, S. Cameron, A. Borsatti, V.E. Rubinkelly, G. Remuzzi. Growth factors in glomerulonephritis (Nephrology Forum). *Kidney Int* 1993;43:252-267.
 306. G. Remuzzi. Immunotherapeutic intervention in glomerular diseases. In: *The Handbook of Immunopharmacology*. Edited by C. Tetta. Academic Press Limited, London 1993, pp. 119-136.
 307. G. Remuzzi, T. Bertani, A. Schieppati. Idiopathic membranous nephropathy. *Lancet* 1993;342:1277-1280.
 308. P. Ruggenenti, G. Remuzzi. Haemolytic-Uraemic Syndrome and Thrombotic Thrombocytopenic Purpura. *J Vasc Med Rev* 1993;4:273-292.
 309. N. Perico, G. Remuzzi. Edema of the nephrotic syndrome: the role of the atrial peptide system. *Am J Kidney Dis* 1993;22:355-366.
 310. M. Noris, D. Macconi, V. Nanni, M. Salmona, M. Todeschini, G. Remuzzi. Defective glomerular [3H]lysoPAF metabolism in the autologous phase of rabbit nephrotoxic nephritis. *Kidney Int* 1993;44:747-754.
 311. N. Perico, G. Remuzzi. Renal handling of sodium in the nephrotic syndrome. *Am J Nephrol* 1993;13:413-421.

312. C. Zoja, A. Benigni, G. Piccinini, M. Figliuzzi, L. Longaretti, G. Remuzzi. Interleukin-6 stimulates gene expression of extracellular matrix components in bovine mesangial cells in culture. *Mediators Inflamm* 1993;2:429-433.
313. P. Ruggenenti, G. Remuzzi. Angiotensin converting enzyme inhibition in patients with impaired renal function: helpful or harmful? In: *ACE inhibition, Hypertension and Related Diseases*. Edited by T. Unger, C. Dal Palù. Sixth European Meeting on Hypertension, Milan, June 8. Media Medica Publications Ltd, Chichester, United Kingdom 1993, pp. 27-40.
314. S. De Cosmo, J. Walker, P. Ruggenenti, A. Benigni, G. Remuzzi. Glucose-induced changes in renal haemodynamics in proteinuric insulin-dependent diabetic patients: inhibition by acetylsalicylic acid infusion. *Diabetologia* 1993;36:622-627.
315. D. Ostermann, N. Perico, O. Imberti, C. Barbui, M. Bontempelli, G. Remuzzi. Colchicine allows prolonged survival of highly reactive renal allograft in the rat. *J Am Soc Nephrol* 1993;4:1294-1299.
316. G. Remuzzi, P. Ruggenenti, S.M. Mauer. Pancreas, and kidney/pancreas transplant: experimental medicine or real improvement? *Lancet* 1994;343:27-31.
317. A. Remuzzi, G. Remuzzi. Glomerular perm-selective function. *Kidney Int* 1994;45:398-402.
318. G. Remuzzi, P. Ruggenenti, T. Bertani. Thrombotic Microangiopathy. In: *Renal Pathology (2nd Edition)*. Edited by C.G. Tisher, B.M. Brenner. J.B. Lippincott Company, Philadelphia 1994, pp. 1154-1184.
319. G. Remuzzi, A. Benigni. Endothelin and renal disease progression. *Exp Nephrol* 1994;2:133.
320. G. Remuzzi. Glomerular hypertrophy and progression: summary and concluding remarks. *Kidney Int* 1994;45:S30-S31.
321. G. Remuzzi, P. Ruggenenti, M. Mauer. Kidney/pancreas transplantation. *Lancet* 1994;343:971-972.
322. G. Remuzzi, A. Schieppati, S. Garattini. Treatment of idiopathic membranous glomerulopathy. *Curr Opin Nephrol Hypertens* 1994;3:155-163.
323. M.H. Sayegh, N. Perico, L. Gallon, O. Imberti, W.W. Hancock, G. Remuzzi, C.B. Carpenter. Mechanisms of acquired thymic unresponsiveness to renal allografts. *Transplantation* 1994;58:125-132.
324. N. Perico, C.S. Amuchastegui, B. Malanchini, T. Bertani, G. Remuzzi. Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage. *Exp Nephrol* 1994;2:220-228.

325. G. Viganò, G. Remuzzi. Disorders of hemostasis in dialysis patients. In *The Principles and Practice of Dialysis*. Edited by W.L. Henrich. Williams & Wilkins, Baltimore 1994, pp. 287-296.
326. A. Benigni, G. Remuzzi. The role of eicosanoids in the pathogenesis of hemolytic uremic syndrome. *Prostaglandins Leukotr Essen Fatty Acids* 1994;51:75-79.
327. A. Benigni, G. Remuzzi. Inflammation and glomerular injury. *Springer Seminars in Immunopathology* 1994;16:39-51.
328. P. Ruggenenti, N. Perico, C.S. Amuchastegui, P. Ferrazzi, F. Mamprin, G. Remuzzi. Following an initial decline, glomerular filtration rate stabilizes in heart transplant patients on chronic cyclosporine. *Am J Kidney Dis* 1994;24:549-553.
329. G. Remuzzi, M. Noris, A. Benigni, O. Imberti, M.H. Sayegh, N. Perico. Thromboxane A2 receptor blocking abrogate donor specific unresponsiveness to renal allografts triggered by thymic recognition of histocompatibility allopeptides. *J Exp Med* 1994;180:1967-1972.
330. P. Ruggenenti, L. Mosconi, L. Bianchi, L. Cortesi, M. Campana, G. Pagani, G. Mecca. Long-term treatment with either enalapril or nitrendipine stabilizes albuminuria and increases glomerular filtration rate in non-insulin dependent diabetics. *Am J Kidney Dis* 1994;24:753-761.
331. N. Perico, C.S. Amuchastegui, V. Colosio, G. Sonzogni, T. Bertani, G. Remuzzi. Evidence that an angiotensin converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. *J Am Soc Nephrol* 1994;5:1139-1146.
332. S. Garattini, G. Remuzzi. Clinical Research Center for Rare Diseases Villa Camozzi. *Food and Drug Law Journal* 1994;49:1-6.
333. C.S. Amuchastegui, G. Remuzzi, N. Perico. Calcitonin gene-related peptide reduces renal vascular resistance and modulates endothelin-1 induced renal vasoconstriction. *Am J Physiol* 1994;267:F839-F844.
334. A. Remuzzi, O. Imberti, S. Puntorieri, B. Malanchini, D. Macconi, L. Magrini, T. Bertani, G. Remuzzi. Dissociation between antiproteinuric and antihypertensive effect of angiotensin converting enzyme inhibitors in rats. *Am J Physiol* 1994;267:F1034-F1044.
335. B. Ene Iordache, O. Imberti, C. Foglieni, G. Remuzzi, T. Bertani, A. Remuzzi. Effects of angiotensin-converting enzyme inhibition on glomerular capillary wall ultrastructure in MWF/Ztm rats. *J Am Soc Nephrol* 1994;5:1378-1384.
336. G. Remuzzi, C. Zoja, N. Perico. Proinflammatory mediators of glomerular injury and mechanisms of activation of autoreactive T cells. *Kidney Int* 1994;45(Suppl.44):S8-S16.

337. J.H. Joist, G. Remuzzi, P.M. Mannucci. Abnormal bleeding and thrombosis in renal disease. In: Hemostasis and Thrombosis (3rd edition). Edited by R.W. Colman, J. Hirsh, V.J. Marder, E.W. Salzman. J.B. Lippincott Company, Philadelphia 1994, pp. 921-935.
338. G. Remuzzi, C. Zoja. Endothelial cell physiology. Recent advances in verocytotoxin-producing *Escherichia coli* infections. Proceedings of 2nd International Symposium on Verocytotoxin. Edited by M.A. Karmali, A.G. Goglio. Bergamo June 27-30- Amsterdam, Elsevier Science 1994, pp. 309-316.
339. C. Zoja, M. Morigi, M. Foppolo, M. Figliuzzi, M.J. Gallego, M.A. Karmali, G. Remuzzi. Verotoxin-1 (VT-1 increases leukocyte adhesion to endothelial cells under dynamic flow conditions. Recent advances in verocytotoxin-producing *Escherichia coli* infections. Proceedings of 2nd International Symposium on Verocytotoxin. Edited by M.A. Karmali, A.G. Goglio. Bergamo June 27-30- Amsterdam, Elsevier Science 1994, pp. 329-332.
340. G. Remuzzi. Renal pathophysiology. (Editorial overview) *Curr Opin Nephrol Hypertens* 1994;3:431-435.
341. M. Galbusera, P. Ruggenti, M. Noris, M. Burnouf-Radosevich, A. Benigni, P.M. Mannucci, G. Remuzzi. Alpha1-antitrypsin therapy in a case of thrombotic thrombocytopenic purpura. *Lancet* 1995;345:224-225.
342. E. Akalin, W.W. Hancock, N. Perico, G. Remuzzi, O. Imberti, C.B. Carpenter, M.H. Sayegh. Blocking cell microtubule assembly inhibits the alloimmune response in vitro and prolongs renal allograft survival by inhibition of Th1 and sparing of Th2 cell function in vivo. *J Am Soc Nephrol* 1995;5:1418-1425.
343. N. Perico, O. Imberti, M. Bontempelli, G. Remuzzi. Toward novel antirejection strategies: in vivo immunosuppressive properties of CTLA4Ig. *Kidney Int* 1995;47:241-246.
344. G. Remuzzi, N. Perico, C.B. Carpenter, M.H. Sayegh. The thymic way to transplantation tolerance. *J Am Soc Nephrol* 1995;5:1639-1646.
345. M. Noris, M. Morigi, R. Donadelli, S. Aiello, M. Foppolo, M. Todeschini, S. Orisio, G. Remuzzi, A. Remuzzi. Nitric oxide synthesis by cultured endothelial cells is modulated by flow conditions. *Circ Res* 1995;76:536-543.
346. W. Laurens, C. Battaglia, C. Foglieni, R. De Vos, B. Malanchini, B. Van Damme, Y. Vanrenterghem, G. Remuzzi, A. Remuzzi. Direct podocyte damage in the single nephron leads to albuminuria in vivo. *Kidney Int* 1995;47:1078-1086.
347. A. Remuzzi, G. Remuzzi. The effects of nonsteroidal anti-inflammatory drugs on glomerular filtration of proteins and their therapeutic utility. *Semin Nephrol* 1995;15:236-243.

348. N. Perico, O. Imberti, M. Bontempelli, G. Remuzzi. Immunosuppressive therapy abrogates unresponsiveness to renal allograft induced by thymic recognition of donor antigens. *J Am Soc Nephrol* 1995;5:1618-1623.
349. M. Morigi, C. Zoja, M. Figliuzzi, M. Foppolo, G. Micheletti, M. Bontempelli, M. Saronni, G. Remuzzi, A. Remuzzi. Fluid shear stress modulates surface expression of adhesion molecules by endothelial cells. *Blood* 1995;85:1696-1703.
350. A. Remuzzi, A. Benigni, B. Malanchini, I. Bruzzi, C. Foglieni, G. Remuzzi. ACE inhibition prevents renal failure and death in uninephrectomized MWF/Ztm rats. *Kidney Int* 1995;47:1319-1326.
351. A. Remuzzi, M. Mazerska, G.N. Gephardt, A.C. Novick, B.M. Brenner, G. Remuzzi. Three-dimensional analysis of glomerular morphology in patients with subtotal nephrectomy. *Kidney Int* 1995;48:155-162.
352. G. Remuzzi, P. Ruggenenti. The hemolytic uremic syndrome. *Kidney Int* 1995;48:2-19.
353. M. Abbate, G. Remuzzi. Glomerulonephritis: from new knowledge on the mechanisms of tissue damage to novel therapies. *Curr Opin Nephrol Hypertens* 1995;4:374-382.
354. G. Remuzzi. Abnormal protein traffic through the glomerular barrier induces proximal tubular cell dysfunction and causes renal injury (Editorial Review). *Curr Opin Nephrol Hypertens* 1995;4:339-342.
355. A. Benigni, G. Remuzzi. Endothelin in the progressive renal disease of glomerulopathies. *Miner Electrolyte Metab* 1995;21:283-291.
356. C. Zoja, G. Remuzzi. The role of the endothelium in thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome. In: *Immunological Aspects of the Vascular Endothelium*. Edited by D.B.G. Oliveira, D.K. Peters, A.P. Weetman. Cambridge University Press, Cambridge 1995, pp. 213-232.
357. M. Abbate, G. Remuzzi. Innovative strategies for pharmacological intervention in immune damage to the kidney. *Nephrol Dial Transplant* 1995;10:1131-1136.
358. C. Zoja, G. Remuzzi. Interleukin-6 and Interleukin-8 as potential inflammatory mediators of injury in renal diseases. In: *Molecular Nephrology Kidney Function in Health and Disease*. Edited by D. Schlondorff and J.V. Bonventre. Marcel Dekker Inc. New York 1995;617-630.
359. M. Noris, G. Remuzzi. New insights into circulating cell-endothelium interactions and their significance for glomerular pathophysiology. *Am J Kidney Dis* 1995;26:541-548.
360. G. Remuzzi, E. Gotti. Clinical Problem Solving: The girl with the curl. *N Engl J Med* 1995;333:928-931.

361. G. Remuzzi, N. Perico. Immunotolerance: from new knowledges on mechanisms of self tolerance to future perspectives for transplant tolerance induction. *Exp Nephrol* 1995;3:319-330.
362. G. Viganò, G. Remuzzi. Bleeding and coagulation abnormalities. In: *Textbook of Nephrology*. Edited by S.G. Massry, R.J. Glasscock (3rd Edition). Vol. 2, Williams & Wilkins, Baltimore 1995, pp. 1373-1378.
363. P. Ruggenenti, G. Remuzzi. Preeclampsia/Eclampsia. In: *The Principles and Practice of Nephrology*. Edited by H.R. Jacobson, S. Klahr, G.E. Striker (2nd Edition). Mosby-Year Book Inc, Saint Louis 1995, pp. 436-440.
364. P. Ruggenenti, G. Remuzzi. Management of hypertension and hypertensive emergency in pregnancy. In: *The Principles and Practice of Nephrology*. Edited by H.R. Jacobson, S. Klahr, G.E. Striker (2nd Edition). Mosby-Year Book Inc, Saint Louis 1995, pp. 474-478.
365. F. Gaspari, N. Perico, P. Ruggenenti, L. Mosconi, C.S. Amuchastegui, E. Guerini, E. Daina, G. Remuzzi. Plasma clearance of nonradioactive iothexol as a measure of glomerular filtration rate. *J Am Soc Nephrol* 1995;6:257-263.
366. D. Macconi, M. Foppolo, S. Paris, M. Noris, S. Aiello, G. Remuzzi, A. Remuzzi. PAF mediates neutrophil adhesion to thrombin or TNF-stimulated endothelial cells under shear stress. *Am J Physiol* 1995;269:C42-C47.
367. P. Ruggenenti, G. Remuzzi. Treatment of thrombotic microangiopathy. *J Nephrol* 1995;8:255-272.
368. C. Zoja, G. Remuzzi. Role of platelets in progressive glomerular diseases. *Pediatr Nephrol* 1995;9:495-502.
369. G. Remuzzi, N. Perico. Cyclosporine-induced renal dysfunction in experimental animals and humans. *Kidney Int* 1995;48(Suppl. 52):S70-S74.
370. P. Ruggenenti, G. Remuzzi. Anti-hypertensive agents and incipient diabetic nephropathy. In: *The Diabetes Annual/9*. Edited by S.M. Marshall, P.D. Home, R.A. Rizza. Elsevier Science B.V., Amsterdam, The Netherlands 1995, pp. 295-317.
371. C. Zoja, M. Morigi, M. Figliuzzi, I. Bruzzi, S. Oldroyd, A. Benigni, P. Ronco, G. Remuzzi. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. *Am J Kidney Dis* 1995;26:934-941.
372. G. Remuzzi, P. Ferrazzi, M. Bontempelli, M. Senni, M. Glauber, P. Ruggenenti, N. Perico. Preliminary results of intrathymic injection of donor cells to prevent acute rejection in human heart transplantation. *J Am Soc Nephrol* 1995;6:1291-1294.
373. A. Benigni, C. Zoja, G. Remuzzi. The renal toxicity of sustained glomerular protein traffic. *Lab Invest* 1995;73:461-468.

374. M. Morigi, G. Micheletti, M. Figliuzzi, B. Imberti, M.A. Karmali, A. Remuzzi, G. Remuzzi, C. Zoja. Verotoxin-1 promotes leukocyte adhesion to cultured endothelial cells under physiologic flow conditions. *Blood* 1995;86:4553-4558.
375. M. Noris, S. Bernasconi, F. Casiraghi, S. Sozzani, E. Gotti, G. Remuzzi, A. Mantovani. Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. *Lab Invest* 1995;73:804-809.
376. G. Remuzzi, E.C. Rossi. Hematological Consequences of Renal Failure. In: *The Kidney*. Edited by B.M. Brenner, F.C. Rector Jr. (5th Edition). W.B. Saunders Company, Philadelphia 1996, pp. 2170-2186.
377. A. Remuzzi, B. Malanchini, C. Battaglia, T. Bertani, G. Remuzzi. Comparison of the effects of ACE inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats. *Exp Nephrol* 1996;4:19-25.
378. G. Remuzzi, M. Galbusera, M. Salvadori, G. Rizzoni, S. Paris, P. Ruggenenti. Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma. *Kidney Int* 1996;49:282-286.
379. A. Perna, G. Remuzzi. Abnormal permeability to proteins and glomerular lesions: A meta-analysis of experimental and human studies. *Am J Kidney Dis* 1996;27:34-41.
380. P. Ruggenenti, G. Remuzzi. Malignant vascular disease of the kidney: nature of the lesions, mediators of disease progression, and the case for bilateral nephrectomy. *Am J Kidney Dis* 1996;27:459-475.
381. A. Benigni, C. Zoja, D. Corna, S. Orisio, D. Facchinetti, L. Benatti, G. Remuzzi. Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. *Am J Kidney Dis* 1996;27:416-423.
382. A. Benigni, G. Remuzzi. Glomerular protein trafficking and progression of renal disease to terminal uremia. *Semin Nephrol* 1996;16:151-159.
383. G. Remuzzi, A. Perna, A. Benigni. Proteins abnormally filtered throughout glomerular capillary have an intrinsic renal toxicity. Edited by H. Koide, I. Ichikawa. *Progression of Chronic Renal Diseases*. Contrib Nephrol. Basel Karger, 1996, 118:pp. 164-172.
384. N. Perico, A. Detcheva, E.I. Khalil, G. Remuzzi. Cyclosporine induces glomerulosclerosis: three-dimensional definition of the lesions in a rat model of renal transplant. *Kidney Int* 1996;49:1283-1288.
385. P. Ruggenenti, G. Remuzzi. The pathophysiology and management of thrombotic thrombocytopenic purpura. *Eur J Haematol* 1996;56:191-207.
386. M. Noris, P. Ruggenenti, M. Todeschini, M. Figliuzzi, D. Macconi, C. Zoja, S. Paris, F. Gaspari, G. Remuzzi. Increased nitric oxide formation in recurrent thrombotic microangiopathies: a possible mediator of microvascular injury. *Am J Kidney Dis*

1996;27:790-796.

- 387. L. Mosconi, P. Ruggenti, A. Perna, G. Mecca, G. Remuzzi. Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. *Kidney Int* 1996;49(Suppl. 55): S91-S93.
- 388. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. *Transplantation* 1996;61:1029-1037.
- 389. N. Perico, D. Ostermann, M. Bontempelli, M. Morigi, C.S. Amuchastegui, C. Zoja, E. Akalin, M.H. Sayegh, G. Remuzzi. Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T-cell activation. *J Am Soc Nephrol* 1996;7:594-601.
- 390. M.J. Gallego, C. Zoja, M. Morigi, G. Micheletti, B. Imberti, M. Foppolo, A. Remuzzi, G. Remuzzi. Cyclosporine enhances leukocyte adhesion to vascular endothelium under physiologic flow conditions. *Am J Kidney Dis* 1996;28:23-31.
- 391. G. Viganò, A. Schieppati, G. Remuzzi. Thrombogenesis and anticoagulation in patients undergoing chronic hemodialysis. In: *Replacement of renal function by dialysis*. Edited by C. Jacobs, C.M. Kjellstrand, K.M. Koch, J.F. Winchester (4th Edition). Kluwer, Dordrecht, The Netherlands 1996, pp. 323-332.
- 392. C. Zoja, D. Corna, I. Bruzzi, C. Foglieni, T. Bertani, G. Remuzzi, A. Benigni. Passive Heymann nephritis: Evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury. *Exp Nephrol* 1996;4:213-221.
- 393. N. Perico, S. Amuchastegui, M. Bontempelli, G. Remuzzi. CTLA4Ig alone or in combination with low-dose cyclosporine fails to reverse acute rejection of renal allograft in the rat. *Transplantation* 1996;61:1320-1322.
- 394. R. Lapinski, N. Perico, A. Remuzzi, F. Sangalli, A. Benigni, G. Remuzzi. Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. *J Am Soc Nephrol* 1996;7:653-660.
- 395. A. Perna, E. Gotti, E. de Bernardis, N. Perico, G. Remuzzi. A logistic-regression model provides novel guidelines to maximize the anti-acute rejection properties of cyclosporine with a minimum of toxicity. *J Am Soc Nephrol* 1996;7:786-791.
- 396. M. Noris, A. Benigni, G. Remuzzi. The role of vasoactive molecules of endothelial origin in the pathophysiology of normal pregnancy and pregnancy-induced hypertension (Editorial Review). *Curr Opin Nephrol Hypertens* 1996;5:347-352.
- 397. A. Schieppati, E. Daina, B. Vasile, G. Remuzzi, S. Garattini. A clinical research center for rare diseases. *J Rare Dis* 1996;11:7-12.
- 398. A. Del Favero, G. Barro, G. Vicari, F. Rovelli, G. Tognoni, L. Bozzini, N. Martini, L. Pagliaro, S. Garattini, G. Remuzzi Country Profile Italy. *Lancet* 1996;348:167-175.

399. M. Noris, G. Remuzzi. Evidence for a role of nitric oxide in hypertension and in renal disease in man. In: Contributions to Nephrology: Clinical Hypertension in Nephrology. Edited by C. Zoccali. Basel, Karger 1996, 119 pp. 8-15.
400. G. Remuzzi. Role of endothelin in the development of glomerulosclerosis. *Kidney & Blood Press Res* 1996;19:182-183.
401. G. Piccinini, F. Gaspari, O. Signorini, G. Remuzzi, N. Perico. Recovery of blood mononuclear cell calcineurin activity segregates two populations of renal transplant patients with different sensitivities to cyclosporine inhibition. *Transplantation* 1996;61:1526-1531.
402. M. Abbate, G. Remuzzi. Acceleration of recovery in acute renal failure: from cellular mechanisms of tubular repair to innovative targeted therapies. *Renal Failure* 1996;18(3):377-388.
403. G. Viganò, G. Remuzzi. Bleeding time in uremia. *Seminars in Dialysis* 1996;9:34-38.
404. N. Perico, G. Remuzzi. New antirejection drugs. *Exp Opin Ther Patents* 1996;6(9):871-891.
405. G. Finazzi, G. Remuzzi. Heparin-induced thrombocytopenia-background and implications for haemodialysis. *Nephrol Dial Transplant* 1996;11:2120-2122.
406. G. Remuzzi. Introductory Editorial. *Exp Nephrol* 1996;4(Suppl. 1):1.
407. P. Ruggenenti, G. Remuzzi. The renoprotective action of angiotensin-converting enzyme inhibitors in diabetes. *Exp Nephrol* 1996;4(Suppl. 1):53-60.
408. A. Schieppati, G. Remuzzi. The year of the pores. *Lancet* 1996;348 (Suppl. 2):13.
409. E. Gotti, F. Suter, S. Baruzzo, V. Perani, F. Moioli, G. Remuzzi. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia. *Clin Transplantation* 1996;10:550-555.
410. F. Gaspari, E. Guerini, N. Perico, L. Mosconi, P. Ruggenenti, G. Remuzzi. Glomerular filtration rate determined from a single plasma sample after intravenous iohexol injection: is it reliable? *J Am Soc Nephrol* 1996;7:2689-2693.
411. N. Perico, S. Amuchastegui, M. Bontempelli, G. Remuzzi. The kidney triggers graft-versus-host disease in experimental combined transplantation of kidney and stem cell-enriched peripheral leukocytes. *J Am Soc Nephrol* 1996;7:2254-2258.
412. T. Bertani, V. Gambarà, G. Remuzzi. Structural basis of diabetic nephropathy in microalbuminuric NIDDM patients: a light microscopy study. *Diabetologia* 1996;39:1625-1628.

413. P. Ruggenenti, A. Schieppati, T. Bertani, G. Remuzzi. Thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, and acute cortical necrosis. In: Diseases of the Kidney. Edited by R.W. Schrier and C.W. Gottschalk (6th Edition) Vol. II. Little, Brown and Company, Boston 1997, pp. 1823-1850.
414. E. Gotti, G. Remuzzi. Post-transplant Kaposi's Sarcoma. *J Am Soc Nephrol* 1997;8:130-137.
415. C. Zoja, G. Remuzzi. Coagulation and thrombosis in immunologic renal diseases. In: Immunologic Renal Diseases: Edited by E.G. Neilson, W.G. Couser. Lippincott-Raven Publishers, Philadelphia 1997, pp. 489-496.
416. A. Benigni, G. Remuzzi. The renoprotective potential of endothelin receptor antagonists. *Exp Opin Ther Patents* 1997;7(2):139-149.
417. N. Perico, G. Remuzzi. Xenotransplantation: problems and prospects. *Nephrol Dial Transplant* 1997;12(1):59-64.
418. C. Zoja, R. Donadelli, D. Corna, D. Testa, D. Facchinetti, R. Maffi, E. Luzzana, V. Colosio, T. Bertani, G. Remuzzi. The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: Evidence based on comparative studies with a receptor antagonist. *Am J Kidney Dis* 1997;29:254-264.
419. G. Remuzzi, P. Ruggenenti, A. Benigni. Understanding the nature of renal disease progression. *Kidney Int* 1997;51:2-15.
420. P. Ruggenenti, G. Remuzzi. The diagnosis of renal involvement in non-insulin-dependent diabetes mellitus. *Curr Opin Nephrol Hypertens* 1997;6:141-145.
421. G. Remuzzi, A. Benigni. Progression of proteinuric diabetic and nondiabetic renal diseases: A possible role for renal endothelin. *Kidney Int* 1997;51(Suppl. 58):S66-S68.
422. P. Ruggenenti, J. Lutz, G. Remuzzi. Pathogenesis and treatment of thrombotic microangiopathy. *Kidney Int* 1997;51(Suppl. 58):S97-S101.
423. D. Corna, M. Morigi, D. Facchinetti, T. Bertani, C. Zoja, G. Remuzzi. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. *Kidney Int* 1997;51:1583-1589.
424. P. Ruggenenti, G. Remuzzi. Hypertension and Renal Disease. In: International Handbook of Hypertension. Edited by R. Campbell and G.S. Francis. Warwick Printing Company Ltd., United Kingdom 1997, pp. 37-52.
425. A. Schieppati, A. Perna, G. Remuzzi. Recent developments in the management of membranous nephropathy. *Exp Opin Invest Drugs* 1997;6(5):521-532.
426. C. Zoja, X-H. Liu, R. Donadelli, M. Abbate, D. Testa, D. Corna, G. Taraboletti, A.

- Vecchi, Q.G. Dong, B.J. Rollins, T. Bertani, G. Remuzzi. Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice. *J Am Soc Nephrol* 1997;8:720-729.
427. C. Zoja, M. Morigi, S. Angioletti, G. Remuzzi, G. Corbetta. Effect of intravenous immunoglobulins (Sandoglobulin) on leukocyte-endothelium interaction under flow conditions. 4th International Congress on 'The Immune Consequences of Trauma, Shock and Sepsis'. Edited by Monduzzi Editore. Munich (Germany), March 4-8, 1997, pp. 781-785.
 428. P. Ruggenenti, A. Perna, L. Mosconi, M. Matalone, G. Garini, M. Salvadori, C. Zoccali, F. Scolari, Q. Maggiore, G. Tognoni, G. Remuzzi (for The GISEN Group). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. *Lancet* 1997;349:1857-1863.
 429. S. Aiello, M. Noris, M. Todeschini, S. Zappella, C. Foglieni, A. Benigni, D. Corna, C. Zoja, D. Cavallotti, G. Remuzzi. Renal and systemic nitric oxide synthesis in rats with renal mass reduction. *Kidney Int* 1997;52:171-181.
 430. J.M. MacLeod, K.E. White, H. Tate, R.W. Bilous, on behalf of the European Study of the Progression of Renal Disease in Type 1 (Insulin Dependent) Diabetes (ESPRIT) Study Group (G. Remuzzi, P. Ruggenenti). Efficient morphometric analysis of glomerular mesangium in insulin-dependent diabetic patients with early nephropathy. *Kidney Int* 1997;51:1624-1628.
 431. I. Bruzzi, G. Remuzzi, A. Benigni. Endothelin: A mediator of renal disease progression. *J. Nephrol* 1997;10:179-183.
 432. F. Gaspari, M.F. Anedda, O. Signorini, G. Remuzzi, N. Perico. Prediction of cyclosporine area under the curve using a three-point sampling strategy after neoral administration. *J Am Soc Nephrol* 1997;8:647-652.
 433. G. Remuzzi, A. Schieppati. Dearing-a report to be embraced. *Lancet* 1997;350:308.
 434. M. Abbate, G. Remuzzi. The glomerulus: Mechanisms of injury. In: *Comprehensive Toxicology*. Edited by R.S. Goldstein. Elsevier Science Limited, Oxford UK 1997, pp. 213-243.
 435. P. Ruggenenti, G. Remuzzi. Angiotensin-converting enzyme inhibitor therapy for non-diabetic progressive renal disease. *Curr Opin Nephrol Hypertens* 1997;6:489-495.
 436. N. Perico, R. Lapinski, K. Konopka, S. Aiello, M. Noris, G. Remuzzi. Platelet-activating factor mediates angiotensin II-induced proteinuria in isolated perfused rat kidney. *J Am Soc Nephrol* 1997;8:1391-1398.
 437. A. Boletta, A. Benigni, J. Lutz, G. Remuzzi, M.R. Soria, L. Monaco. Nonviral gene delivery to the rat kidney with polyethylenimine. *Human Gene Therapy* 1997;8:1243-1251.

438. N. Perico, G. Remuzzi. Prevention of transplant rejection. Current treatment guidelines and future developments. *Drugs* 1997;54:533-570.
439. M. Galbusera, C. Zoja, R. Donadelli, S. Paris, M. Morigi, A. Benigni, M. Figliuzzi, G. Remuzzi, A. Remuzzi. Fluid shear stress modulates von Willebrand Factor release from human vascular endothelium. *Blood* 1997;90:1558-1564.
440. N. Perico, G. Remuzzi. Acquired transplant tolerance. *Int J Clin Lab Res* 1997;27:165-177.
441. P. Ruggenenti, A. Perna, G. Remuzzi, on behalf of the GISEN Group. Ramipril in non-diabetic renal failure (REIN Study) (Correspondence). *Lancet* 1997;350:736-737.
442. S. Aiello, M. Noris, G. Remuzzi. Nitric oxide synthesis and L-arginine in uremia. *Miner Electrolyte Metab* 1997;23:151-156.
443. I. Bruzzi, A. Benigni, G. Remuzzi. Role of increased glomerular protein traffic in the progression of renal failure. *Kidney Int* 1997;52(Suppl. 62):S29-S31.
444. I. Bruzzi, D. Corna, C. Zoja, S. Orisio, E.L. Schiffrin, D. Cavallotti, G. Remuzzi, A. Benigni. Time course and localization of endothelin-1 gene expression in a model of renal disease progression. *Am J Pathol.* 1997;151:1241-1247.
445. F. Gaspari, N. Perico, G. Remuzzi. Measurement of glomerular filtration rate. *Kidney Int.* 1997;52(Suppl. 63):S151-S154.
446. P. Ruggenenti, A. Perna, L. Mosconi, M. Matalone, R. Pisoni, F. Gaspari, G. Remuzzi, on behalf of the "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. *Kidney Int* 1997;52(Suppl. 63):S54-S57.
447. A. Benigni, I. Bruzzi, G. Remuzzi. The role of protein traffic. ACE Inhibition and Renoprotection. Proceedings of the Symposium held at Sydney on May 24, 1997. Euromed Communications Ltd, U.K.1997, pp. 39-51.
448. P. Ruggenenti, A. Perna, L. Mosconi, M. Matalone, R. Pisoni, F. Gaspari, G. Remuzzi on behalf of the "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). The REIN study. ACE Inhibition and Renoprotection. Proceedings of the Symposium held at Sydney on May 24, 1997. Euromed Communications Ltd, U.K.1997, pp. 73-81.
449. M. Noris, G. Remuzzi. A putative role of NO and oxidant injury in the pathogenesis of hemolytic uremic syndrome. In: Nitric oxide and the kidney. Physiology and Pathophysiology. Edited by M.S. Goligorsky, S.S. Gross. Chapman & Hall, New York, NY 1997, pp. 418-427.
450. N. Perico, A. Benigni, M. Noris, G. Remuzzi. Vasoactive mediators in blood pressure control and the regulation of renal function. In: Nephrology, Edited by R.L. Jamison

and Wilkinson R. Chapman & Hall, London 1997, pp. 150-168.

451. D. Macconi, W. Laurens, S. Paris, C. Battaglia, T. Bertani, G. Remuzzi, A. Remuzzi. Selective dietary restriction of protein and calorie intakes prevents spontaneous proteinuria in male MWF rats. *Exp Nephrol* 1997;5:404-413.
452. F. Casiraghi, P. Ruggenenti, M. Noris, G. Locatelli, N. Perico, A. Perna, G. Remuzzi. Sequential monitoring of urine-soluble interleukin 2 receptor and interleukin 6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunction. *Transplantation* 1997;63:1508-1514.
453. G. Viganò, M. Noris, G. Remuzzi. Coagulation disorders. In: *Oxford Textbook of Clinical Nephrology* (2nd Edition). Edited by A.M. Davison, J.S. Cameron, J-P. Grunfeld, D.N.S. Kerr, E. Ritz. Oxford University Press, Oxford, New York 1998, pp. 1989-1995.
454. A. Benigni, G. Remuzzi. Endothelin receptor antagonists: which are the therapeutic perspectives in renal diseases? (Editorial Comments). *Nephrol Dial Transplant* 1998;13:5-7.
455. P. Ruggenenti, F. Gaspari, A. Perna, G. Remuzzi. Cross sectional longitudinal study of spot morning urine protein: creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. *Br Med J* 1998;316:504-509.
Correction: *Br Med J* 1998;317:1491.
456. F. Gaspari, N. Perico, M. Matalone, O. Signorini, N. Azzollini, M. Mister, G. Remuzzi. Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease. *J Am Soc Nephrol* 1998;9:310-313.
457. P. Ruggenenti, G. Remuzzi, on behalf of the Bergamo Diabetic Nephropathy Study Group. Primary prevention of renal failure in diabetic patients: the Bergamo Nephrologic Diabetes Complication Trial. *J Hypertens* 1998;16(Suppl. 1):S95-S97.
458. A. Remuzzi, A. Fassi, F. Sangalli, B. Malanchini, E.I. Mohamed, T. Bertani, G. Remuzzi. Prevention of renal injury in diabetic MWF rats by angiotensin II antagonism. *Exp Nephrol* 1998;6:28-38.
459. P. Ruggenenti, G. Remuzzi. Thrombotic microangiopathy. In: *Suki and Massry's Therapy of Renal Diseases and Related Disorders* (3rd Edition). Edited by W.N. Suki, S.G. Massry. Kluwer Academic Publishers, Boston 1998, pp. 513-527.
460. C. Zoja, D. Corna, G. Benedetti, M. Morigi, R. Donadelli, A. Guglielmotti, M. Pinza, T. Bertani, G. Remuzzi. Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. *Kidney Int* 1998;53:726-734.
461. G. Remuzzi. Cellular basis of long-term organ transplant acceptance: pivotal role of intrathymic clonal deletion and thymic dependence of bone marrow microchimerism-associated tolerance. *Am J Kidney Dis* 1998;31:197-212.

462. H. Dieperink, N. Perico, F.T. Nielsen, G. Remuzzi. Cyclosporine/tacrolimus (FK-506). In: Clinical Nephrotoxins: Renal Injury from Drugs and Chemicals. Edited by M.E. De Broe, G.A. Porter, W.M. Bennett, G.A. Verpooten. Kluwer Academic Publishers, Dordrecht, The Netherlands 1998, pp. 275-300.
463. A. Benigni, V. Colosio, C. Brena, I. Bruzzi, T. Bertani, G. Remuzzi. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. *Diabetes* 1998;47:450-456.
464. G. Crepaldi, Q. Carta, G. Deferrari, R. Mangili, R. Navalesi, F. Santeusano, A. Spalluto, A. Vanasia, G.M. Villa, R. Nosadini & The Italian Microalbuminuria Study Group in IDDM. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. *Diabetes Care* 1998;21:104-110.
465. M. Morigi, C. Zoja, S. Colleoni, S. Angioletti, B. Imberti, A. Remuzzi, G. Remuzzi. Xenogeneic human serum promotes leukocyte adhesion to porcine endothelium under flow conditions, possibly through the activation of the transcription factor NF-kB. *Xenotransplantation* 1998;5:57-60.
466. C. Zoja, M. Abbate, D. Corna, M. Capitanio, R. Donadelli, I. Bruzzi, S. Oldroyd, A. Benigni, G. Remuzzi. Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF- β in experimental mesangioproliferative glomerulonephritis. *Am J Kidney Dis* 1998;31:453-463.
467. P. Ruggenenti, A. Perna, L. Mosconi, M. Matalone, R. Pisoni, F. Gaspari, G. Remuzzi on behalf of the "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). The nephroprotective effect of ACE inhibitors. Results of the ramipril efficacy in nephropathy (REIN) study. ACE Inhibition and Target Organ Protection. Proceedings of the Symposium held at Milan on June 12, 1997. Euromed Communications Ltd, U.K 1998, pp. 87-94.
468. S. Aiello, G. Remuzzi, M. Noris. Nitric oxide/endothelin balance after nephron reduction. *Kidney Int* 1998;53(Suppl. 65):S63-S67.
469. C. Zoja, X-H Liu, M. Abbate, D. Corna, E.L. Schiffrin, G. Remuzzi, A. Benigni. Angiotensin II blockade limits tubular protein overreabsorption and the consequent upregulation of endothelin 1 gene in experimental membranous nephropathy. *Exp Nephrol* 1998;6:121-131.
470. G. Remuzzi, P. Ruggenenti. The hemolytic uremic syndrome. *Kidney Int* 1998;53 (Suppl. 66):S54-S57.
471. M. Noris, G. Remuzzi. Are HUS and TTP genetically determined? (Editorial). *Kidney Int* 1998;53:1085-1086.
472. P. Ruggenenti, A. Perna, L. Mosconi, R. Pisoni, G. Remuzzi, on behalf of the (GISEN). Urinary protein excretion rate is the best independent predictor of ESRF in

- non-diabetic proteinuric chronic nephropathies. *Kidney Int* 1998;53:1209-1216.
473. M. Morigi, S. Angioletti, B. Imberti, R. Donadelli, G. Micheletti, M. Figliuzzi, A. Remuzzi, C. Zoja, G. Remuzzi. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF- κ B-dependent fashion. *J Clin Invest* 1998;101:1905-1915.
 474. C. Zoja, R. Donadelli, S. Colleoni, M. Figliuzzi, S. Bonazzola, M. Morigi, G. Remuzzi. Protein overload stimulates RANTES production by proximal tubular cells depending on NF- κ B activation. *Kidney Int* 1998;53:1608-1615.
 475. A. Benigni, G. Remuzzi. Transplant tolerance: will genes protect the graft? (Commentary). *Lancet* 1998;351:1749-1751.
 476. S. Tomasoni, M. Noris, S. Zappella, E. Gotti, F. Casiraghi, S. Bonazzola, A. Benigni, G. Remuzzi. Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis. *J Am Soc Nephrol* 1998;9:1202-1212.
 477. M. Abbate, C. Zoja, D. Corna, M. Capitanio, T. Bertani, G. Remuzzi. In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. *J Am Soc Nephrol* 1998;9:1213-1224.
 478. G. Remuzzi, N. Perico. Protecting single-kidney allografts from long-term functional deterioration. *J Am Soc Nephrol* 1998;9:1321-1332.
 479. R. Donadelli, L. Benatti, A. Remuzzi, M. Morigi, S.R. Gullans, A. Benigni, G. Remuzzi, M. Noris. Identification of a novel gene -SSK1- in human endothelial cells exposed to shear stress. *Biochem Biophys Res Commun* 1998;246:881-887.
 480. A. Fassi, F. Sangalli, R. Maffi, F. Colombi, E.I. Mohamed, B.M. Brenner, G. Remuzzi, A. Remuzzi. Progressive glomerular injury in the MWF rat is predicted by inborn nephron deficit. *J Am Soc Nephrol* 1998;9:1399-1406.
 481. G. Remuzzi. Xenotransplantation: a challenge for the future of transplant medicine. *Schweiz Med Wochenschr* 1998;128:952-960.
 482. A. Benigni, D. Corna, R. Maffi, G. Benedetti, C. Zoja, G. Remuzzi. Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. *Kidney Int* 1998;54:353-359.
 483. G. Remuzzi, P. Boccardo. Coagulation abnormalities. In: *Current Therapy in Nephrology and Hypertension* (4th Edition). Edited by R.J. Glasscock. Mosby-Year Book, Inc. Philadelphia, USA 1998, pp. 306-309.
 484. G. Remuzzi, P. Ruggenenti. Prognosis of diabetic nephropathy: how to improve the outcome. *Diabetes Res Clin Pract* 1998;39(Suppl.):S49-S53.
 485. P. Boccardo, G. Remuzzi. Hemostasis in renal failure. *Intensivmed* 1998;35:382-389.

486. S.C. Amuchastegui, N. Azzollini, M. Mister, A. Pezzotta, N. Perico, G. Remuzzi. Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. *J Am Soc Nephrol* 1998;9:1948-1955.
487. A. Benigni, G. Remuzzi. Mechanism of progression of renal disease: growth factors and related mechanisms. *J Hypertens* 1998;16(Suppl. 4):S9-S12.
488. G. Remuzzi, L. Minetti. Anemia and coagulopathy. In: *Therapy in Nephrology and Hypertension: A companion to Brenner and Rector's The Kidney* (1st Edition). Edited by H.R. Brady, C.S. Wilcox. W.B. Saunders Company, Philadelphia 1999, pp. 480-487.
489. P. Ruggenenti, G. Remuzzi. Thrombotic Microangiopathy. In: *Therapy in Nephrology and Hypertension: A companion to Brenner and Rector's The Kidney* (1st Edition). Edited by H.R. Brady, C.S. Wilcox. W.B. Saunders Company, Philadelphia 1999, pp. 225-231.
490. N. Perico, G. Remuzzi. Angiotensin II receptor antagonists and treatment of hypertension and renal disease. *Curr Opin Nephrol Hypertens* 1998;7:571-578.
491. P. Ruggenenti, A. Perna, G. Gherardi, F. Gaspari, R. Benini, G. Remuzzi, on behalf of GISEN. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. *Lancet* 1998;352:1252-1256.
492. G. Remuzzi, P. Boccardo. Disorders of hemostasis in dialysis patients. In: *Principles and Practice of Dialysis* (2nd Edition). Edited by W.L. Henrich. Williams & Wilkins, Baltimore 1999, pp. 387-397.
493. G. Remuzzi, T. Bertani. Pathophysiology of progressive nephropathies. *N Engl J Med* 1998;339:1448-1456.
494. F. Gaspari, M.F. Anedda, O. Signorini, S.C. Amuchastegui, N. Perico, G. Remuzzi. Pharmacokinetics and renal function after conversion from standard to microemulsion formulation of cyclosporine in stable renal transplant patients. *Transplant Proc* 1998;30:1654-1655.
495. G. Remuzzi, N. Perico, F. Gaspari. Optimization of cyclosporine therapy in kidney transplantation. *Transplant Proc* 1998;30:1673-1676.
496. E. Gotti, M. Abbate, P. Ferrante, G. Remuzzi. Abdominal pain and acute nephritis in a man with a recent renal transplant. *J Nephrol* 1998;11:196-198.
497. M. Furlan, R. Robles, M. Galbusera, G. Remuzzi, P.A. Kyrle, B. Brenner, M. Krause, I. Scharrer, V. Aumann, U. Mittler, M. Solenthaler, B. Lammle. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. *N Engl J Med* 1998;339:1578-1584.

498. P. Ruggenenti, G. Remuzzi. Nephropathy of type-2 diabetes mellitus. *J Am Soc Nephrol* 1998;9:2157-2169.
499. P. Ruggenenti, A. Perna, R. Benini, G. Remuzzi for the "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. *J Am Soc Nephrol* 1998;9:2096-2101.
500. F. Gaspari, N. Perico, G. Remuzzi. Application of newer clearance techniques for the determination of glomerular filtration rate. *Curr Opin Nephrol Hypertens* 1998;7:675-680.
501. R. Plata, C. Silva, J. Yahuita, L. Perez, A. Schieppati, G. Remuzzi. The first clinical and epidemiological programme on renal disease in Bolivia: a model for prevention and early diagnosis of renal diseases in the developing countries. *Nephrol Dial Transplant* 1998;13:3034-3036.
502. N. Perico, A. Remuzzi, F. Sangalli, N. Azzollini, M. Mister, P. Ruggenenti, G. Remuzzi. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. *J Am Soc Nephrol* 1998;9:2308-2317.
503. P. Ruggenenti, V. Gambarà, A. Perna, T. Bertani, G. Remuzzi. The nephropathy of non-insulin-dependent diabetes: predictors of outcome relative to diverse patterns of renal injury. *J Am Soc Nephrol* 1998;9:2336-2343.
504. A. Benigni, G. Remuzzi. Novel strategies to retard renal disease progression: combining ACE inhibition with endothelin receptor blocking? *Nephrol Dial Transplant* 1998;13:2734-2738.
505. A. Schieppati, G. Remuzzi. Reducing mortality and increasing awareness. *Lancet* 1998;352(Suppl. IV):20.
506. M. Abbate, R. Kalluri, D. Corna, N. Yamaguchi, R.T. McCluskey, B.G. Hudson, G. Andres, C. Zoja, G. Remuzzi. Experimental Goodpasture's syndrome in Wistar-Kyoto rats immunized with $\alpha 3$ chain of type IV collagen. *Kidney Int* 1998;54:1550-1561.
507. M. Noris, M. Todeschini, F. Casiraghi, D. Rocco, G. Martina, L. Minetti, B. Imberti, F. Gaspari, M. Atti, G. Remuzzi. Effect of acetate, bicarbonate dialysis, and acetate-free biofiltration on nitric oxide synthesis: implications for dialysis hypotension. *Am J Kidney Dis* 1998;32:115-124.
508. F. Gaspari, N. Perico, O. Signorini, R. Caruso, G. Remuzzi. Abbreviated kinetic profiles in area-under-the curve monitoring of cyclosporine therapy. *Kidney Int* 1998;54:2146-2150.
509. P. Ruggenenti, A. Perna, G. Remuzzi. REIN follow-up trial (Correspondence, Authors' reply). *Lancet* 1998;352:2020-2022.
510. A. Benigni, G. Remuzzi. Endothelin antagonists. *Lancet* 1999;353:133-138

511. A. Remuzzi, G. Remuzzi. Assessment of glomerular size-selective function with fractional clearance of neutral dextran (Editorial). *J Lab Clin Med* 1998;132:360-362.
512. M. Noris, P. Ruggenenti, A. Perna, S. Orisio, J. Caprioli, C. Skerka, B. Vasile, P.F. Zipfel, G. Remuzzi on behalf of the Italian Registry of familial and recurrent HUS/TTP. Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. *J Am Soc Nephrol* 1999;10:281-293.
513. A. Benigni, G. Remuzzi. Genes and molecular medicine in the future of organ transplantation. *Curr Opin Organ Transplant* 1999;4:65-72.
514. G. Remuzzi. Tolerance in organ transplantation (Editorial Overview). *Curr Opin Organ Transplant* 1999;4:41-43.
515. E. Daina, A. Schieppati, G. Remuzzi. Mycophenolate mofetil for the treatment of Takayasu arteritis: Report of three cases. *Ann Intern Med* 1999;130:422-426.
516. P. Ruggenenti, G. Remuzzi. Pathophysiology and management of thrombotic microangiopathies. *J Nephrol* 1998;11:300-310.
517. F. Gaspari, N. Perico, R. Pisoni, M.F. Anedda, O. Signorini, R. Caruso, E. Gotti, G. Remuzzi. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients? *Clin Transplant* 1998;12:379-390.
518. M. Abbate, A. Benigni, T. Bertani, G. Remuzzi. Nephrotoxicity of increased glomerular protein traffic. *Nephrol Dial Transplant* 1999;14:304-312.
519. G. Sirchia, F. Poli, M. Cardillo, M. Scalamogna, P. Rebulli, E. Taioli, G. Remuzzi, A. Nocera on behalf of the North Italy Transplant program. Cadaver kidney allocation in the North Italy Transplant program on the eve of the new millennium. In: *Clinical Transplants Chapter 11*. Edited by Cecka and Terasaki, UCLA Tissue Typing Laboratory, Los Angeles, California 1998, pp. 133-145.
520. M. Abbate, C. Zoja, D. Rottoli, D. Corna, N. Perico, T. Bertani, G. Remuzzi. Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and complement-dependent interstitial inflammation in experimental renal disease. *J Am Soc Nephrol* 1999;10:804-813.
521. A. Benigni, I. Bruzzi, M. Mister, N. Azzollini, F. Gaspari, N. Perico, E. Gotti, T. Bertani, G. Remuzzi. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. *Kidney Int* 1999;55:674-685.
522. A. Fassi, F. Sangalli, F. Colombi, N. Perico, G. Remuzzi, A. Remuzzi. Beneficial effects of calcium channel blockade on acute glomerular hemodynamic changes induced by cyclosporine. *Am J Kidney Dis* 1999;33:267-275.
523. P. Ruggenenti, L. Mosconi, F. Sangalli, F. Casiraghi, V. Gambarà, G. Remuzzi, A.

- Remuzzi. Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade. *Kidney Int* 1999;55:984-994.
524. A. Remuzzi, N. Perico, F. Sangalli, G. Vendramin, M. Moriggi, P. Ruggenenti, G. Remuzzi. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. *Am J Physiol* 1999;276:F457-F466.
 525. G. Remuzzi, A. Schieppati. Lessons from the Di Bella affair (Commentary). *Lancet* 1999;353:1289.
 526. G. Remuzzi. Basiliximab (Viewpoint). *Drugs* 1999;57:214.
 527. P. Ruggenenti, A. Perna, R. Benini, T. Bertani, C. Zoccali, Q. Maggiore, M. Salvadori, G. Remuzzi. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. *J Am Soc Nephrol* 1999;10:997-1006.
 528. G. Remuzzi. Sympathetic overactivity in hypertensive patients with chronic renal disease. (Editorial). *N Engl J Med* 1999;340:1360-1361.
 529. T. Bertani, G. Remuzzi. Renal proliferative arteriopathy and thrombotic angiopathies. In: *Renal Disease. Classification and Atlas of Tubulointerstitial and Vascular Diseases*. Edited by S. Venkata Seshan, V.D. D'Agati, G.A. Appel, J. Churg, Williams & Wilkins, Baltimore 1999, pp. 365-372.
 530. G. Remuzzi. Cigarette smoking and renal function impairment (Journal Club). *Am J Kidney Dis* 1999;33:807-813.
 531. A. Benigni, C. Zoja, M. Noris, D. Corna, G. Benedetti, I. Bruzzi, M. Todeschini, G. Remuzzi. Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. *Am J Kidney Dis* 1999;33:746-753.
 532. M. Galbusera, A. Benigni, S. Paris, P. Ruggenenti, C. Zoja, C. Rossi, G. Remuzzi. Unrecognized pattern of von Willebrand Factor abnormalities in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. *J Am Soc Nephrol* 1999;10:1234-1241.
 533. G. Remuzzi, C. Zoja, E. Gagliardini, D. Corna, M. Abbate, A. Benigni. Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. *J Am Soc Nephrol* 1999;10:1542-1549.
 534. M. Noris, E. Daina, S. Gamba, S. Bonazzola, G. Remuzzi. Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? *Circulation* 1999;100:55-60.
 535. P. Ruggenenti, A. Perna, G. Gherardi, G. Garini, C. Zoccali, M. Salvadori, F. Scolari, F.P. Schena, G. Remuzzi. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. *Lancet* 1999;354:359-364.
 536. M. Abbate, G. Remuzzi. Proteinuria as a mediator of tubulointerstitial injury. *Kidney*

Blood Press Res 1999;22:37-46.

537. M. Noris, N. Azzollini, M. Mister, A. Pezzotta, G. Piccinini, F. Casiraghi, D. Cugini, N. Perico, S. Orisio, G. Remuzzi. Peripheral donor leukocytes prolong survival of rat renal allografts. *Kidney Int* 1999;56:1101-1112.
538. M. Galbusera, M. Noris, C. Rossi, S. Orisio, J. Caprioli, Z.M. Ruggeri, B. Amadei, P. Ruggenenti, B. Vasile, G. Casari, G. Remuzzi on behalf of the Italian Registry of Familial and Recurrent HUS/TTP. Increased fragmentation of von Willebrand factor, due to abnormal cleavage of the subunit, parallels disease activity in recurrent hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and discloses predisposition in families. *Blood* 1999;94:610-620.
539. M. Morigi, C. Zoja, S. Colleoni, S. Angioletti, B. Imberti, R. Donadelli, A. Remuzzi, G. Remuzzi. Xenogeneic serum promotes leukocyte-endothelium interaction under flow through two temporally distinct pathways: Role of complement and nuclear factor-kB. *J Am Soc Nephrol* 1999;10:2197-2207.
540. N. Perico, G. Remuzzi. Diabetic nephropathy: animal models of human type 2 diabetes. In: *Nephropathy in type 2 Diabetes*. Edited by E. Ritz, I. Rychlik. Oxford University Press, Oxford UK 1999, pp. 47-57.
541. C. Zoja, A. Benigni, G. Remuzzi. Protein overload activates proximal tubular cells to release vasoactive and inflammatory mediators. *Exp Nephrol* 1999;7:420-428.
542. M. Noris, G. Remuzzi. IgA nephropathy: A stem cell disease? (Editorial). *Kidney Int* 1999;56:1964-1966.
543. G. Remuzzi, J. Grinyo, P. Ruggenenti, M. Beatini, E.H. Cole, E.L. Milford, B.M. Brenner and the Double Kidney Transplant Group (DKG). Early experience with dual kidney transplantation in adults using expanded donor criteria. *J Am Soc Nephrol* 1999;10:2591-2598.
544. A. Remuzzi, N. Perico, G. Remuzzi. Pharmacological and clinical profile of valsartan. *Drugs of Today* 1998;34:973-986.
545. G. Remuzzi. Transplant tolerance: facts and future. *Transplant Proc* 1999;31:2955-2957.
546. G. Remuzzi. Double transplant of marginal kidneys. *Transplant Proc* 1999;31:2962-2964.
547. G. Remuzzi. Nephropathic nature of proteinuria. *Curr Opin Nephrol Hypertens* 1999;8:655-663.
548. M. Noris, G. Remuzzi. Uremic bleeding: closing the circle after 30 years of controversies? *Blood* 1999;94:2569-2574.
549. A. Remuzzi, A. Fassi, T. Bertani, N. Perico, G. Remuzzi. ACE inhibition induces

- regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy. *Am J Kidney Dis* 1999;34:626-632.
550. P. Ruggenti, A. Perna, G. Remuzzi. Non-diabetic nephropathies and ACE inhibition. (Correspondence, Authors' reply). *Lancet* 1999;354:1905-1906.
 551. G. Remuzzi. Renoprotective effect of ACE inhibitors: dissecting the molecular clues and expanding the blood pressure goal (Editorial). *Am J Kidney Dis* 1999;34:951-954.
 552. M. Noris, G. Remuzzi. Physiology and pathophysiology of nitric oxide in chronic renal disease. *Proc Assoc Am Phys* 1999;111:602-610.
 553. S. Aiello, M. Noris, G. Remuzzi. Nitric oxide/L-arginine in uremia. *Miner Electrolyte Metab* 1999;25:384-390.
 554. A. Remuzzi, N. Monaci, M.E. Bonassi, D. Corna, C. Zoja, E.I. Mohammed, G. Remuzzi. Angiotensin-converting enzyme inhibition prevents loss of glomerular hydraulic permeability in passive Heymann nephritis. *Lab Invest* 1999;79:1501-1510.
 555. P. Ruggenti, G. Remuzzi. Non diabetic chronic renal disease: mechanisms of progression and guidelines to treatment. In: *International Handbook of Renal Disease*. Edited by B.M. Brenner, K. Kurokawa. Hoechst Marion Roussel, France 1999, pp. 63-76.
 556. P. Ruggenti, G. Remuzzi. Future therapeutic options. In: *International Handbook of Renal Disease*. Edited by B.M. Brenner, K. Kurokawa. Hoechst Marion Roussel, France 1999, pp. 87-93.
 557. G. Remuzzi. Current antirejection treatments and future therapeutic perspectives in organ transplantation. *Jornal Brasileiro de Transplantes (JBT)* 1999;2:30-44.
 558. P. Ruggenti, G. Remuzzi. Thrombotic microangiopathies including hemolytic uremic syndrome. In: *Comprehensive Clinical Nephrology*, Chapter n. 33, Section 5: Glomerular Disease. Edited by R.J. Johnson, J. Feehally. Mosby, London 2000, pp. 33.1-33.12.
 559. P. Ruggenti, A. Perna, C. Zoccali, G. Gherardi, R. Benini, A. Testa, G. Remuzzi for the (GISEN). Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. *J Am Soc Nephrol* 2000;11:88-96.
 560. G. Remuzzi, L. Minetti. Hematological consequences of renal failure. In: *Brenner and Rector's The Kidney*, 6^o ed., Vol. II, chapter n. 50. Edited by B.M. Brenner. W.B. Saunders Company, Philadelphia 2000, pp. 2079-2102.
 561. D. Macconi, M. Ghilardi, M.E. Bonassi, E.I. Mohamed, M. Abbate, F. Colombi, G. Remuzzi, A. Remuzzi. Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats. *J Am Soc Nephrol* 2000;11:477-489.

562. P. Ruggenenti, L. Mosconi, G. Vendramin, M. Moriggi, A. Remuzzi, F. Sangalli, G. Remuzzi. ACE inhibition improves glomerular size-selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome. *Am J Kidney Dis* 2000;35:381-391.
563. P. Ruggenenti, G. Remuzzi. The role of protein traffic in the progression of renal diseases. *Annu Rev Med* 2000;51:315-327.
564. S. Tomasoni, N. Azzollini, F. Casiraghi, M.C. Capogrossi, G. Remuzzi, A. Benigni. CTLA4Ig gene transfer prolongs survival and induces donor-specific tolerance in a rat renal allograft. *J Am Soc Nephrol* 2000;11:747-752.
565. A. Perna, P. Ruggenenti, A. Testa, B. Spoto, R. Benini, V. Misefari, G. Remuzzi, C. Zoccali for the Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies. *Kidney Int* 2000;57:274-281.
566. A. Benigni, G. Remuzzi. Prostacyclin and thromboxane and the development of preeclampsia (Letter). *JAMA* 2000;283:1568-1569.
567. J.M. MacLeod, K.E. White, H. Tate, R.W. Bilous on behalf of the ESPRIT Study Group (P. Ruggenenti, F. Gaspari, G. Remuzzi). Measurement of glomerular volume in needle biopsy specimens. *Nephrol Dial Transplant* 2000;15:239-243.
568. G. Remuzzi. Effect of cigarette smoking on renal function and vascular endothelium. In: *Cigarette Smoking and the Kidney. Contrib Nephrol*. Edited by A. Sessa, F. Conte, M. Meroni, G. Battini. Karger, Basel 2000, vol.130, pp. 45-52.
569. S. Aiello, M. Noris, G. Piccinini, S. Tomasoni, F. Casiraghi, S. Bonazzola, M. Mister, M.H. Sayegh, G. Remuzzi. Thymic dendritic cells express inducible nitric oxide synthase and generate nitric oxide in response to self- and alloantigens. *J Immunol* 2000;164:4649-4658.
570. P. Ruggenenti, A. Perna, G. Gherardi, R. Benini, G. Remuzzi. Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. *Am J Kidney Dis* 2000;35:1155-1165.
571. G. Dotti, R. Fiocchi, T. Motta, A. Gamba, E. Gotti, B. Gridelli, G. Borleri, C. Manzoni, P. Viero, G. Remuzzi, T. Barbui, A. Rambaldi. Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. *Transplantation* 2000;69:827-833.
572. R. Pisoni, G. Remuzzi. How much must blood pressure be reduced in order to obtain the remission of chronic renal disease? *J Nephrol* 2000;13:228-231.
573. G. Remuzzi, P. Ruggenenti. Renal transplantation: single or dual for donors aging $\geq$ 60 years? Analyses & Commentaries. *Transplantation* 2000;69:2000-2004.

574. B. Gridelli, G. Remuzzi. Strategies for making more organs available for transplantation. *N Engl J Med* 2000;343:404-410.
575. R. Pisoni, G. Remuzzi. Thrombotic microangiopathy. *Eur J Int Med* 2000;11:135-139.
576. B. Imberti, M. Morigi, C. Zoja, S. Angioletti, M. Abbate, A. Remuzzi, G. Remuzzi. Shear stress-induced cytoskeleton rearrangement mediates NF- κ B dependent endothelial expression of ICAM-1. *Microvasc Res* 2000;60:182-188.
577. A. Benigni, S. Tomasoni, J. Lutz, S. Amuchastegui, M.C. Capogrossi, G. Remuzzi. Nonviral and viral gene transfer to the kidney in the context of transplantation. *Nephron* 2000;85:307-316.
578. A. Benigni, N. Perico, G. Remuzzi. Endothelin antagonists and renal protection. *J Cardiovasc Pharmacol* 2000;35(Suppl. 2):S75-S78.
579. G. Remuzzi. A unifying hypothesis for renal scarring linking protein trafficking to the different mediators of injury. *Nephrol Dial Transplant* 2000;15(Suppl. 6):58-60.
580. G. Remuzzi. Renal protection: progression, regression, remission from nephropathy beyond blood pressure control. *Int J Clin Practice* 2000;110(Suppl.):9-15.
581. P. Ruggenenti, G. Remuzzi. Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology, same treatment? (Editorial Comments). *Nephrol Dial Transplant* 2000;15:1900-1902.
582. P. Ruggenenti, A. Perna, M. Lesti, R. Pisoni, L. Mosconi, F. Arnoldi, I. Ciocca, F. Gaspari, G. Remuzzi. Pretreatment blood pressure reliably predicts progression of chronic nephropathies. *Kidney Int* 2000;58:2093-2101.
583. G. Remuzzi, B. Gridelli. Organs for transplantation (Correspondence). *N Engl J Med* 2000;343:1730-1732.
584. L. Naldi, A. Belloni Fortina, S. Lovati, A. Barba, E. Gotti, G. Tessari, D. Schena, A. Diociaiuti, G. Nanni, I. Lesnoni La Parola, C. Masini, S. Piaserico, A. Peserico, T. Cainelli, G. Remuzzi. Risk of nonmelanoma skin cancer in Italian organ transplant recipients. A registry-based study. *Transplantation* 2000;70:1479-1484.
585. G. Remuzzi. Hemolytic uremic syndrome: past and present. *Am J Kidney Dis* 2000;36:LIV-LVI.
586. M. Noris, M. Todeschini, S. Zappella, S. Bonazzola, C. Zoja, D. Corna, F. Gaspari, F. Marchetti, S. Aiello, G. Remuzzi. 17 β -estradiol corrects hemostasis in uremic rats by limiting vascular expression of nitric oxide synthases. *Am J Physiol: Renal Physiology* 2000;279:F626-F635.
587. M. Galbusera, A. Remuzzi, A. Benigni, C. Rossi, G. Remuzzi. A novel interpretation of the role of von Willebrand Factor in thrombotic microangiopathies based on platelet adhesion studies at high shear rate flow. *Am J Kidney Dis* 2000;36:695-702.

588. P. Ruggenenti, G. Remuzzi. Treatment of adult hemolytic-uremic syndrome. *Advances in Nephrology* 2000;30:83-94.
589. G. Remuzzi, A. Benigni. Repairing renal lesions: Will VEGF be the builder? (Editorial) *Kidney Int* 2000;58:2594-2595.
590. G. Remuzzi, N. Perico, E. Gotti, P. Ruggenenti, G. Rota, G. Locatelli. The kidney transplant program at the Bergamo Center. In: *Clinical Transplants*, chapter 15. Edited by Cecka and Terasaki. UCLA Immunogenetics Center, Los Angeles, California 2000, pp. 179-191.
591. B.M. Brenner, M.E. Cooper, D. de Zeeuw, J-P Grunfeld, W.F. Keane, K. Kurokawa, J.B. McGill, W.E. Mitch, H.H. Parving, G. Remuzzi, A.B. Ribeiro, M.D. Schluchter, D. Snavely, Z. Zhang, R. Simpson, D. Ramjit, S. Shahinfar, for the RENAAL Study Investigators. The losartan renal protection study - rationale, study design and baseline characteristics of RENAAL (Reduction of endpoints in NIDDM with the angiotensin II antagonist losartan). *J Renin Angiotensin Aldosterone System* 2000;1:328-335.
592. R. Donadelli, M. Abbate, C. Zanchi, D. Corna, S. Tomasoni, A. Benigni, G. Remuzzi, C. Zoja. Protein traffic activates NF-kB gene signaling and promotes MCP-1 dependent interstitial inflammation. *Am J Kidney Dis* 2000;36:1226-1241.
593. Blood Pressure Lowering Treatment Trialists' Collaboration (G. Remuzzi, P. Ruggenenti). Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. *Lancet* 2000;356:1955-1964.
594. M. Noris, J. Caprioli, G. Remuzzi. Pathophysiology of thrombotic microangiopathies. *Int Med* 2000;8:37-43.
595. P. Ruggenenti, G. Remuzzi. Nephropathy in NIDDM patients, predictors of outcome. In: *The Kidney and Hypertension in Diabetes Mellitus*. Edited by C.E. Mogensen, Kluwer Academic Publisher, Boston (USA) 2000, pp. 237-246.
596. A. Benigni, N. Perico, G. Remuzzi. Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression. Special commentary. *Curr Opin Nephrol Hypertens* 2001;10:1-6.
597. J. Caprioli, P. Bettinaglio, P.F. Zipfel, B. Amadei, E. Daina, S. Gamba, C. Skerka, N. Marziliano, G. Remuzzi, M. Noris on behalf of the Italian Registry of Familial and Recurrent HUS/TTP. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. *J Am Soc Nephrol* 2001;12:297-307.
598. P. Ruggenenti, E. Pagano, L. Tammuzzo, R. Benini, L. Garattini, G. Remuzzi, on behalf of the Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. *Kidney Int* 2001;59:286-294.

599. G. Dotti, F. Gaspari, R. Caruso, N. Perico, G. Remuzzi, T. Barbui, A. Rambaldi. Pharmacokinetic study of the new cyclosporin-A formulation (NeoralTM) in adult allogeneic bone marrow transplant recipients. *Haematologica* 2001;86:311-315.
600. C. Zoja, P. Ruggenenti, G. Remuzzi. Role of coagulation in glomerular and vascular diseases. Part 1. In: *Textbook of Nephrology*, 4° ed, chapter n. 37. Edited by S.G. Massry, R.J. Glassock. Lippincott Williams & Wilkins, Philadelphia 2001, pp. 589-594.
601. P. Boccardo, G. Remuzzi. Bleeding and coagulation. Part. 2. In: *Textbook of Nephrology*, 4° ed, chapter n. 72. Edited by S.G. Massry, R.J. Glassock. Lippincott Williams & Wilkins, Philadelphia 2001, pp.1324-1329.
602. M. Abbate, G. Remuzzi. Progression of renal insufficiency. Part. 2. Mechanisms. In: *Textbook of Nephrology*, 4° ed, chapter n. 67. Edited by S.G. Massry, R.J. Glassock. Lippincott Williams & Wilkins, Philadelphia 2001, pp.1210-1217.
603. R. Pisoni, G. Remuzzi. Pathophysiology and management of progressive chronic renal failure. In: 'Primer on Kidney Diseases', National Kidney Foundation. 3rd ed, chapter n.58. Edited by Arthur Greenberg, Academic Press, San Diego, California 2001, pp. 385-396.
604. P. Ruggenenti, A. Schieppati, G. Remuzzi. Progression, remission, regression of chronic renal diseases. *Lancet* 2001;357:1601-1608.
605. P. Ruggenenti, G. Remuzzi. Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. In: 'Nephrology', Clinical Medicine Series. Chapter n. 36. Edited by Francesco P. Schena, McGraw-Hill International, Berkshire, England 2001, pp. 361-370.
606. The European Study for the Prevention of Renal disease in Type 1 diabetes (ESPRIT) P. Ruggenenti, F. Gaspari, G. Remuzzi. Effect of three years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria. *Diabetes* 2001;50:843-850.
607. P. Ruggenenti, C. Aros, G. Remuzzi. Thrombotic microangiopathies in the intensive care unit: many questions, some answers. In: *Blood Purification in Intensive Care. Contrib Nephrol*. Edited by C. Ronco, R. Bellomo. Karger, Basel 2001;132:53-67.
608. A. Benigni, G. Remuzzi. How renal cytokines and growth factors contribute to renal disease progression. *Am J Kidney Dis* 2001;37(Suppl. 2):S21-S24.
609. A. Benigni, S. Tomasoni, E. Gagliardini, C. Zoja, J.A. Grunkemeyer, R. Kalluri, G. Remuzzi. Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. *J Am Soc Nephrol* 2001;12:941-948.
610. R. Pisoni, P. Ruggenenti, G. Remuzzi. Drug-induced thrombotic microangiopathy: incidence, prevention and management. *Drug Safety* 2001;24(7):491-501.

611. P.F. Zipfel, C. Skerka, J. Caprioli, T. Manuelian, H. H. Neumann, M. Noris, G. Remuzzi. Complement factor H and hemolytic uremic syndrome. *International Immunopharmacology* 2001;1:461-468.
612. M. Abbate, G. Remuzzi. Novel mechanism(s) implicated in tubular albumin reabsorption and handling. (J Club Discussion) *Am J Kidney Dis* 2001;38(1):196-204.
613. P. Ruggenenti, B.M. Brenner, G. Remuzzi. Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion. *Nephron* 2001;88:254-259.
614. T.H. Jafar, C.H. Schmid, M. Landa, I. Giatras, R. Toto, G. Remuzzi, G. Maschio, B.M. Brenner, A. Kamper, P. Zucchelli, G. Becker, A. Himmelmann, K. Bannister, P. Landais, S. Shahinfar, P.E. de Jong, D. de Zeeuw, J. Lau, A.S. Levey. Using a type of blood pressure medicine, angiotensin-converting enzyme inhibitors, to prevent worsening of kidney disease unrelated to diabetes. *Ann Intern Med* 2001;135(2):S-21.
615. T.H. Jafar, C.H. Schmid, M. Landa, I. Giatras, R. Toto, G. Remuzzi, G. Maschio, B.M. Brenner, A. Kamper, P. Zucchelli, G. Becker, A. Himmelmann, K. Bannister, P. Landais, S. Shahinfar, P.E. de Jong, D. de Zeeuw, J. Lau, A.S. Levey. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. *Ann Intern Med* 2001;135(2):73-87.
616. P. Ruggenenti, L. Mosconi, S. Bruno, A. Remuzzi, F. Sangalli, M.S. Lepre, R. Agazzi, R. Nani, G. Fasolini, G. Remuzzi. Post-transplant renal artery stenosis: the hemodynamic response to revascularization. *Kidney Int* 2001;60:309-318.
617. B. Ene-Iordache, L. Mosconi, G. Remuzzi, A. Remuzzi. Computational fluid dynamics of a vascular access case for hemodialysis. *J Biomech Eng* 2001;123:284-292.
618. R. Pisoni, P. Ruggenenti, G. Remuzzi. Renoprotective therapy in patients with non-diabetic nephropathies. *Drugs* 2001;61(6):733-745.
619. C. Zoja, A. Benigni, M. Noris, D. Corna, F. Casiraghi, M. Pagnoncelli, D. Rottoli, M. Abbate, G. Remuzzi. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis and prolongs animal life. *Kidney Int* 2001;60:653-663.
620. M. Morigi, M. Galbusera, E. Binda, B. Imberti, S. Gastoldi, A. Remuzzi, C. Zoja, G. Remuzzi. Verotoxin-1-induced upregulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. *Blood* 2001;98(6):1828-1835.
621. P. Ruggenenti, M. Noris, G. Remuzzi. Thrombotic microangiopathy, hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. *Kidney Int* 2001;60:831-846.

622. F. Gaspari, N. Perico, G. Remuzzi. Pharmacologic monitoring of immunosuppressive drugs. *Current & Future Immunosuppressive Therapies Following Transplantation*. Edited by M.H. Sayegh, G. Remuzzi. Kluwer Academic Publisher, The Netherlands 2001;1:43-59.
623. T.H. Jafar, P.C. Stark, C.H. Schmid. M. Landa, G. Maschio, C. Marcantoni, P.E. de Jong, D. de Zeeuw, S. Shahinfar, P. Ruggenenti, G. Remuzzi, A.S. Levey. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. *Kidney Int* 2001;60:1131-1140.
624. A. Benigni, N. Perico, G. Remuzzi. Molecular medicine in organ transplantation: how and when? *Current & Future Immunosuppressive Therapies Following Transplantation*. Edited by M.H. Sayegh, G. Remuzzi. Kluwer Academic Publisher, The Netherlands 2001, vol. 1, pp. 317-334.
625. B.M. Brenner, M.E. Cooper, D. de Zeeuw, W.F. Keane, W.E. Mitch, H-H. Parving, G. Remuzzi, S.M. Snapinn, Z. Zhang, S. Shahinfar. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 2001;345(12):861-869.
626. A.D. Salama, G. Remuzzi, W.E. Harmon, M.H. Sayegh. Challenges to achieving clinical transplantation tolerance. *J Clin Invest* 2001;108:943-948.
627. A. Schieppati, G. Remuzzi. The uses of error: diagnostic preferences. *Lancet* 2001;358:1005.
628. M. Noris, N. Azzollini, A. Pezzotta, M. Mister, A. Benigni, G. Marchetti, E. Gagliardini, N. Perico, G. Remuzzi. Combined treatment with mycophenolate mofetil and an angiotensin II receptor antagonist fully protects from chronic rejection in a rat model of renal allograft. *J Am Soc Nephrol* 2001;12:1937-1946.
629. R. Caruso, N. Perico, D. Cattaneo, G. Piccinini, S. Bonazzola, G. Remuzzi, F. Gaspari. Whole blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients. *Clinical Chemistry* 2001;47:1679-1687.
630. M. Noris, G. Remuzzi. Familial and recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. *Rare Kidney Diseases*. In: *Contribution to Nephrology*. Edited by A. Schieppati, E. Daina, A. Sessa, G. Remuzzi. Basel, Karger 2001, vol. 136, pp. 125-139.
631. S. Tomasoni, G. Remuzzi, A. Benigni. Gene therapy to the kidney. *Rare Kidney Diseases*. In: *Contribution to Nephrology*. Edited by A. Schieppati, E. Daina, A. Sessa, G. Remuzzi. Basel, Karger 2001, vol. 136, pp. 140-156.
632. P. Ruggenenti, C. Aros, G. Remuzzi. Renin-Angiotensin System, proteinuria and tubulointerstitial damage. *The Renin-Angiotensin System and Progression of Renal Diseases*. *Contrib Nephrol*. Edited by G. Wolf. Karger, Basel 2001;135:187-199.
633. L. Antiga, B. Ene-Iordache, G. Remuzzi, A. Remuzzi. Automatic generation of

- glomerular capillary topological organization. *Microvasc Res* 2001;62:346-354.
634. A. Schieppati, G. Remuzzi, S. Garattini. Modulating the profit motive to meet needs of the lesss-developed world. *Lancet* 2001;358:1638-1641.
 635. A. Benigni, E. Gagliardini, A. Remuzzi, D. Corna, G. Remuzzi. ACE inhibition prevents glomerular-tubule disconnection and atrophy in passive Heymann nephritis, an effect not observed with a calcium antagonist. *Am J Pathol* 2001;159:1743-1750.
 636. M. Jonker, Y. van den Hout, R.C. Noort, M.F. Versteeg-van der Voort Maarschalk, F.H.J. Claas, F.J. van der Woude, D. Hollander, N. Perico, G. Remuzzi. Immunomodulation by intrathymic injection of donor leukocytes in rhesus monkeys. *Transplantation* 2001;72:1432-1436.
 637. D. Cattaneo, F. Gaspari, S. Ferrari, N. Stucchi, L. Del Priore, N. Perico, E. Gotti, G. Remuzzi. Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. *Clinical Transpl* 2001;15:402-409.
 638. B. Gridelli, N. Perico, G. Remuzzi. Scarsa disponibilità di organi: strategie di adattamento. *Scienza e Cultura nel Mondo*. Edited by Duebi Nuove Frontiere. Roma 2001, vol. 2, pp. 7-14.
 639. C. Zoja, M. Morigi, G. Remuzzi. The role of the endothelium in hemolytic uremic syndrome. *J Nephrol* 2001;14(Suppl. 4):S58-62.
 640. F. Gaspari, R. Caruso, D. Cattaneo, N. Perico, G. Remuzzi. Optimization of cyclosporine therapy in the Neoral era: abbreviated AUC, single blood sampling? *Transplant Proc* 2001;33:3117-3119.
 641. M. Noris, D. Cugini, F. Casiraghi, N. Azzollini, L. De Deus Viera Moraes, M. Mister, A. Pezzotta, R. Aparecida Cavinato, S. Aiello, N. Perico, G. Remuzzi. Thymic microchimerism correlates with the outcome of tolerance-inducing protocols for solid organ transplantation. *J Am Soc Nephrol* 2001;12:2815-2826.
 642. P. Ruggenenti, M. Galli, G. Remuzzi. Hemolytic uremic syndrome, Thrombotic thrombocytopenic purpura, and antiphospholipid antibody syndromes. In: *Immunologic Renal Diseases*: Edited by E.G. Neilson, W.G. Couser. Lippincott Williams & Wilkins Publishers, Philadelphia 2001, pp. 1173-1201.
 643. C. Zoja, M. Morigi, G. Remuzzi. Coagulation and thrombosis in immunologic renal diseases. In: *Immunologic Renal Diseases*. Edited by E.G. Neilson, W.G. Couser. Lippincott Williams & Wilkins Publishers, Philadelphia 2001, pp. 511-520.
 644. P. Ruggenenti, A. Perna, G. Remuzzi. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a Post Hoc analysis of the REIN trial results. *J Am Soc Nephrol* 2001;12:2832-2837.
 645. P. Ruggenenti, A. Schieppati, T. Bertani, G. Remuzzi. Thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, and acute cortical necrosis. In: *Diseases of the*

Kidney & Urinary Tract, 7th ed., Vol. II, chapter n. 67. Edited by Robert W. Schrier. Wolters Kluwer, Lippincott Williams & Wilkins, Philadelphia 2001, pp. 1883-1910.

646. P. Boccardo, M. Noris, G. Remuzzi. Prevention and therapeutic management of bleeding in dialysis patients. In: *Dialysis Therapy*, (3rd edition). Edited by A.R. Nissenson, R.N. Fine. Hanley & Belfus Inc., Philadelphia 2002, vol. 3, pp. 190-194.
647. P. Boccardo, M. Galbusera, G. Remuzzi. Platelets and renal diseases. In: *Platelets in thrombotic and non-thrombotic disorders: Pathophysiology, pharmacology and therapeutics*. Edited by: P. Gresele, C.P. Page, V. Fuster, J. Vermynen, Cambridge University Press, Cambridge 2002, pp. 837-851.
648. G. Remuzzi, N. Perico. Routine renin-angiotensin system blockade in renal transplantation? *Curr Opin Nephrol Hypertens* 2002;11:1-10.
649. N. Perico, A. Benigni, G. Remuzzi. Xenotransplantation in the 21st century. *Blood Purif* 2002; 20:45-54.
650. R. Plata, A. Cornejo, C. Arratia, A. Anabaya, A. Perna, B. Dimitrov, G. Remuzzi, P. Ruggenenti for the Commission on Global Advancement of Nephrology (COMGAN). Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomized trial. *Lancet* 2002;359:663-666.
651. B.D. Dimitrov, G. Remuzzi. Combination therapy for renal disease. *Hospital Prescriber Europe* 2002;3:21-23.
652. M. Mister, M. Noris, J. Szymczuk, N. Azzollini, S. Aiello, M. Abbate, L. Trochimowicz, E. Gagliardini, A. Arduini, N. Perico, G. Remuzzi. Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion. *Kidney Int* 2002;61:1064-1078.
653. G. Remuzzi, P. Ruggenenti, N. Perico. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. *Ann Intern Med* 2002;136:604-615.
654. N. Perico, G. Remuzzi. Nitric oxide and renal perfusion in humans. *J Hypertens* 2002;20:391-393.
655. M. Noris, G. Remuzzi. ACE inhibitors and AT₁ receptor antagonists: Is two better than one? *Kidney Int* 2002;61:1545-1547.
656. A. Benigni, S. Tomasoni, G. Remuzzi. Impediments to successful gene transfer to the kidney in the context of transplantation and how to overcome them. *Kidney Int* 2002;61 (Symposium 1):S115-S119.
657. G. Remuzzi, A. Schieppati, P. Ruggenenti. Clinical Practice: Nephropathy in patients with type 2 diabetes. *N Engl J Med* 2002;346:1145-1151.
658. C. Zoja, D. Corna, D. Rottoli, D. Cattaneo, C. Zanchi, S. Tomasoni, M. Abbate, G. Remuzzi. Effect of combining ACE inhibitor and statin in severe experimental

- nephropathy. *Kidney Int* 2002;61:1635-1645.
659. G. Remuzzi, P. Ruggenenti, D. Codazzi, M. Noris, J. Caprioli, G. Locatelli, B. Gridelli. Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. *Lancet* 2002;359:1671-1672.
 660. C. Chiurchiu, P. Ruggenenti, G. Remuzzi. Thrombotic microangiopathy in renal transplantation. *Annals of Transpl* 2002;7:28-33.
 661. C. Aros, G. Remuzzi. The renin-angiotensin system in progression, remission and regression of chronic nephropathies. *J Hypertens* 2002;20:S45-S53.
 662. M. Abbate, C. Zoja, D. Rottoli, D. Corna, S. Tomasoni, G. Remuzzi. Proximal tubular cells promote fibrogenesis by TGF- β 1-mediated induction of peritubular myofibroblasts. *Kidney Int* 2002;61:2066-2077.
 663. M. Morigi, D. Macconi, C. Zoja, R. Donadelli, S. Buelli, C. Zanchi, M. Ghilardi, G. Remuzzi. Protein overload-induced NF-kB activation in proximal tubular cells requires H₂O₂ through a PKC-dependent pathway. *J Am Soc Nephrol* 2002;13:1179-1189.
 664. G. Remuzzi, M. Galbusera, M. Noris, M.T. Canciani, E. Daina, E. Bresin, S. Contaretti, J. Caprioli, S. Gamba. Von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. *Blood* 2002;100:778-785.
 665. D. Cattaneo, N. Perico, F. Gaspari, E. Gotti, G. Remuzzi. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. *Kidney Int* 2002;62:1060-1067.
 666. R.C. Campbell, G. Remuzzi. Halting the progression of renal disease: where we stand? (Editorial). *Nefrologia* 2002;XXII(4):303-305.
 667. A. Schieppati, N. Perico, G. Remuzzi. Tacrolimus and ciclosporin microemulsion in renal transplantation (Correspondence). *Lancet* 2002;360:799-800.
 668. G. Remuzzi, C. Chiurchiu, M. Abbate, V. Brusegan, M. Bontempelli, P. Ruggenenti. Rituximab for idiopathic membranous nephropathy (Research Letter). *Lancet* 2002;360:923-924. **Correction:** *Lancet* 2002;360:2090
 669. R. Pisoni, R. Faraone, P. Ruggenenti, G. Remuzzi. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency. *J Nephrol* 2002;15:428-430.
 670. C. Zoja, S. Angioletti, R. Donadelli, C. Zanchi, S. Tomasoni, E. Binda, B. Imberti, M. te Loo, L. Monnens, G. Remuzzi, M. Morigi. Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kB dependent up-regulation of IL-8 and MCP-1. *Kidney Int* 2002;62:846-856.

671. A. Remuzzi, E. Gagliardini, C. Donadoni, A. Fassi, F. Sangalli, M.S. Lepre, G. Remuzzi, A. Benigni. Effect of angiotensin II antagonism on the regression of kidney disease in the rat. *Kidney Int* 2002;62:885-894.
672. R. Pisoni, P. Ruggenenti, F. Sangalli, M.S. Lepre, A. Remuzzi, G. Remuzzi. Effect of high dose ramipril with or without indomethacin on glomerular selectivity. *Kidney Int* 2002;62:1010-1019.
673. A. Schieppati, N. Perico, G. Remuzzi. Conflict of interest as seen from a researcher's perspective. *Science and Engineering Ethics* 2002;8:337-342.
674. R. Pisoni, C. Aros, P. Ruggenenti, G. Remuzzi. Mechanisms of progression of chronic renal disease. *Saudi J Kidney Dis Transplant* 2002;13:250-256.
675. B. Ene-Iordache, S. Bruno, A. Remuzzi, G. Remuzzi. Effect of hemodynamic conditions on arteriovenous fistula for hemodialysis access. *Hemodialysis Technology. Contrib Nephrol.* Edited by C. Ronco and G. La Greca. Karger, Basel 2002, vol. 137, pp. 54-59.
676. P. Bettinaglio, A. Galbusera, J. Caprioli, S. Orisio, A. Perna, F. Arnoldi, S. Bucchioni, M. Noris on behalf of the BENEDICT Study Group. Single Strand Conformation Polymorphism (SSCP) as a quick and reliable method to genotype M235T polymorphism of angiotensinogen gene. *Clinical Biochemistry* 2002;35:363-368.
677. M. Todeschini, D. Macconi, N. Garcia Fernandez, M. Ghilardi, A. Anabaya, E. Binda, M. Morigi, D. Cattaneo, E. Perticucci, G. Remuzzi, M. Noris. Effect of acetate-free biofiltration and bicarbonate hemodialysis on neutrophil activation. *Am J Kidney Dis* 2002;40:783-793.
678. G. Remuzzi, N. Perico, A. Benigni. New therapeutics that antagonize endothelin: promises and frustrations. *Nature Reviews Drug Discovery* 2002;1:986-1001.
679. W.C. Gerth, G. Remuzzi, G. Viberti, T. Hannedouche, A. Martinez-Castelao, S. Shahinfar, G.W. Carides, B. Brenner. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union. *Kidney Int* 2002;62:S68-S72.
680. R.C. Campbell, P. Ruggenenti, G. Remuzzi. Halting the progression of chronic nephropathy. *J Am Soc Nephrol* 2002;13:S190-S195.
681. N. Perico, P. Ruggenenti, M. Scalapogna, G. Locatelli, G. Remuzzi. One or two marginal organs for kidney transplantation? *Transplant Proc* 2002;34:3091-3096.
682. M. Abbate, C. Zoja, M. Morigi, D. Rottoli, S. Angioletti, S. Tomasoni, C. Zanchi, L. Longaretti, R. Donadelli, G. Remuzzi. Transforming Growth Factor-b1 is upregulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. *Am J Pathol* 2002;161:2179-2193.
683. C. Zoja, D. Corna, D. Camozzi, D. Cattaneo, D. Rottoli, C. Batani, C. Zanchi, M.

- Abbate, G. Remuzzi. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. *J Am Soc Nephrol* 2002;13:2898-2908.
684. A. Parvanova, I. Iliev, B.D. Dimitrov, F. Arnoldi, J. Zaletel, G. Remuzzi, P. Ruggenenti. Hyperhomocysteinemia and increased risk of retinopathy: a cross-sectional, case-control study in patients with type 2 diabetes (Letter to the Editor). *Diabetes Care* 2002;25:2361.
 685. G. Remuzzi, M. Galbusera, P.M. Mannucci. ADAMTS13 in thrombotic microangiopathies (Response to Tsai's Letter to the Editor). *Blood* 2002;100:3842
 686. G. Dotti, R. Fiocchi, T. Motta, C. Mammana, E. Gotti, S. Riva, P. Cornelli, B. Gridelli, P. Viero, E. Oldani, P. Ferrazzi, G. Remuzzi, T. Barbui, A. Rambaldi. Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. *Transplantation* 2002;74:1095-1102.
 687. K.E. White, R.W. Bilous, S.M. Marshall, M. El Nahas, G. Remuzzi, G. Piras, S. De Cosmo G. Viberti on behalf of the European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT). Podocyte number in normotensive type 1 diabetic patients with albuminuria. *Diabetes* 2002;51:3083-3089.
 688. P.F. Zipfel, C. Skerka, J. Hellwage, S.T. Jokiranta, S. Meri, V. Brade, P. Kraiczy, M. Noris, G. Remuzzi. Structure-function studies of the complement system. *Biochemical Society Transaction* 2002;30:971-978.
 689. M. Abbate, G. Remuzzi. Renoprotection: Clues from knockout models of rare disease. *Kidney Int* 2003;63:764-766.
 690. R. Campbell, F. Sangalli, E. Perticucci, C. Aros, C. Viscarra, A. Perna, A. Remuzzi, F. Bertocchi, L. Fagiani, G. Remuzzi, P. Ruggenenti. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. *Kidney Int* 2003;63:1094-1103.
 691. B.D. Dimitrov, A. Perna, P. Ruggenenti, G. Remuzzi. Predicting end-stage renal disease: Bayesian perspective of information transfer in the clinical decision-making process at the individual level. *Kidney Int* 2003;63:1924-1933.
 692. C. Chiurchiu, A. Firrincieli, M. Santostefano, M. Fusaroli, G. Remuzzi, P. Ruggenenti. Adult non-diarrhea hemolytic uremic syndrome associated with shiga toxin *Escherichia coli* 0157:H7 bacteremia and urinary tract infection. *Am J Kidney Dis* 2003;41:E4.
 693. P. Ruggenenti, N. Mise, R. Pisoni, F. Arnoldi, A. Pezzotta, A. Perna, D. Cattaneo, G. Remuzzi. Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. *Circulation* 2003;107:586-592.
 694. A. Schieppati, N. Perico, G. Remuzzi. Preventing end-stage renal disease: the potential impact of screening and intervention in developing countries. *Kidney Int* 2003;63:1948-1950.

695. A. Schieppati, N. Perico, G. Remuzzi. Preventing end-stage renal disease: the potential impact of screening and intervention in developing countries (Editorial commentary). *Nephrol Dial Transplant* 2003;18:858-859.
696. E. Gotti, N. Perico, A. Perna, F. Gaspari, D. Cattaneo, R. Caruso, S. Ferrari, N. Stucchi, G. Marchetti, M. Abbate, G. Remuzzi. Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings. *J Am Soc Nephrol* 2003;14:755-766.
697. P. Ruggenenti, A. Perna, G. Remuzzi on behalf of the Investigators of the GISEN Group. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. *Kidney Int* 2003;63:2254-2261.
698. A. Benigni, C. Zoja, D. Corna, C. Zatelli, S. Conti, M. Campana, E. Gagliardini, D. Rottoli, C. Zanchi, M. Abbate, S. Ledbetter, G. Remuzzi. Add-on anti-TGF- β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. *J Am Soc Nephrol* 2003;14:1816-1824.
699. C. Zoja, M. Morigi, G. Remuzzi. Proteinuria and phenotypic change of proximal tubular cells. *J Am Soc Nephrol* 2003;14:S36-S41.
700. P. Ruggenenti, C. Chiurciu, V. Brusegan, M. Abbate, A. Perna, C. Filippi, G. Remuzzi. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. *J Am Soc Nephrol* 2003;14:1851-1857.
701. The BENEDICT Group. The Bergamo NEphrologic Diabetes Complications Trial (BENEDICT): design and baseline characteristics. *Controlled Clinical Trials* 2003;24:442-461.
702. B. Ene-Iordache, L. Mosconi, L. Antiga, S. Bruno, A. Anghileri, G. Remuzzi, A. Remuzzi. Radial artery remodeling in response to shear stress increase within arteriovenous fistula for hemodialysis access. *Endothelium* 2003;10:95-102.
703. P. Ruggenenti, C. Flores, C. Aros, B. Ene-Iordache, R. Trevisan, C. Ottomano, G. Remuzzi. Renal and metabolic effects of insulin lispro in type 2 diabetic subjects with overt nephropathy. *Diabetes Care* 2003;26:502-509.
704. C. Zoja, A. Benigni, D. Camozzi, D. Corna, L. Longaretti, M. Todeschini, G. Remuzzi. Combining lisinopril and L-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis. *Kidney Int* 2003;64:857-863.
705. M. Abbate, G. Remuzzi. Can we really lessen kidney damage to the point that the loss of renal function of progressive nephropathy may revert? *J Am Soc Nephrol* 2003;14:1411-1414.
706. G. Remuzzi. Is ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? No. *J Thromb Haemost* 2003;1:631-634.

707. S. Bruno, S. Ferrari, G. Remuzzi, P. Ruggenenti. Doppler ultrasonography in posttransplant renal artery stenosis: a reliable tool for assessing effectiveness of revascularization? *Transplantation* 2003;76:147-153.
708. T.H. Jafar, C.H. Schmid, P.C. Stark, R. Toto, G. Remuzzi, P. Ruggenenti, C. Marcantoni, G. Becker, S. Shahinfar, P.E. de Jong, D. de Zeeuw, A-L. Kamper, S. Strangaard, A.S. Levey for the AIPRD Study Group. The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. *Nephrol Dial Transplant* 2003;18:2047-2053.
709. N. Perico, P. Ruggenenti, M. Scalapogno, G. Remuzzi. Tackling the shortage of donor kidneys: how to use the best that we have. *Am J Nephrol* 2003;23:245-259.
710. A. Remuzzi, B. Ene-Iordache, L. Mosconi, S. Bruno, A. Anghileri, L. Antiga, G. Remuzzi. Radial artery wall shear stress evaluation in patients with arteriovenous fistula for hemodialysis access. *Biorheology* 2003;40:423-430.
711. R. Donadelli, C. Zanchi, M. Morigi, S. Buelli, C. Batani, S. Tomasoni, D. Corna, D. Rottoli, A. Benigni, M. Abbate, G. Remuzzi, C. Zoja. Protein overload induces fractalkine upregulation in proximal tubular cells through nuclear factor κ B- and p38 mitogen-activated protein kinase-dependent pathways. *J Am Soc Nephrol* 2003;14:2436-2446.
712. A. Schieppati, P. Ruggenenti, A. Perna, G. Remuzzi. Nonimmunosuppressive therapy of membranous nephropathy. *Semin Nephrol* 2003;23:333-339.
713. B.D. Dimitrov, P. Ruggenenti, R. Stefanov, A. Perna, G. Remuzzi. Chronic Nephropathies: individual risk for progression to end-stage renal failure as predicted by an integrated probabilistic model. *Nephron Clin Pract* 2003;95:c47-c59.
714. G. Laverman, P. Ruggenenti, G. Remuzzi. Angiotensin-converting enzyme inhibition or angiotensin receptor blockade in hypertensive diabetics? *Curr Hypertens Rep* 2003;5:364-367.
715. M. Noris, S. Brioschi, J. Caprioli, M. Todeschini, E. Bresin, F. S. Gamba, G. Remuzzi for the International Registry of Recurrent and Familial HUS/TTP. Familial hemolytic uraemic syndrome and an MCP mutation. *Lancet* 2003;362:1542-1547.
716. G. Remuzzi. Deficiency of ADAMTS-13 in thrombotic and thrombocytopenic purpura. *J Thromb Haemost* 2003;1:2040-2041.
717. G.D. Laverman, G. Remuzzi. Antihypertensive therapy in chronic renal disease: a place for sympatholytic agents? *J Hypertens* 2003;21:1625-1626.
718. G. Remuzzi, M. Galbusera, P. Boccardo. Disorders of hemostasis in dialysis patients. In: *Principles and Practice of Dialysis (3rd Edition)*. Edited by W.L. Henrich, Lippincott Williams & Wilkins, Philadelphia 2003, pp. 453-463.
719. M. Galbusera, G. Remuzzi. The role of vWF and vWF cleaving protease in the

- pathogenesis of TTP and HUS. In: Haematology 2003 – Proceedings of the XVII Meeting of the International Society of Haematology, Edited by W. Linkesch, Monduzzi Editore, Graz, Austria 2003, pp. 73-78.
720. T. Manuelian, J. Hellwage, S. Meri, J. Caprioli, M. Noris, S. Heinen, M. Jozsi, H.P.H. Neumann, G. Remuzzi, P. Zipfel. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. *J Clin Invest* 2003;111:1181-1190.
 721. Blood pressure lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *Lancet* 2003;362:1527-1535.
 722. M. Noris, M. Mister, A. Pezzotta, N. Azzolini, P. Cassis, A. Benigni, E. Gagliardini, N. Perico, G. Remuzzi. ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established. *Kidney Int* 2003;64:2253-2261.
 723. A. Schieppati, G. Remuzzi. The future of renoprotection: Frustration and promises. *Kidney Int* 2003;64:1947-1955.
 724. J. Caprioli, F. Castelletti, S. Bucchioni, P. Bettinaglio, E. Bresin, G. Pianetti, S. Gamba, S. Brioschi, E. Daina, G. Remuzzi, M. Noris for the International registry of Recurrent and Familial HUS/TTP. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. *Hum Mol Genet* 2003;12:3385-3395.
 725. R.C. Campbell, P. Ruggenenti, G. Remuzzi. Proteinuria in diabetic nephropathy: treatment and evolution. *Curr Diabet Rep* 2003;3:497-504.
 726. E. Gagliardini, A. Benigni, S. Tomasoni, M. Abbate, R. Kalluri, G. Remuzzi. Targeted downregulation of extracellular nephrin in human IgA nephropathy. *Am J Nephrol* 2003;23:277-286.
 727. Ruiz-Torres MP, Casiraghi F, Noris M, Macconi D, Galbusera M, Remuzzi G. Mechanisms of endothelial damage in thrombotic microangiopathy. *Nefrologia* 2003;23 (Suppl 3):25-27.
 728. P. Ruggenenti, G. Remuzzi. Is therapy with combined ACE inhibitor and angiotensin receptor antagonist the new gold standard of treatment for nondiabetic, chronic proteinuric nephropathies? *NephSAP* 2003;2:235-237.
 729. J. Caprioli, S. Brioschi, G. Remuzzi. Molecular basis of familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. *Saudi J Kidney Dis Transplant* 2003;14:342-350.
 730. R. Pisoni, P. Ruggenenti, G. Remuzzi. Thrombotic microangiopathies including hemolytic uremic syndrome (2nd Edition). In: *Comprehensive Clinical Nephrology*.

Edited by R.J. Johnson and J. Feehally, Mosby – Elsevier Science, Philadelphia, USA 2003, pp. 413-423.

731. P. Ruggenenti, M. Noris, G. Remuzzi. Thrombotic Microangiopathies. In: Therapy in Nephrology and Hypertension – A companion to Brenner and Rector's The Kidney (2nd Edition), chapter n. 29. Edited by H.R Brady, C.S. Wilcox. Saunders, Toronto 2003, pp. 283-295.
732. G. Remuzzi, A. Schieppati, L. Minetti. Anemia and Coagulopathy. In: Therapy in Nephrology and Hypertension – A companion to Brenner and Rector's The Kidney (2nd Edition), chapter n. 72. Edited by H.R Brady, C.S. Wilcox. Saunders, Toronto 2003, pp. 689-700.
733. A. Schieppati, G. Remuzzi. Proteinuria and its consequences in renal disease. *Acta Paediatric Suppl* 2003;443:9-13.
734. W.E. Mitch, G. Remuzzi. Diets for patients with chronic kidney disease, still worth prescribing. *J Am Soc Nephrol* 2004;15:234-237.
735. C. Zoja, A. Benigni, G. Remuzzi. Cellular responses to protein overload: key event in renal disease progression. *Curr Opin Nephrol Hypertens* 2004;13:31-37.
736. S. Bruno, G. Remuzzi, P. Ruggenenti. Transplant Renal Artery Stenosis. *J Am Soc Nephrol* 2004;15:134-141.
737. M. Noris, M. Todeschini, P. Cassis, F. Pasta, A. Cappellini, S. Bonazzola, D. Macconi, R. Maucci, F. Porriati, A. Benigni, C. Picciolo, G. Remuzzi. L-Arginine Depletion in Preeclampsia Orients Nitric Oxide Synthase Toward Oxidant Species. *Hypertension* 2004;43:614-622.
738. A. Schieppati, G. Remuzzi. Fighting Renal Diseases in Poor Countries: Building a Global Fund with the Help of the Pharmaceutical Industry. *J Am Soc Nephrol* 2004;15:704-707.
739. D. Cattaneo, N. Perico, F. Gaspari, G. Remuzzi. Nephrotoxic Aspects of Cyclosporine. *Transplant Proc* 2004;36:234S-239S.
740. P. Ruggenenti, G. Remuzzi. Introduction. *Semin Nephrol* 2004;24:91-92.
741. A. Benigni, E. Gagliardini, G. Remuzzi. Changes in Glomerular Perm-Selectivity Induced by Angiotensin II Imply Podocyte Dysfunction and Slit Diaphragm Protein Rearrangement. *Semin Nephrol* 2004;24:131-140.
742. N. Perico, P. Ruggenenti, E. Gotti, F. Gaspari, D. Cattaneo, U. Valente, M. Salvadori, G. Segoloni, D. Donati, S. Sandrini, M. Ganeva, B. D. Dimitrov, G. Remuzzi on behalf of the MY.S.S. Study Investigators. In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: Insights from the MY.S.S. Trial. *Kidney Int* 2004;65:1084-1090.

743. G.D. Laverman, G. Remuzzi, P. Ruggenenti. Ace Inhibition versus Angiotensin Receptor Blockade: Which Is Better for Renal and Cardiovascular Protection? *J Am Soc Nephrol* 2004;15:S64-S70.
744. C.H. Beerenhaut, M. Noris, J.P. Koomen, F. Porrati, E. Binda, M. Morigi, O. Bekers, F.M. van der Sande, M. Todeschini, D. Maconi, K.M.L. Leunissen, G. Remuzzi. Nitric Oxide Synthetic Capacity in Relation to Dialysate Temperature. *Blood Purif* 2004;22:203-209.
745. D. Cattaneo, N. Perico, G. Remuzzi. From Pharmacokinetics to Pharmacogenomics: A New Approach to Tailor Immunosuppressive Therapy. *Am J Transplant* 2004;4:299-310.
746. D. de Zeeuw, G. Remuzzi, H.H. Parving, W.F. Keane, Z. Zhang, S. Shahinfar, S. Snapinn, M.E. Cooper, W.E. Mitch, B.M. Brenner. Proteinuria, a target for renoprotection in patients with type diabetic nephropathy: Lesson from RENAAL. *Kidney Int* 2004;65:2309-2320.
747. P. Pedotti, M. Cardillo, P. Rigotti, G. Gerunda, R. Merenda, U. Cillo, G. Zanusi, U. Baccarani, M.L. Berardinelli, L. Boschiero, L. Caccamo, G. Calconi, S. Chiaramonte, A. dal Canton, L. de Carlis, V. di Carlo, D. Donati, A. Pulvirenti, G. Remuzzi, S. Sandrini, U. Valente, M. Scalamogna. A comparative prospective study of two available solutions for kidney and liver preservation. *Transplantation* 2004;77:1540-1545.
748. S. Tomasoni, L. Longaretti, N. Azzolini, E. Gagliardini, M. Mister, T. Buehler, G. Remuzzi, A. Benigni. Favourable Effect of Contransfection with TGF- β and CTLA4lg of the Donor Kidney on Allograft Survival. *Am J Nephrol* 2004;24:275-283.
749. N. Perico, P. Ruggenenti, G. Remuzzi. Losartan in diabetic nephropathy. *Expert Rev Cardiovasc Ther* 2004; 2(4): 473-483.
750. A. Benigni, E. Gagliardini, S. Tomasoni, M. Abbate, P. Ruggenenti, R. Kalluri, G. Remuzzi. Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. *Kidney Int* 2004;65:2193-2200.
751. D. Cattaneo, S. Merlini, M. Pellegrino, F. Carrara, S. Zenoni, S. Murgia, S. Baldelli, F. Gaspari, G. Remuzzi, N. Perico. Therapeutic Drug Monitoring of Sirolimus: Effect of Concomitant Immunosuppressive Therapy and Optimization of Drug Dosing. *Am J Transplant* 2004;1345-1351.
752. M. Morigi, B. Imberti, C. Zoja, D. Corna, S. Tomasoni, M. Abbate, D. Rottoli, S. Angioletti, A. Benigni, N. Perico, M. Alison, G. Remuzzi. Mesenchymal Stem Cells Are Renotropic, Helping to Repair the Kidney and Improve Function in Acute Renal Failure. *J Am Soc Nephrol* 2004;15:1794-1804.
753. A. Perna, A. Schieppati, J. Zamora, G.A. Giuliano, N. Braun, G. Remuzzi. Immunosuppressive Treatment for Idiopathic Membranous Nephropathy: A Systematic Review. *Am J Kidney Dis* 2004;44:385-401.

754. G. Remuzzi, M.D. Lesti, E. Gotti, M. Ganeva, B.D. Dimitrov, B. Ene-Iordache, G. Gherardi, D. Donati, M. Salvadori, S. Sandrini, U. Valente, G. Segoloni, G. Mourad, S. Federico, P. Rigotti, V. Sparacino, J. Bosmans, N. Perico, P. Ruggenti, for the MYSS Study Group. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomized trial. *Lancet* 2004;364:503-512.
755. I. Codreanu, P. Cravedi, G. Remuzzi, P. Ruggenti. Dual Kidney Transplantation. *Transplantationsmedizin* 2004;16:13-18.
756. G. Remuzzi. Challenges to achieving clinical transplantation tolerance. *Curr Opin Organ Transplant* 2004;9:277-278.
757. D. de Zeeuw, G. Remuzzi, H.H. Parving, W.F. Keane, Z. Zhang, S. Shahinfar, S. Snapinn, M.E. Cooper, W.E. Mitch, B.M. Brenner. Albuminuria, a therapeutic target for cardiovascular protection in type diabetic patients with nephropathy. *Circulation* 2004;210:921-927.
758. C. Zoja, M. Morigi, A. Benigni, G. Remuzzi. Genetics of rare diseases of the kidney: learning from mouse models. *Cytogenet Genome Research* 2004;105:479-484.
759. A. Parvanova, I. Iliev, M. Filipponi, B.D. Dimitrov, M. Vedovato, A. Tiengo, R. Trevisan, G. Remuzzi, P. Ruggenti. Insulin resistance and proliferative retinopathy: a cross-sectional, case control study in 115 patients with type 2 diabetes. *J Clin Endocrinol Metab* 2004;89: 4371-4376.
760. P. Ruggenti, A. Fassi, A. Parvanova, S. Bruno, I. Iliev, V. Brusegan, N. Rubis, G. Gherardi, F. Arnoldi, M. Ganeva, B. Ene-Iordache, F. Gaspari, A. Perna, A. Bossi, R. Trevisan, A.R. Dodesini, G. Remuzzi for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. *N Engl J Med* 2004;351:1941-1951.
761. G. Remuzzi, C. Chiurciu, P. Ruggenti. Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN). *Kidney Int* 2004;66:S90-S96.
762. N. Perico, D. Cattaneo, M.H. Sayegh, G. Remuzzi. Delayed graft function in kidney transplantation. *Lancet* 2004;364:1814-1827.
763. F. Gaspari, S. Ferrari, N. Stucchi, E. Centemeri, F. Carrara, M. Pellegrino, G. Gherardi, E. Gotti, G. Segoloni, M. Salvadori, P. Rigotti, U. Valente, D. Donati, S. Sandrini, V. Sparacino, G. Remuzzi, N. Perico on the behalf of the MY.S.S. study investigators. Performance of different prediction equations for estimating renal function in kidney transplantation. *Am J Transplant* 2004;4:1826-1835.
764. A. Benigni, D. Corna, C. Zoja, L. Longaretti, E. Gagliardini, N. Perico, T.M. Coffman, G. Remuzzi. Targeted deletion of angiotensin II type 1A receptor does not protect mice from progressive nephropathy of overload proteinuria. *J Am Soc Nephrol* 2004;15:2666-2674.

765. N. Perico, F. Gaspari, D. Cattaneo, G. Kainer, G. Remuzzi. Blood cyclosporine concentration after kidney transplant: major determinant of rejection. *Am J Urol Rev* 2004;2:514-518.
766. G. Remuzzi, A. Schieppati, J-P. Boissel, S. Garattini, R. Horton. Independent clinical research in Europe. *Lancet* 2004;364:1723-1726.
767. A. Benigni, N. Perico, G. Remuzzi. The potential of endothelin antagonism as a therapeutic approach. *Expert Opin Investig Drugs* 2004;13:1419-1435.
768. D. Cattaneo, S. Baldelli, S. Merlini, S. Zenoni, N. Perico, G. Remuzzi. Therapeutic use of HMG-CoA reductase inhibitors: current practice and future perspectives. *Expert Opin Ther Patents* 2004;14:1553-1566.
769. D. Cattaneo, A. Tankiewicz, S. Merlini, N. Perico, G. Remuzzi. Pharmacogenetics and pharmacogenomics of immunosuppressive agents: perspective for individualized therapy. *Personalized Med* 2004;1:53-62.
770. G. Remuzzi, P. Ruggenenti, A. Perna, B.D. Dimitrov, D. De Zeeuw, D.A. Hillie, S. Shahinfar, G.W. Carides, B.M. Brenner for the Renaal study froup. Continuum of renoprotection with Losartan at all stages of type 2 diabetic nephropathy: a post-hoc analysis of the renal trial results. *J Am Soc Nephrol* 2004;15:3117-3125.
771. P. Ruggenenti, G. Remuzzi. The way to cardio-renal protection in non-diabetic nephropathies. *Rocz Akad Med Bialymst* 2004;49:116-123.
772. A. Schieppati, A. Perna, J. Zamora, G.A. Giuliano, N. Braun, G. Remuzzi. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. *Cochrane Database of Systematic Reviews* 2004;Issue 4. Art.No: CD004293.pub2. DOI: 10.1002/14651858.CD004293.pub2.
773. G. Remuzzi, A. Schieppati, L. Minetti. Hematologic consequences of renal failure. In: Brenner and Rector's *The Kidney*, 7th ed., Vol. II, chapter n. 49. Edited by B.M. Brenner. Saunders Elsevier, Philadelphia 2004, pp. 2165-2188.
774. N. Perico, M. Noris, G. Remuzzi. Vasoactive and inflammatory substances. In: *Toxicology of the Kidney*, 3rd ed., chapter n. 14. Edited by J.B. Tarloff, L.H. Lash. CRC Press, London 2004, pp. 527-618.
775. P. Boccardo, G. Remuzzi, M. Galbusera. Platelet Dysfunction in Renal Failure. *Semin Thromb Haemost* 2004;30:579-589.
776. A. Benigni, C. Zoja, C. Zatelli, D. Corna, L. Longaretti, D. Rottoli, P. Maggioni, M. Todeschini, M. Noris, G. Remuzzi. Vasoepitidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. *Kidney Int* 2004;66:1959-1965.
777. D. Cattaneo, F. Gaspari, S. Zenoni, S. Baldelli, E. Gotti, A. Perna, N. Perico, G. Remuzzi. Two-hour post-dose cyclosporine monitoring does not fit all in kidney

transplantation. *Therapy* 2005;2:95-105.

- 778. M.H. Sayegh, N. Perico, G. Remuzzi. Transplantation tolerance: a complex scenario awaiting clinical applicability. In: *Contributions to Nephrology: Kidney Transplantation: strategies to prevent organ rejection*. Edited by C. Ronco, S. Chiamonte, G. Remuzzi. Basel, Karger 2005, vol. 146, pp. 95-104.
- 779. N. Perico, I. Codreanu, M. Caruso, G. Remuzzi. Hyperuricemia in kidney transplantation. In: *Contributions to Nephrology: Hyperuricemic Syndromes: Pathophysiology and therapy*. Edited by C. Ronco, F. Rodeghiero. Basel, Karger 2005, vol. 147, pp.124-131.
- 780. S. Baldelli, S. Murgia, S. Merlini, S. Zenoni, N. Perico, G. Remuzzi, D. Cattaneo. High-performance liquid chromatography with ultraviolet detection for therapeutic drug monitoring of everolimus. *J Chromatogr* 2005;816:99-105.
- 781. G. Remuzzi. Microalbuminuria in type 2 diabetes. *Nephropathy* 2005;2:34-35.
- 782. M. Galbusera, S. Buelli, S. Gastoldi, D. Macconi, S. Angioletti, C. Testa, G. Remuzzi, M. Morigi. Activation of porcine endothelium in response to xenogeneic serum causes thrombosis independently of platelet activation. *Xenotransplantation* 2005;12;110-120.
- 783. M.P. Ruiz-Torres, F. Casiraghi, M. Galbusera, D. Macconi, S. Gastoldi, M. Todeschini, F. Porrati, D. Belotti, E. M. Pogliani, M. Noris, G. Remuzzi. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. *Thromb Haemost* 2005;93:443-452.
- 784. P. Ruggenenti, A. Perna, G. Loriga, M. Ganeva, B. Ene-Iordache, M. Turturro, M. Lesti, E. Perticucci, I. Nedyyalkov, D. Leonardis, G. Garini, A. Sessa, C. Basile, M. Alpa, R. Scanziani, G. Sorba, C. Zoccali, G. Remuzzi. Blood-pressure control for renoprotection in patients with non-diabetic chronic disease (REIN-2): multicentre, randomized controlled trial. *Lancet* 2005;365:939-946.
- 785. D. Cattaneo, N. Perico, G. Remuzzi. Generic cyclosporine formulations: more open questions than answers. *Transplant Int* 2005;18:371-378.
- 786. D. Cattaneo, G. Remuzzi. Lipid Oxidative stress and the Anti-inflammatory properties of statins and ACE inhibitors. *J Ren Nutr* 2005;15:71-76.
- 787. T.H. Mix, R.M. Brenner, M.E. Cooper, D.D. Zeeuw, P. Ivanovich, A.S. Levey, J.B. McGill, J.J.V. McMurray, P.S. Parfrey, H.H. Parving, B.J. Pereira, G. Remuzzi, A. Singh, S. Solomon, C. Stehman-Breen, R. Toto, M. Pfeffer. Rationale-Trial to reduce cardiovascular events with aranesp therapy (TREAT): evolving the management of cardiovascular risk inpatients with chronic kidney disease. *Am Heart J* 2005;149(3):408-413.
- 788. G. Remuzzi, J.J. Weening. Albuminuria as early test for vascular disease (Comment). *Lancet* 2005;365:556-557.

789. P. Kam-Tao Li, J.J. Weening, J. Dirks, S. Leung Lui, C.C. Szeto, S. Tang, R. Atkins, W.E. Mitch, K. Ming Chow, G. D'Amico, B. Freedman, D. Harris, L-S Hoog, P.E. De Jong, P. Kincaid-Smith, K.N. Lai, E. Lee, F. Keung Li, S.Y. Lin, W.K. Lo, M.K. Mani, T. Mathew, M. Murakami, J. Qi Qian, S. Ramirez, T. Reiser, Y. Tomino, M.K. Tong, W.K. Tsang, K. Tungsanga, H. Wang, A.K. Wong, K.M. Wong, W.C. Yang, D. De Zeeuw, A.W. Yu, G. Remuzzi on behalf of the participants of ISN consensus workshop on prevention of progression of renal disease. A report with consensus statements of the International Society of Nephrology 2004 consensus workshop on prevention of Progression of renal disease. Hong Kong, June 2004. *Kidney Int* 2005;67(94): S2-S7.
790. P. Ruggenenti, A. Schieppati, N. Perico, I. Codreanu, L. Peng, G. Remuzzi. Kidney prevention recipes for your office practice. *Kidney Int* 2005;67(94):S136-S141.
791. N. Perico, I. Codreanu, A. Schieppati, G. Remuzzi. Pathophysiology of disease progression in proteinuric nephropathies. *Kidney Int* 2005;67(94):S79-S82.
792. N. Perico, I. Codreanu, A. Schieppati, G. Remuzzi. The scientific care for prevention: An overview. *Kidney Int* 2005;67(94):S8-S13.
793. G. Remuzzi, C. Ronco, S. Chiaramonte. Introduction. In: Contributions to Nephrology: Kidney Transplantation: strategies to prevent organ rejection. Edited by C. Ronco, S. Chiaramonte, G. Remuzzi. Karger, Basel 2005, vol. 146, pp. VII-VIII.
794. D. Cugini, N. Azzollini, E. Gagliardini, P. Cassis, R. Bertini, F. Colotta, M. Noris, G. Remuzzi, A. Benigni. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. *Kidney Int* 2005;67:1753-1761.
795. D. Cattaneo, S. Zenoni, S. Murgia, S. Merlini, S. Baldelli, N. Perico, E. Gotti, C. Ottomano, A. Crippa, G. Remuzzi. Comparison of different cyclosporine immunoassays to monitor C₀ and C₂ blood levels from kidney transplant recipients: Not simply overestimation. *Clin Chim Acta* 2005;355:153-164.
796. M. Figliuzzi, R. Cornolti, T. Plati, N. Rajan, F. Adobati, G. Remuzzi, A. Remuzzi. Subcutaneous xenotransplantation of bovine pancreatic islets. *Biomaterials* 2005;26:5640-5647.
797. M. Morigi, S. Buelli, S. Angioletti, C. Zanchi, L. Longaretti, C. Zoja, M. Galbusera, S. Gastoldi, P. Mundel, G. Remuzzi, A. Benigni. In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. *Am J Pathol* 2005;166:1309-1320.
798. G. Remuzzi, P. Ruggenenti, M. Colledan, B. Gridelli, A. Bertani, P. Bettinaglio, S. Bucchioni, A. Sonzogni, E. Bonanomi, V. Sonzogni, J.L. Platt, N. Perico, M. Noris. Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor H gene mutation. *Am J Transpl* 2005;5:1146-1150.

799. P. Ruggenenti, A. Remuzzi, P. Ondeì, G. Fasolini, L. Antiga, B. Ene-Iordache, G. Remuzzi, F.H. Epstein. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. *Kidney Int* 2005;68:206-216.
800. R. Aparecida Cavinato, F. Casiraghi, N. Azzollini, P. Cassis, D. Cugini, M. Mister, A. Pezzotta, S. Aiello, G. Remuzzi, M. Noris. Pretransplant donor peripheral blood mononuclear cells infusion induces transplantation tolerance by generating regulatory T cells. *Transplantation* 2005;79:1034-1039.
801. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Results of prospectively designed overviews of randomized trials. *Arch Intern Med* 2005;165:1410-1419.
802. S. Tomasoni, S. Aiello, L. Cassis, M. Noris, L. Longaretti, R.A. Cavinato, N. Azzollini, A. Pezzotta, G. Remuzzi, A. Benigni. Dendritic cells genetically engineered with adenoviral vector encoding dnIKK2 induce the formation of potent CD4⁺ T-regulatory cells. *Transplantation* 2005;79:1056-1061.
803. G. Merlini, G. Remuzzi. Autologous stem cell and kidney transplantation for primary amyloidosis associated with ESRD: which should come first? *Am J Transpl* 2005;5:1585-1586.
804. M. Noris, S. Bucchioni, M. Galbusera, R. Donadelli, E. Bresin, F. Castelletti, J. Caprioli, S. Brioschi, F. Scheiflinger, G. Remuzzi. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. *J Am Soc Nephrol* 2005;16:1177-1183.
805. P. Hill, E. Gagliardini, P. Ruggenenti, G. Remuzzi. Severe early humoral rejection resulting in allograft loss in a renal transplant recipient with Campath-1H induction therapy. *Nephrol Dial Transplant* 2005;20:1741-1744.
806. P. Boccardo, C. Zoja, G. Remuzzi: Coagulation disorders. In: *Oxford Textbook of Clinical Nephrology* (Third Edition), edit by: M. Davison, J. S. Cameron, J-P. Grunfeld, C. Ponticelli, E. Ritz, C. G. Winearls and C. van Ypersele 2005;3:1875-1878.
807. A. Pezzotta, M. Mister, P. Cravedi, N. Azzolini, L. Cassis, V. Ruggiero, R. De Santis, P. Carminati, G. Remuzzi, M. Noris. Effect of a novel immunosuppressant, ST1959, on the immune system and renal allograft survival in rats. *Transplantation* 2005;80:231-236.
808. J.H. Dirks, D. de Zeeuw, S.K. Agarwal, R.C. Atkins, R. Correa-Rotter, G. D'Amico, P.H. Bennett, M. El-Nahas, R. Herrera Valdes, D. Kaseje, I.J. Katz, S. Naicker, B. Rodriguez-Iturbe, A. Schieppati, F. Shaheen, C. Sitthi-Amorn, K. Solez, G. Viberti, G. Remuzzi and J.J. Weening, on behalf of the International Society of Nephrology Commission for the Global Advancement of Nephrology Study Group 2004. Prevention of chronic kidney and vascular disease: toward global health equity – The

Bellagio 2004 Declaration. *Kidney Int* 2005;68(98):S1-S6.

809. A. Schieppati, G. Remuzzi. Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. *Kidney Int* 2005;68(98):S7-S10.
810. N. Perico, I. Codreanu, A. Schieppati, G. Remuzzi. Prevention of progression and remission/regression strategies for chronic renal diseases: can we do better now than five years ago? *Kidney Int* 2005;68(98):S21-S24.
811. N. Perico, R. Plata, A. Anabaya, I. Codreanu, A. Schieppati, P. Ruggenenti, G. Remuzzi. Strategies for national health care system in emerging countries: the case of screening and prevention of renal disease progression in Bolivia. *Kidney Int* 2005;68(98):S87-S94.
812. N. Perico, I. Codreanu, A. Schieppati, G. Remuzzi. The future of renoprotection. *Kidney Int* 2005;68(98):S95-S101.
813. A. Parvanova, C. Chiurciu, P. Ruggenenti, G. Remuzzi. Inhibition of the renin-angiotensin system and cardiorenal protection: focus on losartan and angiotensin receptor blockade. *Expert Opin Pharmacother* 2005;6:1931-1942.
814. S. Bruno, D. Cattaneo, N. Perico, G. Remuzzi. Emerging drugs for diabetic nephropathy. *Expert Opin Emerging Drugs* 2005;10:747-771.
815. P. Cravedi, I. Codreanu, A. Satta, M. Turturro, M. Sghirlanzoni, G. Remuzzi, P. Ruggenenti. Cyclosporine prolongs delayed graft function in kidney transplantation. Are rabbit anti-human thymocyte globulins the answer? *Nephron Clin Pract* 2005;101:c65-c71.
816. T.S. Jokiranta, Z-Z. Cheng, H. Seeberger, M. Jòzsi, S. Heinen, M. Noris, G. Remuzzi, R. Ormsby, D.L. Gordon, S. Meri, J. Hellwage, P.F. Zipfel. Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. *Am J Pathol* 2005;167:1173-1181.
817. A. Schieppati, R. Pisoni, G. Remuzzi. Pathophysiology and management of chronic kidney disease. In: 'Primer on Kidney Diseases', National Kidney Foundation. 4th ed, chapter n.58. Edited by Arthur Greenberg, Elsevier Saunders, Philadelphia 2005, pp. 444-454.
818. M. Noris, G. Remuzzi. Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management? *Nat Clin Pract Nephrol* 2005;1:2-3.
819. D. Cattaneo, S. Merlini, S. Zenoni, S. Baldelli, E. Gotti, G. Remuzzi, N. Perico. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. *Am J Transpl* 2005;5:2937-2944.
820. M. Rieger, P.M. Mannucci, J.A. Kremer Hovinga, A. Herzog, G. Gerstenbauer, C. Konetschny, K. Zimmermann, I. Scharrer, F. Peyvandi, M. Galbusera, G. Remuzzi,

- M. Bohm, B. Plaimauer, B. Lammle, F. Scheiflinger. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. *Blood* 2005;106:1262-1267.
821. M. Noris, G. Remuzzi. Hemolytic Uremic Syndrome (Disease of the Month). *J Am Soc Nephrol* 2005;16:1035-1050.
 822. G. Remuzzi, N. Perico, M. Macia, P. Ruggenenti. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. *Kidney Int* 2005;68(99):S57-S65.
 823. M. Galbusera, E. Bresin, M. Noris, S. Gastoldi, D. Belotti, C. Capoferri, E. Daina, P. Perseghin, F. Scheiflinger, F. Fakhouri, J.P. Grunfeld, E. Pogliani, G. Remuzzi. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. *Blood* 2005;106:925-928.
 824. M. Noris, N. Perico, G. Remuzzi. Mechanisms of disease: pre-eclampsia. *Nat Clin Pract Nephrol* 2005;1:98-114.
 825. J. Caprioli, L. Peng, G. Remuzzi. The hemolytic uremic syndromes. *Curr Opin Crit Care* 2005;11:487-492.
 826. N. Perico, F. Gaspari, G. Remuzzi. Assessing renal function by GFR prediction equations in kidney transplantation (Editorial). *Am J Transpl* 2005;5:1175-1176.
 827. G. Remuzzi, A. Remuzzi. Is regression of chronic nephropathies a therapeutic target? (Editorial) *J Am Soc Nephrol* 2005;16:840-842.
 828. E. Gotti, N. Perico, F. Gaspari, D. Cattaneo, M.D. Lesti, P. Ruggenenti, G. Segoloni, M. Salvadori, P. Rigotti, U. Valente, D. Donati, S. Sandrini, S. Federico, V. Sparacino, G. Mourad, J-L. Bosmans, B. Dimitrov, B. Ene Iordache, G. Remuzzi on the behalf of the MY.S.S. study investigators. Blood cyclosporine level soon after kidney transplantation is a major determinant of rejection: insights from the Mycophenolate Steroid-Sparing Trial. *Transplant Proc* 2005;37:2037-2040.
 829. D. Cattaneo, E. Gotti, N. Perico, G. Bertolini, G. Kainer, G. Remuzzi. Cyclosporine formulation and kaposi's sarcoma after renal transplantation. *Transplantation* 2005;80:743-748.
 830. I. Codreanu, N. Perico, G. Remuzzi. Dual blockade of the Renin-Angiotensin System: the ultimate treatment for renal protection? *J Am Soc Nephrol* 2005;16:S34-S38.
 831. C. Chiurciu, G. Remuzzi, P. Ruggenenti. Angiotensin-Converting Enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses. *J Am Soc Nephrol* 2005;16:S58-S63.
 832. P. Ruggenenti, A. Perna, G. Remuzzi. Preventing microalbuminuria in type 2 diabetes. (Correspondence, Authors' reply) *N Eng J Med* 2005;352:833-834.

833. A. Schieppati, P. Ruggenenti, G. Remuzzi. Diabetic Nephropathy: present and future challenges. In: *Kidney Diseases in the Developing World and Ethnic Minorities*. Chapter 8. Edited by M. El-Nahas, Taylor & Francis Group, New York 2005, pp. 161-189.
834. I. Codreanu, N. Perico, A. Anabaya, G. Remuzzi. Links between Bolivia, Moldova, and Italy for prevention of chronic nephropathies. In: *Kidney Diseases in the Developing World and Ethnic Minorities*. Chapter 8. Edited by M. El-Nahas, Taylor & Francis Group, New York 2005, pp. 457-467.
835. M. El-Nahas, G. Remuzzi. The emerging nephrologist: a training vision. In: *Kidney Diseases in the Developing World and Ethnic Minorities*. Chapter 8. Edited by M. El-Nahas, Taylor & Francis Group, New York 2005, pp. 495-507.
836. N. Perico, P. Cravedi, P. Ruggenenti, E. Gotti, G. Rota, G. Locatelli, V. Gambarà, A. Perna, S. Rota, G. Remuzzi. The Bergamo Kidney Transplant Program. In: *Clinical Transplants 2005*. Chapter 7. Edited by J.M. Cecka and P.I. Terasaki, UCLA Immunogenetics Center, Los Angeles, California 2005, pp. 85-100.
837. F. Gaspari, N. Perico, G. Remuzzi. Timed urine collections are not needed to measure urine protein excretion in clinical practice. *Am J Kidney Dis* 2006;47:1-7.
838. D. Macconi, M. Bonomelli, A. Benigni, T. Plati, F. Sangalli, L. Longaretti, S. Conti, H. Kawachi, P. Hill, G. Remuzzi, A. Remuzzi. Pathophysiologic implications of reduced podocyte number in a rat model of progressive glomerular injury. *Am J Pathol* 2006;168:42-54.
839. G. Remuzzi, P. Cravedi, A. Perna, B.D. Dimitrov, M. Turturro, G. Locatelli, P. Rigotti, N. Baldan, M. Beatini, U. Valente, M. Scalamogna, P. Ruggenenti. Dual Kidney Transplant Group. Long-term outcome of renal transplantation from older donors. *N Engl J Med* 2006;354:343-352.
840. G. Remuzzi, A. Benigni, A. Remuzzi. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. *J Clin Invest* 2006;116:288-296.
841. E. Bresin, E. Daina, M. Noris, F. Castelletti, R. Stefanov, P. Hill, T.M. Goodship, G. Remuzzi for the International Registry of Recurrent and Familial HUS/TTP. Outcome of renal transplantation in patients with non-Shiga Toxin-associated haemolytic uremic syndrome: prognostic significance of genetic background. *Clin J Am Soc Nephrol* 2006;1:88-99.
842. M. Figliuzzi, T. Plati, R. Cornolti, F. Adobati, A. Fagiani, L. Rossi, G. Remuzzi, A. Remuzzi. Biocompatibility and function of microencapsulated pancreatic islets. *Acta Biomaterialia* 2006;2:221-227.
843. G. Remuzzi, M. Macia, P. Ruggenenti. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT Study. *J Am Soc Nephrol* 2006;17:S90-S97.

844. M. Galbusera, M. Noris, G. Remuzzi. Thrombotic thrombocytopenic purpura – Then and now. *Semin Thromb Hemost* 2006;32:81-89.
845. C. Zoja, M. Abbate, G. Remuzzi. Progression of chronic kidney disease: insights from animal models. *Curr Opin Nephrol Hypertens* 2006;15:250-257.
846. D. Cattaneo, N. Perico, G. Remuzzi. Let's assume that hepatitis C reduces the cardiovascular risk in dialysis patients. Are there practical implications? *J Hepatol* 2006;44:837-838.
847. D. Macconi, M. Abbate, M. Morigi, S. Angioletti, M. Mister, S. Buelli, M. Bonomelli, P. Mundel, K. Endlich, A. Remuzzi, G. Remuzzi. Permeable dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention. *Am J Pathol* 2006;168:1073-1085.
848. A. Remuzzi, E. Gagliardini, F. Sangalli, M. Bonomelli, M. Piccinelli, A. Benigni, G. Remuzzi. ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. *Kidney Int* 2006;69:1124-1130.
849. A.I. Parvanova, R. Trevisan, I.P. Iliev, B.D. Dimitrov, M. Vedovato, A. Tiengo, G. Remuzzi, P. Ruggerenti. Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion. *Diabetes* 2006;55:1456-1462.
850. D. de Zeeuw, D. Ramjit, Z. Zhang, A.B. Ribeiro, K. Kurokawa, J.P. Lash, J. Chan, G. Remuzzi, B.M. Brenner, S. Shahinfar. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post-hoc analysis of RENAAL. *Kidney Int* 2006;69:1675-1682.
851. P. Ruggerenti, I. Codreanu, P. Cravedi, A. Perna, E. Gotti, G. Remuzzi. Basiliximab combined with low-dose Rabbit Anti-Human Thymocyte Globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation. *Clin J Am Soc Nephrol* 2006;1:546-554.
852. L. Gallon, E. Gagliardini, A. Benigni, D. Kaufman, A. Waheed, M. Noris, G. Remuzzi. Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with Alemtuzumab (Campath-1H). *Clin J Am Soc Nephrol* 2006;1:539-545.
853. C. Zoja, D. Corna, D. Rottoli, C. Zanchi, M. Abbate, G. Remuzzi. Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. *Kidney Int* 2006;70:97-103.
854. A. Benigni, S. Tomasoni, L.A. Turka, L. Longaretti, L. Zentilin, M. Mister, A. Pezzotta, N. Azzollini, M. Noris, S. Conti, M. Abbate, M. Giacca, G. Remuzzi. Adeno-Associated Virus-mediated CTLA4Ig gene transfer protects MHC-mismatched renal allografts from chronic rejection. *J Am Soc Nephrol* 2006;17:1665-1672.

855. A. Benigni, C. Zoja, S. Tomasoni, M. Campana, D. Corna, C. Zanchi, E. Gagliardini, E. Garofano, D. Rottoli, T. Ito, G. Remuzzi. Transcriptional regulation of nephrin gene by peroxisome proliferators-activated receptor- γ agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. *J Am Soc Nephrol* 2006;17:1624-1632.
856. W.F. Keane, Z. Zhang, P.A. Lyle, M.E. Cooper, D. de Zeeuw, J-P. Grunfeld, J.P. Lash, J.B. McGill, W.E. Mitch, G. Remuzzi, S. Shahinfar, S.M. Snapinn, R. Toto, B.M. Brenner for the RENAAL Study Investigators. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL Study. *Clin J Am Soc Nephrol* 2006;1:761-767.
857. J. Caprioli, M. Noris, S. Brioschi, G. Pianetti, F. Castelletti, P. Bettinaglio, C. Mele, E. Bresin, L. Cassis, S. Gamba, F. Porrati, S. Bucchioni, G. Monteferrante, C.J. Fang, M.K. Liszewski, D. Kavanagh, J.P. Atkinson, and G. Remuzzi for the International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. *Blood* 2006;108:1267-1279.
858. H-H. Parving, J.B. Lewis, M. Ravid, G. Remuzzi, L.G. Hunsicker, for the DEMAND investigators. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. *Kidney Int* 2006;69:2057-2063.
859. L. Gallon, N. Perico, B.D. Dimitrov, J. Winoto, G. Remuzzi, J. Laventhal, F. Gaspari, D. Kaufman. Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. *Am J Transpl* 2006;6:1617-1623.
860. I. Codreanu, N. Perico, S.K. Sharma, A. Schieppati, G. Remuzzi. Prevention programmes of progressive renal disease in developing nations. *Nephrology* 2006;11:321-328.
861. M. Rieger, S. Ferrari, J.A. Kremer Hovinga, C. Konetschny, A. Herzog, L. Koller, A. Weber, G. Remuzzi, M. Dockal, B. Plaimauer, F. Sheiflinger. Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). *Thromb Haemost* 2006;95:212-220.
862. G. Remuzzi, P. Ruggenti. Overview of randomised trials of ACE inhibitors (Comment). *Lancet* 2006;368:555-556.
863. J.M. Saland, S.H. Emre, B.L. Shneider, C. Benchimol, S. Ames, J.S. Bromberg, G. Remuzzi, L. Strain, T.H.J. Goodship. Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation (Brief Communication). *Am J Transpl* 2006;6:1948-1952.
864. H. Haller, G.C. Viberti, A. Mimran, G. Remuzzi, A.J. Rabelink, E. Ritz, L.C. Rump, L.M. Ruilope, S. Katayama, S. Ito, J.L. Izzo Jr, A. Januszewicz. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. *J Hypertens* 2006;24:403-408.

865. M. Morigi, A. Benigni, G. Remuzzi, B. Imberti. The regenerative potential of stem cells in acute renal failure. *Cell Transplant* 2006;15(Suppl. 1):S111-S117.
866. R. Donadelli, F. Banterla, M. Galbusera, C. Capoferri, S. Bucchioni, S. Gastoldi, S. Nosari, G. Monteferrante, Z.M. Ruggeri, E. Bresin, F. Scheifflinger, E. Rossi, C. Martinez, R. Coppo, G. Remuzzi, M. Noris on behalf of the International Registry of Recurrent and Familial HUS/TTP. In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. *Thromb Haemost* 2006;96:454-464.
867. S. Rota Jr, P. Cravedi, G. Remuzzi. Management of proteinuria in chronic kidney disease. *Eur J Hosp Pharm Pract* 2006;12:55-56.
868. M. Abbate, C. Zoja, G. Remuzzi. How does proteinuria cause progressive renal damage? *J Am Soc Nephrol* 2006;17:2974-2984.
869. D. Cattaneo, S. Merlini, S. Baldelli, B. Bartolini, A. Nicastri, E. Gotti, G. Remuzzi, N. Perico. Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients. *Ther Drug Monit* 2006;28:643-649.
870. P. Ruggenenti, G. Remuzzi. Time to abandon microalbuminuria? *Kidney Int* 2006;70:1214-1222.
871. C. Zoja, G. Remuzzi. Interstitial nephritis. In: *Principles of Molecular Medicine*, 2nd ed. chapter n° 62. Edited by M.S. Runge, Humana Press, Totowa, New Jersey 2006, pp. 636-642.
872. P. Ruggenenti, C. Chiurciu, M. Abbate, A. Perna, P. Cravedi, M. Bontempelli, G. Remuzzi. Rituximab for idiopathic membranous nephropathy: who can benefit? *Clin J Am Soc Nephrol* 2006;1:738-748.
873. R. Donadelli, J.N. Orje, C. Capoferri, G. Remuzzi, Z.M. Ruggeri. Size regulation of von Willebrand factor-mediated platelet thrombi by ADAMTS13 in flowing blood. *Blood* 2006;107:1943-1950.
874. L. Antiga, M. Piccinelli, G. Fasolini, B. Ene-Iordache, P. Ondei, S. Bruno, G. Remuzzi, A. Remuzzi. Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress report. *Clin J Am Soc Nephrol* 2006;1:754-760.
875. M. Noris, G. Remuzzi. Non-Shiga toxin-associated hemolytic uremic syndrome. In: *Complement and Kidney Disease*. Edited by P.F. Zipfel, Birkhauser Verlag, Basel. Switzerland 2006, pp. 65-83.
876. G. Tessari, L. Naldi, L. Boschiero, C. Cordiano, S. Piaserico, A. Belloni Fortina, D. Cerimele, I. Lesnori La Parola, M. Capuano, E. Gotti, P. Ruggenenti, F. Sassi, G. Remuzzi, G. Girolimoni. Incidence and clinical predictors of Kaposi's sarcoma

- among 1721 Italian solid organ transplant recipients: a multicenter study. *Eur J Dermatol* 2006;16:553-557.
877. G. Remuzzi, J.R. Ingelfinger. Correction of anemia – payoffs and problems (Editorial). *N Engl J Med* 2006;355:2144-2146.
 878. P. Ruggenenti, G. Remuzzi. Is mycophenolate mofetil better than azathioprine in organ transplantation? *Transplantation* 2006;82:1242-1243.
 879. M.G. Lira, L. Provezza, G. Malerba, L. Naldi, G. Remuzzi, L. Boschiero, A. Forni, C. Rugiu, S. Piaserico, M. Alaibac, A. Turco, G. Girolomoni, G. Tessari. Glutathione S-transferase and CYP1A1 gene polymorphisms and non-melanoma skin cancer risk in Italian transplanted patients. *Exp Dermatol* 2006;15:958-965.
 880. P. Ruggenenti, A. Perna, M. Ganeva, B. Ene-Iordache, G. Remuzzi for the BENEDICT Study Group. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a *post hoc* analysis of the BENEDICT trial. *J Am Soc Nephrol* 2006;17:3472-3481.
 881. M. Noris, G. Remuzzi. Complement factor H gene abnormalities in haemolytic uraemic syndrome: from point mutations to hybrid gene. *PLoS Med* 2006;3:1719-1720.
 882. J.H. Dirks JH, S.W. Robinson, M. Alderman, W.G. Couser, S.M. Grundy, S.C. Smith, G. Remuzzi, N. Unwin. Meeting report on the Bellagio Conference 'prevention of vascular diseases in the emerging world: An approach to global health equity'. *Kidney Int* 2006;70:1397-402.
 883. P. Ruggenenti, G. Remuzzi. Ways to boost kidney transplant viability: a real need for the best use of older donors. *Am J Transpl* 2006; 6:2543-2547.
 884. M. Morigi, S. Buelli, C. Zanchi, L. Longaretti, D. Macconi, A. Benigni, D. Moioli, G. Remuzzi, C. Zoja. Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling. *Am J Pathol* 2006;169:1965-1975.
 885. A. Benigni, C. Zoja, M. Campana, D. Corna, F. Sangalli, D. Rottoli, E. Gagliardini, S. Conti, S. Ledbetter, G. Remuzzi. Beneficial effect of TGF β antagonism in treating diabetic nephropathy depends on when treatment is started. *Nephron Exp Nephrol* 2006;104:e158-e168.
 886. P. Ruggenenti, G. Remuzzi. Is mycophenolate mofetil better than azathioprine in organ transplantation? (Letter to the Editor) *Transplantation* 2006;82:1242-1243.
 887. N. Besbas, D. Karpman, D. Landau, C. Loirat, W. Proesmans, G. Remuzzi, G. Rizzoni, C.M. Taylor, N. Van de Kar, L.B. Zimmerhackl for the European Paediatric Research Group for HUS. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. *Kidney Int* 2006;70:423-431.

888. A. Remuzzi, G. Remuzzi. Potential protective effects of telmisartan on renal function deterioration. *JRAAS* 2006;7:185-191.
889. P. Ruggenenti, G. Remuzzi. What blood-pressure level provides greatest renoprotection in patients with diabetic nephropathy and hypertension. (Practice Point) *Nat Clin Pract Nephrol* 2006;2:250-251.
890. P. Ruggenenti, M. Macia, G. Remuzzi. Angiotensin-receptor blockers for renal protection in type 2 diabetes. *Aging Health* 2006;2:295-301.
891. A. Schieppati, A. Falanga, G. Remuzzi. Hematologic abnormalities in chronic kidney disease. In: *Clinical Hematology*, chapter n°83. Edited by N. S. Young, S.L. Gerson, K.A. High, Mosby Elsevier, Philadelphia 2006, pp. 1060-1072.
892. G. Monteferrante, S. Brioschi, J. Caprioli, G. Pianetti, P. Bettinaglio, E. Bresin, G. Remuzzi, M. Noris. Genetic analysis of the complement factor H related 5 gene in haemolytic uraemic syndrome. *Mol Immunol* 2007;44:1704-1708.
893. M. Montalbano, L. Pasulo, A. Sonzogni, G. Remuzzi, M. Colledan, M. Strazzabosco. Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient (Case Report). *J Clin Gastroenterol* 2007;41:216-220.
894. S. Heinen, M. Jozsi, A. Hartmann, M. Noris, G. Remuzzi, C. Skerka, P.F. Zipfel. Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells. *J Am Soc Nephrol* 2007;18:506-514.
895. P. Ruggenenti, G. Remuzzi. How should patients with, or at risk of, cardiovascular disease be screened for chronic kidney disease? (Practice Point) *Nat Clin Pract Nephrol* 2007;3:126-127.
896. M. Noris, F. Casiraghi, M. Todeschini, P. Cravedi, D. Cugini, G. Monteferrante, S. Aiello, L. Cassis, E. Gotti, F. Gaspari, D. Cattaneo, N. Perico, G. Remuzzi. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. *J Am Soc Nephrol* 2007;18:1007-1018.
897. S. Aiello, P. Cassis, L. Cassis, S. Tomasoni, A. Benigni, A. Pezzotta, R.A. Cavinato, D. Cugini, N. Azzollini, M. Mister, L. Longaretti, A.W. Thomson, G. Remuzzi, M. Noris. DnIKK2-transfected dendritic cells induce a novel population of inducible nitric oxide synthase-expressing CD4⁺CD25⁻ cells with tolerogenic properties. *Transplantation* 2007;83:474-484.
898. A. Gianella, E. Nobili, M. Abbate, C. Zoja, P. Gelosa, L. Mussoni, S. Bellosta, M. Canavesi, D. Rottoli, U. Guerrini, M. Brioschi, C. Banfi, E. Tremoli, G. Remuzzi, L. Sironi. Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. *Am J Pathol* 2007;170:1165-1177.

899. W.B. Eijkelkamp, Z. Zhang, B.M. Brenner, M.E. Cooper, R.B. Devereux, B. Dahlöf, H. Ibsen, W.F. Keane, L.H. Lindholm, M.H. Olsen, H.H. Parving, G. Remuzzi, S. Shahinfar, S.M. Snapinn, K. Wachtell, D. de Zeeuw. Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. *J Hypertens* 2007;25:871-876.
900. W.B. Eijkelkamp, Z. Zhang, G. Remuzzi, H-H. Parving, M.E. Cooper, W.F. Keane, S. Shahinfar, G.W. Gleim, M.R. Weir, B.M. Brenner, D. de Zeeuw. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) trial. *J Am Soc Nephrol* 2007;18:1540-1546.
901. R.E. Saunders, C. Abarrategui-Garrido, V. Fremeaux-Bacchi, E. Goicoechea de Jorge, T.H. Goodship, M. Lopez Trascasa, M. Noris, I.M. Ponce Castro, G. Remuzzi, S. Rodriguez de Cordoba, P. Sanchez-Corral, C. Skerka, P.F. Zipfel, S.J. Perkins. The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. *Hum Mutat* 2007;28:222-234.
902. J.R. Ingelfinger, G. Remuzzi. Target haemoglobin concentrations in chronic kidney disease. (Correspondence) *Lancet* 2007;369:1515; author reply 1516-1517.
903. P. Murray, G. Camussi, J.A. Davies, D. Edgar, M. Hengstschlager, S. Kenny, G. Remuzzi, C. Werner. The KIDSTEM European Research Training Network: Developing a Stem Cell Based Therapy to Replace Nephrons Lost through Reflux Nephropathy. *Organogenesis* 2007;3:2-5.
904. C. Zoja, F. Casiraghi, S. Conti, D. Corna, D. Rottoli, R.A. Cavinato, G. Remuzzi, A. Benigni. Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus. *Arthritis & Rheum* 2007;56:1629-1637.
905. A. Benigni, C. Caroli, L. Longaretti, E. Gagliardini, C. Zoja, M. Galbusera, D. Moioli, P. Romagnani, A. Tincani, L. Andreoli, G. Remuzzi. Involvement of renal tubular toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. *Arthritis & Rheum* 2007;56:1569-1578.
906. P. Cravedi, P. Ruggenenti, G. Remuzzi. Does remission of renal disease associated with antihypertensive treatment exist? *Curr Hypertens Rep.* 2007;9:160-165.
907. G. Remuzzi, P. Cravedi, M. Costantini, M. Lesti, M. Ganeva, G. Gherardi, B. Ene-Iordache, E. Gotti, D. Donati, M. Salvadori, S. Sandrini, G. Segoloni, S. Federico, P. Rigotti, V. Sparacino, P. Ruggenenti, for the MYSS Follow-Up Study Group. Mycophenolate Mofetil versus Azathioprine for Prevention of Chronic Allograft Dysfunction in Renal Transplantation: The MYSS Follow-Up Randomized, Controlled Clinical Trial. *J Am Soc Nephrol* 2007;18:1973-1985.
908. M.H. Sayegh, G. Remuzzi. Clinical update: immunosuppression minimisation. (Comment) *Lancet* 2007;369:1676-1678.

909. N. Perico, M. Abbate, G. Remuzzi. More on renal disease progression: is interstitial inflammation truly protective? (Editorial) *J Am Soc Nephrol* 2007;18:1630-1632.
910. D.M. Kent, T.H. Jafar, R.A. Hayward, H. Tighiouart, M. Landa, P. de Jong, D. de Zeeuw, G. Remuzzi, A.L. Kamper, A.S. Levey. Progression Risk, Urinary Protein Excretion, and Treatment Effects of Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Kidney Disease. *J Am Soc Nephrol* 2007;18:1959-1965.
911. P. Cravedi, M. Noris, G. Remuzzi. Report of the first World Transplant Congress. (Special Feature) *Clin J Am Soc Nephrol* 2007;2:393-400.
912. D. Corna, F. Sangalli, D. Cattaneo, F. Carrara, F. Gaspari, A. Remuzzi, C. Zoja, A. Benigni, N. Perico, G. Remuzzi. Effects of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation. *Am J Nephrol* 2007;27:630-638.
913. Cavinato, F. Casiraghi, N. Azzollini, M. Mister, A. Pezzotta, P. Cassis, D. Cugini, N. Perico, G. Remuzzi, M. Noris. Role of thymic- and graft-dependent mechanisms in tolerance induction to rat kidney transplant by donor PBMC infusion. *Kidney Int* 2007;71:1132-1141.
914. P. Ruggenenti, G. Remuzzi. Kidney failure stabilizes after a two-decade increase: impact on global (renal and cardiovascular) health. (Editorial) *Clin J Am Soc Nephrol* 2007;2:146-150.
915. P. Cravedi, P. Ruggenenti, M.C. Sghirlanzoni, G. Remuzzi. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. *Clin J Am Soc Nephrol* 2007;2:932-937.
916. N.K. Hollenberg, H-H. Parving, G. Viberti, G. Remuzzi, S. Ritter, S. Zelenkofske, A. Kandra, W.L. Daley, R. Rocha. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. *J Hypertens* 2007;25:1921-1926.
917. D. Kavanagh, A. Richards, V. Fremeaux-Bacchi, M. Noris, T. Goodship, G. Remuzzi, J.P. Atkinson. Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome. *Clin J Am Soc Nephrol* 2007;2:591-596.
918. J. Caprioli, G. Remuzzi. Complement hyperactivation may cause atypical haemolytic uraemic syndrome-gain-of-function mutations in factor B. (Editorial) *Nephrol Dial Transplant* 2007;22:2452-2454.
919. M. Gomez Lira, S. Mazzola, G. Tessari, G. Malerba, M. Ortombina, L. Naldi, G. Remuzzi, L. Boschiero, A. Forni, C. Rugiu, S. Piaserico, G. Girolomoni, A. Turco. Association of functional gene variants in the regulatory regions of COX-2 gene (*PTGS2*) with nonmelanoma skin cancer after organ transplantation. *Br J Dermatol* 2007;157:49-57.
920. S.K. Sharma, P. Ruggenenti, G. Remuzzi. Managing hypertension in diabetic patients – focus on trandolapril/verapamil combination. *Vasc Health Risk Manag* 2007;3:453-

465.

921. D. Cattaneo, M. Cortinovis, S. Baldelli, A. Bitto, E. Gotti, G. Remuzzi, N. Perico. Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients. *Clin J Am Soc Nephrol* 2007;2:1147-1155.
922. S. Baldelli, S. Merlini, N. Perico, A. Nicastrì, M. Cortinovis, E. Gotti, G. Remuzzi, D. Cattaneo. C-440T/T-331C polymorphisms in the *UGT1A9* gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. *Pharmacogenomics* 2007;8:1127-1141.
923. P. Ruggenenti, P. Cravedi, G. Remuzzi. Latest treatment strategies for membranous nephropathy. *Expert Opin Pharmacother* 2007;8:3159-3171.
924. P. Cravedi, P. Ruggenenti, G. Remuzzi. Intensified inhibition of renin-angiotensin system: a way to improve renal protection? *Curr Hypertens Rep* 2007;9:430-436.
925. N. Perico, G. Remuzzi. Inhibition of TGF- β expression: a novel role for thiazolidinediones to implement renoprotection in diabetes. (Comment) *Kidney Int* 2007;72:1419-1421.
926. A. Remuzzi, F. Sangalli, A. Fassi, G. Remuzzi. Albumin concentration in the Bowman's capsule: multiphoton microscopy vs micropuncture technique. (Letter to the Editor) *Kidney Int* 2007;72:1410-1411.
927. P. Ruggenenti, N. Perico, E. Gotti, P. Cravedi, V. D'Agati, E. Gagliardini, M. Abbate, F. Gaspari, D. Cattaneo, M. Noris, F. Casiraghi, M. Todeschini, D. Cugini, S. Conti, G. Remuzzi. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. *Transplantation* 2007;84:956-964.
928. B. Imberti, M. Morigi, S. Tomasoni, C. Rota, D. Corna, L. Longaretti, D. Rottoli, F. Valsecchi, A. Benigni, J. Wang, M. Abbate, C. Zoja, G. Remuzzi. Insulin-like growth factor-1 sustains stem cell-mediated renal repair. *J Am Soc Nephrol* 2007;18:2921-2928.
929. P. Ruggenenti, M. Ceruti, G. Remuzzi. Thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, and acute cortical necrosis. In: *Diseases of the Kidney & Urinary Tract*, 8th ed., Vol. II, chapter n. 67. Edited by Robert W. Schrier. Wolters Kluwer, Lippincott Williams & Wilkins, Philadelphia 2007, pp. 1719-1747.
930. N. Chaturvedi, R. Bilous, R. Hardy, G. Remuzzi, P. Ruggenenti, G.C. Viberti. Misleading meta-analysis: a need to look beyond the headlines. (Special Report) *Diabet Med* 2007;24:587-591.
931. P. Ruggenenti, M. Ceruti, G. Remuzzi. Thrombotic microangiopathies, including hemolytic uremic syndrome. In: *Comprehensive Clinical Nephrology* (3rd Edition). Edited by J. Feehally, J. Floege and R.J. Johnson, Mosby Elsevier, Philadelphia, USA

2007, pp. 343-352.

932. S.G. Tullius, M.H. Sayegh, G. Remuzzi. Organ quality determines outcome after kidney transplantation. *Eur Renal Dis* 2007;1:51-54.
933. G. Remuzzi. Clinical perspectives in the prevention and treatment of chronic nephropathy, including an overview of the DEMAND study. *Clin Ther* 2007;29(Suppl. B):S64-S72.
934. A. Richards, M.K. Liszewski, D. Kavanagh, C.J. Fang, E. Moulton, V. Fremeaux-Bacchi, G. Remuzzi, M. Noris, T.H.J. Goodship, J.P. Atkinson. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. *Mol Immunol* 2007;44:111-122.
935. H. Jalanko, S. Peltonen, A. Koskinen, J. Puntila, H. Isoniemi, C. Holmberg, A. Pinomaki, E. Armstrong, A. Koivusalo, E. Tukiainen, H. Makisalo, J. Saland, G. Remuzzi, S. de Cordoba, R. Lassila, S. Meri, T.S. Jokiranta. Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H. *Am J Transpl* 2008;8:216-221.
936. G. Remuzzi, N. Perico, M.E. De Broe. Tubulointerstitial Diseases. In: Brenner and Rector's *The Kidney*, 8th ed., Vol. II, chapter n. 33. Edited by B.M. Brenner. Saunders Elsevier, Philadelphia 2008, pp. 1174-1202.
937. S.K. Sharma, N. Perico, P. Ruggenenti, G. Remuzzi. Prevention of chronic renal diseases in the elderly. In: *The Aging Kidney in Health and Disease*, chapter n. 13. Edited by J.F. Macias Nunez, J.S. Cameron, D.G. Oreopoulos. Springer, New York 2008, pp. 231-255.
938. M. Abbate, G. Remuzzi, C. Zoja. Role of proteinuria in progression. In: *The Kidney: Physiology and Pathophysiology*, 4th ed., chapter n. 89. Edited by R.J. Alpern, S.C. Hebert. Elsevier, London 2008, pp. 2563-2576.
939. M. Noris, G. Remuzzi, T.H.J. Goodship. Hemolytic uremic syndrome/Thrombotic thrombocytopenic purpura. In: *Handbook of Systemic Autoimmune Diseases*, Vol. 7, chapter n. 14. Edited by J.C. Mason, C.D. Pusey. Elsevier, London 2008, pp. 257-282.
940. M. Noris, E. Bresin, C. Mele, G. Remuzzi, J. Caprioli. Atypical hemolytic-uremic syndrome. In: *GeneReviews* [Internet] Edited by R.A. Pragon, T.C. Bird, C.R. Dolan, K. Stephens. University of Washington, Seattle 2008. Available at <http://www.genetests.org>
941. A. Schieppati, G. Remuzzi. Novel therapies of lupus nephritis. *Curr Opin Nephrol Hypertens* 2008;17:156-161.
942. F. Castelletti, R. Donadelli, F. Banterla, F. Hildebrandt, P.F. Zipfel, E. Bresin, E. Otto, C. Skerka, A. Renieri, M. Todeschini, J. Caprioli, M.R. Caruso, R. Artuso, G. Remuzzi, M. Noris. Mutations in *FNI* cause glomerulopathy with fibronectin deposits. *Proc Natl Acad Sci USA* 2008;105:2538-2543.

943. M. Noris, G. Remuzzi. Translational Mini-Review Series on Complement Factor H: Therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis. *Clin Exp Immunol* 2008;151:199-209.
944. J. Caprioli, G. Remuzzi. A mouse model of non-Shiga toxin-associated haemolytic uraemic syndrome. (Editorial) *Nephrol Dial Transplant* 2008;23:462-465.
945. R. Martinez-Barricarte, G. Pianetti, R. Gautard, J. Misselwitz, L. Strain, V. Fremeaux-Bacchi, C. Skerka, P.F. Zipfel, T. Goodship, M. Noris, G. Remuzzi, S.R. de Cordoba on behalf of the European Working Party on the genetics of HUS. The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. *J Am Soc Nephrol* 2008;19:639-646.
946. A. Pezzotta, M. Mister, G. Monteferrante, L. Cassis, N. Azzollini, S. Aiello, M. Satta, A. Benigni, G. Remuzzi, M. Noris. Effect of seliciclib (CYC202, R-roscovitine) on lymphocyte alloreactivity and acute kidney allograft rejection in rat. *Transplantation* 2008;85:1476-1482.
947. C. Zanchi, C. Zoja, M. Morigi, F. Valsecchi, X.Y. Liu, D. Rottoli, M. Locatelli, S. Buelli, A. Pezzotta, P. Mapelli, J. Geelen, G. Remuzzi, J. Hawiger. Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin. *J Immunol* 2008;181:1460-1469.
948. P. Ruggenenti, I. Iliev, G.M. Costa, A. Parvanova, A. Perna, G.A. Giuliano, N. Motterlini, B. Ene-Iordache, G. Remuzzi, and the BENEDICT Study Group. Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes. *Diabetes Care* 2008;31:1629-1634.
949. M.H. de Borst, A. Benigni, G. Remuzzi. Primer: strategies for identifying genes involved in renal disease. *Nat Clin Pract Nephrol* 2008;4:265-276.
950. H-H. Parving, F. Persson, J.B. Lewis, E.J. Lewis, N.K. Hollenberg, for the AVOID study investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. *N Engl J Med* 2008;358:2433-2446.
951. P. Ruggenenti, E. Peticucci, P. Cravedi, V. Gambarà, M. Costantini, S.K. Sharma, A. Perna, G. Remuzzi. Role of remission clinics in the longitudinal treatment of CKD. *J Am Soc Nephrol* 2008;19:1213-1224.
952. M. Abbate, C. Zoja, D. Corna, D. Rottoli, C. Zanchi, N. Azzollini, S. Tomasoni, S. Berlingerì, M. Noris, M. Morigi, G. Remuzzi. Complement-mediated dysfunction of glomerular filtration barrier accelerates progressive renal injury. *J Am Soc Nephrol* 2008;19:1158-1167.
953. P. Ruggenenti, A. Remuzzi, G. Remuzzi. Decision time for pancreatic islet-cell transplantation. (Comment) *Lancet* 2008;371:883-884.

954. M. Cortinovis, D. Cattaneo, N. Perico, G. Remuzzi. Investigational drugs for diabetic nephropathy. *Expert Opin Investig Drugs* 2008;17:1487-1500.
955. S. Tomasoni, G. Remuzzi, A. Benigni. Allograft rejection: acute and chronic studies. In: *Contributions to Nephrology: Gene therapy for renal diseases and transplantation*. Edited by C. Ronco, A. Benigni, G. Remuzzi. Karger, Basel 2008, Vol. 159, pp. 122-134.
956. N. Perico, A. Benigni, G. Remuzzi. Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection. *Nat Rev Drug Discov* 2008;7:936-953.
957. H-H. Parving, D. de Zeeuw, M.E. Cooper, G. Remuzzi, N. Liu, J. Luncford, S. Shahinfar, P.H. Wong, P.A. Lyle, P. Rossing, B.M. Brenner. ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. *J Am soc Nephrol* 2008;19:771-779.
958. M. Morigi, M. Introna, B. Imberti, D. Corna, M. Abbate, C. Rota, D. Rottoli, A. Benigni, N. Perico, C. Zoja, A. Rambaldi, A. Remuzzi, G. Remuzzi. Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. *Stem Cells* 2008;26:2075-2082.
959. P. Ruggenenti, P. Bettinaglio, F. Pinares, G. Remuzzi. Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. *Clin J Am Soc Nephrol* 2008;3:1511-1525.
960. F. Casiraghi, N. Azzollini, P. Cassis, B. Imberti, M. Morigi, D. Cugini, R.A. Cavinato, M. Todeschini, S. Solini, A. Sonzogni, N. Perico, G. Remuzzi, M. Noris. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. *J Immunol* 2008;181:3933-3946.
961. P. Ruggenenti, M. Noris, G. Remuzzi. Thrombotic Microangiopathies. In: *Therapy in Nephrology and Hypertension – A companion to Brenner and Rector’s The Kidney (3rd Edition)*, chapter n. 26. Edited by C.S. Wilcox. Saunders Elsevier, Philadelphia 2008, pp. 294-312.
962. G. Remuzzi, L. Minetti, A. Schieppati. Treatment of Anemia and Bleeding in Chronic Kidney Disease. In: *Therapy in Nephrology and Hypertension – A companion to Brenner and Rector’s The Kidney (3rd Edition)*, chapter n. 68. Edited by C.S. Wilcox. Saunders Elsevier, Philadelphia 2008, pp. 756-764.
963. M. Figliuzzi, F. Adobati, R. Cornolti, P. Cassis, G. Remuzzi, A. Remuzzi. Assessment of in vitro differentiation of bovine pancreatic tissue in insulin-expressing cells. *JOP* 2008;9:601-611.
964. N. Azzollini, D. Cugini, P. Cassis, A. Pezzotta, E. Gagliardini, M. Abbate, A. Arduini, A. Pescechera, G. Remuzzi, M. Noris. Propionyl-L-carnitine prevents early graft dysfunction in allogeneic rat kidney transplantation. *Kidney Int* 2008; 74:1420-1428.

965. P. Cravedi, R.B. Mannon, P. Ruggenenti, A. Remuzzi, G. Remuzzi. Islet transplantation: need for a time-out? (Viewpoint) *Nat Clin Pract Nephrol* 2008;4:660-661.
966. P. Cravedi, R.B. Mannon, G. Remuzzi. Lymphocyte depletion for kidney transplantation: back to the past? (Viewpoint) *Nat Clin Pract Nephrol* 2008;4:534-535.
967. P. Ruggenenti, P. Cravedi, M.C. Sghirlanzoni, E. Gagliardini, S. Conti, F. Gaspari, F. Marchetti, M. Abbate, G. Remuzzi. Effects of Rituximab on morphofunctional abnormalities of membranous glomerulopathy. *Clin J Am Soc Nephrol* 2008;3:1652-1659.
968. Blood Pressure Lowering Treatment Trailists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. *BMJ* 2008;336:1121-1123.
969. J. Caprioli, C. Mele, C. Mossali, L. Gallizioli, G. Giacchetti, M. Noris, G. Remuzzi, A. Benigni. Polymorphisms of EDNRB, ATG, and ACE genes in salt-sensitive hypertension. *Can J Physiol Pharmacol* 2008;86:505-510.
970. D. Kavanagh, A. Richards, M. Noris, R. Hauhart, M.K. Liszewski, D. Karpman, J.A. Goodship, V. Fremeaux-Bacchi, G. Remuzzi, T.H.J. Goodship, J.P. Atkinson. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. *Mol Immunol* 2008;45:95-105.
971. G. Remuzzi, D. Cattaneo, N. Perico. The aggravating mechanisms of aldosterone on kidney fibrosis. (Editorial) *J Am Soc Nephrol* 2008;19:1459-1462.
972. B. Canaud, G. Mingardi, J. Braun, P. Aljama, P.G. Kerr, F. Locatelli, G. Villa, B. Van Vlem, A.W. McMahon, C. Kerloeguen, U. Beyer on behalf of the STRIATA Study Investigators. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. *Nephrol Dial Transplant* 2008;23:3654-3661.
973. P. Cravedi, G. Remuzzi. Treating the kidney to cure the heart. *Kidney Int* 2008;74(Suppl. 111):S2-S3.
974. N. Braun, F. Schmutzler, C. Lange, A. Perna, G. Remuzzi, N.S. Willis. Immunosuppressive treatment for focal segmental glomerulosclerosis in adults (Review). *Cochrane Database of Systematic Reviews* 2008, Issue 3. Art. No.: CD003233. DOI:10.1002/14651858.CD003233.pub2.
975. D. Macconi, G. Remuzzi. Candesartan and renal protection: more than blocking angiotensin type 1 receptor? (Comment) *Kidney Int* 2008;74:1112-1114.
976. P. Boccardo, M. Galbusera, G. Remuzzi. Prevention and therapeutic management of bleeding in dialysis patients. In: *Handbook of Dialysis Therapy* (4th Edition), chapter

- n. 29. Edited by A.R. Nissenson, R.N. Fine. Saunders Elsevier, Philadelphia 2008, pp. 445-456.
977. G. Remuzzi, S. Garattini. Rare diseases: what's next? *Lancet* 2008;371:1978-1979.
 978. D. Cattaneo, A. Bitto, S. Baldelli, M. Cortinovis, E. Gotti, N. Perico, G. Remuzzi. Pharmacokinetic/pharmacodynamic drug interaction between rosiglitazone and mycophenolate mofetil in kidney transplantation: a case report. *Transplantation* 2008;85:921-922.
 979. B. Imberti, M. Morigi, G. Remuzzi. Mesenchymal Stem Cells and Their Use in Acute Renal Injury. In: *Critical Care Nephrology* (2nd Edition), chapter n. 40. Edited by C. Ronco, R. Bellomo, J.A. Kellum. Saunders Elsevier, Philadelphia 2008, pp. 216-220.
 980. C. Mele, G. Remuzzi. Hemolytic Uremic Syndrome. In: *Critical Care Nephrology* (2nd Edition), chapter n. 68. Edited by C. Ronco, R. Bellomo, J.A. Kellum. Saunders Elsevier, Philadelphia 2008, pp. 373-378.
 981. M. Galbusera, G. Remuzzi. Bleeding and Hemostasis in Acute Renal Failure. In: *Critical Care Nephrology* (2nd Edition), chapter n. 70. Edited by C. Ronco, R. Bellomo, J.A. Kellum. Saunders Elsevier, Philadelphia 2008, pp. 385-390.
 982. P. Cravedi, N. Perico, G. Remuzzi. Acute Renal Failure in Kidney Transplant Recipients. In: *Critical Care Nephrology* (2nd Edition), chapter n. 303. Edited by C. Ronco, R. Bellomo, J.A. Kellum. Saunders Elsevier, Philadelphia 2008, pp. 1660-1665.
 983. D. Macconi, C. Chiabrando, S. Schiarea, S. Aiello, L. Cassis, E. Gagliardini, M. Noris, S. Buelli, C. Zoja, D. Corna, C. Mele, R. Fanelli, G. Remuzzi, A. Benigni. Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides. *J Am Soc Nephrol* 2009;20:123-130.
 984. N. Perico, D. Cattaneo, B. Bikbov, G. Remuzzi. Hepatitis C infection and chronic renal diseases. *Clin J Am Soc Nephrol* 2009;4:207-220.
 985. D. Macconi, F. Sangalli, M. Bonomelli, S. Conti, L. Condorelli, E. Gagliardini, G. Remuzzi, A. Remuzzi. Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition. *Am J Pathol* 2009;174:797-807.
 986. P. Cravedi, P. Ruggenenti, G. Mingardi, M.C. Sghirlanzoni, G. Remuzzi. Thrice-weekly in-center nocturnal hemodialysis: an effective strategy to optimize chronic dialysis therapy. *Int J Artif Organs* 2009;32:12-19.
 987. E. Bresin, S. Gastoldi, E. Daina, D. Belotti, E. Pogliani, P. Perseghin, P.R. Scalzulli, R. Paolini, R. Marcenò, G. Remuzzi, M. Galbusera. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. *Thromb Haemost* 2009;101:233-238.

988. J.M. Saland, B.L. Shneider, J.S. Bromberg, P.A. Shi, S.C. Ward, M.S. Magid, C. Benchimol, M.G. Seikaly, S.H. Emre, E. Bresin, G. Remuzzi. Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome. *Clin J Am Soc Nephrol* 2009;4:201-206.
989. G. Remuzzi, B. Simini. Medicine and art: one culture? (Editorial) *Kidney Int* 2009;75:347-348.
990. M. Cortinovis, N. Perico, D. Cattaneo, G. Remuzzi. Aldosterone and progression of kidney disease. *Ther Adv Cardiovasc Dis* 2009;3:133-143.
991. M. Galbusera, M. Noris, G. Remuzzi. Inherited thrombotic thrombocytopenic purpura. *Haematologica* 2009;94:166-170.
992. N. Perico, D. Cattaneo, G. Remuzzi. Kidney injury molecule 1: in search of biomarkers of chronic tubulointerstitial damage and disease progression. (Editorial) *Am J Kidney Dis* 2009;53:1-4.
993. B.C. Fellström, A.G. Jardine, R.E. Schmieder, H. Holdaas, K. Bannister, J. Beutler, D-W. Chae, A. Chevaile, S.M. Cobbe, C. Grönhagen-Riska, J.J. De Lima, R. Lins, G. Mayer, A.W. McMahon, H-H. Parving, G. Remuzzi, O. Samuelsson, S. Sonkodi, G. Süleymanlar, D. Tsakiris, V. Tesar, V. Todorov, A. Wiecek, R.P. Wüthrich, M. Gottlow, E. Johnsson, F. Zannad, for the AURORA Study Group. Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. *N Engl J Med* 2009;360:1395-1407.
994. P. Ruggenenti, P. Cravedi, G. Remuzzi. Rituximab for membranous nephropathy and immune disease: less might be enough. (Viewpoint) *Nat Clin Pract Nephrol* 2009;5:76-77.
995. M. Noris, G. Remuzzi. Thrombotic microangiopathy: what not to learn from a meta-analysis. (News & Views) *Nat Rev Nephrol* 2009;5:186-188.
996. B. Ene-Iordache, S. Carminati, L. Antiga, N. Rubis, P. Ruggenenti, G. Remuzzi, A. Remuzzi. Developing regulatory-compliant electronic case report forms for clinical trials: experience with the Demand Trial. *J Am Med Inform Assoc* 2009;16:404-408.
997. D. Cattaneo, P. Ruggenenti, S. Baldelli, N. Motterlini, E. Gotti, S. Sandrini, M. Salvadori, G. Segoloni, P. Rigotti, D. Donati, N. Perico, G. Remuzzi for the Mycophenolate Steroids Sparing (MYSS) Genetics Study Group. ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. *J Am Soc Nephrol* 2009;20:1404-1415.
998. A. Benigni, D. Corna, C. Zoja, A. Sonzogno, R. Latini, M. Salio, S. Conti, D. Rottoli, L. Longaretti, P. Cassis, M. Morigi, T.M. Coffman, G. Remuzzi. Disruption of the Ang II type 1 receptor promotes longevity in mice. *J Clin Invest* 2009;119:524-530.
999. P. Ruggenenti, G. Remuzzi. Proteinuria: Is the ONTARGET renal substudy actually off target? (News & Views) *Nat Rev Nephrol* 2009;5:436-437.
1000. P. Ruggenenti, P. Cravedi, G. Remuzzi. Proteinuria: Increased angiotensin-receptor

blocking is not the first option. (News & Views) *Nat Rev Nephrol* 2009;5:367-368.

1001. P. Rigotti, B. Ekser, L. Furian, N. Baldan, M.L. Valente, L. Boschiero, N. Motterlini, A. Perna, G. Remuzzi, P. Ruggenenti. Outcome of renal transplantation from very old donors. (Letter) *N Engl J Med* 2009;360:1464-1465.
1002. M. Delvaeye, M. Noris, A. De Vriese, C.T. Esmon, N.L. Esmon, G. Farrell, J. Del-Favero, S. Plaisance, B. Claes, D. Lambrechts, C. Zoja, G. Remuzzi, E.M. Conway. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. *N Engl J Med* 2009;361:345-357
1003. P. Cravedi, A. Perna, P. Ruggenenti, G. Remuzzi. Mycophenolate mofetil versus azathioprine in organ transplantation. (Letter to the Editor) *Am J Transpl* 2009;9:2856-2857.
1004. M. Noris, P. Cassis, N. Azzollini, R. Cavinato, D. Cugini, F. Casiraghi, S. Aiello, S. Solini, L. Cassis, M. Mister, M. Todeschini, M. Abbate, A. Benigni, P. Trionfini, S. Tomasoni, C. Mele, C. Garlanda, N. Polentarutti, A. Mantovani, G. Remuzzi. The Toll-IL-1R member Tir8/SIGIRR negatively regulates adaptive immunity against kidney grafts. *J Immunol* 2009;183:4249-4260.
1005. E. Gagliardini, D. Corna, C. Zoja, F. Sangalli, F. Carrara, M. Rossi, S. Conti, D. Rottoli, L. Longaretti, A. Remuzzi, G. Remuzzi, A. Benigni. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. *Am J Physiol Renal Physiol* 2009;297:F1448-F1456.
1006. N. Perico, C. Zoja, D. Corna, D. Rottoli, F. Gaspari, L. Haskell, G. Remuzzi. V1/V2 vasopressin receptor antagonism potentiates the renoprotection of rennin-angiotensin system inhibition in rats with renal mass reduction. *Kidney Int* 2009;76:960-967.
1007. P. Ruggenenti, D. Cattaneo, G. Loriga, F. Ledda, N. Motterlini, G. Gherardi, S. Orisio, G. Remuzzi. Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy. *Hypertension* 2009;54:567-574.
1008. S. De Cosmo, N. Motterlini, S. Prudente, F. Pellegrini, R. Trevisan, A. Bossi, G. Remuzzi, V. Trischitta, P. Ruggenenti on behalf of the BENEDICT Study Group. Impact of the PPAR-g2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT. *Diabetes* 2009;58:2920-2929.
1009. M.A. Pfeffer, E.A. Burdmann, C-Y. Chen, M.E. Cooper, D. de Zeeuw, K-U. Eckardt, P. Ivanovich, R. Kewalramani, A.S. Levey, E.F. Lewis, J. McGill, J.J.V. McMurray, P. Parfrey, H-H. Parving, G. Remuzzi, A.K. Singh, S.D. Solomon, R. Toto, H. Uno, on behalf of the TREAT Investigators. Baseline characteristics in the Trial to Reduce cardiovascular Events with Aranesp Therapy (TREAT). *Am J Kidney Dis* 2009;54:59-69.
1010. M. Figliuzzi, R. Cornolti, N. Perico, C. Rota, M. Morigi, G. Remuzzi, A. Remuzzi, A. Benigni. Bone marrow-derived mesenchymal stem cells improve islet graft function in diabetic rats. *Transplant Proc* 2009;41:1797-1800.

1011. J.M. Saland, P. Ruggenenti, G. Remuzzi. Consensus Study Group. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome (Review). *J Am Soc Nephrol*. 2009;20:940-949.
1012. G. Remuzzi, S. Chiaramonte, N. Perico, C. Ronco. Humoral immunity in kidney transplantation: what clinicians need to know. Preface. *Contrib Nephrol*. 2009;162:vii-ix.
1013. N. Perico, R.F. Bravo, F.R. De Leon, G. Remuzzi. Screening for chronic kidney disease in emerging countries: feasibility and hurdles. *Nephrol Dial Transplant* 2009;24:1355-1358.
1014. S. Buelli, M. Abbate, M. Morigi, D. Moioli, C. Zanchi, M. Noris, C. Zoja, C.D. Pusey, P.F. Zipfel, G. Remuzzi. Protein load impairs factor H binding promoting complement-dependent dysfunction of proximal tubular cells. *Kidney Int* 2009;75:1050-1059.
1015. C. Zoja, P.B. Garcia, G. Remuzzi. The role of chemokines in progressive renal disease (Review). *Front Biosci* 2009;14:1815-1822.
1016. P. Cravedi, P. Ruggenenti, G. Remuzzi. Intensified inhibition of renin-angiotensin system: a way to improve renal protection? *Curr Hypertens Rep* 2009;11:118-124.
1017. P. Cravedi, P. Ruggenenti, G. Remuzzi. Sirolimus to replace calcineurin inhibitors? Too early yet (Review) *Lancet* 2009;11;373:1235-1236.
1018. A. Lauder, A. Schieppati, F. Conte, G. Remuzzi, D. Battle. Low mortality and key aspects of delivery of care for end-stage renal disease in Italy. *Scientific World Journal* 2009;9:349-359.
1019. D. Cattaneo, M. Cortinovis, S. Baldelli, E. Gotti, G. Remuzzi, N. Perico. Limited sampling strategies for the estimation of sirolimus daily exposure in kidney transplant recipients on a calcineurin inhibitor-free regimen. *J Clin Pharmacol* 2009;49:773-781.
1020. A. Benigni, G. Remuzzi. Treatment of chronic proteinuric kidney disease: what next? *Hypertension* 2009;54:29-31.
1021. H.J. Lambers Heerspink, R. Agarwal, D.W. Coyne, H.H. Parving, E. Ritz, G. Remuzzi, P. Audhya, M.J. Amdahl, D.L. Andress, D. de Zeeuw. The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics. *Am J Nephrol* 2009;30:280-286.
1022. M. Galbusera, G. Remuzzi, P. Boccardo. Treatment of bleeding in dialysis patients (Review). *Semin Dial* 2009;22:279-286.
1023. P. Trionfini, S. Tomasoni, M. Galbusera, D. Motto, L. Longaretti, D. Corna, G. Remuzzi, A. Benigni. Adenoviral-mediated gene transfer restores plasma ADAMTS13 antigen and activity in ADAMTS13 knockout mice. *Gene Ther* 2009;16:1373-1379.

1024. S. Vegter, A. Perna, W. Hiddema, P. Ruggenenti, G. Remuzzi, G. Navis, M.J. Postma. Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism. *Pharmacogenet Genomics* 2009;19:695-703
1025. M.H. Dahlke, M. Hoogduijn, E. Eggenhofer, F.C. Popp, P. Renner, P. Slowik, A. Rosenauer, P. Piso, E.K. Geissler, C. Lange, D. Chabannes, B. Mazzanti, S. Bigenzahn, P. Bertolino, U. Kunter, M. Introna, A. Rambaldi, C. Capelli, N. Perico, F. Casiraghi, M. Noris, E. Gotti, M. Seifert, R. Saccardi, H.W. Verspaget, B. van Hoek, A. Bartholomew, T. Wekerle, H.D. Volk, G. Remuzzi, R. Deans, H. Lazarus, H.J. Schlitt, C.C. Baan; MISOT Study Group. Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. *Transplantation*. 2009;88:614-619.
1026. M. Noris, G. Remuzzi. Atypical hemolytic-uremic syndrome (Review). *N Engl J Med* 2009;361:1676-1687.
1027. M.D. Säemann, G. Remuzzi. Transplantation: time to rethink immunosuppression by mTOR inhibitors? *Nat Rev Nephrol* 2009;5:611-612.
1028. B. Smeets, M.L. Angelotti, P. Rizzo, H. Dijkman, E. Lazzeri, F. Mooren, L. Ballerini, E. Parente, C. Sagrinati, B. Mazzinghi, E. Ronconi, F. Becherucci, A. Benigni, E. Steenbergen, L. Lasagni, G. Remuzzi, J. Wetzels, P. Romagnani. Renal progenitor cells contribute to hyperplastic lesions of podocytopathies and crescentic glomerulonephritis. *J Am Soc Nephrol* 2009;20:2593-2603.
1029. M.A. Pfeffer, E.A. Burdmann, C.Y. Chen, M.E. Cooper, D. de Zeeuw, K.U. Eckardt, J.M. Feyzi, P. Ivanovich, R. Kewalramani, A.S. Levey, E.F. Lewis, J.B. McGill, J.J. McMurray, P. Parfrey, H.H. Parving, G. Remuzzi, A.K. Singh, S.D. Solomon, R. Toto; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. *N Engl J Med* 2009;361:2019-2032.
1030. G. Remuzzi, M. Galbusera, P. Boccardo. Disorders of hemostasis in dialysis patients. In: *Principles and Practice of Dialysis* (4th edition), chapter n. 29. Edited by W.L. Henrich. Lippincott Williams & Wilkins, Philadelphia 2009, pp. 489-498.
1031. A. Schieppati, E. Daina, G. Remuzzi. Lupus Nephritis. In: *Evidence-based Nephrology*, chapter n. 22. Edited by D.A. Molony, J.C. Craig. Wiley-Blackwell, Oxford (UK) 2009, pp. 244-252.
1032. P. Ruggenenti, G. Remuzzi. Diabetes Mellitus. In: *Evidence-based Nephrology*, chapter n. 21. Edited by D.A. Molony, J.C. Craig. Wiley-Blackwell, Oxford (UK) 2009, pp. 231-243.
1033. A. Schieppati, R. Pisoni, G. Remuzzi. Pathophysiology of chronic kidney disease. In: *Primer on Kidney Diseases* (5th Edition), chapter n. 52. Edited by A. Greenberg. Saunders Elsevier, Philadelphia 2009, pp. 422-435.
1034. G. Remuzzi. The global burden of chronic kidney diseases waits for better renoprotection. *Arch Med Sci* 2009;5(3A):S393-S394.

1035. M.R. Weir, N.K. Hollenberg, D.H. Zappe, X. Meng, H.H. Parving, G. Viberti, G. Remuzzi. Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria. *J Hypertens* 2010;28:186-193.
1036. P. Cassis, S. Conti, G. Remuzzi, A. Benigni. Angiotensin receptors as determinants of life span. *Pflugers Arch* 2010;459:325-332.
1037. D.G. Warnock, E. Daina, G. Remuzzi, M. West. Enzyme replacement therapy and Fabry nephropathy. *Clin J Am Soc Nephrol* 2010;5:371-378.
1038. D.G. Warnock, G. Remuzzi, B.M. Brenner, A. Levin, C. Wanner. Introduction to Focus on Fabry Nephropathy: Biomarkers, Progression, and Disease Severity. *Clin J Am Soc Nephrol* 2010;5:359.
1039. M. Morigi, C. Rota, T. Montemurro, E. Montelatici, V. Lo Cicero, B. Imberti, M. Abbate, C. Zoja, P. Cassis, L. Longaretti, P. Rebulla, M. Introna, C. Capelli, A. Benigni, G. Remuzzi, L. Lazzari. Life-Sparing Effect of Human Cord-Blood Mesenchymal Stem Cells in Experimental Acute Kidney Injury. *Stem Cells* 2010; 28: 513-522.
1040. M. Cortinovis, E. Gotti, G. Remuzzi, N. Perico, D. Cattaneo, S. Baldelli. Omega-3 polyunsaturated fatty acids affect sirolimus exposure in kidney transplant recipients on calcineurin inhibitor-free regimen. *Transplantation* 2010;89:126-127.
1041. A.F. Dominiczak, S. Herget-Rosenthal, C. Delles, D. Fliser, I. Fournier, A. Graber, M. Girolami, E. Holmes, F. Lang, F. Molina, J. Nicholson, G. Remuzzi, P. Rossing, K.L. Rudolph, O. Wolkenhauer, I. Xenarios, R. Zubarev, D. Zubov, A. Vlahou, J.P. Schanstra. Systems biology to battle vascular disease. *Nephrol Dial Transplant*. 2010;25:1019-1022.
1042. R. Coppo, M.R. Daha, J. Egido, M. El-Nahas, J. Feehally, J. Floege, L. Gesualdo, H. Holthofer, G. Remuzzi, P. Ronco; on behalf of the ERA-EDTA Immunonephrology working group. ERA-EDTA Immunonephrology working group. *Nephrol Dial Transplant*. 2010;25:1706-1707.
1043. A. Caroli, L. Antiga, M. Cafaro, G. Fasolini, A. Remuzzi, G. Remuzzi, P. Ruggenenti. Reducing Polycystic Liver Volume in ADPKD: Effects of Somatostatin Analogue Octreotide. *Clin J Am Soc Nephrol*. 2010;5:783-789.
1044. P. Cravedi, P. Ruggenenti, G. Remuzzi. Low-Dose Rituximab for Posttransplant Recurrent Membranous Nephropathy. *Am J Transplant* 2010;10:1336.
1045. V.P. Persy, G. Remuzzi, N. Perico, M. Benganem Gharbi, D. Adu, V. Jha, A. Rizvi, M. Ben Ammar, S. Fongoro, M.E. De Broe. Prevention and Transplantation in Chronic Kidney Disease: What Is Achievable in Emerging Countries? Meeting Report: Bamako Meeting December 4-6, 2008. *Nephron Clin Pract*. 2010;115:c122-c132.
1046. F. Gaspari, P. Cravedi, M. Mandalà, N. Perico, F.R. de Leon, N. Stucchi, S. Ferrari, R. Labianca, G. Remuzzi, P. Ruggenenti. Predicting Cisplatin-Induced Acute Kidney

- Injury by Urinary Neutrophil Gelatinase-Associated Lipocalin Excretion: A Pilot Prospective Case-Control Study. *Nephron Clin Pract.* 2010;115:c154-c160.
1047. F. Casiraghi, S. Aiello, G. Remuzzi. Transplant tolerance: progress and challenges. *J Nephrol.* 2010;23:263-270. Review.
 1048. P. Ruggenenti, I.M. van der Meer, G. Remuzzi. Oral acetyl-L-carnitine therapy and insulin resistance. *Hypertension.* 2010;55:e26.
 1049. A. Benigni, M. Morigi, G. Remuzzi. Kidney regeneration. *Lancet.* 2010;375:1310-1317.
 1050. N. Perico, L. Antiga, A. Caroli, P. Ruggenenti, G. Fasolini, M. Cafaro, P. Ondeì, N. Rubis, O. Diadei, G. Gherardi, S. Prandini, A. Panozo, R.F. Bravo, S. Carminati, F.R. De Leon, F. Gaspari, M. Cortinovis, N. Motterlini, B. Ene-Iordache, A. Remuzzi, G. Remuzzi. Sirolimus therapy to halt the progression of ADPKD. *J Am Soc Nephrol.* 2010;21:1031-1040.
 1051. A. Benigni, P. Cassis, G. Remuzzi. Angiotensin II revisited: new roles in inflammation, immunology and aging. *EMBO Mol Med.* 2010; 2:247-257. Review
 1052. C. Zoja, D. Corna, E. Gagliardini, S. Conti, L. Arnaboldi, A. Benigni, G. Remuzzi. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. *Am J Physiol Renal Physiol.* 2010;299:F1203-1211.
 1053. M. Noris, G. Remuzzi. Thrombotic microangiopathy after kidney transplantation. *Am J Transplant.* 2010;10:1517-1523.
 1054. P. Ruggenenti, A. Perna, M. Tonelli, G. Loriga, N. Motterlini, N. Rubis, F. Ledda, S. Jr Rota, A. Satta, A. Granata, G. Battaglia, F. Cambareri, S. David, F. Gaspari, N. Stucchi, S. Carminati, B. Ene-Iordache, P. Cravedi, G. Remuzzi; for the ESPLANADE Study Group. Effects of Add-on Fluvastatin Therapy in Patients with Chronic Proteinuric Nephropathy on Dual Renin-Angiotensin System Blockade: The ESPLANADE Trial. *Clin J Am Soc Nephrol.* 2010;5:1928-1938.
 1055. M.J. Hoogduijn, F.C. Popp, A. Grohnert, M.J. Crop, M. van Rhijn, A.T. Rowshani, E. Eggenhofer, P. Renner, M.E. Reinders, T.J. Rabelink, L.J. van der Laan, F.J. Dor, J.N. Ijzermans, P.G. Genever, C. Lange, A. Durrbach, J.H. Houtgraaf, B. Christ, M. Seifert, M. Shagidulin, V. Donckier, R. Deans, O. Ringden, N. Perico, G. Remuzzi, A. Bartholomew, H.J. Schlitt, W. Weimar, C.C. Baan, M.H. Dahlke; MISOT Study Group. Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). *Transplantation.* 2010;90:124-126.
 1056. P. Cravedi, P. Ruggenenti, G. Remuzzi. Sirolimus for calcineurin inhibitors in organ transplantation: contra. *Kidney Int.* 2010;78:1068-1074.
 1057. P. Ruggenenti, I. Iliev, M. Filipponi, S. Tadini, A. Perna, M. Ganeva, B. Ene-Iordache, P. Cravedi, R. Trevisan, A. Bossi, G. Remuzzi. Effect of trandolapril on regression of retinopathy in hypertensive patients with type 2 diabetes: a prespecified analysis of the benedict trial. *J Ophthalmol.* 2010;2010:106384. Epub 2010 Jun 10.

1058. K.J. Bell, A. Hayen, P. Macaskill, J.C. Craig, B.C. Neal, K.M. Fox, W.J. Remme, F.W. Asselbergs, W.H. van Gilst, S. Macmahon, G. Remuzzi, P. Ruggenenti, K.K. Teo, L. Irwig. Monitoring initial response to Angiotensin-converting enzyme inhibitor-based regimens: an individual patient data meta-analysis from randomized, placebo-controlled trials. *Hypertension*. 2010;56:533-539.
1059. S.D. Solomon, H. Uno, E.F. Lewis, K.U. Eckardt, J. Lin, E.A. Burdmann, D. de Zeeuw, P. Ivanovich, A.S. Levey, P. Parfrey, G. Remuzzi, A.K. Singh, R. Toto, F. Huang, J. Rossert, J.J. McMurray, M.A. Pfeffer. Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes. *N Engl J Med*. 2010;363:1146-1155.
1060. P. Ruggenenti, P. Cravedi, G. Remuzzi; Medscape. The RAAS in the pathogenesis and treatment of diabetic nephropathy. *Nat Rev Nephrol*. 2010;6:319-330. Review.
1061. F. Casiraghi, M. Noris, G. Remuzzi. Immunomodulatory effects of mesenchymal stromal cells in solid organ transplantation. *Curr Opin Organ Transplant*. 2010; 15; 731-737.
1062. P. Cravedi, V. Brusegan, P. Ruggenenti, R. Campbell, G. Remuzzi, Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: does it really work? *Pharmaceuticals*. 2010; 3; 1-9.
1063. E. Gagliardini, S. Conti, A. Benigni, G. Remuzzi, A. Remuzzi. Imaging of the porous ultrastructure of the glomerular epithelial filtration slit. *J Am Soc Nephrol*. 2010;21:2081-2089.
1064. D. de Zeeuw, R. Agarwal, M. Amdahl, P. Audhya, D. Coyne, T. Garimella, HH. Parving, Y. Pritchett, G. Remuzzi, E. Ritz, D. Andress. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. *Lancet*. 2010;376:1543-1551.
1065. P. Cravedi, P. Ruggenenti, G. Remuzzi. Which antihypertensive drugs are the most nephroprotective and why? *Expert Opin Pharmacother*. 2010;11:2651-2663.
1066. M. Figliuzzi, B. Bonandrini, I. Cattaneo, G. Remuzzi, A. Remuzzi. Effect of inborn pancreatic islet deficit in the Munich Wister Frömter rat. *Islets*. 2010;2:318-322.
1067. N. Perico, G. Remuzzi. Do mTOR inhibitors still have a future in ADPKD? *Nat Rev Nephrol*. 2010;6:696-698.
1068. P. Ruggenenti, D. Cattaneo, S. Rota, I. Iliev, A. Parvanova, O. Diadei, B. Ene-Iordache, S. Ferrari, A.C. Bossi, R. Trevisan, A. Belviso, G. Remuzzi; Ezetimibe and Simvastatin in Dyslipidemia of Diabetes (ESD) Study Group. Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial. *Diabetes Care*. 2010;33:1954-1956.
1069. P. Cravedi, N. Perico, G. Remuzzi. Non-immune interventions to protect kidney allografts in the long term. *Kidney Int*. 2010;78 Suppl 119:S71-S75.

1070. P. Cravedi, P. Ruggenti, G. Remuzzi. Nondiabetic kidney disease. In: *Cardiorenal Syndrome – Mechanisms, risk and treatment*, chapter n. 27. Edited by A.E. Berbari, G. Mancia. Springer-Verlag, Italia 2010, pp. 341-356.
1071. M. Noris, M. Galbusera, G. Remuzzi. Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. In: *Management of Acute Kidney Problems*, chapter n. 6.9. Edited by A. Jorres, C. Ronco, J.A. Kellum. Springer-Verlag Berlin Heidelberg 2010, pp. 349-364.
1072. P. Ruggenti, P. Cravedi, G. Remuzzi. Thrombotic Microangiopathies, including Hemolytic Uremic Syndrome. In: *Comprehensive Clinical Nephrology* (4th Edition), chapter n. 28. Edited by J. Floege, R.J. Johnson, J. Feehally. Elsevier Saunders, Missouri (USA) 2010, pp. 344-355.
1073. P. Cravedi, A. Remuzzi, G. Remuzzi. Comment on: Robertson (2010) Islet transplantation a decade later and strategies for filling a half-full glass. *Diabetes*;59:1285-1291. *Diabetes* 2010;59:e13.
1074. N. Perico, G. Remuzzi. The role of mTOR inhibition in the control of autosomal dominant polycystic kidney disease. *Drugs of the Future* 2010;35:929-938.
1075. M. Noris, J. Caprioli, E. Bresin, C. Mossali, G. Pianetti, S. Gamba, E. Daina, C. Fenili, F. Castelletti, A. Sorosina, R. Piras, R. Donadelli, R. Maranta, I. van der Meer, E.M. Conway, P.F. Zipfel, T.H. Goodship, G. Remuzzi. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. *Clin J Am Soc Nephrol*. 2010;5:1844-1859.
1076. M. Noris, G. Remuzzi. Genetics and genetic testing in hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. *Semin Nephrol*. 2010;30:395-408.
1077. C. Zoja, D. Corna, E. Gagliardini, S. Conti, L. Arnaboldi, A. Benigni, G. Remuzzi. [Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes which translates into full renoprotection.](#) *Am J Physiol Renal Physiol* 2010;299:F1203-F1211.
1078. P. Cravedi, I. van der Meer, S. Cattaneo, P. Ruggenti, G. Remuzzi. Successes and disappointments with clinical islet transplantation. In: *The Islets of Langerhans – Advances in Experimental Medicine and Biology*, volume 654, chapter n. 33. Edited by Md Shahidul Islam. Springer, 2010, pp. 749-769.
1079. I. van der Meer, P. Ruggenti, G. Remuzzi. The diabetic CKD patient-a major cardiovascular challenge. *J Ren Care* 2010;36:(Suppl.1):34-46.
1080. I. van der Meer, P. Cravedi, G. Remuzzi. The role of renin angiotensin system inhibition in kidney repair. *Fibrogenesis Tissue Repair* 2010;3:7.
1081. B. Bikbov, N. Perico, M. Abbate, G. Remuzzi. The glomerulus: mechanisms of injury. In: *Comprehensive Toxicology*, volume 7. Edited by C.A. McQueen. Academic Press, Oxford 2010, pp. 245-261.

1082. P. Cravedi, I. van der Meer, S. Cattaneo, P. Ruggenenti, G. Remuzzi. Successes and disappointments with clinical islet transplantation. *Adv Exp Med Biol* 2010;654:749-769.
1083. M. Noris, E. Bresin, C. Mele, G. Remuzzi, J. Caprioli. Atypical hemolytic-uremic syndrome. In: *GeneReviews* [Internet] Edited by R.A. Pragon, T.C. Bird, C.R. Dolan, K. Stephens. University of Washington, Seattle 1997-2010. Available at <http://www.genetests.org>
1084. P. Cravedi, P. Ruggenenti, G. Remuzzi. Old Donors for Kidney Transplantation: How Old? *Gerontology* 2011;57:513-520.
1085. P. Ruggenenti, P. Cravedi, G. Remuzzi. Optimizing allocation of kidneys from older donors. *Am J Transplant*. 2011;11:182
1086. J. Caprioli, G. Remuzzi, M. Noris. Thrombotic microangiopathies: from animal models to human disease and cure. *Contrib Nephrol* 2011;169:337-350.
1087. P. Ruggenenti, A. Fassi, A.P. Ilieva, I.P. Iliev, C. Chiurciu, N. Rubis, G. Gherardi, B. Ene-Iordache, F. Gaspari, A. Perna, P. Cravedi, A. Bossi, R. Trevisan, N. Motterlini, G. Remuzzi; BENEDICT-B Study Investigators. Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. *J Hypertens* 2011;29:207-216.
1088. A. Benigni, G. Remuzzi. Cells for treating organ damage: how long will we need them? (Editorial) *J Am Soc Nephrol* 2011;22:590-592.
1089. N. Perico, G. Remuzzi, A. Benigni. Aging and the kidney. (Review) *Curr Opin Nephrol Hypertens* 2011; 20:312-317.
1090. P. Ruggenenti, G. Remuzzi. Initial combination therapy for treatment of hypertension. (Correspondence) *Lancet* 2011;377:1491.
1091. B. Imberti, F. Casiraghi, D. Cugini, N. Azzollini, P. Cassis, S. Solini, V. Sebastiano, M. Zuccotti, S. Garagna, C.A. Redi, M. Noris, M. Morigi, G. Remuzzi. Embryonic stem cells, derived either after in vitro fertilization or nuclear transfer, prolong survival of semiallogeneic heart transplants. *J Immunol* 2011;186:4164-4174.
1092. N. Perico, F. Casiraghi, M. Inrona, E. Gotti, M. Todeschini, R.A. Cavinato, C. Capelli, A. Rambaldi, P. Cassis, P. Rizzo, M. Cortinovia, M. Marasà, J. Golay, M. Noris, G. Remuzzi. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. *Clin J Am Soc Nephrol* 2011;6:412-422.
1093. P. Ruggenenti, G. Remuzzi. Chronic kidney disease: Staging CKD: can we rely on estimated GFRs? (News & Views) *Nature Reviews Nephrology* 2011;7:307-308.
1094. H. Debiec, F. Lefeu, M.J. Kemper, P. Niaudet, G. Deschênes, G. Remuzzi, T. Ulinski, P. Ronco. Early-childhood membranous nephropathy due to cationic bovine serum albumin. *N Engl J Med* 2011;364:2101-2110.

1095. G. Remuzzi, A. Schieppati. Why rare diseases? *Ann Ist Super Sanità* 2011;47:94-97.
1096. H. Trachtman, F.C. Fervenza, D.S. Gipson, P. Heering, D.R. Jayne, H. Peters, S. Rota, G. Remuzzi, L.C. Rump, L.K. Sellin, J.P. Heaton, J.B. Streisand, M.L. Hard, S.R. Ledbetter, F. Vincenti. A phase 1, single-dose study of fresolimumab, an anti-TGF- β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. *Kidney Int* 2011;79:1236-1243.
1097. F. Sangalli, F. Carrara, F. Gaspari, D. Corna, C. Zoja, L. Botti, G. Remuzzi, A. Remuzzi. Effect of ACE inhibition on glomerular permselectivity and tubular albumin concentration in the renal ablation model. *Am J Physiol Renal Physiol* 2011;300:F1291-F1300.
1098. F.A. Holtkamp, D. de Zeeuw, P.A. de Graeff, G.D. Laverman, T. Berl, G. Remuzzi, D. Packham, J.B. Lewis, H.H. Parving, H.J. Lambers Heerspink. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. *Eur Heart J* 2011;32:1493-1499.
1099. B.C. Astor, K. Matsushita, R.T. Gansevoort, M. van der Velde, M. Woodward, A.S. Levey, P.E. de Jong, J. Coresh and the Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. *Kidney Int* 2011;79:1331-1340.
1100. P. Cravedi, M. Abbate, E. Gagliardini, M. Galbusera, S. Buelli, E. Sabadini, M. Marasà, L.H. Beck, D.J. Salant, A. Benigni, V. D'Agati, G. Remuzzi. Membranous nephropathy associated with IgG4-related disease. (Case Report) *Am J Kidney Dis* 2011;58:272-275.
1101. P. Cravedi, G. Remuzzi, P. Ruggenti. Targeting the renin angiotensin system in dialysis patients. (Review) *Semin Dial* 2011;24:290-297.
1102. C. Mele, P. Iatropoulos, R. Donadelli, A. Calabria, R. Maranta, P. Cassis, S. Buelli, S. Tomasoni, R. Piras, M. Krendel, S. Bettoni, M. Morigi, M. Delledonne, C. Pecoraro, I. Abbate, M.R. Capobianchi, F. Hildebrandt, E. Otto, F. Schaefer, F. Macciardi, F. Ozaltin, S. Emre, T. Ibsirlioglu, A. Benigni, G. Remuzzi, M. Noris; the PodoNet Consortium. MYO1E Mutations and Childhood Familial Focal Segmental Glomerulosclerosis. *N Engl J Med* 2011;365:295-306.
1103. M. Abbate, P. Cravedi, I. Iliev, G. Remuzzi, P. Ruggenti. Prevention and treatment of diabetic retinopathy: evidence from clinical trials and perspectives. *Curr Diabetes Rev* 2011;7:190-200.
1104. P. Cravedi, P. Ruggenti, G. Remuzzi. Circulating anti-PLA2R autoantibodies to monitor immunological activity in membranous nephropathy. *J Am Soc Nephrol* 2011;22:1400-1402.

1105. P. Cravedi, M.C. Sghirlanzoni, M. Marasà, A. Salerno, G. Remuzzi, P. Ruggenenti. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. *Am J Nephrol* 2011;33:461-468.
1106. F. Rocchetta, S. Solini, M. Mister, C. Mele, P. Cassis, M. Noris, G. Remuzzi, S. Aiello. Erythropoietin enhances immunostimulatory properties of immature dendritic cells. *Clin Exp Immunol* 2011;165:202-210.
1107. M. Morigi, M. Galbusera, S. Gastoldi, M. Locatelli, S. Buelli, A. Pezzotta, C. Pagani, M. Noris, M. Gobbi, M. Stravalaci, D. Rottoli, F. Tedesco, G. Remuzzi, C. Zoja. Alternative pathway activation of complement by shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. *J Immunol* 2011;187:172-180.
1108. P. Ruggenenti, G. Remuzzi. A German outbreak of haemolytic uraemic syndrome. (Comment) *Lancet* 2011;378:1057-1058.
1109. A. Benigni, M. Morigi, P. Rizzo, E. Gagliardini, C. Rota, M. Abbate, S. Ghezzi, A. Remuzzi, G. Remuzzi. Inhibiting angiotensin-converting enzyme promotes renal repair by limiting progenitor cell proliferation and restoring the glomerular architecture. *Am J Pathol* 2011;179:628-638.
1110. M.R. Weir, N.K. Hollenberg, G. Remuzzi, D.H. Zappe, X. Meng, H.H. Parving. Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients. *J Hypertens* 2011;29:2031-2037.
1111. P. Cassis, N. Azzollini, S. Solini, M. Mister, S. Aiello, D. Cugini, P. Scudeletti, E. Gagliardini, M. Abbate, L. Gallon, G. Remuzzi, M. Noris. Both darbepoetin alfa and carbamylated erythropoietin prevent kidney graft dysfunction due to ischemia/reperfusion in rats. *Transplantation* 2011;92:271-279.
1112. C. Xinari, B. Imberti, G. Remuzzi, M. Morigi. Bone Marrow Mesenchymal Stem Cells in Organ Repair and Strategies to Optimize their Efficacy. In: *Regenerative Nephrology*. Edited by Michael S. Goligorsky, Academic Press, USA 2011, pp. 299-312.
1113. P. Ruggenenti, G. Remuzzi. Worsening kidney function in decompensated heart failure: treat the heart, don't mind the kidney. (Editorial) *Eur Heart J* 2011;32:2476-2478.
1114. A. Caroli, L. Antiga, S. Conti, A. Sonzogni, G. Fasolini, P. Ondei, N. Perico, G. Remuzzi, A. Remuzzi. Intermediate volume on computed tomography imaging defines a fibrotic compartment that predicts glomerular filtration rate decline in autosomal dominant polycystic kidney disease patients. *Am J Pathol* 2011;179:619-627.
1115. S. Aiello, P. Cassis, M. Mister, S. Solini, F. Rocchetta, M. Abbate, E. Gagliardini, A. Benigni, G. Remuzzi, M. Noris. Rabbit anti-rat thymocyte immunoglobulin preserves renal function during ischemia/reperfusion injury in rat kidney transplantation. *Transplant Int* 2011;24:829-838.

1116. C. Zoja, S. Cattaneo, F. Fiordaliso, V. Lionetti, V. Zambelli, M. Salio, D. Corna, C. Pagani, D. Rottoli, C. Bisignini, G. Remuzzi, A. Benigni. Distinct cardiac and renal effects of ET_A receptor antagonist and ACE inhibitor in experimental type 2 diabetes. *Am J Physiol Renal Physiol* 2011;301:F1114-F1123.
1117. P. Ruggenenti, G. Lauria, I. Iliev, A. Fassi, A. Parvanova, S. Rota, C. Chiurchiu, D. Pongrac Barlovic, A. Sghirlanzoni, R. Lombardi, P. Penza, G. Cavaletti, M.L. Piatti, B. Frigeni, M. Filippini, N. Rubis, G. Noris, N. Motterlini, B. Ene-Iordache, F. Gaspari, A. Perna, J. Zaletel, A. Bossi, A.R. Dodesini, R. Trevisan, G. Remuzzi; for the DEMAND Study Investigators. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. *Hypertension* 2011;58:776-783.
1118. P. Ruggenenti, E. Perticucci, R. Trevisan, A.R. Dodesini, V. Gambarà, B. Ene-Iordache, S. Carminati, N. Rubis, G. Gherardi, A. Perna, P. Cravedi, A. Remuzzi, G. Remuzzi, The Remission Clinic Task Force. The Remission Clinic approach to halt the progression of kidney disease. *J Nephrol* 2011;24:274-281.
1119. M. Marasà, G. Remuzzi, P. Cravedi. Hypertension after kidney transplantation: an important, but still neglected issue. (Editorial Comment) *J Hypertens* 2011;29:2310-2311.
1120. W.G. Couser, G. Remuzzi, S. Mendis, M. Tonelli. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. (Policy Forum) *Kidney Int* 2011;80:1258-1270.
1121. F. Mallamaci, P. Ruggenenti, A. Perna, D. Leonardis, R. Tripepi, G. Tripepi, G. Remuzzi, C. Zoccali for the REIN Study Group. ACE inhibition is renoprotective among obese patients with proteinuria. *J Am Soc Nephrol* 2011;22:1122-1128.
1122. C. Zoccali, P. Ruggenenti, A. Perna, D. Leonardis, R. Tripepi, G. Tripepi, F. Mallamaci, G. Remuzzi for the REIN Study Group. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. *J Am Soc Nephrol* 2011;22:1923-1930.
1123. F. Casiraghi, M. Todeschini, G. Remuzzi. Mesenchymal stromal cells in kidney transplantation. *European Nephrology* 2011;5:61-67.
1124. A. Ble, M. Mosca, G. Di Loreto, A. Guglielmotti, G. Biondi, S. Bombardieri, G. Remuzzi, P. Ruggenenti. Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis. *Am J Nephrol* 2011;34:367-372.
1125. S. De Cosmo, S. Prudente, O. Lamacchia, E. Lapice, E. Morini, R. Di Paola, M. Copetti, P. Ruggenenti, G. Remuzzi, O. Vaccaro, M. Cignarelli, V. Trischitta. PPAR γ P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies. *Nephrol Dial Transplant* 2011;26:4011-4016.

1126. S. Czernichow, A. Zanchetti, F. Turnbull, F. Barzi, T. Ninomiya, A. Kengne, H.J. Lambers Heerspink, V. Perkovic, R. Huxley, H. Arima, A. Patel, J. Chalmers, M. Woodward, S. MacMahon, B.C. Neal, G. Remuzzi, P. Ruggenenti, Blood Pressure Lowering treatment Trialists' Collaboration. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. *J Hypertens* 2011;29:4-16.
1127. G. Remuzzi. Ethical disputes still beset Italian medicine 150 years after Count Cavour's death. *Lancet* 2012;379:1068-1073.
1128. S. Vegter, A. Perna, M.J. Postma, G. Navis, G. Remuzzi, P. Ruggenenti. Sodium intake, ACE inhibition, and progression to ESRD. *J Am Soc Nephrol* 2012;23:165-173.
1129. P. Ruggenenti, F. Gaspari, A. Cannata, F. Carrara, C. Cella, S. Ferrari, N. Stucchi, S. Prandini, B. Ene-Iordache, O. Diadei, N. Perico, P. Ondeì, A. Pisani, E. Buongiorno, P. Messa, M. Dugo, G. Remuzzi; for the GFR-ADPKD Study Group. [Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study](#). *PLoS One* 2012;7:e32533..
1130. E. Daina, M. Noris, G. Remuzzi. Eculizumab in a patient with dense-deposit disease. (Letter) *N Engl J Med* 2012;366:1161-1163.
1131. J.P. Dwyer, H-H. Parving, L.G. Hunsicker, M. Ravid, G. Remuzzi, J.B. Lewis, for the DEMAND Investigators. Renal dysfunction in the presence of normoalbuminuria in type 2 diabetes: results from the DEMAND study. *Cardiorenal Med* 2012;2:1-10.
1132. P. Cassis, L. Gallon, A. Benigni, M. Mister, A. Pezzotta, S. Solini, E. Gagliardini, D. Cugini, M. Abbate, S. Aiello, F. Rocchetta, P. Scudeletti, N. Perico, M. Noris, G. Remuzzi. Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury. *Kidney Int* 2012;81:903-918.
1133. P. Cravedi, P. Ruggenenti, G. Remuzzi. Proteinuria should be used as a surrogate in CKD. *Nat Rev Nephrol* 2012;8:301-306.
1134. I. Martinelli, P. Ruggenenti, I. Cetin, G. Pardi, A. Perna, P. Vergani, B. Acaia, F. Facchinetti, G.B. La Sala, M. Bozzo, S. Rampello, L. Marozio, O. Diadei, G. Gherardi, S. Carminati, G. Remuzzi, P.M. Mannucci; for the HAPPY Study Group. Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. *Blood* 2012;119:3269-3275.
1135. C. Rota, B. Imberti, M. Pozzobon, M. Piccoli, P. De Coppi, A. Atala, E. Gagliardini, C. Xinaris, V. Benedetti, A.S. Fabricio, E. Squarcina, M. Abbate, A. Benigni, G. Remuzzi, M. Morigi. Human Amniotic Fluid Stem Cell Preconditioning Improves Their Regenerative Potential. *Stem Cells Dev* 2012;21:1911-1923.
1136. A. Gennarini, P. Cravedi, M. Marasà, A. Perna, G. Rota, M. Bontempelli, S. Sandrini, G. Remuzzi, P. Ruggenenti. Perioperative minimal induction therapy: a further step

- toward more effective immunosuppression in transplantation. *J Transplant* 2012;2012:426042.
1137. F. Casiraghi, N. Azzollini, M. Todeschini, R.A. Cavinato, P. Cassis, S. Solini, C. Rota, M. Morigi, M. Introna, R. Maranta, N. Perico, G. Remuzzi, M. Noris. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. *Am J Transplant* 2012;12:2373-2383.
 1138. P. Iatropoulos, E. Daina, C. Mele, R. Maranta, G. Remuzzi, M. Noris. Discordant phenotype in monozygotic twins with renal coloboma syndrome and a PAX2 mutation. *Pediatr Nephrol* 2012;27:1989-1993.
 1139. Ruggenenti P, Cravedi, A. Chianca, A. Perna, B. Ruggiero, F. Gaspari, A. Rambaldi, M. Marasà, G. Remuzzi. Rituximab in idiopathic membranous nephropathy. *J Am Soc Nephrol* 2012;23:1416-1425.
 1140. D. Macconi, S. Tomasoni, P. Romagnani, P. Trionfini, F. Sangalli, B. Mazzinghi, P. Rizzo, E. Lazzeri, M. Abbate, G. Remuzzi, A. Benigni. MicroRNA-324-3p promotes renal fibrosis and is a target of ACE inhibition. *J Am Soc Nephrol* 2012;23:1496-1505.
 1141. A. Schieppati, G. Remuzzi. Cavour's death and the political difficulties of Italian medicine. (Correspondence) *Lancet* 2012;380:108-109.
 1142. L.A. Lotta, H.M. Wu, I.J. Mackie, M. Noris, A. Veyradier, M.A. Scully, G. Remuzzi, P. Coppo, R. Liesner, R. Donadelli, C. Loirat, R.A. Gibbs, A. Horne, S. Yang, I. Garagiola, K.M. Musallam, F. Peyvandi. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. *Blood* 2012;120:440-448.
 1143. P. Cravedi, S.K. Sharma, R.F. Bravo, N. Islam, I. Tchokhanelidze, M. Ghimire, B. Pahari, S. Thapa, A. Basnet, A. Tataradze, D. Tinatin, L. Beglarishvili, C-W. Fwu, J.B. Kopp, P. Eggers, B. Ene-Iordache, S. Carminati, A. Perna, A. Chianca, W.G. Couser, G. Remuzzi, N. Perico. Preventing renal and cardiovascular risk by renal function assessment: insights from a cross-sectional study in low-income countries and the USA. *BMJ Open* 2012;2:e001357. doi: 10.1136/bmjopen-2012-001357.
 1144. P. Ruggenenti, E. Porrini, N. Motterlini, A. Perna, A. Parvanova, I. Iliev, A.R. Dodesini, R. Trevisan, A. Bossi, G. Sampietro, E. Capitoni, F. Gaspari, N. Rubis, B. Ene-Iordache, G. Remuzzi; for the BENEDICT Study Investigators. Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. *J Am Soc Nephrol* 2012;23:1717-1724.
 1145. P. Ruggenenti, G. Remuzzi. Thrombotic microangiopathy: E. coli O104:H4 German out break: a missed opportunity. *Nat Rev Nephrol* 2012;8:558-560.
 1146. P. Ruggenenti, E.L. Porrini, F. Gaspari, N. Motterlini, A. Cannata, F. Carrara, C. Cella, S. Ferrari, N. Stucchi, A. Parvanova, I. Iliev, A.R. Dodesini, R. Trevisan, A. Bossi, J. Zaletel, G. Remuzzi; for the GFR Study Investigators. Glomerular Hyperfiltration and Renal Disease Progression in Type 2 Diabetes. *Diabetes Care* 2012;35:2061-2068.

1147. C. Zoja, M. Locatelli, C. Pagani, D. Corna, C. Zanchi, B. Isermann, G. Remuzzi, E.M. Conway, M. Noris. Lack of the lectin-like domain of thrombomodulin worsens shiga toxin-associated hemolytic uremic syndrome in mice. *J Immunol* 2012;189:3661-3668.
1148. P. Ruggenenti, G. Remuzzi. Dealing with renin-angiotensin inhibitors, don't mind serum creatinine. *Am J Nephrol* 2012;36:427-429.
1149. N. Perico, G. Remuzzi. Chronic kidney disease: a research and public health priority. *Nephrol Dial Transplant* 2012;27(Suppl. 3):iii19-iii26.
1150. C. Zoja, P. Bautista Garcia, C. Rota, S. Conti, E. Gagliardini, D. Corna, C. Zanchi, P. Bigini, A. Benigni, G. Remuzzi, M. Morigi. Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy. *Am J Physiol Renal Physiol* 2012;303:F1370-F1381.
1151. C. Xinaris, V. Benedetti, P. Rizzo, M. Abbate, D. Corna, N. Azzollini, S. Conti, M. Unbekandt, J.A. Davies, M. Morigi, A. Benigni, G. Remuzzi. *In vivo* maturation of functional renal organoids formed from embryonic cell suspensions. *J Am Soc Nephrol* 2012;23:1857-1868.
1152. M. Noris, F. Mescia, G. Remuzzi. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. *Nat Rev Nephrol* 2012;8:622-633.
1153. J.A. Salomon, T. Vos, D.R. Hogan, M. Gagnon, M. Naghavi, A. Mokdad, N. Begum, R. Shah, M. Karyana, S. Kosen, N. Perico, G. Remuzzi, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. *Lancet* 2012;380:2129-2143.
1154. R. Lozano, M. Naghavi, K. Foreman, S. Lim, K. Shibuya, V. Aboyans, J. Abraham, T. Adair, R. Aggarwal, M. Cortinovis, F. Gaspari, N. Perico, G. Remuzzi, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;380:2095-2128.
1155. C.J.L. Murray, T.Vos, R. Lozano, M. Naghavi, A.D. Flaxman, C. Michaud, M. Ezzati, K. Shibuya, J.A. Salomon, S. Abdalla, C. Cella, M. Cortinovis, F. Gaspari, V. Miglioli, N. Perico, G. Remuzzi, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;380:2197-2223.
1156. T. Vos, A.D. Flaxman, M. Naghavi, R. Lozano, C. Michaud, M. Ezzati, K. Shibuya, J.A. Salomon, S. Abdalla, V. Aboyans, C. Cella, M. Cortinovis, F. Gaspari, V. Miglioli, N. Perico, G. Remuzzi. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;380:2163-2196.
1157. P. Ruggenenti, P. Cravedi, G. Remuzzi. Mechanisms and treatment of CKD. (Brief Review) *J Am Soc Nephrol* 2012;23:1917-1928.

1158. I. Codreanu, V. Sali, S. Gaibu, L. Suveica, S. Popa, N. Perico, B. Ene-Iordache, S. Carminati, J. Feehally, G. Remuzzi. Prevalence of hypertension and diabetes and coexistence of chronic kidney disease and cardiovascular risk in the population of the republic of moldova. *Int J Hypertens* 2012;2012:1-8.
1159. M. Noris, G. Remuzzi. Non-muscle myosins and the podocyte. *Clin Kidney J* 2012;5:94-101.
1160. N. Perico, A. Remuzzi, G. Remuzzi. Mechanisms and consequences of proteinuria. In: Brenner and Rector's *The Kidney*, 9th ed., Vol. II, chapter n. 52. Edited by B.M. Brenner. Saunders Elsevier, Philadelphia 2012, pp. 1972-1999.
1161. P. Ruggenenti, P. Cravedi, G. Remuzzi. Microvascular and macrovascular diseases of the kidney. In: Brenner and Rector's *The Kidney*, 9th ed., Vol. II, chapter n. 34. Edited by B.M. Brenner. Saunders Elsevier, Philadelphia 2012, pp. 1297-1331.
1162. M. Noris, G. Remuzzi. Thrombotic Microangiopathies. In: *Nephrology Secrets* (3rd Edition) chapter n. 39. Edited by E.V. Lerma, A.R. Nissenson,. Elsevier Mosby, Philadelphia 2012, pp. 278-282.
1163. F. Casiraghi, N. Perico, G. Remuzzi. Mesenchymal stromal cells to promote solid organ transplantation tolerance. *Curr Opin Organ Transplant* 2013;18:51-58.
1164. P. Romagnani, G. Remuzzi. Renal progenitors in non-diabetic and diabetic nephropathies. *Trends Endocrinol Metab* 2013;24:13-20.
1165. S.M. Marcovina, C. Sirtori, A. Peracino, M. Gheorghiade, P. Borum, G. Remuzzi, H. Ardehali. Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine. *Transl Res* 2013;161:73-84.
1166. P. Cravedi, J.B. Kopp, G. Remuzzi. Recent progress in the pathophysiology and treatment of FSGS recurrence. *Am J Transplant* 2013;13:266-274.
1167. M. Abbate, D. Macconi, G. Remuzzi, C. Zoja. Role of proteinuria in the progression of renal disease. In: Seldin and Giebisch's *The Kidney – Physiology and Pathophysiology* 5th edition. Edited by R.J. Alpern, M.J. Caplan, O.W. Moe. Academic Press 2013, pp. 2961-2983.
1168. S. Tomasoni, L. Longaretti, C. Rota, M. Morigi, S. Conti, E. Gotti, C. Capelli, M. Introna, G. Remuzzi, A. Benigni. Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells. *Stem Cells Dev* 2013;22:772-780.
1169. H. Skali, J. Lin, M. Pfeffer, C.Y. Chen, M.E. Cooper, J.J.V. McMurray, A.R. Nissenson, G. Remuzzi, J. Rossert, P.S. Parfrey, N.W. Scott-Douglas, A.K. Singh, R. Toto, H. Uno, P. Ivanovich. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. *Am J Kidney Dis* 2013;61:238-246.

1170. P. Romagnani, L. Lasagni, G. Remuzzi. Renal progenitors: an evolutionary conserved strategy for kidney re generation. *Nat Rev Nephrol* 2013;9:137-146.
1171. F. Casiraghi, G. Remuzzi, M. Abbate, N. Perico. Multipotent Mesenchymal Stromal Cell Therapy and Risk of Malignancies. *Stem Cell Rev* 2013;9:65-79.
1172. A. Benigni, S. Orisio, M. Noris, P. Iatropoulos, D. Castaldi, K. Kamide, H. Rakugi, Y. Arai, M. Todeschini, G. Ogliari, E. Imai, Y. Gondo, N. Hirose, D. Mari, G. Remuzzi. Variations of the angiotensin II type 1 receptor gene are associated with extreme human longevity. *Age* 2013;35:993-1005.
1173. C. Xinari, M. Morigi, V. Benedetti, B. Imberti, A.S. Fabricio, E. Squarcina, A. Benigni, E. Gagliardini, G. Remuzzi. A novel strategy to enhance mesenchymal stem cell migration capacity and promote tissue repair in an injury specific fashion. *Cell Transplant* 2013;22:423-436.
1174. C. Zoja, D. Corna, V. Nava, M. Locatelli, M. Abbate, F. Gaspari, F. Carrara, F. Sangalli, G. Remuzzi, A. Benigni. Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. *Am J Physiol Renal Physiol* 2013;304:F808-F819.
1175. P. Ruggenenti, G. Remuzzi. Idiopathic membranous nephropathy: back to the future? *Lancet* 2013;381:706-708.
1176. E. Bresin, E. Rurali, J. Caprioli, P. Sanchez-Corral, V. Fremeaux-Bacchi, S. Rodriguez de Cordoba, S. Pinto, T.H.J. Goodship, M. Alberti, D. Ribes, E. Valoti, G. Remuzzi, M. Noris; European Working Party on Complement Genetics in Renal Diseases. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. *J Am Soc Nephrol* 2013;24:475-486.
1177. S.K. Sharma, S. Dhakal, L. Thapa, A. Ghimire, R. Tamrakar, S. Chaudhary, R. Deo, D. Manandhar, N. Perico, A. Perna, G. Remuzzi, M. Lamsal. Community-based screening for chronic kidney disease, hypertension and diabetes in Dharan. *J Nepal Med Assoc* 2013;52:205-212.
1178. D. de Zeeuw, T. Akizawa, R. Agarwal, P. Audhya, G.L. Bakris, M. Chin, M. Krauth, H.J. Lambers Heerspink, C.J. Meyer, J.J. McMurray, H-H. Parving, P.E. Pergola, G. Remuzzi, R.D. Toto, N.D. Vaziri, C. Wanner, D.G. Warnock, J Wittes, G.M. Chertow. Rationale and trial design of Bardoxolone methyl Evaluation in patients with Chronic kidney disease and type 2 diabetes: the Occurrence of renal events (BEACON). *Am J Nephrol* 2013;37:212-222.
1179. P. Ruggenenti, G. Remuzzi. Renin-angiotensin system: Meta-analyses can misdirect decisions on treatment. (News & Views) *Nat Rev Nephrol* 2013;9:311-312.
1180. J.J. Weening, P. Ronco, G. Remuzzi. Advances in the pathology of glomerular diseases. In: *Contributions to Nephrology: New Insights into Glomerulonephritis: Pathogenesis and Treatment*. Edited by C. Ronco, N. Chen. Basel, Karger 2013, vol. 181, pp.12-21.

1181. C.M. Legendre, C. Licht, P. Muus, L.A. Greenbaum, S. Babu, C. Bedrosian, C. Bingham, D.J. Cohen, Y. Delmas, K. Douglas, F. Eitner, T. Feldkamp, D. Fouque, R.R. Furman, O. Gaber, M. Herthelius, M. Hourmant, D. Karpman, Y. Lebranchu, C. Mariat, J. Menne, B. Moulin, J. Nürnberger, M. Ogawa, G. Remuzzi, T. Richard, R. Sberro-Soussan, B. Severino, N.S. Sheerin, A. Trivelli, L.B. Zimmerhackl, T. Goodship, C. Loirat. Terminal complement inhibitor Eculizumab in atypical hemolytic-uremic syndrome. *N Engl J Med* 2013;368:2169-2181.
1182. F. Gaspari, P. Ruggenti, E. Porrini, N. Motterlini, A. Cannata, F. Carrara, A. Jiménez Sosa, C. Cella, S. Ferrari, N. Stucchi, A. Parvanova, I. Iliev, R. Trevisan, A. Bossi, J. Zaletel, G. Remuzzi for the GFR Study Investigators. The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. *Kidney Int* 2013;84:164-173.
1183. G. Remuzzi, J.S. Bromberg. Mesenchymal stromal cells: what's in the name? (and for what?) Literature Watch Implications for transplantation. *Am J Transpl* 2013;13:1625.
1184. P. Cravedi, G. Remuzzi. Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. *Br J Clin Pharmacol* 2013;76:516-523.
1185. M. Franquesa, M.J. Hoogduijn, M.E. Reinders, E. Eggenhofer, A.U. Engela, F. Mensah, J. Torras, A. Pileggi, C. van Kooten, B. Mahon, O. Detry, F.C. Popp, V. Benseler, F. Casiraghi, C. Johnson, J. Ancans, B. Fillenberg, O. DelaRosa, J.M. Aran, M. Roemeling-VanRhijn, J. Pinxteren, N. Perico, E. Gotti, B. Christ, J. Reading, M. Introna, R. Deans, M. Shagidulin, R. Farré, A. Rambaldi, A. Sanchez-Fueyo, N. Obermajer, A. Pulin, F.J. Dor, I. Portero-Sanchez, C.C. Baan, T.J. Rabelink, G. Remuzzi, M.G. Betjes, M.H. Dahlke, J. Grinyo; the MiSOT Study Group. Mesenchymal stem cells in solid organ transplantation (MiSOT) Fourth Meeting: Lessons learned from first clinical trials. *Transplantation* 2013;96:234-238.
1186. G. Remuzzi, P. Ruggenti. ACP Journal Club. Prednisolone plus chlorambucil preserved renal function in membranous nephropathy. *Ann Intern Med* 2013;158:JC9.
1187. C. Zanchi, M. Locatelli, A. Benigni, D. Corna, S. Tomasoni, D. Rottoli, F. Gaspari, G. Remuzzi, C. Zoja. Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor. *PLoS ONE* 2013;8:e70775.
1188. M. Noris, G. Remuzzi. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. *Curr Opin Nephrol Hypertens* 2013;22:704-712.
1189. M. Alberti, E. Valoti, R. Piras, E. Bresin, M. Galbusera, C. Tripodo, F. Thaïss, G. Remuzzi, M. Noris. Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations. *Am J Transplant* 2013;13:2201-2206.
1190. H.J. Lambers Heerspink, G.M. Chertow, T. Akizawa, P. Audhya, G.L. Bakris, A. Goldsberry, M. Krauth, P. Linde, J.J. McMurray, C.J. Meyer, H-H. Parving, G. Remuzzi, H. Christ-Schmidt, R.D. Toto, N.D. Vaziri, C. Wanner, J. Wittes, D. Wroldstad, D. de Zeeuw. Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the

- Occurrence of renal events (BEACON) trial. *Nephrol Dial Transplant* 2013;28:2841-2850.
1191. M. Todeschini, M. Cortinovis, N. Perico, F. Poli, A. Innocente, R.A. Cavinato, E. Gotti, P. Ruggenenti, F. Gaspari, M. Noris, G. Remuzzi, F. Casiraghi. In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development. *J Immunol* 2013;191:2818-2828.
 1192. G. Remuzzi, A. Benigni, F.O. Finkelstein, J.P. Grunfeld, D. Joly, I. Katz, Z.H. Liu, T. Miyata, N. Perico, B. Rodriguez-Iturbe, L. Antiga, F. Schaefer, A. Schieppati, R.W. Schrier, M. Tonelli. Kidney failure: aims for the next 10 years and barriers to success. *Lancet* 2013;382:353-362.
 1193. E. Gagliardini, N. Perico, P. Rizzo, S. Buelli, L. Longaretti, L. Perico, S. Tomasoni, C. Zoja, D. Macconi, M. Morigi, G. Remuzzi, A. Benigni. Angiotensin II contributes to diabetic renal dysfunction in rodents and humans via Notch1/Snail pathway. *Am J Pathol* 2013;183:119-130.
 1194. M. Cozzolino, G. Gentile, S. Mazzaferro, D. Brancaccio, P. Ruggenenti, G. Remuzzi. Blood pressure, proteinuria, and phosphate as risk factors for progressive kidney disease: a hypothesis. *Am J Kidney Dis* 2013;62:984-992.
 1195. A. Caroli, N. Perico, A. Perna, L. Antiga, P. Brambilla, A. Pisani, B. Visciano, M. Imbriaco, P. Messa, R. Cerutti, M. Dugo, L. Cancian, E. Buongiorno, A. De Pascalis, F. Gaspari, F. Carrara, N. Rubis, S. Prandini, A. Remuzzi, G. Remuzzi, P. Ruggenenti, for the ALADIN study group. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. *Lancet* 2013;382:1485-1495.
 1196. M. Noris, G. Remuzzi. Overview of complement activation and regulation. *Semin Nephrol* 2013;33:479-492.
 1197. P. Ruggenenti, G. Remuzzi. Dual RAS blockade-controversy resolved (Correspondence). *Nat Rev Nephrol* 2013;9:640.
 1198. E. Rurali, M. Noris, A. Chianca, R. Donadelli, F. Banterla, M. Galbusera, G. Gherardi, S. Gastoldi, A. Parvanova, I. Iliev, A. Bossi, C. Haefliger, R. Trevisan, G. Remuzzi, P. Ruggenenti; for the BENEDICT Study Group. ADAMTS13 predicts renal and cardiovascular events in type 2 diabetics and response to therapy. *Diabetes* 2013;62:3599-3609.
 1199. P. Rizzo, N. Perico, E. Gagliardini, R. Novelli, M.R. Alison, G. Remuzzi, A. Benigni. Nature and mediators of parietal epithelial cell activation in glomerulonephritides of human and rat. *Am J Pathol* 2013;183:1769-1778.
 1200. D. de Zeeuw, T. Akizawa, P. Audhya, G.L. Bakris, M. Chin, H. Christ-Schmidt, A. Goldsberry, M. Houser, M. Krauth, H.J. Lambers Heerspink, J.J. McMurray, C.J. Meyer, H-H. Parving, G. Remuzzi, R.D. Toto, N.D. Vaziri, C. Wanner, J. Wittes, D.

- Wrolstad, G.M. Chertow; BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. *N Engl J Med* 2013;369:2492-2503.
1201. Blood Pressure Lowering Treatment Trialists' Collaboration (G. Remuzzi, P. Ruggenenti). Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. *BMJ* 2013;347:f5680.
 1202. N. Perico, F. Casiraghi, E. Gotti, M. Inrona, M. Todeschini, R.A. Cavinato, C. Capelli, A. Rambaldi, P. Cassis, P. Rizzo, M. Cortinovis, M. Noris, G. Remuzzi. Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. *Transpl Int* 2013;26:867-878.
 1203. A. Caroli, S. Manini, L. Antiga, K. Passera, B. Ene-Iordache, S. Rota, G. Remuzzi, A. Bode, J. Leermakers, F.N. van de Vosse, R. Vanholder, M. Malovrh, J. Tordoir, A. Remuzzi. Validation of a patient-specific hemodynamic computational model for surgical planning of vascular access in hemodialysis patients. *Kidney Int* 2013;84:1237-1245.
 1204. G. Remuzzi, R. Horton. Acute renal failure: an unacceptable death sentence globally. (Comment) *Lancet* 2013;382:2041-2042.
 1205. S. Fagioli, E. Daina, L. D'Antiga, M. Colledan, G. Remuzzi. Monogenic diseases that can be cured by liver transplantation. *J Hepatol* 2013;59:595-612.
 1206. A. Parvanova, I.M. van der Meer, I. Iliev, A. Perna, F. Gaspari, R. Trevisan, A. Bossi, G. Remuzzi, A. Benigni, P. Ruggenenti; for the Daglutril in Diabetic Nephropathy Study Group. Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial. *Lancet Diabetes Endocrinol* 2013;1:19-27.
 1207. M. Galbusera, G. Remuzzi, P. Onnei. Hemostatic abnormalities in renal disease. In: Hemostasis and thrombosis: Basic principles and clinical practice. Chapter n. 127. Edited by V.J. Marder, W.C. Aird, J.S. Bennett, S. Schulman, G.C. White II. Wolters Kluwer, Lippincott Williams & Wilkins, Philadelphia (USA) 2013, pp. 1491-1497.
 1208. M. Noris, G. Remuzzi, P. Ruggenenti. Hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, and acute cortical necrosis. In: Schrier's Diseases of The Kidney, 9th Edition, Chapter n. 55. Edited by T.M. Coffman, R.J. Falk, B.A. Molitoris, E.G. Neilson, R.W. Schrier. Lippincott Williams & Wilkins, Philadelphia 2013, pp. 1578-1604.
 1209. P. Cravedi, P. Ruggenenti, A. Remuzzi, G. Remuzzi. Current status of islet transplantation. In: Regenerative medicine applications in organ transplantation. Chapter n. 40. Edited by G. Orlando, J.P. Lerut, S. Soker, R.J. Stratta. Academic Press Elsevier, London (UK) 2014, pp. 583-598.
 1210. C. Zoja, A. Benigni, G. Remuzzi. The Nrf2 pathway in the progression of renal disease. *Nephrol Dial Transplant* 2014;29:i19-i24.

1211. B. Bikbov, N. Perico, G. Remuzzi. Mortality landscape in the Global Burden of Diseases, injuries and risk factors study. *European Journal of Internal Medicine* 2014;25:1-5.
1212. S. Livigni, G. Bertolini, C. Rossi, F. Ferrari, M. Giardino, M. Pozzato, G. Remuzzi, GiViTI: Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva (Italian Group for the Evaluation of Interventions in Intensive Care Medicine). Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: A multi center randomised controller clinical trial. *BMJ Open* 2014;4:e003536.
1213. F. Casiraghi, G. Remuzzi, N. Perico. Mesenchymal stromal cells to promote kidney transplantation tolerance. *Curr Opin Organ Transplant* 2014;19:47-53.
1214. S. Garattini, G. Remuzzi, G. Vago, A. Zangrillo. Stamina terapie: time to call a halt (Correspondence). *Nature* 2014;506:434.
1215. P. Cassis, S. Solini, N. Azzollini, S. Aiello, F. Rocchetta, S. Conti, R. Novelli, E. Gagliardini, M. Mister, F. Rapezzi, S. Rapezzi, A. Benigni, G. Remuzzi, E. M. Conway, M. Noris. An unanticipated role of survivin in organ transplant damage. *Am J Transpl* 2014;14:1046-1060.
1216. D.J. Birmingham, G. Shidham, A. Perna, D.M. Fine, M. Bissell, R. Rodby, G. Remuzzi, M. Petri, P. Hebert, B.H. Rovin. L.A. Hebert. Spot PC ratio estimates of 24-hour proteinuria are more unreliable in lupus nephritis than in other forms of chronic glomerular disease. *Ann Rheum Dis* 2014;73:475-476.
1217. P.A. Modesti, P. Agostoni, C. Agyemang, S. Basu, A. Benetos, F.P. Cappuccio, A. Ceriello, S. Del Prato, R. Kalyesubula, E. O'Brien, M.O. Kilama, S. Perlini, E. Picano, G. Reboldi, G. Remuzzi, D. Stuckler, M. Twagirumukiza, L.M. Van Bortel, G. Watfa, D. Zhao, G. Parati. Cardiovascular risk assessment in low-resource settings: a consensus document of the european society of hypertension working group on hypertension and cardiovascular risk in low resource settings. *J Hypertens* 2014;32:951-960.
1218. G. Remuzzi, N. Perico. International Society of Nephrology's perspective on the emergence of chronic kidney diseases of unknown/undetermined etiology. (Viewpoint) *MEDICC Review* 2014;16:75-76.
1219. A. Benigni, E. Gagliardini, G. Remuzzi. Abatacept in B7-1-positive proteinuric kidney disease. *N Engl J Med* 2014;370:1261-1263.
1220. S. Buelli, L. Rosanò, E. Gagliardini, D. Corna, L. Longaretti, A. Pezzotta, L. Perico, S. Conti, P. Rizzo, R. Novelli, M. Morigi, C. Zoja, G. Remuzzi, A. Bagnato, A. Benigni. β -arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury. *J Am Soc Nephrol* 2014;25:523-533.
1221. O. Devuyst, N.V.A.M. Knoers, G. Remuzzi, F. Schaefer, for the Board of the Working Group for Inherited Kidney Diseases of the European Renal Association and European Dialysis and Transplant Association. Rare inherited kidney diseases: challenges, opportunities, and perspectives. *Lancet* 2014;383:1844-1859.

1222. P. Ruggenenti, B. Ruggiero, P. Cravedi, M. Vivarelli, L. Massella, M. Marasà, A. Chianca, N. Rubis, B. Ene-Iordache, M. Rudnicki, R.M. Pollastro, G. Capasso, A. Pisani, M. Pennesi, F. Emma, G. Remuzzi; for the Rituximab in Nephrotic Syndrome of Steroid-Dependent or Frequently Relapsing Minimal Change Disease Or Focal Segmental Glomerulosclerosis (NEMO) Study Group. *J Am Soc Nephrol* 2014;25:850-863.
1223. D. de Zeeuw, B. Coll, D. Andress, J.J. Brennan, H. Tang, M. Houser, R. Correa-Rotter, D. Kohan, H.J. Lambers Heerspink, H. Makino, V. Perkovic, Y. Pritchett, G. Remuzzi, S.W. Tobe, R. Toto, G. Viberti, H-H. Parving. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. *J Am Soc Nephrol* 2014;25:1083-1093.
1224. M. Figliuzzi, G. Remuzzi, A. Remuzzi. Renal bioengineering with scaffolds generated from rat and pig kidneys. *Nephron Exp Nephrol* 2014;126:113-118.
1225. A. Levin, G. Remuzzi. Clinical trials: ISN-ACCTS: global initiatives to improve clinical research. *Nat Rev Nephrol* 2014;10:426-427.
1226. P. Ruggenenti, G. Remuzzi. Dreaming of normoglycaemia with fewer diet restrictions. *Lancet Diabetes Endocrinol* 2014;2:350-351.
1227. J. Feehally, W. Couser, S. Dupuis, F. Finkelstein, P. Harden, D. Harris, N. Lameire, S. Naicker, G. Remuzzi, L. Segantini, M. Tonelli. Nephrology in developing countries: the ISN's story. *Lancet* 2014;383:1271-1272.
1228. K. Petzold, R.T. Gansevoort, A.C.M. Ong, O. Devuyst, L. Rotar, K. Eckardt, A. Kottgen, Y. Pirson, G. Remuzzi, R. Sandford, V. Tesar, T. Ecder, D. Chaveau, R. Torra, K. Budde, Y. Le Meur, R.P. Wuthrich, A.L. Serra. Building a network of ADPKD reference centres across Europe: the EuroCYST initiative. *Nephrol Dial Transpl* 2014;29:iv26-iv32.
1229. M. Noris, G. Remuzzi. Cardiovascular complications in atypical haemolytic uraemic syndrome. *Nat Rev Nephrol* 2014;10:174-180.
1230. A. Levin, G. Remuzzi. ISN-ACCTS: global initiatives to improve clinical research. *Nat Rev Nephrol* 2014;10:426-427.
1231. M. Noris, M. Galbusera, S. Gastoldi, P. Macor, F. Banterla, E. Bresin, C. Tripodo, S. Bettoni, R. Donadelli, E. Valoti, F. Tedesco, A. Amore, R. Coppo, P. Ruggenenti, E. Gotti, G. Remuzzi. Dynamics of complement activation in atypical HUS and how to monitor eculizumab therapy. *Blood* 2014;124:1715-1726.
1232. S.K. Sharma, A. Ghimire, S. Carminati, G. Remuzzi, N. Perico. Management of chronic kidney disease and its risk factors in eastern Nepal. *Lancet Glob Health* 2014;2:e506-507.
1233. E.M. Spithoven, A. Kramer, E. Meijer, B. Orskov, C. Wanner, J.M. Abad, N. Aresté, R.A. de la Torre, F. Caskey, C. Couchoud, P. Finne, J. Heaf, A. Hoitsma, J. De Meester, J. Pascual, M. Postorino, P. Ravani, O. Zurriaga, K.J. Jager, R.T. Gansevoort,

- on behalf of the ERA-EDTA Registry, the EuroCYST Consortium and the WGIKD. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival - an analysis of data from the ERA-EDTA Registry. *Nephrol Dial Transplant* 2014;29:iv15-iv25.
1234. B. Bikbov, N. Perico, G. Remuzzi. High serum cholesterol: a missed risk factor for chronic kidney disease mortality. *Lancet Diabetes Endocrinol* 2014;2:613-614.
 1235. C.J. Murray, F.K. Ortblad, C. Guinovart, S.S. Lim, T.M. Wolock, D.A. Roberts, E.A. Dansereau, N. Graetz, R.M. Barber, J.C. Brown, H. Wang, H.C. Duber, G. Remuzzi, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2014;384:1005-1070.
 1236. J. Radhakrishnan, G. Remuzzi, R. Saran, D.E. Williams, N. Rios-Burrows, N. Powe, for the CDC-CKD Surveillance Team, K. Brück, C. Wanner, V.S. Stel, on behalf of the European CKD Burden Consortium, S.K. Venuthurupalli, W.E. Hoy, H.G. Healy, A. Salisbury, R.G. Fassett, on behalf of the CKD.QLD group, D. O'Donoghue, P. Roderick, S. Matsuo, A. Hishida, E. Imai S. Iimuro. Taming the chronic kidney disease epidemic: a global view of surveillance efforts. *Kidney Int* 2014;86:246-250.
 1237. M. Locatelli, S. Buelli, A. Pezzotta, D. Corna, L. Perico, S. Tomasoni, D. Rottoli, P. Rizzo, D. Conti, J.M. Thurman, G. Remuzzi, C. Zoja, M. Morigi. Shiga-toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement. *J Am Soc Nephrol* 2014;25:1786-1798.
 1238. N. Perico, G. Remuzzi. Chronic kidney disease in sub-Saharan Africa: a public health priority. *Lancet Glob Health* 2014;2:e124-e125.
 1239. F. Mescia, G. Remuzzi, M. Noris. Hemolytic uremic syndrome. In: *Clinical Genomics: Practical applications in adult patient care*. Chapter n. 81. Edited by M.F. Murray, M.W. Babyatsky, M.A. Giovanni. McGraw-Hill Education, USA 2014, pp. 401-405.
 1240. B. Bonandrini, M. Figliuzzi, E. Papadimou, M. Morigi, N. Perico, F. Casiraghi, F. Sangalli, S. Conti, A. Benigni, A. Remuzzi, G. Remuzzi. Recellularization of well preserved acellular kidney scaffold using embryonic stem cells. *Tissue Eng Part A* 2014;20:1486-1498.
 1241. F. Mescia, R. Piras, M. Noris, G. Marchetti, G. Rossini, G. Remuzzi, P. Ruggenenti. Kidney transplantation from a donor with acute kidney injury: an unexpected outcome. *Am J Transplant* 2014;14:977-978.
 1242. C. Mele, G. Remuzzi, M. Noris. Hemolytic uremic syndrome. *Semin Immunopathol* 2014;36:399-420.
 1243. G. Gentile, D. Mastroluca, P. Ruggenenti, G. Remuzzi. Novel effective drugs for diabetic kidney disease? Or not? *Expert Opin Emerging Drugs* 2014;19:571-601.

1244. The Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. *Lancet* 2014;384:591-598.
1245. A.P. de Vries, P. Ruggenenti, X.Z. Ruan, M. Praga, J.M. Cruzado, I.M. Bajema, V.D. D'Agati, H.J. Lamb, D. Ponrgrac Barlovic, R. Hojs, M. Abbate, R. Rodriguez, C.E. Mogensen, E. Porrini; ERA-EDTA Working Group Diabetes. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. *Lancet Diabetes Endocrinol* 2014;2:417-426.
1246. L.A. Inker, A.S. Levey, K. Pandya, N. Stoycheff, A. Okparavero, T. Greene, on behalf of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. *Am J Kidney Dis* 2014;64:74-85.
1247. M.A. Rodger, M. Carrier, G. Le Gal, I. Martinelli, A. Perna, E. Rey, J.I.P. de Vries, J-C. Gris, on behalf of the Low-Molecular-Weight Heparin for Placenta-Mediated Pregnancy Complications Study Group. Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. *Blood* 2014;123:822-828.
1248. P. Romagnani, L. Lasagni, G. Remuzzi. Reply: Nephrons are generated via a series of committed progenitors. (Reply) *Nat Rev Nephrol* 2014;10:491.
1249. P. Romagnani, G. Remuzzi. CD133+ renal stem cells always co-express CD24 in adult human kidney tissue. *Stem Cell Research* 2014;12:828-829.
1250. D. Macconi, G. Remuzzi, A. Benigni. Key fibrogenic mediators: old players. *Renin-angiotensin system. Kidney Int Suppl* 2014;4:58-64.
1251. B. Bikbov, N. Perico, M. Abbate, G. Remuzzi. The Glomerulus: mechanisms and patterns of injury. In: *Reference Module in Biomedical Science*. Elsevier 2014, pp. 1-18.
1252. E.M. Spithoven, A. Kramer, E. Meijer, B. Orskov, C. Wanner, F. Caskey, F. Collart, P. Finne, D.G. Fogarty, J.W. Groothoff, A. Hoitsma, M.B. Nogier, M. Postorino, P. Ravani, O. Zurriaga, K.J. Jager, R.T. Gansevoort; on behalf of the ERA-EDTA Registry; EuroCYST Consortium; the WGIKD; EuroCYST Consortium; the WGIKD. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. *Kidney Int* 2014;86:1244-1252.
1253. P. Cravedi, G. Remuzzi, P. Ruggenenti. Rituximab in primary membranous nephropathy: first-line therapy, why not? *Nephron Clin Pract* 2014;128:261-269.
1254. L.M. Ruilope, R. Agarwal, J.C. Chan, M.E. Cooper, R.T. Gansevoort, H. Haller, G. Remuzzi, P. Rossing, R.E. Schmieder, C. Nowack, A.C. Ferreira, A. Pieper, N. Kimmekamp-Kirschbaum, G.L. Bakris. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. *Am J Nephrol* 2014;40:572-581.

1255. R. Coppo, L. Peruzzi, A. Amore, S. Martino, L. Vergano, I. Lastauka, A. Schieppati, M. Noris, P.A. Tovo, G. Remuzzi. Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. *Pediatr Nephrol* 2015;30:167-172.
1256. E. Valoti, M. Alberti, A. Tortajada, J. Garcia-Fernandez, S. Gastoldi, L. Besso, E. Bresin, G. Remuzzi, S. Rodriguez de Cordoba, M. Noris. A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation. *J Am Soc Nephrol* 2015;26:209-219.
1257. P. Trionfini, A. Benigni, G. Remuzzi. MicroRNAs in kidney physiology and disease. *Nat Rev Nephrol* 2015;11:23-33.
1258. M. Noris, P. Ruggenenti, G. Remuzzi. Thrombotic microangiopathies, including hemolytic uremic syndrome. In: *Comprehensive Clinical Nephrology* (5th Edition), Chapter n. 29. Edited by R.J. Johnson, J. Feehally, J. Floege. Elsevier Saunders, Philadelphia (USA) 2015, pp. 339-351.
1259. M. Cortinovis, F. Casiraghi, G. Remuzzi, N. Perico. Mesenchymal stromal cells to control donor-specific memory T cells in solid organ transplantation. *Curr Opin Organ Transplant* 2015;20:79-85.
1260. A.K. Bello, A. Levin, B.J. Manns, J. Feehally, T. Drueke, L. Faruque, B.R. Hemmelgarn, C. Kernahan, J. Mann, S. Klarenbach, G. Remuzzi, M. Tonelli, on behalf of the Kidney Health for Life Initiative. Effective CKD care in european countries: challenges and opportunities for health policy. *Am J Kidney Dis* 2015;65:15-25.
1261. G. Gentile, C. Somma, A. Gennarini, D. Mastroluca, G. Rota, F. Lacanna, B. Locatelli, G. Remuzzi, P. Ruggenenti. Low-dose RATG with or without basiliximab in renal transplantation: a matched-cohort observational study. *Am J Nephrol* 2015;41:16-27.
1262. C. Zoja, D. Corna, M. Locatelli, D. Rottoli, A. Pezzotta, M. Morigi, C. Zanchi, S. Buelli, A. Guglielmotti, N. Perico, A. Remuzzi, G. Remuzzi. Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease. *Nephron* 2015;129:52-61.
1263. M. Morigi, L. Perico, C. Rota, L. Longaretti, S. Conti, D. Rottoli, R. Novelli, G. Remuzzi, A. Benigni. Sirtuin 3-dependent mitochondrial dynamic improvements protect against acute kidney injury. *J Clin Invest* 2015;125:715-726.
1264. G. Gentile, G. Remuzzi, P. Ruggenenti. Dual renin-angiotensin system blockade for nephroprotection: still under scrutiny. *Nephron* 2015;129:39-41.
1265. B. Imberti, S. Tomasoni, O. Ciampi, A. Pezzotta, M. Derosas, C. Xinaris, P. Rizzo, E. Papadimou, R. Novelli, A. Benigni, G. Remuzzi, M. Morigi. Renal progenitors derived from human iPSCs engraft and restore function in a mouse model of acute kidney injury. *Sci Rep* 2015;5:8826.

1266. N. Perico, G. Remuzzi. Need for chronic kidney disease prevention programs in disadvantaged populations. *Clin Nephrol* 2015;83(Suppl.1):42-48.
1267. A. Schieppati, N. Perico, G. Remuzzi. Eliminating treatable deaths due to acute kidney injury in resource-poor settings. *Semin Dial* 2015;28:193-197.
1268. D. de Zeeuw, D.A. Anzalone, V.A. Cain, M.D. Cressman, H.J. Lambers Heerspink, B.A. Molitoris, J.T. Monyak, H-H. Parving, G. Remuzzi, J.R. Sowers, D.G. Vidt. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomized clinical trial. *Lancet Diabetes Endocrinol* 2015;3:181-190.
1269. A. Trautmann, M. Bodria, F. Ozaltin, A. Gheisari, A. Melk, M. Azocar, A. Anarat, S. Caliskan, F. Emma, J. Gellermann, J. Oh, E. Baskin, J. Ksiazek, G. Remuzzi, O. Erdogan, S. Akman, J. Dusek, T. Davitaia, O. Ozkaya, F. Papachristou, A. Firszt-Adamczyk, T. Urasinski, S. Testa, R.T. Krmar, L. Hyla-Klekot, A. Pasini, Z.B. Ozcar, P. Sallay, N. Cakar, M. Galanti, J. Terzic, B. Aoun, A. Caldas Afonso, H. Szymanik-Grzelak, B.S. Lipska, S. Schnaidt, F. Schaefer for the PodoNet Consortium. Spectrum of steroid-resistant and congenital nephritic syndrome in children: the PodoNet registry cohort. *Clin J Am Soc Nephrol* 2015;10:592-600.
1270. B. Imberti, D. Corna, P. Rizzo, C. Xinari, M. Abbate, L. Longaretti, P. Cassis, V. Benedetti, A. Benigni, C. Zoja, G. Remuzzi, M. Morigi. Renal primordia activate kidney regenerative events in a rat model of progressive renal disease. *PLoS One* 2015;10:e0120235.
1271. E. Papadimou, M. Morigi, P. Iatropoulos, C. Xinari, S. Tomasoni, V. Benedetti, L. Longaretti, C. Rota, M. Todeschini, P. Rizzo, M. Introna, M.G. De Simoni, G. Remuzzi, M.S. Goligorsky, A. Benigni. Direct reprogramming of human bone marrow stromal cells into functional renal cells using cell-free extracts. *Stem Cell Reports* 2015;4:685-698.
1272. J. Sundstrom, H. Arima, R. Jackson, F. Turnbull, K. Rahimi, J. Chalmers, M. Woodward, B. Neal, on behalf of the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of blood pressure reduction in mild hypertension – A systematic review and meta-analysis. *Ann Intern Med* 2015;162:184-191.
1273. M. Trillini, M. Cortinovis, P. Ruggenenti, J. Reyes Loaeza, K. Courville, C. Ferrer-Siles, S. Prandini, F. Gaspari, A. Cannata, A. Villa, A. Perna, E. Gotti, M.R. Caruso, D. Martinetti, G. Remuzzi, N. Perico. Paricalcitol for secondary hyperparathyroidism in renal transplantation. *J Am Soc Nephrol* 2015;26:1205-1214.
1274. L. Luzzatto, C.E. Hollak, T.M. Cox, A. Schieppati, C. Licht, H. Kaariainen, G. Merlini, F. Schaefer, S. Simoons, L. Pani, S. Garattini, G. Remuzzi. Rare diseases and effective treatments: are we delivering? *Lancet* 2015;385:750-752.
1275. C. Mele, M. Lemaire, P. Iatropoulos, R. Piras, E. Bresin, S. Bettoni, D. Bick, D. Helbling, R. Veith, E. Valoti, R. Donadelli, L. Murer, M. Neunhauserer, M. Breno, V. Fremaux-Bacchi, R. Lifton, G. Remuzzi, M. Noris. Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome. *Clin J Am Soc Nephrol* 2015;10:1011-1019.

1276. P. Ruggenenti, G. Remuzzi. Combined neprilysin and RAS inhibition for the failing heart: straining the kidney to help the heart? *Eur J Heart Fail* 2015;17:468-471.
1277. D. Macconi, L. Perico, L. Longaretti, M. Morigi, P. Cassis, S. Buelli, N. Perico, G. Remuzzi, A. Benigni. Sirtuin3 dysfunction is the key determinant of skeletal muscle insulin resistance by angiotensin II. *PLoS One* 2015;10:e0127172.
1278. S. Buelli, L. Perico, M. Galbusera, M. Abbate, M. Morigi, R. Novelli, E. Gagliardini, C. Tentori, D. Rottoli, E. Sabadini, T. Saito, M. Kawano, T. Saeki, C. Zoja, G. Remuzzi, A. Benigni. Mitochondrial-dependent autoimmunity in membranous nephropathy of IgG4-related disease. *EBioMedicine* 2015;2:456-466.
1279. R.L. Mehta, J. Cerda, E.A. Burdmann, M. Tonelli, G. Garcia-Garcia, V. Jha, P. Susantitaphong, M. Rocco, R. Vanholder, M.S. Sever, D. Cruz, B. Jaber, N.H. Lameire, R. Lombardi, A. Lewington, J. Feehally, F. Finkelstein, N. Levin, N. Pannu, B. Thomas, E. Aronoff-Spencer, G. Remuzzi. International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. *Lancet* 2015;385:2616-2643.
1280. L. Perico, G. Remuzzi, A. Benigni. Sirtuin 3 in acute kidney injury. *Oncotarget* 2015;6:16814-16815.
1281. C. Zoja, M. Abbate, G. Remuzzi. Progression of renal injury toward interstitial inflammation and glomerular sclerosis is dependent on abnormal protein filtration. *Nephrol Dial Transpl* 2015;30:706-712.
1282. C. Xinaris, V. Brizi, G. Remuzzi. Organoid models and applications in biomedical research. *Nephron* 2015;130:191-199.
1283. N. Perico, G. Remuzzi. Acute kidney injury in poor countries should no longer be a death sentence: The ISN '0 by 25' project. *Ann Nutr Metab* 2015;66(Suppl. 3):42-44.
1284. G.L. Bakris, R. Agarwal, J.C. Chan, M.E. Cooper, R.T. Gansevoort, H. Haller, G. Remuzzi, P. Rossing, R.E. Schmieder, C. Nowack, P. Kolkhof, A. Joseph, A. Pieper, N. Kimmeskamp-Kirschbaum, L.M. Ruilope; Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. *JAMA* 2015;314:884-94.
1285. M. Noris, C. Mele, G. Remuzzi. Podocyte dysfunction in atypical haemolytic uraemic syndrome. *Nat Rev Nephrol* 2015;11:245-252.
1286. G. Schulman, T. Berl, G.J. Beck, G. Remuzzi, E. Ritz, K. Arita, A. Kato, M. Shimizu. Randomized placebo-controlled EPPIC trials of AST-120 in CKD. *J Am Soc Nephrol* 2015;26:1732-1746.
1287. M. Noris, G. Remuzzi. Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: core curriculum 2015. *Am J Kidney Dis* 2015;66:359-375.

1288. P. Ruggenenti, H. Debiec, B. Ruggiero, A. Chianca, T. Pellé, F. Gaspari, F. Suardi, E. Gagliardini, S. Orisio, A. Benigni, P. Ronco, G. Remuzzi. Anti-phospholipase A₂ receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. *J Am Soc Nephrol* 2015;26:2545-2558.
1289. G. Remuzzi. West meets east. *Kidney Dis* 2015;1:4-7.
1290. GBD 2013 Mortality and Causes of Death Collaborators, E. Beghi, N. Perico, G. Remuzzi, M. Trillini. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2015;385:117-171.
1291. Global Burden of Disease Study 2013 Collaborators, E. Beghi, N. Perico, G. Remuzzi, M. Trillini. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2015;386:743-800.
1292. N. Perico, G. Remuzzi. Acute kidney injury: more awareness needed, globally. *Lancet* 2015;386:1425-1427.
1293. J. Floege, R.H. Mak, B.A. Molitoris, G. Remuzzi, P. Ronco. Nephrology research – the past, present and future. *Nat Rev Nephrol* 2015;11:677-687.
1294. C. Licht, L.A. Greenbaum, P. Muus, S. Babu, C.L. Bedrosian, D.J. Cohen, Y. Delmas, K. Douglas, R.R. Furman, O.A. Gaber, T. Goodship, M. Herthelius, M. Hourmant, C.M. Legendre, G. Remuzzi, N. Sheerinn, A. Trivelli, C. Loirat. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. *Kidney Int* 2015;87:1061-1073.
1295. E. Daina, P. Cravedi, M. Alpa, D. Roccattello, S. Gamba, A. Perna, F. Gaspari, G. Remuzzi, P. Ruggenenti. A multidrug, antiproteinuric approach to Alport syndrome: a ten-year cohort study. *Nephron* 2015;130:13-20.
1296. P. Ruggenenti, G. Remuzzi. RAS blockade: nephroprotection by dual RAS blockade – a welcome back. *Nat Rev Nephrol* 2015;11:507-508.
1297. B. Thomas, S. Wulf, B. Bikbov, N. Perico, M. Cortinovis, K. Courville de Vaccaro, A. Flaxman, H. Peterson, A. Delossantos, D. Haring, R. Mehrotra, J. Himmelfarb, G. Remuzzi, C. Murray, M. Naghavi. Maintenance Dialysis throughout the World in Years 1990 and 2010. *J Am Soc Nephrol* 2015;26:2621-2633.
1298. D.E. Kohan, H.J. Lambers Heerspink, B. Coll, D. Andress, J.J. Brennan, D.W. Kitzman, R. Correa-Rotter, H. Makino, V. Perkovic, F.F. Hou, G. Remuzzi, S.W. Tobe, R. Toto, H.H. Parving, D. de Zeeuw. Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy. *Clin J Am Soc Nephrol* 2015;10:1568-1574.
1299. E. Ruruli, F. Banterla, R. Donadelli, E. Bresin, M. Galbusera, S. Gastoldi, F. Peyvandi, M. Underwood, G. Remuzzi, M. Noris. ADAMTS13 secretion and residual activity

- among patients with congenital thrombotic thrombocytopenic purpura with and without renal impairment. *Clin J Am Soc Nephrol* 2015;10:2002-2012.
1300. C. Pecoraro, A.V. Ferretti, E. Rurali, M. Galbusera, M. Noris, G. Remuzzi. Treatment of congenital thrombotic thrombocytopenic purpura with eculizumab. *Am J Kidney Dis* 2015;66:1067-1070.
 1301. GBD 2013 Risk Factors Collaborators, G. Giussani, N. Perico, G. Remuzzi, M. Trillini. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2015;386:2287-2323.
 1302. GBD 2013 DALYs and HALE Collaborators, E. Beghi, N. Perico, G. Remuzzi, M. Trillini. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. *Lancet* 2015;386:2145-2191.
 1303. P. Cravedi, P. Ruggerenti, G. Remuzzi. Successes and disappointments with clinical islet transplantation. In: *Islets of Langerhans 2nd Edition*, Chapter 44. Editor: Shahidul Islam. Springer Dordrecht 2015, pp. 1245-1274.
 1304. G. Remuzzi, R. Horton. Italy, the land of holy miracles revisited. *Lancet* 2016;387:11-12.
 1305. B. Schievink, T. Kröpelin, S. Mulder, H.H. Parving, G. Remuzzi, J. Dwyer, P. Vemer, D. de Zeeuw, H.J. Lambers Heerspink. Early renin-angiotensin-system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes. *Diabetes Obes Metab* 2016;18:64-71.
 1306. C. Zoja, M. Locatelli, D. Corna, S. Villa, D. Rottoli, V. Nava, R. Verde, F. Piscitelli, V. Di Marzo, J. Fingerle, J.M. Adam, B. Rothenhaeusler, G. Ottaviani, A. Bénardeau, M. Abbate, G. Remuzzi, A. Benigni. Therapy with a selective cannabinoid receptor type 2 agonist limits albuminuria and renal injury in mice with type 2 diabetic nephropathy. *Nephron* 2016;132:59-69.
 1307. D. Macconi, A. Benigni, G. Remuzzi. The onset and resolution of renal fibrosis: a human perspective. In: *Kidney Development, Disease, Repair and Regeneration*, chapter n. 26. Edited by M.H. Little. Elsevier, Amsterdam 2016, pp. 351-366.
 1308. P.A. Modesti, G. Reboldi, F.P. Cappuccio, C. Agyemang, G. Remuzzi, S. Rapi, E. Perruolo, G. Parati; ESH Working Group on CV Risk in low Resource Settings. Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis. *PLoS One* 2016;11:e0147601.
 1309. P. Iatropoulos, M. Noris, C. Mele, R. Piras, E. Valoti, E. Bresin, M. Curreri, E. Mondo, A. Zito, S. Gamba, S. Bettoni, L. Murer, V. Fremeaux-Bacchi, M. Vivarelli, F. Emma, E. Daina, G. Remuzzi. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. *Mol Immunol* 2016;71:131-142.

1310. A. Remuzzi, F. Sangalli, D. Macconi, S. Tomasoni, I. Cattaneo, P. Rizzo, B. Bonandrini, E. Bresciani, L. Longaretti, E. Gagliardini, S. Conti, A. Benigni, G. Remuzzi. Regression of renal disease by angiotensin II antagonism is caused by regeneration of kidney vasculature. *J Am Soc Nephrol* 2016;27:699-705.
1311. R. Novelli, E. Gagliardini, B. Ruggiero, A. Benigni, G. Remuzzi. Any value of podocyte B7-1 as a biomarker in human MCD and FSGS? *Am J Physiol Renal Physiol* 2016;310:F335-F341.
1312. A. Schieppati, G. Remuzzi. Pharmacotherapy options for membranous nephropathy. *Expert Opin Orphan Drugs* 2016;4:185-196.
1313. A. Levin, D. Harris, G. Remuzzi, R. Horton, P. Berman. The Lancet Kidney Campaign: an opportunity for partnerships. *Lancet* 2016;387:1038-1039.
1314. Global Burden of Disease Pediatrics Collaboration, H.H. Kyu, N. Perico, G. Remuzzi. Global and national burden of diseases and injuries among children and adolescent between 1990 and 2013: findings from the Global Burden of Disease 2013 Study. *JAMA Pediatr* 2016;170:267-287.
1315. F. Casiraghi, M. Cortinovis, N. Perico, G. Remuzzi. Recent advances in immunosuppression and acquired immune tolerance in renal transplants. *Am J Physiol Renal Physiol* 2016;310:F446-F453.
1316. F. Casiraghi, N. Perico, M. Cortinovis, G. Remuzzi. Mesenchymal stromal cells in renal transplantation: opportunities and challenges. *Nat Rev Nephrol* 2016;12:241-253.
1317. R. Coppo, R. Bonaudo, R.L. Peruzzi, A. Amore, A. Brunati, R. Romagnoli, M. Salizzoni, M. Galbusera, E. Gotti, E. Daina, M. Noris, G. Remuzzi. Liver transplantation for aHUS: still needed in the eculizumab era? *Pediatr Nephrol* 2016;31:759-768.
1318. N. Perico, G. Remuzzi. Acute kidney injury in low-income and middle-income countries: no longer a death sentence. *Lancet Glob Health* 2016;4:e216-e217.
1319. B. Schievink, D. de Zeeuw, P.A. Smink, D. Andress, J.J. Brennan, B. Coll, R. Correa-Rotter, F.F. Hou, D. Kohan, D.W. Kitzman, H. Makino, H.H. Parving, V. Perkovic, G. Remuzzi, S. Tobe, R. Toto, J. Hoekman, H.J. Lambers Heerspink. Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers. *Eur J Prev Cardiol* 2016;23:758-768.
1320. E. Gagliardini, R. Novelli, D. Corna, C. Zoja, B. Ruggiero, A. Benigni, G. Remuzzi. B7-1 is not induced in podocytes of human and experimental diabetic nephropathy. *J Am Soc Nephrol* 2016;27:999-1005.
1321. N. Perico, G. Remuzzi. Prevention programs for chronic kidney disease in low-income countries. *Intern Emerg Med* 2016;11:385-389.

1322. P. Rizzo, R. Novelli, A. Benigni, G. Remuzzi. Inhibiting angiotensin-converting enzyme promotes renal repair by modulating progenitor cell activation. *Pharmacol Res* 2016;108:16-22.
1323. B. Ene-Iordache, N. Perico, B. Bikbov, S. Carminati, A. Remuzzi, A. Perna, N. Islam, R.F. Bravo, M. Aleckovic-Halilovic, H. Zou, L. Zhang, Z. Gouda, I. Tchokhanelidze, G. Abraham, M. Mahdavi-Mazdeh, M. Gallieni, I. Codreanu, A. Togtokh, S.K. Sharma, P. Koirala, S. Uprety, I. Ulasi, G. Remuzzi. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. *Lancet Glob Health* 2016;4:e307-e319.
1324. P. Ruggerenti, G. Gentile, N. Perico, A. Perna, L. Barcella, M. Trillini, M. Cortinovis, C.P. Ferrer Siles, J.A. Loaeza, M.C. Aparicio, G. Fasolini, F. Gaspari, D. Martinetti, F. Carrara, N. Rubis, S. Prandini, A. Caroli, K. Sharma, L. Antiga, A. Remuzzi, G. Remuzzi; SIRENA 2 Study Group. Effect of sirolimus on disease progression in patients with autosomal dominant polycystic kidney disease and CKD stages 3b-4. *Clin J Am Soc Nephrol* 2016;11:785-794.
1325. C. Xinari, V. Benedetti, R. Novelli, M. Abbate, P. Rizzo, S. Conti, S. Tomasoni, D. Corna, M. Pozzobon, D. Cavallotti, T. Yokoo, M. Morigi, A. Benigni, G. Remuzzi. Functional human podocytes generated in organoids from amniotic fluid stem cells. *J Am Soc Nephrol* 2016;27:1400-1411.
1326. M. Fratelli, M. Bolis, M. Kurosaki, M. Dori, V. Guarnaccia, O. Spinelli, M. Alberti, E. Valoti, S. Pileggi, M. Noris, G. Remuzzi, A. Rambaldi, M. Terao, E. Garattini. Association of CFHR1 homozygous deletion with acute myelogenous leukemia in the European population. *Leuk Lymphoma* 2016;57:1234-1237.
1327. R.L. Mehta, E.A. Burdmann, J. Cerda, J. Feehally, F. Finkelstein, G. Garcia-Garcia, M. Godin, V. Jha, N.H. Lameire, N.W. Levin, A. Lewington, R. Lombardi, E. Macedo, M. Rocco, E. Aronoff-Spencer, M. Tonelli, J. Zhang, G. Remuzzi. Recognition and management of acute kidney injury in the International Society of Nephrology 0by25 Global Snapshot: a multinational cross-sectional study. *Lancet* 2016;387:2017-2025. Erratum in *Lancet* 2016;387:1998.
1328. M. Morigi, C. Rota, G. Remuzzi. Mesenchymal stem cells in kidney repair. *Methods Mol Biol.* 2016;1416:89-107.
1329. O. Ciampi, R. Iacone, L. Longaretti, V. Benedetti, M. Graf, M.C. Magnone, C. Patsch, C. Xinari, G. Remuzzi, A. Benigni, S. Tomasoni. Generation of functional podocytes from human induced pluripotent stem cells. *Stem Cell Res* 2016;17:130-139.
1330. A. Pisani, M. Sabbatini, M. Imbriaco, E. Riccio, N. Rubis, A. Prinster, A. Perna, R. Liuzzi, L. Spinelli, M. Santangelo, G. Remuzzi, P. Ruggerenti: ALADIN Study Group. Long-term effects of ocreotide on liver volume in patients with polycystic kidney and liver disease. *Clin Gastroenterol Hepatol* 2016;14:1022-1030.
1331. M. Morigi, M. Locatelli, C. Rota, S. Buelli, D. Corna, P. Rizzo, M. Abbate, D. Conti, L. Perico, L. Longaretti, A. Benigni, C. Zoja, G. Remuzzi. A previously unrecognized role of C3a in proteinuric progressive nephropathy. *Sci Rep* 2016;6:28445.

1332. M. Noris, E. Bresin, C. Mele, G. Remuzzi. Genetic Atypical Hemolytic-Uremic Syndrome. 2007 Nov 16 [Updated 2016 Jun 9]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK1367/>
1333. R. Novelli, E. Gagliardini, B. Ruggiero, A. Benigni, G. Remuzzi. Another piece of the puzzle of podocyte B7-1 expression: lupus nephritis. *Nephron* 2016; 133:129-138.
1334. W.E. Mitch, G. Remuzzi. Diets for patients with chronic kidney disease, should we reconsider? *BMC Nephrol* 2016;17:80.
1335. G. Gentile, G. Remuzzi. Novel biomarkers for renal diseases? None for the moment (but one). *J Biomol Screen* 2016;21:655-670.
1336. GBD 2015 HIV Collaborators. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. *Lancet HIV* 2016;3:e361-e387.
1337. M. Cortinovis, P. Ruggenenti, G. Remuzzi. Progression, remission and regression of chronic renal diseases. *Nephron* 2016;134:20-24.
1338. G. Remuzzi, R. Glassock. Interplay between diagnostic criteria and prognostic accuracy in chronic kidney disease. *PloS Med* 2016;13:e1002129.
1339. P. Delanaye, N. Ebert, T. Melsom, F. Gaspari, C. Mariat, E. Cavalier, J. Bjork, A. Christensson, U. Nyman, E. Porrini, G. Remuzzi, P. Ruggenenti, E. Schaeffner, I. Soveri, G. Sterner, B.O. Eriksen, S-E. Back. Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: How to measure glomerular filtration rate with iohexol? *Clinical Kidney Journal* 2016;9:682-699.
1340. P. Delanaye, T. Melsom, N. Ebert, S-E. Back, C. Mariat, E. Cavalier, J. Bjork, A. Christensson, U. Nyman, E. Porrini, G. Remuzzi, P. Ruggenenti, E. Schaeffner, I. Soveri, G. Sterner, B.O. Eriksen, F. Gaspari. Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol? *Clinical Kidney Journal* 2016;9:700-704.
1341. G. Schulman, T. Berl, G.J. Beck, G. Remuzzi, E. Ritz, M. Shimizu, Y. Shobu, M. Kikuchi. The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials. *BMC Nephrol* 2016;17(1):141.
1342. GBD 2015 Risk Factors Collaborators. M. Cortinovis, N. Perico, G. Remuzzi. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016;388:1659-1724.
1343. GBD 2015 Mortality and Causes of Death Collaborators. M. Cortinovis, N. Perico, G. Remuzzi. Global, regional, and national life expectancy, all-cause mortality, and

- cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016;388:1459-1544.
1344. GBD 2015 DALYs and HALE Collaborators. N. Perico, G. Remuzzi. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016;388:1603-1658.
 1345. GBD 2015 SDG Collaborators. N. Perico, G. Remuzzi. Measuring the health-related sustainable development goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. *Lancet* 2016;388:1813-1850.
 1346. GBD 2015 Maternal Mortality Collaborators. M. Cortinovis, N. Perico, G. Remuzzi. Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016;388:1775-1812.
 1347. GBD 2015 Child Mortality Collaborators. N. Perico, G. Remuzzi. Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016;388:1725-1774.
 1348. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. M. Cortinovis, N. Perico, G. Remuzzi. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016;388:1545-1602.
 1349. L. Perico, S. Conti, A. Benigni, G. Remuzzi. Podocyte-actin dynamics in health and disease. *Nat Rev Nephrol* 2016;12:692-710.
 1350. T.F. Kropelin, D. de Zeeuw, G. Remuzzi, R. Bilous, H.H. Parving, H.J. Heerspink. Determining the optimal protocol for measuring an albuminuria class transition in clinical trials in diabetic kidney disease. *J Am Soc Nephrol* 2016;27:3405-3412.
 1351. F. Carrara, N. Azzollini, G. Nattino, D. Corna, S. Villa, D. Cerullo, C. Zoja, B. Abrante, S. Luis-Lima, E. Porrini, A. Cannata, S. Ferrari, M. Fois, N. Stucchi, F. Gaspari. Simplified method to measure glomerular filtration rate by iohexol plasma clearance in conscious rats. *Nephron* 2016;133:62-70.
 1352. F.R. Mc Causland, B. Claggett, E.A. Burdmann, K.U. Eckardt, R. Kewalramani, A.S. Levey, J.J. McMurray, P. Parfrey, G. Remuzzi, A.K. Singh, S.D. Solomon, R.D. Toto, M.A. Pfeffer. C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). *Am J Kidney Dis* 2016;68:873-881.
 1353. F. Mescia, M. Galbusera, P. Boccoardo, G. Remuzzi. Disorders of hemostasis in dialysis patients. In: *Henrich's Principles and Practice of Dialysis* (5th edition), chapter n. 28. Edited by E.V. Lerma, M.R. Weir. Kluwer, Philadelphia 2017, pp. 465-474.
 1354. P. Ruggenenti, P. Cravedi, A. Chianca, M. Caruso, G. Remuzzi. Achieving remission of proteinuria in childhood CKD. *Pediatr Nephrol* 2017;32:321-330.

1355. P. Ruggenenti, M. Abbate, B. Ruggiero, S. Rota, M. Trillini, M.C. Aparicio, A. Parvanova, I. Iliev, G. Pisanu, A. Perna, A. Russo, O. Diadei, D. Martinetti, A. Cannata, F. Carrara, S. Ferrari, N. Stucchi, G. Remuzzi, L. Fontana; CRESO Study Group. Renal and systemic effects of calorie restriction in type-2 diabetes patients with abdominal obesity: a randomized controlled trial. *Diabetes* 2017;66:75-86.
1356. I.C. Macdougall, A.H. Bock, F. Carrera, K.U. Eckardt, C. Gaillard, D. Van Wyck, Y. Meier, S. Larroque, S.D. Roger; FIND-CKD Study Investigators. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial. *BMC Nephrol* 2017;18:24.
1357. M. Cortinovis, E. Gotti, M. Trillini, F. Carrara, F. Gaspari, P. Ruggenenti, G. Remuzzi, N. Perico. Conversion from brand-name neoral to the generic ciclosporin in stable renal transplant recipients. *Nephron* 2017;135:173-180.
1358. A. Remuzzi, M. Figliuzzi, B. Bonandrini, S. Silvani, N. Azzollini, R. Nossa, A. Benigni, G. Remuzzi. Experimental evaluation of kidney regeneration by organ scaffold recellularization. *Sci Rep* 2017;7:43502.
1359. M. Bozzetto, S. Rota, V. Vigo, F. Casucci, C. Lomonte, W. Morale, M. Senatore, L. Tazza, M. Lodi, G. Remuzzi, A. Remuzzi. Clinical use of computational modeling for surgical planning of arteriovenous fistula for hemodialysis. *BMC Med Inform Decis Mak* 2017;17:26.
1360. H.J. Heerspink, H. Makino, D. Andress, J.J. Brennan, R. Correa-Rotter, B. Coll, J.W. Davis, K. Idler, D.E. Kohan, M. Liu, V. Perkovic, G. Remuzzi, S.W. Tobe, R. Toto, H.H. Parving, D. de Zeeuw. Comparison of exposure response relationship of atrasentan between North American and Asian Populations. *Diabetes Obes Metab* 2017;19:545-552.
1361. M.J. Pena, D. de Zeeuw, D. Andress, J.J. Brennan, R. Correa-Rotter, B. Coll, D.E. Kohan, H. Makino, V. Perkovic, G. Remuzzi, S.W. Tobe, R. Toto, H.H. Parving, S. Sharma, T. Corringham, K. Sharma, H.J. Heerspink. The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy. *Diabetes Obes Metab* 2017;19:749-753.
1362. P. Cravedi, A. Angeletti, G. Remuzzi. New biologics in the treatment of rare glomerular diseases of childhood. *Curr Opin Pharmacol* 2017;33:27-33.
1363. Low Birth Weight and Nephron Number Working Group; N. Perico, G. Remuzzi, M. Cortinovis. The impact of kidney development on the life course: a consensus document for action. *Nephron* 2017;136:3-49.
1364. N. Perico, P. Ruggenenti, G. Remuzzi. ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease. *Curr Opin Pharmacol* 2017;33:34-40.
1365. V. Jha, D.E. Martin, J.M. Bargman, S. Davies, J. Feehally, F. Finkelstein, D. Harris, M. Misra, G. Remuzzi, A. Levin; International Society of Nephrology Ethical Dialysis Task Force. Ethical issues in dialysis therapy. *Lancet* 2017;389:1851-1856.

1366. C. Zanchi, D. Macconi, P. Trionfini, S. Tomasoni, D. Rottoli, M. Locatelli, M. Rudnicki, J. Vandesompele, P. Mestdagh, G. Remuzzi, A. Benigni, C. Zoja. MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy. *Diabetologia* 2017;60:1114-1125.
1367. S. Tomasoni, P. Trionfini, N. Azzollini, L. Zentilin, M. Giacca, S. Aiello, L. Longaretti, E. Cozzi, N. Baldan, G. Remuzzi, A. Benigni. AAV9-mediated engineering of autotransplanted kidney of non-human primates. *Gene Ther* 2017;24:308-313.
1368. K. Sharma, A. Caroli, L.V. Quach, K. Petzold, M. Bozzetto, A.L. Serra, G. Remuzzi, A. Remuzzi. Kidney volume measurement methods for clinical studies on autosomal dominant polycystic kidney disease. *PLoS One* 2017;12:e0178488.
1369. Global Burden of Disease Child and Adolescent Health Collaboration; N. Perico, G. Remuzzi, et al. Child and adolescent health from 1990 to 2015: findings from the Global Burden of Diseases, Injuries, and Risk Factors 2015 Study. *JAMA Pediatr* 2017;171:573-592.
1370. L. Perico, M. Mandalà, A. Schieppati, C. Carrara, P. Rizzo, S. Conti, L. Longaretti, A. Benigni, G. Remuzzi. BRAF signaling pathway inhibition, podocyte injury, and nephrotic syndrome. *Am J Kidney Dis* 2017;70:145-150.
1371. Global Burden of Disease 2013 GFR Collaborators, CKD Prognosis Consortium, Global Burden of Disease Genitourinary Expert Group, M. Cortinovis, K. Courville de Vaccaro, N. Perico, G. Remuzzi. Global cardiovascular and renal outcomes of reduced GFR. *J Am Soc Nephrol* 2017;28:2167-2179.
1372. E. Vidal, F. Garzotto, M. Parolin, C. Manenti, A. Zanin, M. Bellettato, G. Remuzzi, S.L. Goldstein, L. Murer, C. Ronco. Therapeutic plasma exchange in neonates and infants: successful use of a miniaturized machine. *Blood Purif* 2017;44:100-105.
1373. GBD 2015 Healthcare Access and Quality Collaborators; E. Beghi, G. Giussani, B. Bikbov, M. Cortinovis, N. Perico, G. Remuzzi. Healthcare access and quality index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. *Lancet* 2017;390:231-266.
1374. V.A. Luyckx, N. Perico, M. Somaschini, D. Manfellotto, H. Valensise, I. Cetin, U. Simeoni, K. Allegaert, B.E. Vikse, E.A. Steegers, D. Adu, G. Montini, G. Remuzzi, B.M. Brenner; writing group of the Low Birth Weight and Nephron Number Working Group. A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group. *Lancet* 2017;390:424-428.
1375. S. Bettoni, M. Galbusera, S. Gastoldi, R. Donadelli, C. Tentori, G. Spartà, E. Bresin, C. Mele, M. Alberti, A. Tortajada, H. Yébenes, G. Remuzzi, M. Noris. Interaction between multimeric von Willebrand factor and complement: a fresh look to the pathophysiology of microvascular thrombosis. *J Immunol* 2017;199:1021-1040.

1376. J. Lv, H. Zhang, M.G. Wong, M.J. Jardine, M. Hladunewich, V. Jha, H. Monaghan, M. Zhao, S. Barbour, H. Reich, D. Cattran, R. Glassock, A. Levin, D. Wheeler, M. Woodward, L. Billot, T.M. Chan, Z.H. Liu, D.W. Johnson, A. Cass, J. Feehally, J. Floege, G. Remuzzi, Y. Wu, R. Agarwal, H.Y. Wang, V. Perkovic; TESTING Study Group. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. *JAMA* 2017;318(5):432-442.
1377. P. Ruggenenti, F.C. Fervenza, G. Remuzzi. Treatment of membranous nephropathy: time for a paradigm shift. *Nat Rev Nephrol* 2017;13:563-579.
1378. M. Noris, G. Remuzzi. Genetics of immune-mediated glomerular diseases: Focus on complement. *Semin Nephrol* 2017;37:447-463.
1379. F. Casiraghi, N. Azzollini, M. Todeschini, S. Fiori, R.A. Cavinato, P. Cassis, S. Solini, F. Pezzuto, M. Mister, J.M. Thurman, A. Benigni, G. Remuzzi, M. Noris. Complement alternative pathway deficiency in recipients protects kidney allograft from ischemia/reperfusion injury and alloreactive T cell response. *Am J Transplant* 2017;17:2312-2325.
1380. J.A.J.G. van den Brand, P. Ruggenenti, A. Chianca, J.M. Hofstra, A. Perna, B. Ruggiero, J.F.M. Wetzels, G. Remuzzi. Safety of rituximab compared with setroids and cyclophosphamide for idiopathic membranous nephropathy. *J Am Soc Nephrol* 2017;28:2729-2737.
1381. A. Bruel, D. Kavanagh, M. Noris, Y. Delmas, E.K.S. Wong, E. Bresin, F. Provôt, V. Brocklebank, C. Mele, G. Remuzzi, C. Loirat, V. Frémeaux-Bacchi, F. Fakhouri. Hemolytic Uremic Syndrome in pregnancy and post-partum. *Clin J Am Soc Nephrol* 2017;12:1237-1247.
1382. S. Aiello, F. Rocchetta, L. Longaretti, S. Faravelli, M. Todeschini, L. Cassis, F. Pezzuto, S. Tomasoni, N. Azzollini, M. Mister, C. Mele, S. Conti, M. Breno, G. Remuzzi, M. Noris, A. Benigni. Extracellular vesicles derived from T regulatory cells suppress T cell proliferation and prolong allograft survival. *Sci Rep* 2017;7:11518.
1383. GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017;390:1345-1422.
1384. GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017;390:1260-1344.
1385. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017;390:1211-1259.

1386. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017;390:1151-1210.
1387. GBD 2016 Mortality Collaborators. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017;390:1084-1150.
1388. GBD 2016 SDG Collaborators. Measuring progress and projecting attainment on the basis of past trends of the health-related sustainable development goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. *Lancet* 2017;390:1423-1459.
1389. M. Cortinovis, N. Perico, G. Remuzzi. Should we still believe in randomized controlled trials in nephrology? *Nephron* 2017;136:281-286.
1390. S. Aymé S, D. Bockenhauer, S. Day, O. Devuyst, L.M. Guay-Woodford, J.R. Ingelfinger, J.B. Klein, N.V.A.M. Knoers, R.D. Perrone, J. Roberts, F. Schaefer, V.E. Torres, M. Cheung, D.C. Wheeler, W.C. Winkelmayer; Conference Participants. Common elements in rare kidney diseases: conclusions from a kidney disease: improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int* 2017;92:796-808.
1391. A. Trautmann, S. Schnaidt, B.S. Lipska-Ziętkiewicz, M. Bodria, F. Ozaltin, F. Emma, A. Anarat, A. Melk, M. Azocar, J. Oh, B. Saeed, A. Gheisari, S. Caliskan, J. Gellermann, L.M.S. Higueta, A. Jankauskiene, D. Drozd, S. Mir, A. Balat, M. Szczepanska, D. Paripovic, A. Zurowska, R. Bogdanovic, A. Yilmaz, B. Ranchin, E. Baskin, O. Erdogan, G. Remuzzi, A. Firszt-Adamczyk, E. Kuzma-Mroczkowska, M. Litwin, L. Murer, M. Tkaczyk, H. Jardim, A. Wasilewska, N. Printza, K. Fidan, E. Simkova, H. Borzecka, H. Staude, K. Hees, F. Schaefer; PodoNet Consortium. Long-term outcome of steroid-resistant nephrotic syndrome in children. *J Am Soc Nephrol* 2017;28:3055-3065.
1392. D.M. Charytan, S.D. Solomon, P. Ivanovich, G. Remuzzi, M.E. Cooper, J.B. McGill, H.H. Parving, P. Parfrey, A.K. Singh, E.A. Burdmann, A.S. Levey, D. de Zeeuw, K.U. Eckardt, J.J.V. McMurray, B. Claggett, E.F. Lewis, M.A. Pfeffer. ESRD after heart failure, myocardial infarction, or stroke in type 2 diabetic patients with CKD. *Am J Kidney Dis* 2017;70:522-531.
1393. C. Carrara, M. Abbate, E. Sabadini, G. Remuzzi. Acute kidney injury and hemolytic anemia secondary to mycoplasma pneumoniae infection. *Nephron* 2017;137:148-154.
1394. N. Lee, G. Remuzzi, R. Horton. The Vatican–Mario Negri–Lancet Commission on the value of life. *Lancet* 2017;390:1573.
1395. C. Pollock, A. Zuk, H.J. Anders, M.R. Ganji, D.W. Johnson, B. Kasiske, R.G. Langham, R. Pecoits, G. Remuzzi, J. Rossert, Y. Suzuki, T. Tanaka, R. Walker, C.W. Yang, J.V. Bonventre. The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease. *Kidney Int Suppl* 2017;7:130–137.

1396. L. Perico, M. Morigi, C. Rota, M. Breno, C. Mele, M. Noris, M. Introna, C. Capelli, L. Longaretti, D. Rottoli, S. Conti, D. Corna, G. Remuzzi, A. Benigni. Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function. *Nat Commun* 2017;8:983.
1397. S. Anand, Y. Zheng, M.E. Montez-Rath, W.J. Wei, N. Perico, S. Carminati, K.V. Narayan, N. Tandon, V. Mohan, V. Jha, L. Zhang, G. Remuzzi, D. Prabhakaran, G.M. Chertow. Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries. *BMJ Glob Health*. 2017;2:e000453.
1398. P. Rizzo, R. Novelli, C. Rota, E. Gagliardini, B. Ruggiero, D. Rottoli, A. Benigni, G. Remuzzi. The role of angiotensin II in parietal epithelial cell proliferation and crescent formation in glomerular diseases. *Am J Pathol* 2017;187:2441-2450.
1399. ISN Global Kidney Health Summit participants; Remuzzi G. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. *Lancet* 2017;390:1888-1917.
1400. P. Ruggenenti, C. Silvestre, L. Boschiero, G. Rota, L. Furian, A. Perna, G. Rossini, G. Remuzzi, P. Rigotti. Long- term outcome of renal transplantation from octogenarian donors: A multicenter controlled study. *Am J Transplant* 2017;17:3159-3171.
1401. D.J. Webb, B. Coll, H.J.L. Heerspink, D. Andress, Y. Pritchett, J.J. Brennan, M. Houser, R. Correa-Rotter, D. Kohan, H. Makino, V. Perkovic, G. Remuzzi, S.W. Tobe, R. Toto, R. Busch, P. Pergola, H.H. Parving, D. de Zeeuw. Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial. *Drugs R D*. 2017;17:441-448.
1402. C.M. Legendre, J.M. Campistol, T. Feldkamp, G. Remuzzi, J.F. Kincaid, Å. Lommelé, J. Wang, L.E. Weekers, N.S. Sheerin. Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis. *Transpl Int* 2017;30:1275-1283.
1403. M. Noris, P. Ruggenenti, G. Remuzzi. Kidney transplantation in patients with Atypical Hemolytic Uremic Syndrome: A therapeutic dilemma (or not)? *Am J Kidney Dis* 2017;70:754-757.
1404. P. Romagnani, G. Remuzzi, R. Glasscock, A. Levin, K.J. Jager, M. Tonelli, Z. Massy, C. Wanner, H.J. Anders. Chronic kidney disease. *Nat Rev Dis Primers* 2017;23;3:17088.
1405. F.R. Mc Causland, B. Claggett, M.A. Pfeffer, E.A. Burdmann, K.U. Eckardt, A.S. Levey, J.J.V. McMurray, G. Remuzzi, A.K. Singh, S.D. Solomon, R.D. Toto, P. Parfrey. Change in hemoglobin trajectory and darbepoetin dose approaching end-stage renal disease: Data from the trial to reduce cardiovascular events with aranesp therapy trial. *Am J Nephrol* 2017;46:488-497.

1406. F. Mescia, P. Boccardo, M. Galbusera, G. Remuzzi. Prevention and therapeutic management of bleeding in dialysis patients. In: Handbook of dialysis therapy (5th edition), Chapter n. 26. Edited by A.R. Nissenson, R.N. Fine. Elsevier, Philadelphia 2017, pp. 334-345.
1407. N. Perico, G. Remuzzi. Addressing acute kidney injury in critically ill newborn babies. *Lancet Child Adolesc Health* 2017;1:161-163.
1408. M. Cortinovis, G. Remuzzi, N. Perico. Maintenance immunosuppression in kidney transplantation. In: Kidney transplantation, bioengineering, and regeneration. Chapter n. 20. Edited by G. Orlando, G. Remuzzi, D.F. Williams. Elsevier, London 2017, pp. 259-276.
1409. E. Gagliardini, A. Benigni, G. Remuzzi. Pharmacological induction of kidney regeneration. In: Kidney transplantation, bioengineering, and regeneration. Chapter n. 74. Edited by G. Orlando, G. Remuzzi, D.F. Williams. Elsevier, London 2017, pp. 1025-1037.
1410. M. Trillini, N. Perico, G. Remuzzi. Epidemiology of end-stage renal failure: the burden of kidney diseases to global health. In: Kidney transplantation, bioengineering, and regeneration, Chapter n. 1. Edited by G. Orlando, G. Remuzzi, D.F. Williams. Elsevier, London 2017, pp. 5-11.
1411. V. Benedetti, B. Imberti, C. Xinari, G. Remuzzi. Developmental approaches to kidney regeneration. In: Kidney transplantation, bioengineering, and regeneration, Chapter n. 75. Edited by G. Orlando, G. Remuzzi, D.F. Williams. Elsevier, London 2017, pp. 1039-1050.
1412. M. Figliuzzi, G. Remuzzi, A. Remuzzi. Recellularization of kidney scaffold with stem cells. In: Kidney transplantation, bioengineering, and regeneration, Chapter n. 63. Edited by G. Orlando, G. Remuzzi, D.F. Williams. Elsevier, London 2017, pp. 877-886.
1413. S. Anand, B. Thomas, G. Remuzzi, M. Riella, M.E. Nahas, S. Naicker, J. Dirks. Kidney disease. In: Cardiovascular, respiratory, and related disorders, 3rd edition, vol 5, Chapter n. 13. Edited by: D. Prabhakaran, S. Anand, T.A. Gaziano, J.C. Mbanya, Y. Wu, R. Nugent. World Bank Group, Washington 2017, pp. 235-252.
1414. R. Rodrigues-Diez, V. Benedetti, G. Remuzzi, C. Xinari. Tissue engineering of renal tissue (kidney). In: Tissue engineering for artificial organs. Regenerative medicine, smart diagnostics and personalized medicine, vol. 2, Chapter 18. Edited by: A. Hasan. Wiley-VCH 2017, pp. 575-602.
1415. E. Goicoechea de Jorge, A. Tortajada, S.P. García, S. Gastoldi, H.M. Merinero, J. García-Fernández, E. Arjona, M. Cao, G. Remuzzi, M. Noris, S. Rodríguez de Córdoba. Factor H competitor generated by gene conversion events associates with atypical hemolytic uremic syndrome. *J Am Soc Nephrol* 2018;29:240-249.
1416. P. Iatropoulos, E. Daina, M. Curreri, R. Piras, E. Valoti, C. Mele, E. Bresin, S. Gamba, M. Alberti, M. Breno, A. Perna, S. Bettoni, E. Sabadini, L. Murer, M. Vivarelli, M. Noris, G. Remuzzi; Registry of Membranoproliferative

Glomerulonephritis/C3 Glomerulopathy. Cluster analysis identifies distinct pathogenetic patterns in C3 glomerulopathies/immune complex-mediated membranoproliferative GN. *J Am Soc Nephrol* 2018;29:283-294.

1417. A. Parvanova, M. Trillini, M.A. Podestà, I.P. Iliev, B. Ruggiero, M. Abbate, A. Perna, F. Peraro, O. Diadei, N. Rubis, F. Gaspari, F. Carrara, N. Stucchi, A. Belviso, A.C. Bossi, R. Trevisan, G. Remuzzi, M. de Borst, P. Ruggenenti; PROCEED Study Organization and the Scientific Writing Academy (SWA) 2016. Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. *Lancet Diabetes Endocrinol* 2018;6:27-40.
1418. M. Weldegiorgis, D. de Zeeuw, L. Li, H.H. Parving, F.F. Hou, G. Remuzzi, T. Greene, H.J.L. Heerspink. Longitudinal estimated GFR trajectories in patients with and without type 2 diabetes and nephropathy. *Am J Kidney Dis* 2018;71:91-101.
1419. N. Perico, F. Casiraghi, G. Remuzzi. Mesenchymal stromal cells for AKI after cardiac surgery. *J Am Soc Nephrol* 2018;29:7-9.
1420. M.A. Podestà, M. Galbusera, G. Remuzzi. Bleeding and hemostasis in acute renal failure. In: *Critical Care Nephrology* (3rd edition), Chapter n. 102. Edited by C. Ronco, J.A. Kellum, R. Bellomo, Z. Ricci. Elsevier, Philadelphia 2018, pp. 630-635.e2.
1421. C. Mele, M. Noris, G. Remuzzi. Hemolytic Uremic Syndrome. In: *Critical Care Nephrology* (3rd edition), Chapter n. 50. Edited by C. Ronco, J.A. Kellum, R. Bellomo, Z. Ricci. Elsevier, Philadelphia 2018, pp. 294-301.e2.
1422. N. Perico, F. Casiraghi, G. Remuzzi. Clinical translation of mesenchymal stromal cell therapies in nephrology. *J Am Soc Nephrol* 2018;29:362-375.
1423. G. Schulman, T. Berl, G.J. Beck, G. Remuzzi, E. Ritz, M. Shimizu, M. Kikuchi, Y. Shobu. Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120. *Clin Exp Nephrol* 2018;22:299-308.
1424. A.J. Osborne, M. Breno, N.G. Borsa, F. Bu, V. Frémeaux-Bacchi, D.P. Gale, L.P. van den Heuvel, D. Kavanagh, M. Noris, S. Pinto, P.M. Rallapalli, G. Remuzzi, S. Rodríguez de Cordoba, A. Ruiz, R.J.H. Smith, P. Vieira-Martins, E. Volokhina, V. Wilson, T.H.J. Goodship, S.J. Perkins. Statistical Validation of Rare Complement variants provides insights into the molecular basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. *J Immunol* 2018;200:2464-2478.
1425. S. Conti, N. Perico, R. Novelli, C. Carrara, A. Benigni, G. Remuzzi. Early and late scanning electron microscopy findings in diabetic kidney disease. *Sci Rep* 2018;8:4909.
1426. D. Prabhakaran, S. Anand, D. Watkins, T. Gaziano, Y. Wu, J.C. Mbanya, R. Nugent; Disease Control Priorities-3 Cardiovascular, Respiratory, and Related Disorders Author Group. Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition. *Lancet* 2018;391:1224-1236.

1427. P. Ruggenenti, G. Remuzzi. Invited Letter in Response to: "Is the kidney donor profile index (KDPI) universal or UNOS-specific? Am J Transplant 2018;18:1033-1034.
1428. F. Casiraghi, N. Perico, G. Remuzzi. Mesenchymal stromal cells for tolerance induction in organ transplantation. Hum Immunol 2018;79:304-313.
1429. A. Parvanova, M. Trillini, M.A. Podestà, I.P. Iliev, C. Aparicio, A. Perna, F. Peraro, N. Rubis, F. Gaspari, A. Cannata, S. Ferrari, A.C. Bossi, R. Trevisan, S. Parameswaran, J.S. Chávez-Iñiguez, F. Masnic, S.M. Seck, T. Jiamjariyaporn, M. Cortinovis, L. Perico, K. Sharma, G. Remuzzi, P. Ruggenenti, D.G. Warnock. Blood pressure and metabolic effects of acetyl-L-carnitine in type 2 diabetes: DIABASI Randomized Controlled Trial. J Endocr Soc 2018;2:420-436.
1430. U.E. Ekrikpo, A.P. Kengne, A.K. Bello, E.E. Effa, J.J. Noubiap, B.L. Salako, B.L. Rayner, G. Remuzzi, I.G. Okpechi. Chronic kidney disease in the global adult HIV-infected population: A systematic review and meta-analysis. PLoS One 2018;13:e0195443.
1431. GBD 2016 Healthcare Access and Quality Collaborators, E. Beghi, B. Bikbov, M. Cortinovis, S. Gallus, G. Giussani, N. Perico, G. Remuzzi. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet 2018;391:2236-2271.
1432. FINNDIANE Study centres, A. Perna, E. Rurali, N. Perico, Hong Kong Diabetes Registry TRS Project Group, The Warren 3/UK GoKinD Study Group, DCCT/EDIC group, G. Remuzzi, SUMMIT Consortium, et al. A Genome-Wide association study of diabetic kidney disease in subjects with type 2 diabetes. Diabetes 2018;67:1414-1427.
1433. N. Perico, F. Casiraghi, M. Todeschini, M. Cortinovis, E. Gotti, V. Portalupi, M. Mister, F. Gaspari, A. Villa, S. Fiori, M. Introna, E. Longhi, G. Remuzzi. Long-term clinical and immunological profile of kidney transplant patients given mesenchymal stromal cell immunotherapy. Front Immunol 2018;9:1359.
1434. B. Bikbov, N. Perico, G. Remuzzi; on behalf of the GBD Genitourinary Diseases Expert Group. Disparities in Chronic Kidney Disease prevalence among males and females in 195 countries: Analysis of the Global Burden of Disease 2016 Study. Nephron 2018;139:313-318.
1435. V. Benedetti, V. Brizi, P. Guida, S. Tomasoni, O. Ciampi, E. Angeli, U. Valbusa, A. Benigni, G. Remuzzi, C. Xinaris. Engineered kidney tubules for modeling patient-specific diseases and drug discovery. EBioMedicine 2018;33:253-268.
1436. R. Novelli, A. Benigni, G. Remuzzi. The role of B7-1 in proteinuria of glomerular origin. Nat Rev Nephrol 2018;14:589-596.
1437. C. Rota, M. Morigi, D. Cerullo, M. Introna, O. Colpani, D. Corna, C. Capelli, T.J. Rabelink, D.G. Leuning, D. Rottoli, A. Benigni, C. Zoja, G. Remuzzi. Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease. Stem Cell Res Ther 2018;9:220.

1438. P. Cassis, M. Locatelli, D. Cerullo, D. Corna, S. Buelli, C. Zanchi, S. Villa, M. Morigi, G. Remuzzi, A. Benigni, C. Zoja. SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. *JCI Insight* 2018;3:98720.
1439. N.M. Selby, P.J. Blankestijn, P. Boor, C. Combe, K.U. Eckardt, E. Eikefjord, N. Garcia-Fernandez, X. Golay, I. Gordon, N. Grenier, P.D. Hockings, J.D. Jensen, J.A. Joles, P.A. Kalra, B.K. Krämer, P.B. Mark, I.A. Mendichovszky, O. Nikolic, A. Odudu, A.C.M. Ong, A. Ortiz, M. Pruijm, G. Remuzzi, J. Rørvik, S. de Seigneux, R.J. Simms, J. Slatinska, P. Summers, M.W. Taal, H.C. Thoeny, J.P. Vallée, M. Wolf, A. Caroli, S. Sourbron. Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA. *Nephrol Dial Transplant* 2018;33:ii4-ii14.
1440. S. Borrelli, P. Chiodini, L. De Nicola, R. Minutolo, M. Provenzano, C. Garofalo, G. Remuzzi, C. Ronco, M.G. Cozzolino, C. Manno, A.M. Costanzo, G. Gualberti, G. Conte. Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary care. *PLoS One* 2018;13:e0202417.
1441. M. Cozzolino, P. Bolasco, C. Ronco, G. Conte, P. Menè, M.C. Mereu, M. Di Luca, D. Roccatello, A. Rosati, C. Jommi, A.M. Costanzo, G. Gualberti, U. di Luzio Paparatti, G. Remuzzi. Clinical management of Chronic Kidney Disease patients in Italy: Results from the IRIDE Study. *Nephron* 2018;140:39-47.
1442. L. Luzzatto, H.I. Hyry, A. Schieppati, E. Costa, S. Simoens, F. Schaefer, J.C.P. Roos, G. Merlini, H. Kääriäinen, S. Garattini, C.E. Hollak, G. Remuzzi, on behalf of the Second Workshop on Orphan Drugs participants. Outrageous prices of orphan drugs: a call for collaboration. *Lancet* 2018;392:791-794.
1443. F. Gaspari, S. Thakar, F. Carrara, A. Perna, M. Trillini, M.C. Aparicio, O. Diadei, S. Ferrari, A. Cannata, N. Stucchi, P. Ruggerenti, G. Remuzzi, N. Perico. Safety of Iohexol administration to measure Glomerular Filtration Rate in different patient populations: A 25-year experience. *Nephron* 2018;140:1-8.
1444. P. Cassis, D. Cerullo, C. Zanchi, D. Corna, V. Lionetti, F. Giordano, R. Novelli, S. Conti, V. Casieri, M. Matteucci, M. Locatelli, G. Taraboletti, S. Villa, S. Gastoldi, G. Remuzzi, A. Benigni, C. Zoja. ADAMTS13 deficiency shortens the lifespan of mice with experimental diabetes. *Diabetes* 2018;67:2069-2083.
1445. N. Perico, D. Askenazi, M. Cortinovis, G. Remuzzi. Maternal and environmental risk factors for neonatal AKI and its long-term consequences. *Nat Rev Nephrol* 2018;14:688-703.
1446. B. Bikbov, N. Perico, G. Remuzzi, GBD Genitourinary Diseases Expert Group, C. Cella, M. Cortinovis, F. Gaspari. A comparison of metrics and performance characteristics of different search strategies for article retrieval for a systematic review of the global epidemiology of kidney and urinary diseases. *BMC Med Res Methodol* 2018;18:110.

1447. M. Bozzetto, P. Brambilla, S. Rota, B. Ene-Iordache, S. Sironi, G. Remuzzi, A. Remuzzi. Toward longitudinal studies of hemodynamically induced vessel wall remodeling. *Int J Artif Organs* 2018;41:714-722.
1448. GBD 2017 Mortality Collaborators, Gallus S, Beghi E, Giussani G, Bosetti C, Cortinovis M, Bikbov B, Perico N, Remuzzi G. Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018;392:1684-1735.
1449. GBD 2017 Causes of Death Collaborators, Beghi E, Giussani G, Bikbov B, Perico N, Bosetti C, Cortinovis M, Gallus S, Remuzzi G. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018;392:1736-1788.
1450. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators, Beghi E, Giussani G, Bikbov B, Perico N, Cortinovis M, Remuzzi G. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018;392:1789-1858.
1451. GBD 2017 DALYs and HALE Collaborators, Beghi E, Giussani G, Bikbov B, Perico N, Cortinovis M, Gallus S, Remuzzi G. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018;392:1859-1922.
1452. GBD 2017 Risk Factor Collaborators, Beghi E, Giussani G, Bikbov B, Perico N, Cortinovis M, Gallus S, Remuzzi G. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018;392:1923-1994.
1453. GBD 2017 Population and Fertility Collaborators, Gallus S, Beghi E, Giussani G, Bosetti C, Cortinovis M, Bikbov B, Perico N, Remuzzi G. Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018;392:1995-2051.
1454. GBD 2017 SDG Collaborators, Gallus S, Beghi E, Giussani G, Cortinovis M, Bikbov B, Perico N, Remuzzi G. Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018;392:2091-2138.
1455. C. Jommi, P. Armeni, M. Battista, P. di Procolo, G. Conte, C. Ronco, M. Cozzolino, A.M. Costanzo, U. di Luzio Paparatti, G. Concas, G. Remuzzi; IRIDE Study Group. The cost of patients with chronic kidney failure before dialysis: Results from the IRIDE Observational Study. *Pharmacoecon Open* 2018;2:459-467.
1456. R. Donadelli, P. Pulieri, R. Piras, P. Iatropoulos, E. Valoti, A. Benigni, G. Remuzzi, M. Noris. Unraveling the molecular mechanisms underlying complement

- dysregulation by nephritic factors in C3G and IC-MPGN. *Front Immunol* 2018;9:2329.
1457. L. Spinelli, A. Pisani, G. Giugliano, B. Trimarco, E. Riccio, B. Visciano, G. Remuzzi, P. Ruggenenti. Data on the assessment of LV mechanics by speckle tracking echocardiography in ADPKD patients. *Data Brief* 2018;21:2075-2081.
 1458. M.S. Sever, G. Remuzzi, R. Vanholder. Disaster medicine and response: optimizing life-saving potential. *Am J Disaster Med* 2018;13:253-264.
 1459. M. Cortinovis, N. Perico, G. Remuzzi. Nephrotic syndrome: Nutritional consequences and dietary management. In: *Handbook of nutrition and the kidney* (7th Edition), Chapter n. 10. Edited by T. Alp Ikizler, W.E. Mitch. Wolters Kluwer Health, Philadelphia 2018, pp. 101-108.
 1460. M. Noris, P. Ruggenenti, G. Remuzzi. Thrombotic Microangiopathies, Including Hemolytic Uremic Syndrome. In: *Comprehensive Clinical Nephrology* (6th Edition, Chapter n. 29. Edited by J. Feehally, J. Floege, M. Tonelli, R.J. Johnson. Elsevier, Edinburgh 2019, pp. 343-356.
 1461. A. Benigni, N. Perico, G. Remuzzi. Pathophysiology of disease progression in proteinuric and nonproteinuric kidney disease. In: *Comprehensive Clinical Nephrology* (6th Edition), Chapter n. 78. Edited by J. Feehally, J. Floege, M. Tonelli, R.J. Johnson. Elsevier, Edinburgh 2019, pp. 913-923.
 1462. F. Casiraghi, G. Remuzzi. Mesenchymal stromal cells in kidney transplantation. *Curr Opin Nephrol Hypertens* 2019;28:40-46.
 1463. L. Spinelli, A. Pisani, G. Giugliano, B. Trimarco, E. Riccio, B. Visciano, G. Remuzzi, P. Ruggenenti, ALADIN-Cardiovascular Study Group. Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial. *Int J Cardiol* 2019;275:145-151.
 1464. N. Perico, A. Benigni, G. Remuzzi. Proteinuria and tubulotoxicity. In: *Diabetic nephropathy. Pathophysiology and clinical aspects*, Chapter 13. Edited by J.J. Roelofs, L. Vogt. Springer Nature Switzerland AG, Cham 2019, pp 197-214.
 1465. S. Buelli, C. Zoja, G. Remuzzi, M. Morigi. Complement activation contributes to the pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome. *Microorganisms* 2019;7:E15.
 1466. P. Ruggenenti, G. Remuzzi. Albuminuria regression in diabetes: a therapeutic target for nephro- and cardio-protection, in clinics and research. *Am J Nephrol* 2019;49:143-145.
 1467. H.J.L. Heerspink, T. Greene, H. Tighiouart, R.T. Gansevoort, J. Coresh, et al.; Chronic Kidney Disease Epidemiology Collaboration (G. Remuzzi, P. Ruggenenti). Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. *Lancet Diabetes Endocrinol* 2019;7:128-139.

1468. J. Coresh, H.J.L. Heerspink, Y. Sang, K. Matsushita, J. Arnlov, et al.; Chronic Kidney Disease Prognosis Consortium and Chronic Kidney Disease Epidemiology Collaboration (G. Remuzzi, P. Ruggenti). Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. *Lancet Diabetes Endocrinol* 2019;7:115-127.
1469. E. Porrini, P. Ruggenti, S. Luis-Lima, F. Carrara, A. Jiménez, A. de Vries, A. Torres, F. Gaspari, G. Remuzzi. Estimated GFR: time for a critical appraisal. *Nat Rev Nephrol* 2019;15:177-190.
1470. R.J.H. Smith, G.B. Appel, A.M. Blom, H.T. Cook, V. D'Agati, F. Fakhouri, V. Fremieux-Bacchi, M. Jözi, D. Kavanagh, J.D. Lambris, M. Noris, M.C. Pickering, G. Remuzzi, S.R. de Cordoba, S. Sethi, J. Van der Vlag, P.F. Zipfel, C.M. Nester. C3 glomerulopathy - understanding a rare complement-driven renal disease. *Nat Rev Nephrol* 2019;15:129-143.
1471. P. Ricci, P. Magalhaes, M. Krochmal, M. Pejchinovski, E. Daina, M.R. Caruso, L. Goea, I. Belczacka, G. Remuzzi, M. Umbhauer, J. Drube, L. Pape, H. Mischak, S. Decramer, F. Schaefer, J.P. Schanstra, S. Cereghini, P. Zurbig P. Urinary proteome signature of renal cysts and diabetes syndrome in children. *Sci Rep* 2019;9:2225.
1472. F.R. Mc Causland, B. Claggett, E.A. Burdmann, G.M. Chertow, M.E. Cooper, K.U. Eckardt, P. Ivanovich, A.S. Levey, E.F. Lewis, J.B. McGill, J.J.V. McMurray, P. Parfrey, H.H. Parving, G. Remuzzi, A.K. Singh, S.D. Solomon, R.D. Toto, M.A. Pfeffer. Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: Analyses from the trial to reduce cardiovascular events with Aranesp therapy (TREAT). *Am J Kidney Dis* 2019;73:309-315.
1473. N. Perico, P. Ruggenti, A. Perna, A. Caroli, M. Trillini, S. Sironi, A. Pisani, E. Riccio, M. Imbriaco, M. Dugo, G. Morana, A. Granata, M. Figuera, F. Gaspari, F. Carrara, N. Rubis, A. Villa, S. Gamba, S. Prandini, M. Cortinovis, A. Remuzzi, G. Remuzzi; ALADIN 2 Study Group. Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): a randomized, double-blind, placebo-controlled, multicenter trial. *PLoS Med* 2019;16:e1002777.
1474. G. Remuzzi, W. Ricciardi. Why and how did Leonardo happen: the Renaissance context. *Lancet* 2019;393:1396-1397.
1475. D.M. Charytan, S.D. Solomon, P. Ivanovich, G. Remuzzi, M.E. Cooper, J.B. McGill, H.H. Parving, P. Parfrey, A.K. Singh, E.A. Burdmann, A.S. Levey, K.U. Eckardt, J.J.V. McMurray, L.A. Weinrauch, J. Liu, B. Claggett, E.F. Lewis, M.A. Pfeffer. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. *Diabetes Obes Metab* 2019;21:1199-1208.
1476. P. Ruggenti, M. Trillini, D.P. Barlovic, M. Cortinovis, A. Pisani, A. Parvanova, I.P. Iliev, B. Ruggiero, S. Rota, M.C. Aparicio, A. Perna, F. Peraro, O. Diadei, F. Gaspari, F. Carrara, N. Stucchi, D. Martinetti, A. Janez, N. Gregoric, E. Riccio, A.C. Bossi, R. Trevisan, P. Manunta, G. Battaglia, S. David, F. Aucella, A. Belviso, A. Satta, G. Remuzzi; VALID Study Organization. Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial. *Diabetes Obes Metab* 2019;21:1177-1190.

1477. GBD 2016 Stroke Collaborators, B. Bikbov, N. Perico, M. Cortinovis, G. Remuzzi. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol* 2019;18:439-458.
1478. P. Trionfini, O. Ciampi, M. Todeschini, C. Ascanelli, L. Longaretti, L. Perico, G. Remuzzi, A. Benigni, S. Tomasoni. CRISPR-Cas9-mediated correction of the G189R-PAX2 mutation in induced pluripotent stem cells from a patient with focal segmental glomerulosclerosis. *CRISPR J* 2019;2:108-120.
1479. L. Luzzatto, E. Costa, A. Schieppati, G. Remuzzi. Orphan drugs - authors' reply. *Lancet* 2019;393:1595-1596.
1480. E. Valoti, M. Alberti, P. Iatropoulos, R. Piras, C. Mele, M. Breno, A. Cremaschi, E. Bresin, R. Donadelli, S. Alizzi, A. Amoroso, A. Benigni, G. Remuzzi, M. Noris. Rare functional variants in complement genes and Anti-FH Autoantibodies-Associated aHUS. *Front Immunol* 2019;10:853.
1481. K. Rahimi, D. Canoy, M. Nazarzadeh, G. Salimi-Khorshidi, M. Woodward, et al.; Blood Pressure Lowering Treatment Trialists' Collaboration (G. Remuzzi, P. Ruggenenti). Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC). *BMJ Open* 2019;9:e028698.
1482. O. Ciampi, B. Bonandrini, M. Derosas, S. Conti, P. Rizzo, V. Benedetti, M. Figliuzzi, A. Remuzzi, A. Benigni, G. Remuzzi, S. Tomasoni. Engineering the vasculature of decellularized rat kidney scaffolds using human induced pluripotent stem cell-derived endothelial cells. *Sci Rep* 2019;9:8001.
1483. F. Casiraghi, M. Todeschini, N. Azzollini, P. Cravedi, P. Cassis, S. Solini, S. Fiori, C. Rota, A. Karachi, C. Carrara, M. Noris, N. Perico, G. Remuzzi. Effect of timing and complement receptor antagonism on intragraft recruitment and pro-tolerogenic effects of mesenchymal stromal cells in murine kidney transplantation. *Transplantation* 2019; 103: 1121-1130.
1484. P. Cassis, C. Zoja, L. Perico, G. Remuzzi. A preclinical overview of emerging therapeutic targets for glomerular diseases. *Expert Opin Ther targets* 2019; 23: 593-606.
1485. M. Noris, G. Remuzzi. Terminal complement effectors in atypical hemolytic uremic syndrome: C5a, C5b-9, or a bit of both ? *Kidney Int* 2019; 96: 13-15.
1486. M. Noris, R. Donadelli, G. Remuzzi. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. *Pediatr Nephrol* 2019; 34: 1311-1323.
1487. M. Galbusera, M. Noris, S. Gastoldi, E. Bresin, C. Mele, M. Breno, P. Cuccarolo, M. Alberti, E. Valoti, R. Piras, R. Donadelli, M. Vivarelli, L. Murer, C. Pecoraro, E. Ferrari, A. Perna, A. Benigni, V. Portalupi, G. Remuzzi. An ex vivo test of

- complement activation on endothelium for individualized eculizumab therapy in hemolytic uremic syndrome. *Am J Kidney Dis* 2019; 74: 56-72.
1488. M. A. Podestà, G. Remuzzi, F. Casiraghi. Mesenchymal Stromal Cells for Transplant Tolerance. *Front Immunol* 2019; 10: 1287.
 1489. E. Valoti, M. Alberti, C. Carrara, M. Breno, E. Yilmaz Keskin, E. Bresin, P. Cuccarolo, Y. Açıkgoz, A. Benigni, M. Noris, G. Remuzzi G, C. Mele. Hemolytic uremic syndrome in an infant with primary hyperoxaluria type II: an unreported clinical association. *Nephron* 2019; 142: 264-270.
 1490. P. Ruggenenti, G. Remuzzi. A first step toward a new approach to treating membranous nephropathy. *N Engl J Med* 2019; 381: 86-88.
 1491. P. Ruggenenti, E. Daina, A. Gennarini, C. Carrara, S. Gamba, M. Noris, N. Rubis, F. Peraro, F. Gaspari, A. Pasini, A. Rigotti, R.M. Lerchner, D. Santoro, A. Pisani, A. Pasi, G. Remuzzi; EAGLE Study Group. C5 convertase blockade in membranoproliferative glomerulonephritis: a single-arm clinical trial. *Am J Kidney Dis* 2019; 74: 224-238.
 1492. B. Ruggiero, M. Trillini, L. Tartaglione, S. Rotondi, E. Peticucci, R. Tripepi, C. Aparicio, V. Lecchi, A. Perna, F. Peraro, D. Villa, S. Ferrari, A. Cannata, S. Mazzaferro, F. Mallamaci, C. Zoccali, A. Bellasi, M. Cozzolino, G. Remuzzi, P. Ruggenenti, D.E. Kohan; ANSWER Study Organization. Effects of sevelamer carbonate in patients with CKD and proteinuria: the ANSWER randomized trial. *Am J Kidney Dis* 2019; 74: 338-350.
 1493. E. Valoti, M. Noris, A. Perna, E. Rurali, G. Gherardi, M. Breno, A. Parvanova Ilieva, I. Petrov Iliev, A. Bossi, R. Trevisan, A. R. Dodesini, S. Ferrari, N. Stucchi, A. Benigni, G. Remuzzi, P. Ruggenenti. Impact of a complement factor H gene variant on renal dysfunction, cardiovascular events, and response to ACE inhibitor therapy in type 2 diabetes. *Front Genet* 2019; 10: 681.
 1494. P. Cassis, M. Locatelli, D. Corna, S. Villa, D. Rottoli, D. Cerullo, M. Abbate, G. Remuzzi, A. Benigni, C. Zoja. Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy. *Kidney Int* 2019; 96: 906-917.
 1495. V. Benedetti, A.M. Lavecchia, M. Locatelli, V. Brizi, D. Corna, M. Todeschini, R. Novelli, A. Benigni, C. Zoja, G. Remuzzi, C. Xinaris. Alteration of thyroid hormone signaling triggers the diabetes-induced pathological growth, remodeling, and dedifferentiation of podocytes. *JCI Insight* 2019; 4: 130249.
 1496. M. Gonzalez-Quiroz, D. Nitsch, S. Hamilton, C. O'Callaghan Gordo, R. Saran, J. Glaser, R. Correa-Rotter, K. Jakobsson, A. Singh, N. Gunawardena, A. Levin, G. Remuzzi, B. Caplin, N. Pearce; DEGREE Study Steering Committee. Rationale and population-based prospective cohort protocol for the disadvantaged populations at risk of decline in eGFR (CO-DEGREE). *BMJ Open* 2019; 9: e031169.
 1497. E. Valoti, M. Noris, G. Remuzzi. More about factor H autoantibodies in membranous nephropathy. *N Engl J Med* 2019; 381: 1590-1592.

1498. A. Benigni, P. Cassis, S. Conti, L. Perico, D. Corna, D. Cerullo, L. Zentilin, C. Zoja, A. Perna, V. Lionetti, M. Giacca, P. Trionfini, S. Tomasoni, G. Remuzzi. Sirt3 deficiency shortens lifespan and impairs cardiac mitochondrial function rescued by Opa1 gene transfer. *Antioxid Redox Signal* 2019; 31: 1255-1271.
1499. E. Porrini, P. Ruggenenti, S. Luis-Lima, F. Carrara, A. Jimenez, A.P.J. de Vries, A. Torres, F. Gaspari, G. Remuzzi. Reply to “Strengths and limitations of estimated and measured GFR”. *Nat Rev Nephrol* 2019; 15: 785-786.
1500. GBD 2017 Italy Collaborators, S. Gallus, E. Beghi, G. Giussani, E. Pupillo, C. Bosetti, G. Remuzzi, N. Perico, B. Bikbov. Italy's health performance, 1990-2017: findings from the Global Burden of Disease Study 2017. *Lancet Public Health* 2019; 4: e645-e657.
1501. P. Cravedi, M. Menon, N. Perico, G. Remuzzi. Acute renal failure in kidney transplant recipients. In: *Critical Care Nephrology*, third edition, chapter 213. Edited by C. Ronco, J.A. Kellum, R. Bellomo, Z. Ricci. Elsevier, Philadelphia 2019, pp 1279-1285.e3.
1502. M.A. Podestà, A. Gennarini, V. Portalupi, S. Rota, M.G. Alessio, G. Remuzzi, P. Ruggenenti. Accelerating the depletion of circulating anti-phospholipase A2 receptor antibodies in patients with severe membranous nephropathy: preliminary findings with double filtration plasmapheresis and ofatumumab. *Nephron* 2020; 144: 30-35.
1503. M. Cortinovis, S. Aiello, M. Mister, K. Conde-Knape, M. Noris, R. Novelli, S. Solini, P.Y. Rodriguez-Ordóñez, A. Benigni, G. Remuzzi. Autotaxin inhibitor protects from chronic allograft injury in rat kidney allotransplantation. *Nephron* 2020; 144: 38-48.
1504. S. Fiori, G. Remuzzi, F. Casiraghi. Update on mesenchymal stromal cell studies in organ transplant recipients. *Curr opin Organ Transplant* 2020; 25: 27-34.
1505. Local Burden of Disease Child Growth Failure Collaborators, B. Bikbov, N. Perico, G. Remuzzi. Mapping child growth failure across low and middle income countries. *Nature* 2020; 577: 231-234.
1506. Local Burden of Disease Educational Attainment Collaborators, B. Bikbov, N. Perico, G. Remuzzi. Mapping disparities in education across low and middle income countries. *Nature* 2020; 577: 235-238.
1507. M.A. Podestà, B. Ruggiero, G. Remuzzi, P. Ruggenenti. Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness. *BMJ Case Rep* 2020; 13: e232896.
1508. A. Caroli, A. Remuzzi, G. Remuzzi. Does MRI trump pathology? A new era for staging and monitoring of kidney fibrosis. *Kidney Int* 2020; 97: 442-444.
1509. GBD Chronic Kidney Disease Collaboration, B. Bikbov, N. Perico, G. Remuzzi. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2020; 395: 709-733.

1510. S. Aiello, M.A. Podestà, P.Y. Rodriguez-Ordonez, F. Pezzuto, N. Azzollini, S. Solini, C. Carrara, M. Todeschini, M. Noris, G. Remuzzi, A. Benigni. Transplantation induced ischemia reperfusion injury modulates antigen presentation by donor renal CD11c⁺F4/80⁺ macrophages through IL-1R8 regulation. *J Am Soc Nephrol* 2020; 31: 517-531.
1511. M. Morigi, L. Perico, D. Corna, M. Locatelli, P. Cassis, C.E. Carminati, S. Bolognini, C. Zoja, G. Remuzzi, A. Benigni, S. Buelli. C3a receptor blockade protects podocytes from injury in diabetic nephropathy. *JCI Insight* 2020; 5: 131849.
1512. F. Casiraghi, N. Perico, E. Gotti, M. Todeschini, M. Mister, M. Cortinovis, V. Portalupi, A.R. Plati, F. Gaspari, A. Villa, M. Introna, E. Longhi, G. Remuzzi. Kidney transplant tolerance associated with remote autologous mesenchymal stromal cell administration. *Stem Cells Transl Med* 2020; 9: 427-432.
1513. C. Carrara, M.A. Podestà, M. Abbate, P. Rizzo, R. Piras, M. Alberti, E. Daina, P. Ruggenenti, G. Remuzzi; EAGLE Study Group. Morphofunctional effects of C5 convertase blockade in immune complex-mediated membranoproliferative glomerulonephritis: report of two cases with evidence of terminal complement activation. *Nephron* 2020; 144:195-203.
1514. M. Noris, G. Remuzzi. Challenges in understanding acute postinfectious glomerulonephritis: are anti-factor B autoantibodies the answer? *J Am Soc Nephrol* 2020; 31: 670-672.
1515. A. Remuzzi, G. Remuzzi. COVID-19 and Italy: what next ? *Lancet* 2020; 395: 1225-1228.
1516. LBD Double Burden of Malnutrition Collaborators, B. Bikbov, N. Perico, G. Remuzzi. Mapping local patterns of childhood overweight and wasting in low and middle income countries between 2000 and 2017. *Nat Med* 2020; 26: 750-759.
1517. L. Perico, A. Benigni, G. Remuzzi. Should COVID-19 concern nephrologists ? Why and to what extent ? The emerging impasse of angiotensin blockade. *Nephron* 2020; 144: 213-221.
1518. L. Perico, A. Benigni, G. Remuzzi. Reply to the comment by Dr. Cure on "Should COVID-19 concern nephrologists ? Why and to what extent ? The emerging impasse of angiotensin blockade". *Nephron* 2020; 144: 253-254.
1519. S. Fagiuoli, F.L. Lorini, G. Remuzzi; Covid-19 Bergamo Hospital Crisis Unit. Adaptations and lessons in the province of Bergamo. *N Engl J Med* 2020; 382: e71.
1520. M. Locatelli, C. Zoja, C. Zanchi, D. Corna, S. Villa, S. Bolognini, R. Novelli, L. Perico, G. Remuzzi, A. Benigni, P. Cassis. Manipulating sirtuin 3 pathway ameliorates renal damage in experimental diabetes. *Sci Rep* 2020; 10: 8418.
1521. Local Burden of Disease Diarrhoea Collaborators, Bikbov B, Perico N, Remuzzi G. Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in

- low-income and middle-income countries, 2000-17: analysis for the Global Burden of Disease Study 2017. *Lancet* 2020; 395: 1779-1801.
1522. A. Remuzzi, S. Conti, B. Ene-Iordache, S. Tomasoni, P. Rizzo, A. Benigni, G. Remuzzi. Role of ultrastructural determinants of glomerular permeability in ultrafiltration function loss. *JCI Insight* 2020; 5: 137249.
 1523. M. Chiusa, W. Hu, J. Zienkiewicz, X. Chen X, M.Z. Zhang, R.C. Harris, R.M. Vanacore, J.A. Bentz, G. Remuzzi, A. Benigni, A.B. Fogo, W. Luo, S. Mili, M.H. Wilson, R. Zent, J. Hawiger, A. Pozzi. EGF receptor-mediated FUS phosphorylation promotes its nuclear translocation and fibrotic signaling. *J Cell Biol* 2020; 219: e202001120.
 1524. M. Noris, A. Benigni, G. Remuzzi. The case of complement activation in COVID-19 multiorgan impact. *Kidney Int* 2020; 98: 314-322.
 1525. J. B. Kopp, H. J. Anders, K. Susztak, M. A. Podestà, G. Remuzzi, F. Hildebrandt, P. Romagnani. Podocytopathies. *Nat Rev Dis Primers* 2020; 6: 68.
 1526. Local Burden of Disease WaSH Collaborators, B. Bikbov, N. Perico, G. Remuzzi. Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000-17. *Lancet Glob Health* 2020; 8: e1162-e1185.
 1527. G. Alicandro, G. Remuzzi, C. La Vecchia. Italy's first wave of the COVID-19 pandemic has ended: no excess mortality in May, 2020. *Lancet* 2020; 396: e27-e28.
 1528. M. Salvatore, A. Polizzi, M. C. De Stefano, G. Floridia, S. Baldovino, D. Roccatoello, S. Sciascia, E. Menegatti, G. Remuzzi, E. Daina, P. Iatropoulos, B. Bembi, R. M. Da Rioli, A. Ferlini, M. Neri, G. Novelli, F. Sangiuolo, F. Brancati, D. Taruscio. Improving diagnosis for rare diseases: the experience of the Italian undiagnosed rare diseases network. *Ital J Pediatr* 2020; 46: 130.
 1529. GBD 2019 Viewpoint Collaborators, S. Gallus, A. Lugo, E. Beghi, E. Pupillo, C. Bosetti, G. Giussani, B. Bikbov, N. Perico, G. Remuzzi. Five insights from the Global Burden of Disease Study 2019. *Lancet* 2020; 396: 1135-1159.
 1530. GBD 2019 Demographics Collaborators, S. Gallus, N. Perico, G. Remuzzi. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020; 396: 1160-1203.
 1531. GBD 2019 Diseases and Injuries Collaborators, E. Beghi, A. Lugo, S. Gallus, G. Giussani, E. Pupillo, B. Bikbov, N. Perico, G. Remuzzi. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020; 396: 1204-1222.
 1532. GBD 2019 Risk Factors Collaborators, E. Beghi, C. Bosetti, A. Lugo, S. Gallus, G. Giussani, E. Pupillo, B. Bikbov, N. Perico, G. Remuzzi. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020; 396: 1223-1249.

1533. L. Perico, S. Tomasoni, T. Peracchi, A. Perna, A. Pezzotta, G. Remuzzi, A. Benigni. COVID-19 and Lombardy: TESTing the impact of the first wave of the pandemic. *EBioMedicine* 2020; 61: 103069.
1534. M. Noris, G. Remuzzi. Atypical hemolytic uremic syndrome associated with a factor B genetic variant and fluid-phase complement activation: an exception to the rule ? *Kidney Int* 2020; 98: 1084-1087.
1535. F. Fakhouri, M. Scully, F. Provôt, M. Blasco, P. Coppo, M. Noris, K. Paizis, D. Kavanagh, F. Pene, S. Quezada, A. Hertig, S. Kissling, P. O'Brien, Y. Delmas, L. Alberio, N. Winer, A. Veyradier, S. R. Cataland, V. Fremeaux-Bacchi, C. Loirat, G. Remuzzi, V. Tsatsaris. Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. *Blood* 2020; 136: 2103-2117.
1536. R. Piras, P. Iatropoulos, E. Bresin, M. Todeschini, S. Gastoldi, E. Valoti, M. Alberti, C. Mele, M. Galbusera, P. Cuccarolo, A. Benigni, G. Remuzzi, M. Noris. Molecular studies and an ex vivo complement assay on endothelium highlight the genetic complexity of Atypical Hemolytic Uremic Syndrome: the case of a pedigree with a null CD46 variant. *Front Med (Lausanne)* 2020; 7: 579418.
1537. A. Rambaldi, G. Gritti, M. C. Micò, M. Frigeni, G. Borleri, A. Salvi, F. Landi, C. Pavoni, A. Sonzogni, A. Gianatti, F. Binda, S. Fagioli, F. Di Marco, L. Lorini, G. Remuzzi, S. Whitaker, G. Demopoulos. Endothelial injury and thrombotic microangiopathy in COVID-19: treatment with the lectin-pathway inhibitor narsoplimab. *Immunobiology* 2020; 225: 152001.
1538. A. Caroli, A. Remuzzi, B. Ruggiero, C. Carrara, P. Rizzo, P. Brambilla, P. Ruggenenti, G. Remuzzi. Functional magnetic resonance imaging versus kidney biopsy to assess response to therapy in nephrotic syndrome: a case report. *Kidney Med* 2020; 2: 804-809.
1539. L. Perico, A. Benigni, F. Casiraghi, L. F. P. Ng, L. Renia, G. Remuzzi. Immunity, endothelial injury and complement induced coagulopathy in COVID-19. *Nat Rev Nephrol* 2021; 17: 46-64.
1540. G. A. Roth, G. A. Mensah, C. O. Johnson, G. Addolorato, E. Ammirati, et al., GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group; Collaborators (B. Bikbov, N. Perico, G. Remuzzi). Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: update from the GBD 2019 study. *J Am Coll Cardiol* 2020; 76: 2982-3021.
1541. G. L. Bakris, R. Agarwal, S. D. Anker, B. Pitt, L. M. Ruilope, et al., FIDELIO-DKD Investigators; Collaborators (N. Perico, G. Remuzzi). Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. *N Engl J Med* 2020; 383: 2219-2229.
1542. N.R. van Zuydam, C. Ladenvall, B.F. Voight, R.J. Strawbridge, J. Fernandez-Tajes, et al., SUMMIT Steering Committee; CARDIOGRAMplusC4D Steering Committee; Collaborator (G. Remuzzi). Genetic predisposition to coronary artery disease in type 2 diabetes mellitus. *Circ Genom Precis Med* 2020; 13: e002769.

1543. B. Imberti, D. Cerullo, D. Corna, C. Rota, M. Locatelli, A. Pezzotta, M. Introna, C. Capelli, C.E. Carminati, T.J. Rabelink, D.G. Leuning, C. Zoja, M. Morigi, G. Remuzzi, A. Benigni, V. Luyckx. Protective effects of human nonrenal and renal stromal cells and their conditioned media in a rat model of chronic kidney disease. *Cell Transplant* 2020; 29: 963689720965467.
1544. M. Cortinovis, N. Perico, G. Remuzzi. Long-term follow-up of recovered patients with COVID-19. *Lancet* 2021; 397: 173-175.
1545. N. Perico, A. Remuzzi, G. Remuzzi. Pathophysiology of proteinuria. In: Brenner & Rector's The Kidney (11th edition), chapter 30. Edited by A. S. L. Yu, G. M. Chertow, V. A. Luyckx, P. A. Marsden, K. Skorecki, M. W. Taal. Elsevier, Amsterdam 2020, pp. 978-1006.e9.
1546. E. Macedo, U. Hemmila, S.K. Sharma, R. Claure-Del Granado, H. Mzinganjira, E.A. Burdmann, J. Cerdà, J. Feehally, F. Finkelstein, G. Garcia-Garcia, V. Jha, N.H. Lameire, E. Lee, N.W. Levin, A. Lewington, R. Lombardi, M.V. Rocco, E. Aronoff-Spencer, M. Tonelli, K. Yeates, G. Remuzzi, R.L. Mehta, ISN 0by25 trial study group. Recognition and management of community acquired acute kidney injury in low resource settings in the ISN 0by25 trial: a multi-country feasibility study. *PLoS Med* 2021; 18: e1003408.
1547. L. Perico, A. Benigni, G. Remuzzi. Angiotensin-converting enzyme 2: from a vasoactive peptide to the gatekeeper of a global pandemic. *Curr Opin Nephrol Hypertens* 2021; 30: 252-263.
1548. N. Perico, S. Fagioli, F. Di Marco, A. Laghi, R. Cosentini, M. Rizzi, A. Gianatti, A. Rambaldi, P. Ruggerenti, C. La Vecchia, G. Bertolini, S. Paglia, F.L. Lorini, G. Remuzzi. Bergamo and Covid-19: how the dark can turn to light. *Front Med (Lausanne)* 2021; 8: 609440.
1549. G. Forni, A. Mantovani, COVID-19 Commission of Accademia Nazionale dei Lincei, Rome; G. Remuzzi (Collaborators). COVID-19 vaccines: where we stand and challenges ahead. *Cell Death Differ* 2021; 28: 626-639.
1550. M.A. Podestà, G. Remuzzi, F. Casiraghi. Mesenchymal stromal cell therapy in solid organ transplantation. *Front Immunol* 2021; 11: 618243.
1551. C. Carrara, P. Cravedi, A. Perna, F. Peraro, A. Villa, F. Carrara, M. Cortinovis, E. Gotti, A.R. Plati, A. Amaduzzi, G. Rota, F. Lacanna, G. Rossini, M. Abelli, G. Remuzzi, P. Ruggerenti. Preimplantation histological score associates with 6-month GFR in recipients of perfused, older kidney grafts: results from a pilot study. *Nephron* 2021; 145: 137-149.
1552. A. Vlahou, D. Hallinan, R. Apweiler, A. Argiles, J. Beige, A. Benigni, R. Bischoff, P.C. Black, F. Boehm, J. Céraline, G.P. Chrousos, C. Delles, P. Evenepoel, I. Fridolin, G. Glorieux, A.J. van Gool, I. Heidegger, J.P.A. Ioannidis, J. Jankowski, V. Jankowski, C. Jeronimo, A.M. Kamat, R. Masereeuw, G. Mayer, H. Mischak, A. Ortiz, G. Remuzzi, P. Rossing, J.P. Schanstra, B.J. Schmitz-Dräger, G. Spasovski, J.A. Staessen, D. Stamatialis, P. Stenvinkel, C. Wanner, S.B. Williams, F. Zannad, C.

- Zoccali, R. Vanholder. Data sharing under the general data protection regulation: time to harmonize law and research ethics ? *Hypertension* 2021; 77: 1029-1035.
1553. F. Raimondi, L. Novelli, A. Ghirardi, F.M. Russo, D. Pellegrini, R. Biza, R. Trapasso, L. Giuliani, M. Anelli, M. Amoroso, C. Allegri, G. Imeri, C. Sanfilippo, S. Comandini, E. Hila, L. Manesso, L. Gandini, P. Mandelli, M. Monti, M. Gori, M. Senni, F.L. Lorini, M. Rizzi, T. Barbui, L. Paris, A. Rambaldi, R. Cosentini, G. Guagliumi, S. Cesa, M. Colledan, M. Sessa, A. Masciulli, A. Gavazzi, S. Buoro, G. Remuzzi, P. Ruggenenti, A. Callegaro, A. Gianatti, C. Farina, A. Bellasi, S. Sironi, S. Fagioli, F. Di Marco; HPG23 Covid-19 Study Group. Covid-19 and gender: lower rate but same mortality of severe disease in women-an observational study. *BMC Pulm Med* 2021; 21: 96.
 1554. E. Copland, D. Canoy, M. Nazarzadeh, Z. Bidel, R. Ramakrishnan, M. Woodward, J. Chalmers, K. K. Teo, C. J. Pepine, B. R. Davis, S. Kjeldsen, J. Sundström, K. Rahimi, Blood Pressure Lowering Treatment Trialists' Collaboration; Collaborators (G. Remuzzi, P. Ruggenenti). Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. *Lancet Oncol* 2021; 22: 558-570.
 1555. P. Ruggenenti, M. A. Podestà, M. Trillini, A. Perna, T. Peracchi, N. Rubis, D. Villa, D. Martinetti, M. Cortinovis, P. Ondeì, C. G. Condemi, C. M. Guastoni, A. Meterangelis, A. Granata, E. Mambelli, S. Pasquali, S. Genovesi, F. Pieruzzi, S. V. Bertoli, G. Del Rosso, M. Garozzo, A. Rigotti, C. Pozzi, S. David, G. Daidone, G. Mingardi, G. Mosconi, A. Galfré, G. Romei Longhena, A. Pacitti, A. Pani, J. Hidalgo Godoy, H. J. Anders, G. Remuzzi, ARCADIA Study Organization. Ramipril and cardiovascular outcomes in patients on maintenance hemodialysis: the ARCADIA multicenter randomized controlled trial. *Clin J Am Soc Nephrol* 2021; 16: 575-587.
 1556. M. Cortinovis, G. Remuzzi. *Nephrology Worldwide – A book review*. *Nephron* 2021; 145: 212-213.
 1557. L. Novelli, F. Raimondi , A. Ghirardi, D. Pellegrini, D. Capodanno, G. Sotgiu, G. Guagliumi, M. Senni, F. M. Russo, F. L. Lorini, M. Rizzi, T. Barbui, A. Rambaldi, R. Cosentini, L. S. Grazioli, G. Marchesi, G. F. Sferrazza Papa, S. Cesa, M. Colledan, R. Civiletti, C. Conti, M. Casati, F. Ferri, S. Camagni, M. Sessa, A. Masciulli, A. Gavazzi, A. Falanga, L. F. Da Pozzo, S. Buoro, G. Remuzzi, P. Ruggenenti, A. Callegaro, L. D'Antiga, L. Pasulo, F. Pezzoli, A. Gianatti, P. Parigi, C. Farina, A. Bellasi, P. Solidoro, S. Sironi, F. Di Marco, S. Fagioli, HPG23 COVID-19 Study Group. At the peak of COVID-19 age and disease severity but not comorbidities are predictors of mortality: COVID-19 burden in Bergamo, Italy. *Panminerva Med* 2021; 63: 51-61.
 1558. Blood Pressure Lowering Treatment Trialists' Collaboration; Collaborators (G. Remuzzi, P. Ruggenenti). Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant level data meta analysis. *Lancet* 2021; 397: 1625-1636.
 1559. P. A. Cortesi, C. Fornari, F. Madotto, S. Conti, M. Naghavi, B. Bikbov, P. S. Briant, V. Caso, G. Crotti, C. Johnson, M. Nguyen, L. Palmieri, N. Perico, F. Profili, G. Remuzzi, G. A. Roth, E. Traini, F. Voller, S. Yadgir, G. Mazzaglia, L. Monasta, S.

- Giampaoli, L. G. Mantovani, GBD 2017 Italy Cardiovascular Diseases Collaborators. Trends in cardiovascular diseases burden and vascular risk factors in Italy: The Global Burden of Disease study 1990-2017. *Eur J Prev Cardiol* 2021; 28: 385-396.
1560. R. Piras, M. Breno, E. Valoti, M. Alberti, P. Iatropoulos, C. Mele, E. Bresin, R. Donadelli, P. Cuccarolo, R. J. H. Smith, A. Benigni, G. Remuzzi, M. Noris. CFH and CFHR copy number variations in C3 glomerulopathy and immune complex-mediated membranoproliferative glomerulonephritis. *Front Genet* 2021; 12: 670727.
 1561. F. Casiraghi, P. Y. R. Ordonez, N. Azzollini, M. Todeschini, D. Rottoli, R. Donadelli, R. Gramignoli, A. Benigni, M. Noris, G. Remuzzi. Amnion epithelial cells are an effective source of factor H and prevent kidney complement deposition in factor H-deficient mice. *Stem Cell Res Ther* 2021; 12: 332.
 1562. G. Bassanese, T. Wlodkowski, A. Servais, L. Heidet, D. Roccattello, F. Emma, E. Levtchenko, G. Ariceta, J. Bacchetta, G. Capasso, A. Jankauskiene, M. Miglinas, P. M. Ferraro, G. Montini, J. Oh, S. Decramer, T. K. Levart, J. Wetzels, E. Cornelissen, O. Devuyt, A. Zurowska, L. Pape, A. Buescher, D. Haffner, N. Marcun Varda, G. M. Ghiggeri, G. Remuzzi, M. Konrad, G. Longo, D. Bockenhauer, A. Awan, I. Andersone, J. W. Groothoff, F. Schaefer. The European Rare Kidney Disease Registry (ERKReg): objectives, design and initial results. *Orphanet J Rare Dis* 2021; 16: 251.
 1563. P. Ruggenenti, P. Cravedi, E. Gotti, A. Plati, M. Marasà, S. Sandrini, N. Bossini, F. Citterio, E. Minetti, D. Montanaro, E. Sabadini, R. Tardanico, D. Martinetti, F. Gaspari, A. Villa, A. Perna, F. Peraro, G. Remuzzi. Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial. *PLoS Med* 2021; 18: e1003668.
 1564. D. Curtò, F. Tomatis, S. Gastoldi, M. Galbusera, M. Noris, F. Raimondi, F. L. Lorini, A. Falanga, M. Marchetti, G. Remuzzi, P. Ruggenenti. Case report: Effects of anti-SARS-CoV-2 convalescent antibodies obtained with double filtration plasmapheresis. *Front Immunol* 2021; 12: 711915.
 1565. D. Cerullo, D. Rottoli, D. Corna, P. Rizzo, M. Abbate, D. Macconi, A. Benigni, G. Remuzzi, C. Zoja. Characterization of a rat model of myeloperoxidase anti-neutrophil cytoplasmic antibody associated crescentic glomerulonephritis. *Nephron* 2021; 145: 428-444.
 1566. P. Ruggenenti, M. Cortinovis, A. Parvanova, M. Trillini, I. P. Iliev, A. C. Bossi, A. Belviso, M. C. Aparicio, R. Trevisan, S. Rota, A. Perna, T. Peracchi, N. Rubis, D. Martinetti, S. Prandini, F. Gaspari, F. Carrara, S. De Cosmo, G. Tonolo, R. Mangili, G. Remuzzi, VARIETY Study Organization. Preventing microalbuminuria with benazepril, valsartan, and benazepril-valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study. *PLoS Med* 2021; 18: e1003691.
 1567. F. Casiraghi, N. Perico, M.A. Podestà, M. Todeschini, M. Zambelli, M. Colledan, S. Camagni, S. Fagioli, A.D. Pinna, M. Cescon, V. Bertuzzo, L. Maroni, M. Introna, C. Capelli, J.T. Golay, M. Buzzi, M. Mister, Rodriguez Ordonez PY, M. Breno, C. Mele, A. Villa, G. Remuzzi. Third-party bone marrow-derived mesenchymal stromal cell

- infusion before liver transplantation: a randomized controlled trial. *Am J Transplant* 2021; 21: 2795-2809.
1568. F. Suter, E. Consolaro, S. Pedroni, C. Moroni, E. Pastò, M. V. Paganini, G. Pravettoni, U. Cantarelli, N. Rubis, N. Perico, A. Perna, T. Peracchi, P. Ruggenenti, G. Remuzzi. A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: A retrospective observational matched-cohort study. *EClinicalMedicine* 2021; 37: 100941.
 1569. V. Brizi, S. Buttò, D. Cerullo, A. M. Lavecchia, R. Rodrigues-Diez, R. Novelli, D. Corna, A. Benigni, G. Remuzzi, C. Xinaris. Human iPSC-derived neural crest stem cells can produce EPO and induce erythropoiesis in anemic mice. *Stem Cell Res* 2021; 55: 102476.
 1570. A. Remuzzi, G. Remuzzi. Insights into Glomerular Filtration and Albuminuria. *N Engl J Med* 2021; 385: 477.
 1571. G. Remuzzi. COVID-19 from a pharmacological perspective. *Adv Biol Regul* 2021; 81: 100821.
 1572. GBD 2019 Under-5 Mortality Collaborators, B. Bikbov, N. Perico, G. Remuzzi. Global, regional, and national progress towards sustainable development goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019. *Lancet* 2021; 398: 870-905.
 1573. Blood Pressure Lowering Treatment Trialists' Collaboration; G. Remuzzi, P. Ruggenenti. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. *Lancet* 2021; 398: 1053-1064.1574.
 1574. N. R. van Zuydam, A. Stiby, M. Abdalla, E. Austin, E. H. Dahlström, S. McLachlan, E. Vlachopoulou, E. Ahlqvist, C. Di Liao, N. Sandholm, C. Forsblom, A. Mahajan, N. R. Robertson, N. W. Rayner, E. Lindholm, J. Sinisalo, M. Perola, M. Kallio, E. Weiss, J. Price, A. Paterson, B. Klein, V. Salomaa, C. N. A. Palmer, P. H. Groop, L. Groop, M. I. McCarthy, M. de Andrade, A. P. Morris, J. C. Hopewell, H. M. Colhoun, I. J. Kullo, GoLEAD Consortium, SUMMIT Consortium; Collaborator (G. Remuzzi). Genome-wide association study of peripheral artery disease. *Circ Genom Precis Med* 2021; 14: 002862.
 1575. B. Bikbov, P. Ruggenenti, A. Perna, N. Perico, E. Gotti, A. Plati, F. Gaspari, F. Carrara, V. Gambarà, T. Peracchi, G. Rossini, G. Rota, F. Lacanna, A. Amaduzzi, M. Colledan, G. Remuzzi. Long-term outcomes of kidney transplants from older/marginal donors: A cohort study. *Nephron* 2021; 145: 642-652.
 1576. C. Carrara, P. Ruggenenti, G. Remuzzi. Redefining the role of donor biopsies in the process of kidney graft assessment. *Nephron* 2021; 145: 728-731.
 1577. F. Rastelli, I. Baragetti, L. Buzzi, F. Ferrario, L. Benozzi, F. Di Nardo, E. Devoti, G. Cancarini, N. Mezzina, P. Napodano, M. Gallieni, D. Santoro, M. Buemi, P. Pecchini, F. Malberti, V. Colombo, G. Colussi, E. Sabadini, G. Remuzzi, et al. Renal

involvement in sarcoidosis: histological patterns and prognosis, an italian survey. *Sarcoidosis Vasc Diffuse Lung Dis* 2021; 38: e2021017.

1578. L. Longaretti, P. Trionfini, V. Brizi, C. Xinaris, C. Mele, M. Breno, E. Romano, R. Giampietro, G. Remuzzi, A. Benigni, S. Tomasoni. Unravelling the role of PAX2 mutation in human focal segmental glomerulosclerosis. *Biomedicines* 2021; 9: 1808.
1579. M.G. Wong, J. Lv, M.A. Hladunewich, V. Jha, L.S. Hooi, H. Monaghan, M. Zhao, S. Barbour, H.N. Reich, D. Cattran, R. Glasscock, A. Levin, M.J. Jardine, D.C. Wheeler, M. Woodward, L. Billot, T.M. Chan, Z.H. Liu, D.W. Johnson, A. Cass, J. Feehally, J. Floege, G. Remuzzi, Y. Wu, R. Agarwal, H. Zhang, V. Perkovic; TESTING Study Group. The therapeutic evaluation of steroids in IgA nephropathy global (TESTING) study: trial design and baseline characteristics. *Am J Nephrol* 2021; 52: 827-836.
1580. L. Perico, M. Morigi, A. Pezzotta, D. Corna, V. Brizi, S. Conti, C. Zanchi, F. Sangalli, P. Trionfini, S. Buttò, C. Xinaris, S. Tomasoni, C. Zoja, G. Remuzzi, A. Benigni, B. Imberti. Post-translational modifications by SIRT3 de-2-hydroxyisobutyrylase activity regulate glycolysis and enable nephrogenesis. *Sci Rep* 2021; 11: 23580.
1581. B. Pitt, G. Filippatos, R. Agarwal, S. D. Anker, G. L. Bakris, P. Rossing, A. Joseph, P. Kolkhof, C. Nowack, P. Schloemer, L. M. Ruilope, FIGARO-DKD Investigators; Collaborators (N. Perico, G. Remuzzi). Cardiovascular events with finerenone in kidney disease and type 2 diabetes. *N Engl J Med* 2021; 385: 2252-2263.
1582. P. Ruggenenti, F. Di Marco, M. Cortinovis, L. Lorini, S. Sala, L. Novelli, F. Raimondi, S. Gastoldi, M. Galbusera, R. Donadelli, C. Mele, R. Piras, M. Noris, V. Portalupi, L. Cappelletti, C. Carrara, F. Tomatis, S. Bernardi, A. Perna, T. Peracchi, O. Diadei, A. Benigni, G. Remuzzi. Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. *PLoS One* 2021; 16: e0261113.
1583. A. Munafò, S. Frara, N. Perico, R. Di Mauro, M. Cortinovis, C. Burgaletto, G. Cantarella, G. Remuzzi, A. Giustina, R. Bernardini. In search of an ideal drug for safer treatment of obesity: the false promise of pseudoephedrine. *Rev Endocr Metab Disord* 2021; 22: 1013-1025.
1584. N. Perico, L. Perico, C. Ronco, G. Remuzzi. COVID-19 and the kidney: should 1patients ? In: *Contributions to Nephrology: Nephrology and public health worldwide*. Edited by G.B. Silva Junior, A. Ferreira Fuentes, M. Nangaku, G. Remuzzi, C. Ronco. Basel, Karger 2021, vol. 199, pp. 229-243.
1585. G.B. Silva Junior, G. Gadonski, A. Ferreira Fuentes, M. Nangaku, G. Remuzzi, C. Ronco. The future of nephrology and public health. In: *Contributions to Nephrology: Nephrology and public health worldwide*. Edited by G.B. Silva Junior, A. Ferreira Fuentes, M. Nangaku, G. Remuzzi, C. Ronco. Basel, Karger 2021, vol. 199, pp. 339-350.
1586. P. Ruggenenti, M.R. Caruso, M. Cortinovis, A. Perna, T. Peracchi, G.A. Giuliano, S. Rota, P. Brambilla, G. Invernici, D. Villa, O. Diadei, M. Trillini, G. Natali, G. Remuzzi. Fresh lemon juice supplementation for the prevention of recurrent stones in

calcium oxalate nephrolithiasis: A pragmatic, prospective, randomised, open, blinded endpoint (PROBE) trial. *EClinicalMedicine* 2022; 43: 101227.

1587. S. Liabeuf, M. Pepin, C.F.M. Franssen, D. Viggiano, S. Carriazo, et al., CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target); Collaborators (B. Bikbov, N. Perico, G. Remuzzi). Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle? *Nephrol Dial Transplant* 2022; 37 (suppl 2): ii33-ii44.
1588. M. Pepin, A.C. Ferreira, M. Arici, M. Bachman, M. Barbieri, et al., CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target); Collaborators (B. Bikbov, N. Perico, G. Remuzzi). Cognitive disorders in patients with chronic kidney disease: specificities of clinical assessment. *Nephrol Dial Transplant* 2022; 37 (suppl 2): ii23-ii32.
1589. P.H. Imenez Silva, R. Unwin, E.J. Hoorn, A. Ortiz, F. Trepiccione, et al., CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target); Collaborators (B. Bikbov, N. Perico, G. Remuzzi). Acidosis, cognitive dysfunction and motor impairments in patients with kidney disease. *Nephrol Dial Transplant* 2022; 37 (suppl 2): ii4-ii12.
1590. C. Zoccali, A. Ortiz, I.A. Blumbyte, S. Rudolf, A.G. Beck-Sickinger, J. Malyszko, G. Spasovski, S. Carriazo, D. Viggiano, J. Kurganaite, V. Sarkeviciene, D. Rastenyte, A. Figurek, M. Rroji, C. Mayer, M. Arici, G. Martino, G. Tedeschi, A. Bruchfeld, B. Spoto, I. Rychlik, A. Wiecek, M. Okusa, G. Remuzzi, F. Mallamaci, CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target); Collaborators (B. Bikbov, N. Perico). Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in CKD: translational opportunities and challenges. *Nephrol Dial Transplant* 2022; 37 (suppl 2): ii14-ii23.
1591. B. Bikbov, M.J. Soler, V. Pesic, G. Capasso, R. Unwin, M. Endres, G. Remuzzi, N. Perico, R. Gansevoort, F. Mattace-Raso, A. Bruchfeld, A. Figurek, G. Hafez; CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target). Albuminuria as a risk factor for mild cognitive impairment and dementia-what is the evidence? *Nephrol Dial Transplant* 2022; 37 (suppl 2): ii55-ii62.
1592. G. Capasso, C. Wanner. CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target); Collaborators (B. Bikbov, N. Perico, G. Remuzzi). Present and future of CONNECT: a new and compelling project of modern medicine. *Nephrol Dial Transplant* 2022; 37 (suppl 2): ii1-ii3.
1593. D. Viggiano, A. Bruchfeld, S. Carriazo, A. de Donato, N. Endlich, A.C. Ferreira, A. Figurek, D. Fouque, C.F.M. Franssen, K. Giannakou, D. Goumenos, E.J. Hoorn, D. Nitsch, A. Ortiz, V. Pešić, D. Rastenyte, M.J. Soler, M. Rroji, F. Trepiccione, R.J. Unwin, C.A. Wagner, A. Wiecek, M. Zacchia, C. Zoccali, G. Capasso, CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target); Collaborators (N. Perico, G. Remuzzi). Brain dysfunction in tubular and tubulointerstitial kidney diseases. *Nephrol Dial Transplant* 2022; 37 (suppl 2): ii46-ii55.

1594. P. Ruggenenti, B.J. Kraus, S.E. Inzucchi, B. Zinman, S. Hantel, M. Mattheus, M. von Eynatten, G. Remuzzi, A. Koitka-Weber, C. Wanner. Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes. *EClinicalMedicine* 2022; 43: 101240.
1595. N. Knoers, C. Antignac, C Bergmann, K. Dahan, S. Giglio, L. Heidet, B. S. Lipska-Ziętkiewicz, M. Noris, G. Remuzzi, R. Vargas-Poussou, F. Schaefer; ERA-EDTA Working Group for Inherited Kidney Diseases (WGIKD) and the Molecular Diagnostics Taskforce of the European Rare Kidney Disease Reference Network (ERKNet). Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice. *Nephrol Dial Transplant* 2022; 37: 239-254.
1596. GBD 2019 Tuberculosis Collaborators, B. Bikbov, N. Perico, G. Remuzzi. Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990-2019: results from the Global Burden of Disease Study 2019. *Lancet Infect Dis* 2022; 22: 222-241.
1597. S. Aiello, S. Gastoldi, M. Galbusera, P.L. Ruggenenti, V. Portalupi, S. Rota, N. Rubis, L. Liguori, S. Conti, M. Tironi, S. Gamba, D. Santarsiero, A. Benigni, G. Remuzzi, M. Noris. C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19. *Blood Adv* 2022; 6: 866-881.
1598. S.Conti, G. Remuzzi, A. Benigni, S. Tomasoni. Imaging the kidney with an unconventional scanning electron microscopy technique: Analysis of the subpodocyte space in diabetic mice. *Int J Mol Sci* 2022; 23: 1699.
1599. F. Carrara, P. Ruggenenti, A. Perna, I.P. Iliev, F. Gaspari, S. Ferrari, N. Stucchi, A. Bossi, R. Trevisan, G. Remuzzi, A. Parvanova. Glomerular resistances predict long-term GFR decline in type 2 diabetic patients without overt nephropathy: a longitudinal subgroup analysis of the DEMAND trial. *Acta Diabetol* 2022; 59: 309-317.
1600. P. Ruggenenti, M. Cortinovis, M. Trillini, A. Parvanova, M. Abbate, C. Satriano, F. Salvetti, A.C. Bossi, R. Trevisan, A. Perna, T. Peracchi, N. Rubis, O. Diadei, D. Martinetti, F. Gaspari, L. Fontana, G. Remuzzi, CRESO 2 Study Organization. Long-term kidney and systemic effects of calorie restriction in overweight or obese type 2 diabetic patients (C.Re.S.O. 2 randomized controlled trial). *Diabetes Res Clin Pract* 2022; 185: 109804.
1601. M. Locatelli, C. Zoja, S. Conti, D. Cerullo, D. Corna, D. Rottoli, C. Zanchi, S. Tomasoni, G. Remuzzi, A. Benigni. Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF-A/caveolin-1/PV-1 signaling pathway. *J Pathol* 2022; 256: 468-479.
1602. V.F. Leone, A. Imeraj, S. Gastoldi, C. Mele, L. Liguori, C. Condemi, P. Ruggenenti, G. Remuzzi, C. Carrara. Case Report: Tackling complement hyperactivation with eculizumab in atypical hemolytic uremic syndrome triggered by COVID-19. *Front Pharmacol* 2022; 13: 842473.
1603. L. Perico, M. Morigi, M. Galbusera, A. Pezzotta, S. Gastoldi, B. Imberti, A. Perna, P. Ruggenenti, R. Donadelli, A. Benigni, G. Remuzzi. SARS-CoV-2 spike protein 1

activates microvascular endothelial cells and complement system leading to platelet aggregation. *Front Immunol* 2022; 13: 827146.

1604. C. Zanchi, M. Locatelli, D. Cerullo, V. Aumiller, D. Corna, D. Rottoli, M. Eisermann, R. Donadelli, M. Mousavi, M. Noris, G. Remuzzi, A. Benigni, C. Zoja. Therapeutic small interfering RNA targeting complement C3 in a mouse model of C3 glomerulopathy. *J Immunol* 2022; 208: 1772-1781.
1605. B. Armocida, L. Monasta, S. Sawyer, F. Bustreo, G. Segafredo, G. Castelpietra, L. Ronfani, M. Pasovic, S. Hay, GBD 2019 Europe NCDs in Adolescents Collaborators, B. Bikbov, S. Gallus, N. Perico, G. Remuzzi. Burden of non-communicable diseases among adolescents aged 10-24 years in the EU, 1990-2019: a systematic analysis of the Global Burden of Diseases Study 2019. *Lancet Child Adolesc Health* 2022; 6: 367-383.
1606. E. Consolaro, F. Suter, N. Rubis, S. Pedroni, C. Moroni, E. Pastò, M.V. Paganini, G. Pravettoni, U. Cantarelli, N. Perico, A. Perna, T. Peracchi, P. Ruggenenti, G. Remuzzi. A home-treatment algorithm based on anti-inflammatory drugs to prevent hospitalization of patients with early COVID-19: A matched-cohort study (COVER2). *Front Med (Lausanne)* 2022; 9: 785785.
1607. J. Lv, M.G. Wong, M.A. Hladunewich, V. Jha, L.S. Hooi, H. Monaghan, M. Zhao, S. Barbour, M.J. Jardine, H.N. Reich, D. Cattran, R. Glassock, A. Levin, D.C. Wheeler, M. Woodward, L. Billot, S. Stepien, K. Rogers, T.M. Chan, Z.H. Liu, D.W. Johnson, A. Cass, J. Feehally, J. Floege, G. Remuzzi, Y. Wu, R. Agarwal, H. Zhang, V. Perkovic; TESTING Study Group. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: The TESTING randomized clinical trial. *JAMA* 2022; 327: 1888-1898.
1608. L. Monasta, G. Alicandro, M. Pasovic, M. Cunningham, B. Armocida, L. Ronfani, M. Naghavi, GBD 2019 Italy Causes of Death Collaborators, E. Beghi, C. Bosetti, S. Gallus, N. Perico, G. Remuzzi. Redistribution of garbage codes to underlying causes of death: a systematic analysis on Italy and a comparison with most populous Western European countries based on the Global Burden of Disease Study 2019. *Eur J Public Health* 2022; 32: 456-462.
1609. GBD 2019 Human Resources for Health Collaborators, B. Bikbov, N. Perico, G. Remuzzi. Measuring the availability of human resources for health and its relationship to universal health coverage for 204 countries and territories from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 2022; 399: 2129-2154.
1610. S. Buelli, M. Locatelli, C.E. Carminati, D. Corna, D. Cerullo, B. Imberti, L. Perico, M. Brigotti, M. Abbate, C. Zoja, A. Benigni, G. Remuzzi, M. Morigi. Shiga toxin 2 triggers C3a-dependent glomerular and tubular injury through Mitochondrial dysfunction in hemolytic uremic syndrome. *Cells* 2022; 11: 1755.
1611. M. Cortinovis, N. Perico, P. Ruggenenti, A. Remuzzi, G. Remuzzi. Glomerular hyperfiltration. *Nat Rev Nephrol* 2022; 18: 435-451.

1612. P.M. Mannucci, A. Nobili, M. Tettamanti, B. D'Avanzo, A.A. Galbussera, G. Remuzzi, I. Fortino, O. Leoni, S. Harari. Impact of the post-COVID-19 condition on health care after the first disease wave in Lombardy. *J Intern Med* 2022; 292: 450-462.
1613. M. Nazarzadeh, Z. Bidel, D. Canoy, E. Copland, D.A. Bennett, A. Dehghan, G. Davey Smith, R.R. Holman, M. Woodward, A. Gupta, et al., Blood Pressure Lowering Treatment Trialists' Collaboration; Collaborators (G. Remuzzi, P. Ruggenenti). Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis. *Lancet Diabetes Endocrinol* 2022; 10: 645-654.
1614. M. Locatelli, D. Macconi, D. Corna, D. Cerullo, D. Rottoli, G. Remuzzi, A. Benigni, C. Zoja. Sirtuin 3 deficiency aggravates kidney disease in response to high-fat diet through lipotoxicity-induced mitochondrial damage. *Int J Mol Sci* 2022; 23: 8345.
1615. D. Cerullo, D. Rottoli, D. Corna, M. Abbate, A. Benigni, G. Remuzzi, C. Zoja. Add-On cyclic angiotensin-(1-7) with cyclophosphamide arrests progressive kidney disease in rats with ANCA Associated Glomerulonephritis. *Cells* 2022; 11: 2434.
1616. A. Perna, B. Ruggiero, M.A. Podestà, L. Perico, S. Orisio, H. Debiec, G. Remuzzi, P. Ruggenenti. Sexual dimorphic response to rituximab treatment: A longitudinal observational study in a large cohort of patients with primary membranous nephropathy and persistent nephrotic syndrome. *Front Pharmacol* 2022; 13: 958136.
1617. A. Mantovani, M.C. Morrone, C. Patrono, M. G. Santoro, S. Schiaffino, G. Remuzzi, G. Bussolati; Covid-19 Commission of the Accademia Nazionale dei Lincei. Long Covid: where we stand and challenges ahead. *Cell Death Differ* 2022; 29: 1891-1900.
1618. L. Garattini, M. Bozzetto, G. Remuzzi, N. Freemantle, A. Nobili. Primary care in a national health service: time for radical reform. *Fam Pract* 2022;39: 994-995.
1619. N. Perico, M.D. Griffin, G. Remuzzi. Editorial: Insights in renal pharmacology: 2021. *Front Pharmacol* 2022; 13: 1010691.
1620. A. Pezzotta, L. Perico, M. Morigi, D. Corna, M. Locatelli, C. Zoja, A. Benigni, G. Remuzzi, B. Imberti. Low nephron number induced by maternal protein restriction is prevented by nicotinamide riboside supplementation depending on sirtuin 3 activation. *Cells* 2022; 11: 3316.
1621. GBD 2019 Benign Prostatic Hyperplasia Collaborators, B. Bikbov, N. Perico, G. Remuzzi. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Healthy Longev* 2022; 3: e754-e776.
1622. G. Remuzzi, S. Schiaffino, M.G. Santoro, G.A. FitzGerald, G. Melino, C. Patrono, COVID-19 Committee of the Lincei Academy. Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years. *Front Pharmacol* 2022; 13: 987816.

1623. P.M. Mannucci, A. Nobili, M. Tettamanti, B. D'avanzo, A.A. Galbussera, G. Remuzzi, I. Fortino, O. Leoni, S. Harari. Progressive decrease of the healthcare impact of the post-COVID condition after the first disease wave in Lombardy, Italy. *J Intern Med* 2022; 292: 961-964.
1624. P. Ruggenenti, N. Perico, Remuzzi G. Full-dose NSAIDs at the first sign of respiratory infection? - Authors' reply. *Lancet Infect Dis* 2022; 22: 1534.
1625. P. Vart, M. Vaduganathan, N. Jongs, G. Remuzzi, D.C. Wheeler, F.F. Hou, F. McCausland, G.M. Chertow, H.J.L. Heerspink. Estimated lifetime benefit of combined RAAS and SGLT2 inhibitor therapy in patients with albuminuric CKD without Diabetes. *Clin J Am Soc Nephrol* 2022; 17: 1754-1762.
1626. N. Perico, F. Casiraghi, G. Remuzzi. Clinical kidney xenotransplantation: major progress but more work needs to be done. *Nephron* 2022; 146: 610-615.
1627. GBD 2019 Antimicrobial Resistance Collaborators; N. Perico, G. Remuzzi. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 2022; 400: 2221-2248.
1628. N. Perico, M. Cortinovis, F. Suter, G. Remuzzi. Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents. *Lancet Infect Dis* 2022; 2023; 23: e22-e33
1629. G. Alicandro, C. La Vecchia, G. Remuzzi, A. Gerli, S. Centanni. Excess mortality in Italy in 2020 by sex and age groups accounting for demographic changes and temporal trends in mortality. *Panminerva Med* 2022; 64(4): 472-478
1630. S.D. Podos, H. Trachtman, G.B. Appel, A.S. Bomback, B.P. Dixon, J.F.M. Wetzels, H.T. Cook, S.V. Parikh, M.C. Pickering, J. Tumlin, C.B. Langman, L. Lightstone, C.J. Sperati, E. Daina, K.P. Bouman, K. Rice, J.A. Thanassi, M. Huang, C. Nester, G. Remuzzi. Baseline clinical characteristics and complement biomarkers of patients with C3 glomerulopathy enrolled in two phase 2 studies investigating the factor D inhibitor Danicopan. *Am J Nephrol* 2022; 53: 675-686.
1631. C. Nester, G.B. Appel, A.S. Bomback, K.P. Bouman, H.T. Cook, E. Daina, B.P. Dixon, K. Rice, N. Najafian, J. Hui, S.D. Podosh, C.B. Langman, L. Lightstone, S.V. Parikh, M.C. Pickering, C.J. Sperati, H. Trachtman, J. Tumlin, A.P. de Vries, J.F.M. Wetzels, G. Remuzzi. Clinical outcomes of patients with C3G or IC-MPGN treated with the factor D inhibitor Danicopan: final results from two phase 2 studies. *Am J Nephrol* 2022; 53: 687-700.
1632. M. Noris. G. Remuzzi. Eculizumab-Every fifteen days forever? *Kidney Int. Rep.* 2023; 8: 4-7.
1633. E. Daina, M. Cortinovis, G. Remuzzi. Kidney diseases. *Immunol Rev* 2023; 313: 239-261.
1634. F. Fakhouri, N. Schwotzer, G. Cabiddu, J. Barratt, H. Legardeur, V. Garovic, A. Orozco-Guillen, J. Wetzels, E. Daugas, G. Moroni, M. Noris, V. Audard, M. Praga, E. Llurba, G. Wuerzner, R. Attini, D. Desseuve, E. Zakharova, C. Luders, K. Wiles, F.

- Leone, S. Jesudason, N. Costedoat-Chalumeau, A. Kattah, V. Soto-Abraham, A. Karras, J. Prakash, L. Lightstone, P. M. Ronco, C. Ponticelli, G. Appel, G. Remuzzi, V. Tsatsaris, G. B. Piccoli. Glomerular diseases in pregnancy: pragmatic recommendations for clinical management. *Kidney Int* 2023; 103: 264-281.
1635. A. Chiò, G. Remuzzi, G. Forloni, G. Logroscino. In memoriam Ettore Beghi, 1947-2022. *Amyotroph Lateral Scler Frontotemporal Degener* 2023; 24:1.
1636. R. Piras, E. Valoti, M. Alberti, E. Bresin, C. Mele, M. Breno, L. Liguori, R. Donadelli, M. Rigoldi, A. Benigni, G. Remuzzi and M. Noris. CFH and CFHR structural variants in atypical Hemolytic Uremic Syndrome: Prevalence, genomic characterization and impact on outcome. *Front. Immunol.* 2023; 13:1011580.
1637. M. Trillini, A. Caroli, N. Perico, A. Remuzzi, P. Brambilla, G. Villa, A. Perna, T. Peracchi, N. Rubis, D. Martinetti, M. Caruso, V.F. Leone, D. Cugini, F. Carrara, G. Remuzzi, P. Ruggenenti, for the TOOL Study Group. Effects of octreotide – long - acting release added-on tolvaptan in patients with autosomal dominant polycystic kidney disease: pilot, randomized, placebo-controlled, cross-over trial. *Clin J Am Soc Nephrol* 2023; 18:223-233.
1638. S. Gastoldi, A. Sistiana, M. Galbusera, M. Breno, M. Alberti, E. Bresin, C. Mele, R. Piras, L. Liguori, D. Santarsiero, A. Benigni, G. Remuzzi and M. Noris. An ex vivo test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndrome. *Front. Immunol.* 2023; 14:1112257.
1639. M. Noris, E. Daina, G. Remuzzi. Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment. *Nephrol Dial Transplant* 2023; 38:283-290.
1640. W. Collier, L.A. Inker, B. Haaland, G.B. Appel, S.V. Badve, F. Caravaca-Fontan, J. Chalmers, J. Floege, M. Goicoechea, E. Imai, T. H. Jafar, J. B. Lewis, P.K.T. Li, F. Locatelli, B.D. Maes, B. Neuen, R.D. Perrone, G. Remuzzi, F.P. Schena, C. Wanner, H.J.L. Heerspink, T. Greene, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). Evaluation of variation in the performance of GFR slope as a surrogate end point for kidney failure in clinical trials that differ by severity of CKD. *Clin J Am Soc Nephrol* 2023; 18: 183-192.
1641. E. Ku, C. E. McCulloch, L. A. Inker, H. Tighiouart, F. Schaefer, E. Wühl, P. Ruggenenti, G. Remuzzi, B. A. Grimes and M. J. Sarnak. Intensive BP control in patients with CKD and risk for adverse outcomes. *J Am Soc Nephrol.* 2023; 34: 385-393.
1642. A. Piralla, F. Mojoli, L. Pellegrinelli, F. Ceriotti, A. Valzano, G. Grasselli, M.R. Gismondo, V. Micheli, A. Castelli, C. Farina, M. Arosio, F.L. Lorini, D. Fanti, A. Busni, M. Laratta, F. Maggi, F. Novazzi, L. Cabrini, A.P. Callegaro, R. Keim, G. Remuzzi, A. Cavallero, S.M.I. Malandrini, R. Rona, F. Giardina, G. Ferrari, F. Zavaglio, et al, C. Mele, L. Liguori. Impact of SARS-CoV-2 Omicron and Delta variants in patients requiring intensive care unit (ICU) admission for COVID-19, Northern Italy, December 2021 to January 2022. *Respir Med Res* 2023; 83:100990.

1643. G. Alicandro, C. La Vecchia, G. Remuzzi, A. Gerli, S. Centanni. The impact of COVID-19 on total mortality in Italy up to November 2020. *Panminerva Med* 2023; 65: 94-96.
1644. L. Perico, M. Todeschini, F. Casiraghi, M. Mister, A. Pezzotta, T. Peracchi, S. Tomasoni, P. Trionfini, A. Benigni, G. Remuzzi. Long-term adaptive response in COVID-19 vaccine recipients and the effect of a booster dose. *Front Immunol* 2023; 14:1123158.
1645. F. Casiraghi, M. Todeschini, M.A Podestà, M. Mister, B. Ruggiero, M. Trillini, O. Diadei, A. Villa, A. Benigni, G. Remuzzi. Immunophenotypic alterations in adult patients with steroid-dependent and frequently relapsing nephrotic syndrome. *Int J Mol Sci* 2023; 24:7687.
1646. A. Parvanova, Manuela Abbate, A.M. Yanez, M. Bennasar-Veny, A.A. Lopez-Gonzalez, J. I. Ramirez-Manent, I.P. Iliev, S. Fresneda, M. Arias-Fernandez, G. Remuzzi, P. Ruggenti. MAFLD and glomerular hyperfiltration in subjects with prediabetes, visceral obesity and "preserved" kidney function: A cross-sectional study. *Diabetes Res Clin Pract* 2023; 201:110729.
1647. M. Raynaud, S. Al-Awadhi, I. Juric, G. Divard, Y. Lombardi, N. Basic-Jukic, O. Aubert, L. Dubourg, I. Masson, C. Mariat, D. Prié, V. Pernin, M. Le Quintrec, T. S. L. Larson, M. D. Stegall, B. Bikbov, P. Ruggenti, L. Mesnard, H. N. Ibrahim, M. Bodilsen Nielsen, A. J. Matas, B. J. Nankivell, S. Benjamens, R. A. Pol, S. J. L. Bakker, X. Jouven, C. Legendre, N. Kamar, G. Remuzzi, et al. Race-free estimated glomerular filtration rate equation in kidney transplant recipients: development and validation study. *BMJ* 2023; 381: e073654.
1648. L. Perico, M. Morigi, A. Pezzotta, M. Locatelli, B. Imberti, D. Corna, D. Cerullo, A. Benigni, G. Remuzzi. SARS-CoV-2 spike protein induces lung endothelial cell dysfunction and thrombo-inflammation depending on the C3a/C3a receptor signaling. *Sci Rep* 2023; 13:11392.
1649. GBD 2021 Diabetes Collaborators; G. Remuzzi, N. Perico. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet* 2023; 402: 203-234.
1650. D. Baldassarre, L. Iacoviello, R. Baetta, M.C. Roncaglioni, G. Condorelli, G. Remuzzi, G. Gensini, L. Frati, W. Ricciardi, P.G. Conaldi, A. Uccelli, F. Blandini, S. Bosari, G. Scambia, M. Fini, A. Di Malta, M. Amato, F. Veglia, A. Bonomi, C. Klersy, F. Colazzo, M. Pengo, F. Gorini, L. Auteri, G. Ferrante, M. Baviera, G. Ambrosio, A. Catapano, A. Gialluisi, A.E. Malavazos, S. Castelveccchio, M.M. Corsi-Romanelli, R. Cardani, M.T. Rovere, V. Agnese, B. Pane, D. Prati, L. Spinardi, G. Liuzzo, E. Arbustini, M. Volterrani, M. Visconti, J.P. Werba, S. Genovese, G. Bilo, C. Invitti, A. Di Blasio, C. Lombardi, A. Faini, D. Rosa, L. Ojeda-Fernández, A. Foresta, A. De Curtis, A. Di Castelnuovo, S. Scalvini, A. Pierobon, A. Gorini, L. Valenti, L. Luzi, A. Racca, M. Bandi, E. Tremoli, L. Menicanti, G. Parati, G. Pompilio; CV-PREVITAL Study Group. Rationale and design of the CV-PREVITAL study: an Italian multiple cohort randomised controlled trial investigating innovative digital strategies in primary cardiovascular prevention. *BMJ Open* 2023; 13: e072040.

1651. S. Conti, C. Fornari, P. Ferrara, I. C. Antonazzo, F. Madotto, E. Traini, M. Levi, A. Cernigliaro, B. Armocida, N.L. Bragazzi, E. Cadum, M. Carugno, G. Crotti, S. Deandrea, P.A. Cortesi, D. Guido, I. Iavicoli, S. Iavicoli, C. La Vecchia, P. Lauriola, P. Michelozzi, S. Scondotto, M. Stafoggia, F.S. Violante, C. Abbafati, L. Albano, F. Barone-Adesi, A. Biondi, C. Bosetti, D. Buonsenso, G. Carreras, G. Castelpietra, A. Catapano, M.S. Cattaruzza, B. Corso, G. Damiani, F. Esposito, S. Gallus, D. Golinelli, S.I. Hay, G. Isola, C. Ledda, S. Mondello, P. Pedersini, U. Pensato, N. Perico, G. Remuzzi, F. Sanmarchi, R. Santoro, B. Simonetti, B. Unim, M. Vacante, M. Veroux, J.H. Villafañe, L. Monasta, L.G. Mantovani. Time-Trends in Air Pollution Impact on Health in Italy, 1990-2019: An Analysis From the Global Burden of Disease Study 2019. *Int J Public Health* 2023; 68: 1605959.
1652. C. Zanchi, M. Locatelli, D. Corna, D. Cerullo, E. Fishilevich, D. Desai, D. Rottoli, R. Donadelli, M. Noris, C. Zoja, G. Remuzzi, A. Benigni. Liver Factor B silencing to cure C3 glomerulopathy: evidence from a mouse model of complement dysregulation. *Mol Immunol* 2023; 161: 25-32.
1653. L.A. Inker, W. Collier, T. Greene, S. Miao, J. Chaudhari, G.B. Appel, S.V. Badve, F. Caravaca-Fontan, L. Del Vecchio, J. Floege, M. Goicoechea, B. Haaland, W.G. Herrington, E. Imai, T.H. Jafar, J.B. Lewis, P.K.T. Li, B.D. Maes, B.L. Neuen, R.D. Perrone, G. Remuzzi, F.P. Schena, C. Wanner, J.F.M. Wetzels, M. Woodward, H.J.L. Heerspink, CKD-EPI Clinical Trials Consortium. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. *Nat Met* 2023; 29: 1867-1876.
1654. P. Trionfini, E. Romano, M. Varinelli, L. Longaretti, P. Rizzo, R. Giampietro, Annalina Caroli, S. Aiello, M. Todeschini, F. Casiraghi, G. Remuzzi, A. Benigni, S. Tomasoni. Hypoimmunogenic human pluripotent stem cells as a powerful tool for liver regenerative medicine. *Int J Mol Sci* 2023; 24: 11810.
1655. A. Caroli, G. Villa, P. Brambilla, M. Trillini, K. Sharma, S. Sironi, G. Remuzzi, N. Perico, A. Remuzzi. Diffusion magnetic resonance imaging for kidney cyst volume quantification and non-cystic tissue characterisation in ADPKD. *Eur Radiol* 2023; 33: 6009-6019.
1656. G. Remuzzi. The ethics of peer review process. *Updates Surg* 2023; 75:1391-1392.
1667. M. Vivarelli, M. Colucci, Mattia Algeri, F. Zotta, F. Emma, I. L'Erario, M. Busutti, S. Rota, C. Capelli, M. Introna, M. Todeschini, F. Casiraghi, A. Perna, T. Peracchi, A. De Salvo, N. Rubis, F. Locatelli, G. Remuzzi, P. Ruggerenti. A phase 1 study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndrome. *JCI Insight* 2023; 10:e169424.
1668. M. Breno, M. Noris, N. Rubis, A. Parvanova, D. Martinetti, S. Gamba, L. Liguori, C. Mele, R. Piras, S. Orisio, E. Valoti, M. Alberti, O. Diadei, E. Bresin, M. Rigoldi, S. Prandini, T. Gamba, N. Stucchi, F. Carrara, E. Daina, A. Benigni, G. Remuzzi, ORIGIN study group. A GWAS in the pandemic epicenter highlights the severe COVID-19 risk locus introgressed by Neanderthals. *IScience* 2023; 26: 107629.
1669. N. Perico, G. Remuzzi, M.D. Griffin, P. Cockwell, A.P. Maxwell, F. Casiraghi, N. Rubis, T. Peracchi, A. Villa, M. Todeschini, F. Carrara, B.A. Magee, P. Ruggerenti, S.

- Rota, L. Cappelletti, V. McInerney, T.P. Griffin, M.N. Islam, M. Introna, O. Pedrini, J. Golay, A.A. Finnerty, J. Smythe, W.E. Fibbe, S.J. Elliman, T. O'Brien, NEPHSTROM Trial Consortium. Safety and preliminary efficacy of mesenchymal stromal cell (ORBCEL-M Cell) therapy in diabetic kidney disease: a randomized clinical trial (NEPHSTROM). *J Am Soc Nephrol* 2023; 34: 1733-1751.
1670. F. Casiraghi, N. Perico, G. Remuzzi. Editorial: Global excellence in translational immunology: Europe. *Front Immunol* 2023; 14: 1250624.
 1671. A. M. Lavecchia, P. Mantzouratou, D. Cerullo, M. Locatelli, S. Conti, M. Tironi, F. Sangalli, D. Corna, C. Zoja, G. Remuzzi, C. Xinaris. Thyroid hormone treatment counteracts cellular phenotypical remodeling in diabetic organs. *IScience* 2023; 26: 107826.
 1672. A. Pezzotta, L. Perico, D. Corna, M. Morigi, G. Remuzzi, A. Benigni, B. Imberti. SIRT3 deficiency promotes endothelial dysfunction and aggravates renal injury. *PLoS One* 2023; 18: e0291909.
 1673. G. Salfi, F. Casiraghi, G. Remuzzi. Current understanding of the molecular mechanisms of circulating permeability factor in focal segmental glomerulosclerosis. *Front Immunol* 2023; 14: 1247606.
 1674. GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet* 2023; 402: 203-234.
 1675. Z. Imanifard, L. Liguori, G. Remuzzi. TMA in kidney transplantation. *Transplantation* 2023; 107: 2329-2340.
 1676. GBD 2019 Peripheral Artery Disease Collaborators, G. Remuzzi G, N. Perico. Global burden of peripheral artery disease and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Glob Health* 2023; 11: e1553-e1565.
 1677. M. Locatelli, D. Rottoli, R. M. A. Mahmoud, M. Abbate, D. Corna, D. Cerullo, S. Tomasoni, G. Remuzzi, C. Zoja, A. Benigni, D. Macconi. Endothelial glycocalyx of peritubular capillaries in experimental diabetic nephropathy: a target of ACE inhibitor-induced kidney microvascular protection. *Int J Mol Sci* 2023; 24: 16543.
 1678. G. A. Mensah, V. Fuster, C. J. L. Murray, G. A. Roth, Global Burden of Cardiovascular Diseases and Risks Collaborators, A. Lugo, S. Gallus, G. Remuzzi, N. Perico. Global Burden of Cardiovascular Diseases and Risks, 1990-2022. *J Am Coll Cardiol* 2023; 82: 2350-2473.
 1679. M. Noris, G. Remuzzi. Shiga Toxin-Producing *Escherichia coli* and the Hemolytic-Uremic Syndrome. *N Engl J Med* 2023; 389: 2499.
 1680. S. Liabeuf, V. Pesic, G. Spasovski, R. Maciulaitis, M. Bobot, A. Farinha, C. A. Wagner, R. J. Unwin, G. Capasso, I. Arune Bumblyte, G. Hafez, CONNECT Action

- (Cognitive Decline in Nephro-Neurology European Cooperative Target), G. Remuzzi, N. Perico, et al. Drugs with a negative impact on cognitive function (Part 1): chronic kidney disease as a risk factor. *Clin Kidney J* 2023; 16: 2365-2377.
1681. G. Hafez, J. Malyszko, A. Golenia, A. Klimkowicz-Mrowiec, A. C. Ferreira, M. Arici, A. Bruchfeld, D. Nitsch, Z. A. Massy, M. Pepin, G. Capasso, L. J. Mani, S. Liabeuf, CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target), G. Remuzzi, N. Perico, et al. Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients. *Clin Kidney J* 2023; 16: 2378-2392.
 1682. E. Wong, C. Nester, T. Cavero, A. Karras, M. Le Quintrec, L. Lightstone, U. Eisenberger, M. J. Soler, D. Kavanagh, E. Daina, M. Praga, N. R. Medjeral-Thomas, A. Gäckler, C. Garcia-Carro, A. Biondani, F. Chaperon, K. Kulmatycki, J. Milojevic, N. J. A. Webb, P. Kumar Nidamarthy, G. Junge and G. Remuzzi. Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. *Kidney Int Rep* 2023; 8: 2754-2764.
 1683. R. Donadelli, A. Sinha, A. Bagga, M. Noris, G. Remuzzi. HUS and TTP: traversing the disease and the age spectrum. *Semin Nephrol* 2023; 43: 151436.
 1684. L. Perico, A. Benigni, G. Remuzzi. SARS-CoV-2 and the spike protein in endotheliopathy. *Trends Microbiol* 2024; 32: 53-67.
 1685. G. Remuzzi. Stewart as I Knew Him. *Nephrol* 2024; 148: 124-126.
 1686. M. Noris, G. Remuzzi. C3G and Ig-MPGN - treatment standard. *Nephrol Dial Transplant* 2024; 39: 202-214.
 1687. C. Zanchi, M. Locatelli, D. Cerullo, V. Aumiller, D. Corna, D. Rottoli, S. Schubert, M. Noris, S. Tomasoni, G. Remuzzi, C. Zoja, A. Benigni. Efficacy of GalNAc C3 siRNAs in factor H-deficient mice with C3 glomerulopathy. *Mol Immunol* 2024; 168: 10-16.
 1688. M. A. Podestà, M. Trillini, V. Portalupi, A. Gennarini, F. Tomatis, A. Villa, A. Perna, N. Rubis, G. Remuzzi, P. Ruggerenti. Ofatumumab in rituximab-resistant and rituximab-intolerant patients with primary membranous nephropathy. *Am J Kidney Dis* 2024; 83: 340-349.e1.
 1689. S. Aiello, A. Benigni, G. Remuzzi. Tissue-resident macrophages in solid organ transplantation: harmful or protective?. *J Immunol* 2024; 212: 1051-1061.
 1690. M. Barbieri, P. Chiodini, P. Di Gennaro, G. Hafez, S. Liabeuf, J. Malyszko, L. Y. Mani, F. Mattace-Raso, M. Pepin, N. Perico, M. Simeoni, C. Zoccali, G. Tortorella, A. Capuano, G. Remuzzi, G. Capasso, G. Paolisso, CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target). Efficacy of erythropoietin as a neuroprotective agent in CKD-associated cognitive dysfunction: a literature systematic review. *Pharmacol Res* 2024; 203: 107146.

1691. GBD 2021 Nervous System Disorders Collaborators, G. Remuzzi, N. Perico. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet Neurol* 2024; 23: 344-381.
1692. F. Liu, S. T. Ryan, K. C. Fahnoe, J. G. Morgan, A. E. Cheung, M. J. Storek, A. Best, H. A. Chen, M. Locatelli, S. Xu, E. Schmidt, L. F. Schmidt-Jimenez, K. Bieber, J. M. Henderson, C. G. Lian, A. Verschoor, R. J. Ludwig, A. Benigni, G. Remuzzi, D. J. Salant, S. L. Kalled, J. M. Thurman, V. M. Holers, S. M. Violette, S. Wawersik. C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement. *Mol Ther* 2024; 32: 1061-1079.
1693. L. Perico, F. Casiraghi, F. Sonogo, M. Todeschini, D. Corna, D. Cerullo, A. Pezzotta, P. Isnard-Petit, S. Faravelli, F. Forneris, K. Thiam, A. Benigni, G. Remuzzi. Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases. *Front Immunol* 2024; 15: 1335998.
1694. L. Perico, G. Remuzzi, A. Benigni. Sirtuins in kidney health and disease. *Nat Rev Nephrol* 2024; 20: 313-329.
1695. M. Pippias, G. Alfano, D. M. Kelly, M. J. Soler, L. De Chiara, T. O. Olanrewaju, S. Arruebo, A. K. Bello, F. J. Caskey, S. Damster, J-A. Donner, V. Jha, D. W. Johnson, A. Levin, C. Malik, M. Nangaku, I. G. Okpechi, M. Tonelli, F. Ye, R. Coppo, L. Lightstone, Regional Board and ISN-GKHA Team Authors, G. Remuzzi. Capacity for the management of kidney failure in the International Society of Nephrology Western Europe region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA). *Kidney Int Suppl* 2024; 13: 136-151.
1696. P. Ruggenenti, L. Reinhard, B. Ruggiero, A. Perna, L. Perico, T. Peracchi, D. Fidone, A. Gennarini, A. Benigni, M. Cortinovis, E. Hoxha, G. Remuzzi. Anti-Phospholipase A2 Receptor 1 and Anti-Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study. *Am J Kidney Dis* 2024; 83: 588-600.e1.
1697. GBD 2021 Forecasting Collaborators, G. Remuzzi, N. Perico, S. Gallus, et al. Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021. *Lancet* 2024; 403: 2204-2256.
1698. GBD 2021 Risk Factors Collaborators, G. Remuzzi, N. Perico, S. Gallus, et al. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet* 2024; 403: 2162-2203.
1699. GBD 2021 Demographics Collaborators, G. Remuzzi, N. Perico. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19

pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. *Lancet* 2024; 403: 1989-2056.

1700. GBD 2021 Causes of Death Collaborators, N. Perico, G. Remuzzi, A. Lugo, S. Gallus. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet* 2024; 403: 2100-2132.
1701. GBD 2021 Diseases and Injuries Collaborators, G. Remuzzi, N. Perico. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet* 2024; 403: 2133-2161.
1702. G. Villa, E. Daina, P. Brambilla, S. Gamba, V. F. Leone, C. Carrara, P. Rizzo, M. Noris, G. Remuzzi, A. Remuzzi, A. Caroli. Functional magnetic resonance imaging to monitor disease progression: a prospective study in patients with primary membranoproliferative glomerulonephritis. *Nephron* 2024; 148: 367-378.
1703. C. F. Prendes, B. Rantner, T. Hamwi, J. Stana, V. L. Feigin, K. Stavroulakis, N. Tsilimparis, GBD Collaborators Study Group, G. Remuzzi, N. Perico N, et al. Burden of stroke in Europe: An analysis of the Global Burden of Disease Study findings from 2010 to 2019. *Stroke* 2024; 55: 432-442.
1704. GBD 2021 Tuberculosis Collaborators, G. Remuzzi G, N. Perico. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet Infect Dis* 2024; 24: 698-725.
1705. C. Zoccali, F. Mallamaci, L. Lightstone, V. Jha, C. Pollock, K. Tuttle, P. Kotanko, A. Wiecek, H-J Anders H-J, G. Remuzzi, K. Kalantar-Zadeh, A. Levin, R. Vanholder. A new era in the science and care of kidney diseases. *Nat Rev Nephrol* 2024; 20: 460-472.
1706. F. Carrara, F. Gaspari, M. Trillini, T. Peracchi, D. Fidone, N. Stucchi, S. Ferrari, D. Cugini, N. Perico, A. Parvanova, G. Remuzzi, P. Ruggenti. GFR measurement in patients with CKD: performance and feasibility of simplified iohexol plasma clearance techniques. *PLoS One* 2024; 19: e0306935.
1707. E. Ku, L. A. Inker, H. Tighiouart, C. E. McCulloch, O. M. Adingwupu, T. Greene, R. O. Estacio, M. Woodward, D. de Zeeuw, J. B. Lewis, T. Hannedouche, T. H. Jafar, E. Imai, G. Remuzzi, H. J. L. Heerspink, F. F. Hou, R. D. Toto, P. K. Li, M. J. Sarnak. Angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers for advanced chronic kidney disease : a systematic review and retrospective individual participant-level meta-analysis of clinical trials. *Ann Intern Med* 2024; 177: 953-963.
1708. F. Mori, S. Pascali, S. Berra, A. Lazzarotti, D. Panetta, S. Rocchiccioli, E. Ceccherini, F. Norelli, A. Morlando, R. Donadelli, A. Clivio, C. Farina, M. Noris, P. A. Salvadori, G. Remuzzi. Proof of concept of a new plasma complement Factor H from waste plasma fraction. *Front Immunol* 2024; 15: 1334151.

1709. P. Ruggenenti, A. Perna, A. Caroli, N. Perico, M. Trillini, A. Pisani, L. Spinelli, G. Remuzzi. Octreotide LAR in patients with autosomal dominant polycystic kidney disease: from bench to a novel perspective of therapy. *Medical Research Archives* 2022; [Epub ahead of print]
1710. S. Orisio, M. Noris, M. Rigoldi, E. Bresin, N. Perico, M. Trillini, R. Donadelli, A. Perna, A. Benigni, G. Remuzzi. Mutation analysis of PKD1 and PKD2 genes in a large Italian cohort reveals novel pathogenic variants including a novel complex rearrangement. *Nephron* 2023; [Epub ahead of print]
1711. P. M. Mannucci, A. A. Galbusera, B. D'Avanzo, M. Tettamanti, G. Remuzzi, I. Fortino, O. Leoni, S. Harari, A. Nobili. Two years of SARS-CoV-2 pandemic and COVID-19 in Lombardy, Italy. *Intern Emerg Med* 2023; [Epub ahead of print]
1712. M. Barbieri, P. Chiodini, P. Di Gennaro, G. Hafez, S. Liabeuf, J. Malyszko, L. Y. Mani, F. Mattace-Raso, M. Pepin, N. Perico, M. Simeoni, C. Zoccali, G. Tortorella, A. Capuano, G. Remuzzi, G. Capasso, G. Paolisso, CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target). Efficacy of erythropoietin as a neuroprotective agent in CKD-associated cognitive dysfunction: a literature systematic review. *Pharmacol Res* 2024; [Epub ahead of print]
1713. GBD 2021 Fertility and Forecasting Collaborators, G. Remuzzi, N. Perico. Global fertility in 204 countries and territories, 1950-2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. *Lancet* 2024; [Epub ahead of print]
1714. E. Ku, H. Tighiouart, C. E. McCulloch, L. A. Inker, O. Adingwupu, T. Greene, R. O. Estacio, M. Woodward, D. de Zeeuw, J. B. Lewis, T. Hannedouche, F. F. Hou, E. Ima, G. Remuzzi, H. J. L. Heerspink, R. D. Toto, M. J. Sarnak. Association between acute declines in estimated glomerular filtration rate during renin-angiotensin system inhibition and risk of adverse outcomes. *J Am Soc Nephrol* 2024; [Epub ahead of print]
1715. M. Vivarelli, J. Barratt, L. H. Jr Beck, F. Fakhouri, D. P. Gale, E. Goicoechea de Jorge, Marta Mosca, N. Noris, M. C. Pickering, K. Susztak, J. M. Thurman, M. Cheung, J. M. King, M. Jadoul, W. C. Winkelmayer, R. H. J. Smith, G. Remuzzi, et al. The role of complement in kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. *Kidney Int* 2024; [Epub ahead of print]
1716. C. Nester, D. A. Decker, M. Meier, S. Aslam, A. S. Bomback, F. Caravaca-Fontan, T. H. Cook, D. L. Feldman, V. Fremeaux-Bacchi, D. P. Gale, A. Gooch, S. Johnson, C. Licht, M. Mathur, M. C. Pickering, M. Praga, G. Remuzzi, V. Selvarajah, R. J. Smith, H. Tabriziani, N. Van de Kar, Y. Wang, E. Wong, K. Mistry, M. Lim, C. Portillo, S. Balogun, H. Trachtman, A. Thompson A. Developing therapies for C3G: report of the kidney health initiative C3G trial endpoints work group. *Clin J Am Soc Nephrol* 2024; [Epub ahead of print]

Books

1. Hemostasis, Prostaglandins and Renal Disease. Edited by G. Remuzzi, G. Mecca, G. de Gaetano, Raven Press, New York 1980.
2. Glomerular injury: 300 years after Morgagni. Edited by T. Bertani, G. Remuzzi, Wichtig Editore, Milano 1983.
3. Drugs and Kidney. Edited by T. Bertani, G. Remuzzi, S. Garattini, Raven Press, New York 1986.
4. Haemostasis and the Kidney. Edited by G. Remuzzi, E.C. Rossi, Butterworths, London 1989.
5. Current & Future Immunosuppressive Therapies Following Transplantation, edited by M.H. Sayegh, G. Remuzzi. Kluwer Academic Publishers, The Netherlands 2001.
6. Contributions to Nephrology (136), Rare Kidney Disease. Edited by A. Schieppati, E. Daina, A. Sessa, G. Remuzzi, Karger, Basel 2001.
7. Contributions to Nephrology (146), Kidney Transplantation: Strategies to Prevent Organ Rejection. Edited by C. Ronco, S. Chiaramonte, G. Remuzzi. Karger, Basel, 2005.
8. Kidney Diseases in the Developing World and Ethnic Minorities. Edited by M. El-Nahas, Taylor & Francis Group, New York 2006 (Associated Editor).
9. Tra Igea e Panacea: Riflessioni su medicina e società. Edited by G. Remuzzi, A. Maturo. Edited by Franco Angeli Srl, Milan, Italy, 2006.

10. Contributions to Nephrology (159), Gene Therapy for Renal Diseases and Transplantation. Edited by A. Benigni, G. Remuzzi. Karger, Basel, 2008.
11. Dire, fare, curare: Parole tra medici e malati. Edited by C. Cipolla, G. Remuzzi. Edited by Franco Angeli Srl, Milan, Italy 2008.
12. Antagonisti recettoriali dell'endotelina: quali composti e quali patologie. Edited by A. Benigni, G. Remuzzi. Il Pensiero Scientifico Editore, Rome, Italy 2008.
13. Contributions to Nephrology (162), Humoral Immunity in Kidney Transplantation: What Clinicians Need to Know. Edited by G. Remuzzi, S. Chiaramonte, N. Perico, C. Ronco. Karger, Basel, 2009.
14. Ci curano o ci curiamo? Il malato tra crisi economica e responsabilità individuale. Edited by Franco Angeli Srl, Milan, Italy 2013.
15. La scelta. Perché è importante decidere come vorremmo morire. Edited by Sperling & Kupfer, Milan, Italy, 2015.
16. Siamo geni. Uno straordinario viaggio nel corpo umano in 44 brevi lezioni. Edited by Sperling & Kupfer, Milan, Italy, 2016.
17. Kidney transplantation, bioengineering, and regeneration. Edited by G. Orlando, G. Remuzzi, D.F. Williams. Elsevier, London, 2017.
18. Oxford textbook of clinical nephrology 4th edition. Edited by N. Turner, N. Lameire, D.J. Goldsmith, C.G. Winearls, J. Himmelfarb, G. Remuzzi. Oxford University Press, Oxford, 2016.
19. La salute (non) è in vendita. Edited by Laterza, Roma, Italy, 2018.
20. Le impronte del signor Neanderthal. Come la scienza ricostruisce il passato e disegna il futuro. Edited by Solferino, Milano, Italia, 2021.
21. Covid: prevenire, curare, convivere. Tutte le risposte dell'Istituto Mario Negri. Edited by A. Vallardi, Milano, Italia, 2021.
22. Contributions to Nephrology (199), Nephrology and public health worldwide. Edited by G.B. Silva Junior, A. Ferreira Fuentes, M. Nangaku, G. Remuzzi, C. Ronco. Karger, Basel, 2021.
23. Quando i medici sbagliano. E come discuterne in pubblico. Edited by Gius. Laterza & Figli, Roma, Italia, 2022.
24. Bergamo che non ti aspetti. Edited by Bolis Edizioni, Bergamo, Italia, 2022.
25. Le monetine di Roosevelt. Una storia dell'umanità attraverso i vaccini. Editore: Solferino, Milano, Italia, 2022.

26. La scelta. Perché è importante decidere come vorremmo morire. Nuova edizione aggiornata. Edited by Sperling & Kupfer, Milan, Italy, 2023.